

[illegible]

financial statements. 4 A Tenon Medical, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (In thousands) A Six Months Ended June 30, 2024 A 2023A Cash Flows from Operating Activities A A Net lossA (\$7,402)A (\$9,115) Adjustments to reconcile net loss to net cash used in operating activities: A A A Stock-based compensation expenseA 2,052A 2,094A Depreciation and amortizationA 189A 60A Provision for losses on accounts receivableA 46A A A Amortization of operating right-of-use assetA 121A 111A Increase (decrease) in cash resulting from changes in: A A A A Accounts receivableA (207)A (373) InventoryA (55)A (155) Prepaid expenses and other assetsA (442)A (325) Accounts payableA 678A 362A Accrued expensesA 385A 698A Operating lease liabilityA (123)A (109) Net cash used in operating activitiesA (4,758)A (6,752) A A A A Cash Flows from Investing ActivitiesA A A A Sales of short-term investmentsA A A 6,503A Purchases of short-term investmentsA A A (493) Purchases of property and equipmentA (119)A (212) Net cash (used in) provided by investing activitiesA (119)A 5,798A A A A A Cash Flows from Financing ActivitiesA A A A Proceeds from issuance of Series A Convertible Preferred Stock, netA 2,437A A A A Proceeds from issuance of common stock, netA 1,934A A A A Proceeds from issuance of common stock and warrants, net of issuance costsA A A A 4,808A Deferred offering costsA A A A (143) Net cash provided by financing activitiesA 4,371A A 4,665A A A A A Effect of foreign currency translation on cash flowA 46A A 12A Net (Decrease) Increase in Cash and Cash EquivalentsA (460)A 3,723A A A A A A Cash and Cash Equivalents at Beginning of PeriodA 2,428A A 2,129A Cash and Cash Equivalents at End of PeriodA 1,968A A 5,852A A A A A Supplemental Disclosures of Cash Flow InformationA A A A Non-cash investing and financing activities: A A A A Preferred stock issued upon conversion of debt and accrued interestA \$1,186A A A A Reclassification of deferred offering costs to additional paid-in capitalA \$130A A A A The accompanying notes are an integral part of these condensed consolidated financial statements. A 5 A Notes to Condensed Consolidated Financial Statements (unaudited) (in thousands, except share and per-share data) A 1. Organization and Business A Nature of operations A Tenon Medical, Inc. (the "Company") was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran, a SI Joint Fusion System (the "Catamaran System") that offers a novel, less invasive approach to the sacroiliac joint (the "SI Joint") using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration ("FDA") clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct. A Principles of consolidation A The condensed consolidated financial statements of the Company for the three and six months ended June 30, 2023 and as of December 31, 2023 include the accounts of its wholly-owned subsidiary, Tenon Technology AG ("TTAG"), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. In 2024, TTAG was dissolved and, as such, the financial statements for the three and six months ended June 30, 2024 and as of June 30, 2024 only include the accounts of the Company. A 2. Summary of Significant Accounting Principles A Basis of presentation A The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the "SEC"). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). A The condensed consolidated balance sheet as of December 31, 2023A has been derived from the Company's audited consolidated financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 29, 2024. A These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company's audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022 included in its Annual Report of Form 10-K filed with the SEC on March 29, 2024. A These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in management's opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. A The Company's significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022. There have been no material changes in the Company's significant accounting policies during the six months ended June 30, 2024. A 6 A Going concern uncertainty and liquidity requirements A The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company's ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued. A Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. Based on the Company's expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of June 30, 2024 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. A Notice from Nasdaq A On May 7, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (the "Nasdaq") stating that for the 30 consecutive business day period between March 25, 2024 and May 6, 2024, the common stock of the Company had not maintained a minimum closing bid price of \$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until November 4, 2024 (the "Compliance Period"), to regain compliance with the Bid Price Rule. A If the Company does not regain compliance with the Bid Price Rule by November 4, 2024, the Company may be eligible for an additional 180-day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. A If the Company cannot regain compliance during the Compliance Period or any subsequently granted compliance period, the common stock of the Company will be subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel. A The notice from Nasdaq has no immediate effect on the listing of the Company's common stock. The Company is currently evaluating its options for regaining compliance. On December 21, 2023, the Company's shareholders approved an amendment to its Certificate of Incorporation to provide for a reverse stock split in a ratio ranging from one for two (1:2) to one for fifty (1:50) at the discretion of the Company's Board of Directors. A Use of estimates A The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, allowance for credit losses, and stock-based compensation. A Reverse Stock Split A On November 2, 2023, the Company effected a 1-for-10 reverse stock split by filing an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The reverse stock split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the reverse stock split into one share of common stock. No fractional shares were issued in connection with the reverse stock split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the reverse stock split. The authorized number of shares and the par value per share of the Company's common stock were not affected by the reverse stock split. A 7 A Income Taxes A The Company accounts for income taxes utilizing ASC 740, "Income Taxes". ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company's financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A Net loss per share A Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that certain potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company's weighted average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive. A The Company had the following dilutive common stock equivalents as of June 30, 2024 and 2023 which were excluded from the calculation because their effect was anti-dilutive: A A June 30, 2024 A June 30, 2023A Outstanding restricted stock unitsA 136,690A 93,156A Outstanding stock optionsA 72,563A 96,934A Outstanding warrantsA 2,388,068A 2,009,600A Common shares convertible from preferred stockA 2,625,016A A A TotalA 5,222,337A 2,199,690A A Recent Accounting Pronouncements Not Yet Adopted A In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which increases the disclosures about reportable segments including more detailed information about a reportable segment's expenses. This guidance will be effective for the Company for the fiscal year ending December 31, 2024 and the interim periods thereafter, with early adoption permitted. The guidance will have no effect on the Company's results of operations as the changes are disclosure related. The Company has elected not to early adopt. A In December 2023, the FASB issued Accounting Standards Update 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures", which requires additional tax disclosures about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This guidance will be effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance. A 3. Fixed Assets, Net A Fixed assets, net, consisted of the following: A A June 30, 2024A December 31, 2023A Construction in progressA \$718A \$602A Catamaran tray setsA \$538A \$538A IT equipmentA \$56A \$56A Leasehold improvementsA \$15A \$15A Lab equipmentA \$14A \$14A Office furnitureA \$9A \$9A Fixed assets, grossA \$1,350A \$1,234A Less: accumulated depreciationA (446)A (273) Fixed assets, netA \$904A \$961A A 8 A Construction in progress is made up of reusable components that will become reusable Catamaran Tray Sets. Depreciation expense was approximately \$86 and \$35 for the three months ended June 30, 2024 and 2023, respectively. Depreciation expense was approximately \$173 and \$60 for the six months ended June 30, 2024 and 2023, respectively. A 4. Accrued Expenses A Accrued expenses consisted of the following: A A June 30, 2024A December 31, 2023A Accrued compensationA \$531A \$334A Other accrued expensesA \$401A \$474A Total accrued expensesA \$932A \$808A A 5. Debt A Convertible notes payable A In November 2023, the Company entered into Securities Purchase Agreements with certain investors (the "Investors"), pursuant to which the Company sold to the Investors a total of \$1,250,000 in secured notes (the "Convertible Notes") and warrants to purchase 45,000 shares of the Company's common stock at an exercise price equal to \$1.94 per share. A The Convertible Notes bear an interest rate of 10% per annum with a default rate of 12% per annum and have a maturity date of November 21, 2024. All principal and accrued interest is payable at maturity. At any time

during the term of the Convertible Notes, the principal amount together with all accrued interest thereon (the “Prepayment Amount”) may be paid in full, but not in part, by the Company. The Prepayment Amount may be paid by the Company in cash or by the issuance to the Investors of shares of Series A Preferred Stock, if prior to such payment with Series A Preferred Stock (i) certain stockholder proposals described in the Convertible Notes are approved by the Company’s stockholders; and (ii) the Company has commitments from investors other than the Investors to purchase shares of Series A Preferred Stock with a stated value of at least \$3,750,000. The Convertible Notes are secured by a first priority security interest in all of the assets of the Company. The warrants expire five years from the issuance date. The warrants contain a “cashless exercise” feature and contain anti-dilution rights on subsequent issuances of equity or equity equivalents. On February 20, 2024, the Investors agreed to a complete prepayment of the Company’s obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at \$1.2705 per share and the Convertible Notes were cancelled. See Note 7.

6. Leases In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancellable operating lease expires in June 2026. Operating lease costs for the facility lease were \$73 and \$73 for the three months ended June 30, 2024 and 2023, respectively, and were \$146 and \$146 for the six months ended June 30, 2024 and 2023, respectively. Supplemental balance sheet information related to leases was as follows:

	June 30, 2024	December 31, 2023
Operating lease right-of-use assets	\$525	\$646
Operating lease liability, current	\$(271)	\$(256)
Operating lease liability, noncurrent	\$(290)	\$(428)
Total operating lease liabilities	\$(561)	\$(684)

Future maturities of operating lease liabilities as of June 30, 2024 were as follows:

	2024	2025	2026	2027	2028	Total
Less: imputed interest	\$(47)					
Present value of operating lease liabilities	\$561					

Other information: Cash paid for operating leases for the six months ended June 30, 2024 \$148. Cash paid for operating leases for the six months ended June 30, 2023 \$144. Remaining lease term - operating leases (in years) 2.00. Average discount rate - operating leases 8.0%.

7. Stockholders’ Equity The Company’s current Amended and Restated Certificate of Incorporation dated February 18, 2014 authorizes the issuance of 130,000,000 shares of common stock and 20,000,000 shares of preferred stock, both with a par value of \$0.001 per share. With respect to the preferred stock, 4,500,000 shares are designated Series A Preferred Stock and 491,222 shares are designated Series B Preferred Stock.

At-the-Market Offering Program On May 4, 2023, the Company entered into an Equity Distribution Agreement to establish an at-the-market offering program, under which the Company may sell from time to time, at its option, shares of its common stock having an aggregate gross sales price of \$5.5 million. The Company is required to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares and has also agreed to provide the Sales Agents with customary indemnification rights. During the six months ended June 30, 2024, 1,033,592 shares of the Company’s common stock were sold under the program at a weighted-average price of \$1.83 per share with aggregate proceeds, net of issuance costs, of \$1,834. No shares were sold under the program during the three months ended June 30, 2024. As of the date of this report, the Company may not sell additional shares under this program.

Equity Line of Credit On July 24, 2023, the Company entered into a purchase agreement (“Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), under which, subject to specified terms and conditions, the Company may sell to Lincoln Park up to \$10 million of shares of common stock from time to time during the term of the Purchase Agreement. On September 22, 2023 (the “Commencement Date”) and on May 10, 2024, the Company filed registration statements with the SEC covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement.

Beginning on the Commencement Date and for a period of 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company’s discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to \$10 million of shares of common stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, direct Lincoln Park to purchase on any single business day on which the closing price of its common stock on The Nasdaq Capital Market (“Nasdaq”) is equal to or greater than \$1.50 up to 10,000 shares of common stock (a “Regular Purchase”); provided, that the Company may direct Lincoln Park to purchase in a Regular Purchase (i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least \$15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least \$25.00 per share. In no case, however, will Lincoln Park’s commitment with respect to any single Regular Purchase exceed \$500,000; provided, that the parties may mutually agree at any time to increase the maximum number of shares of common stock the Company may direct Lincoln Park to purchase in any single Regular Purchase to up to 100,000 shares or any number of shares that shall not exceed 4.99% of the then outstanding shares of common stock. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to our common stock. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of the Company’s common stock immediately preceding the time of sale, as determined under the Purchase Agreement.

10. During the six months ended June 30, 2024, 89,847 shares of the Company’s common stock were sold under the program at a weighted-average price of \$1.113 per share with aggregate net proceeds of \$96. No shares were sold under the program during the three months ended June 30, 2024.

Series A Preferred Stock On February 20, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors, pursuant to which the Company agreed to sell, issue and deliver to these investors, in a private placement offering (the “Offering”), a total of 172,239 shares of the Company’s Series A Preferred Stock and warrants (the “Series A Warrants”) to purchase 258,374 shares of common stock, par value \$0.001 per share, of the Company (“Common Stock”) at an exercise price equal to \$1.2705 per share for an aggregate offering price of \$2,605,000. Additionally, on February 20, 2024, the Investors agreed to a complete prepayment of the Company’s obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at \$1.2705 per share and the Convertible Notes were cancelled. The Series A Warrants are immediately exercisable and expire five years from the date of issuance. The Series A Preferred Stock is convertible, at any time, at the option of the holder into shares of Common Stock. Each share of Series A Preferred Stock shall be convertible, at any time after the date of issuance, at the option of the holder thereof (or, upon a Required Conversion (as defined below), at the option of the Corporation), into that number of shares of Common Stock determined by dividing the Stated Value (as defined below) for such share of Series A Preferred Stock by the Conversion Price (as defined below). “Stated Value” means for any share of Series A Preferred Stock, an amount equal to the product of (x) \$15.125 multiplied by (y) the sum of 1 plus the product of (A) 0.06 multiplied by (B) a fraction equal to the number of days that such share of Series A Preferred Stock has been issued divided by 365. “Conversion Price” means (i) for the shares of Series A Preferred Stock issued on the Closing Date, \$1.5125 and (ii) for each share of Series A Preferred Stock issued thereafter, an amount equal to the greater of (x) \$1.5125 and the average of the VWAPs for the 10 Trading Days prior the issuance date of such share of Series A Preferred Stock, in each case subject to adjustment as set forth herein. On any date that ten out of the last 15 daily VWAPs of the Common Stock is 250% higher than the Conversion Price on such date, then the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock. Additionally, on and after the time on which the Company has \$2.25 million in revenues in any single financial quarter, the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock (a “Required Conversion”). No dividends are payable on the Series A Preferred Stock. The Series A Preferred Stock will vote together with the Common Stock on all matters other than as required by law; provided however that any additional shares underlying the Series A Preferred Stock as a result of the anti-dilution provision described below shall not vote on an “as converted” basis and shall only vote when issued upon conversion. Notwithstanding the foregoing, the vote of an individual holder of Series A Preferred Stock (and underlying Common Stock) shall be capped at 9.99% (or 4.99% if selected by the holder). The Conversion Price is subject to anti-dilution adjustment as the result of any subdivision, combination of shares or recapitalization, stock dividends, stock splits and similar transactions affecting the Common Stock. In addition, the Series A Preferred Stock will have weighted average anti-dilution protection providing for adjustment of the Conversion Price in the event of issuance of, or commitments to issue, Common Stock for less than the Conversion Price then in effect immediately prior to such issue or sale (a “Dilutive Issuance”), subject to customary exceptions; provided however the anti-dilution for Dilutive Issuances shall not be operative until the stockholders of the Company have approved the terms of the Series A Preferred Stock. Upon any liquidation or winding up of the Company (a “Liquidation”), the holders of Series A Preferred Stock will be entitled to receive in preference to any other class or series of the Company’s equity securities the greater of (i) the Stated Value plus accrued and unpaid dividends and (ii) what would be paid if the Series A Preferred Stock plus accrued and unpaid dividends had been converted into Common Stock. A consolidation or merger of the Company or sale or transfer of all or substantially all of its assets, or any transaction which results in the stockholders of the Company owning less than 50% of the equity or voting power of the surviving entity (excluding the issuance of Common Stock in any financing transaction unless more than 50% of the Company’s shares are issued to one stockholder or a number of stockholders who act as one group) shall be deemed a Liquidation (a “Deemed Liquidation”) with respect to the shares of Series A Preferred Stock of any holder who opts to have such occurrence treated as a Deemed Liquidation; provided that if the liquidation preference payable on a Deemed Liquidation is less than 110% of the stated value of the Series A Preferred Stock, the dividend rate on any accrued and unpaid dividends payable with respect to such Deemed Liquidation will increase to 10%. All liquidation preferences payable in respect of a Deemed Liquidation will be payable in shares of Common Stock based on the closing price of the Common Stock on the date of such Deemed Liquidation. Consent of the majority of the holders will be required to (i) amend the Certificate of Incorporation or Bylaws of the Company so as to adversely alter the rights, preferences, privileges of the Series A Preferred Stock, (ii) create any new class of shares pari passu or senior to the Series A Preferred Stock or increase or decrease the number of authorized shares of Common Stock or preferred stock, (iii) pay or declare any dividend on Common Stock or other junior securities, or incur indebtedness in any single transaction in excess of \$1 million or (iv) redeem, purchase or otherwise acquire any share or shares of preferred stock or Common Stock (other than (a) the repurchase of shares of Common Stock pursuant to a written benefit plan or employment or consulting agreement, or (b) the repurchase of any equity securities in connection with the Company’s right of first offer with respect to those securities contained in any written agreement with the Company).

11. Voting rights The holders of vested shares of common stock are entitled to vote on any matter submitted to a vote of the stockholders and each such holder is entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock are entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock are entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company’s Amended and Restated Certificate of Incorporation, as amended. Equity awards In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two to four years and have a 10-year expiration date. In April 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 662,516. In July 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 737,516. In August 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan from 737,516 shares to 799,266 shares and approved the form of a 2022 Equity Incentive Plan. On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such

that no new equity awards will be issued by the 2012 Plan. **Å** Option Exchange **Å** On April 8, 2024, the Company issued an offer to holders of outstanding stock options to purchase an aggregate of 90,987 shares of the Companyâ€™s common stock to exchange their options for a lesser number of new restricted stock units (â€™RSUsâ€™) to be granted under the 2022 Plan upon the terms and subject to the conditions set forth in the Offer to Exchange Certain Outstanding Stock Options for Restricted Stock Units (the â€™Offer to Exchangeâ€™). The Offer to Exchange expired on May 6, 2024. A total of 27 eligible participants participated in the exchange. The Company accepted for exchange options to purchase an aggregate of 83,391 shares of common stock of the Company. All surrendered options were cancelled effective as of the expiration of the Option Exchange, and immediately thereafter, in exchange therefor, the Company granted a total of 41,698 new RSUs under the 2022 Plan. The incremental fair value of the new RSUs that were vested at the issuance date was \$32 and was immediately expensed. **Å** 12 **Å** **Å** A summary of the Companyâ€™s stock option and restricted stock unit activity under its plans is as follows: **Å** **Å** Number of Shares Subject **Å** Outstanding Stock Options **Å** Weighted Average Exercise Price per Share **Å** Number of Outstanding Restricted Stock Units **Å** Weighted Average Grant Date Fair Value per Unit **Å** Outstanding at December 31, 2023 **Å** 102,089 **Å** \$42.54 **Å** \$69.50 **Å** 66,967 **Å** \$0.87 **Å** \$119,351 **Å** \$1.00 **Å** Released **Å** **Å** **Å** **Å** (57,077) **Å** \$32.05 **Å** Cancelled or forfeited **Å** (96,493) **Å** \$43.27 **Å** **Å** (2,500) **Å** \$2.91 **Å** Outstanding at June 30, 2024 **Å** 72,563 **Å** \$3.12 **Å** **Å** 136,690 **Å** \$26.55 **Å** The following table sets forth stock-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023: **Å** **Å** Three months ended June 30, **Å** Six months ended June 30, **Å** **Å** 2024 **Å** 2023 **Å** Research and development **Å** \$358 **Å** \$378 **Å** \$725 **Å** \$750 **Å** Sales and marketing **Å** **Å** 34 **Å** **Å** 58 **Å** **Å** 77 **Å** **Å** 116 **Å** General, and administrative **Å** **Å** 64 **Å** **Å** 618 **Å** **Å** 1,250 **Å** **Å** 1,228 **Å** Total stock-based compensation expense **Å** \$1,034 **Å** \$1,054 **Å** \$2,052 **Å** \$2,094 **Å** **Å** At June 30, 2024, there were 54,173 shares available for issuance under the 2022 Plan. **Å** Warrants **Å** In April 2022, in association with the Companyâ€™s initial public offering, the Company granted to The Benchmark Company, LLC and Valuable Capital Limited warrants to purchase a total of 9,600 shares of the Companyâ€™s common stock. The warrants were immediately exercisable at an exercise price of \$50.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was \$27.50 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 62.55%, dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of \$264 as an issuance cost to additional paid-in capital in 2022. **Å** In June 2023, in connection with a registered offering of stock, the Company issued warrants to purchase a total of 2,000,000 shares of the Companyâ€™s common stock (the â€™Offering Warrantsâ€™). The Offering Warrants were exercisable upon issuance and will expire five years from the date of issuance. Per the terms of the Offering Warrants, the exercise price of the Offering Warrants reset on July 16, 2023, to \$3.146 per share. The fair value of the Offering Warrants on the grant date of \$3,164, or \$1.58 per warrant, was calculated using a Monte-Carlo simulation to estimate the final exercise price, which is considered a Level 3 fair value measurement, using as inputs; the starting value of \$3.00 per share, the Companyâ€™s VWAP on June 16; an assumed daily distribution of returns; a mean daily return of 5.18%; a short-term annual volatility of 100% and a standard deviation of 6.3%. The model used Black-Scholes to then calculate the estimated fair value of the Offering Warrants, using an estimated time to maturity of 4.9 years, a risk-free interest rate of 3.99% and a long-term volatility of 60%. **Å** In November 2023, in connection with the issuance of the Convertible Notes, the Company issued warrants to purchase a total of 45,000 shares of the Companyâ€™s common stock at an exercise price equal to \$1.94 per share. The warrants expire five years from the issuance date. The fair value of the warrants on the grant date was \$1.29 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.89%, dividend yield of 0%, and risk-free interest rate of 4.41%. The Company recorded the fair value of these warrants of approximately \$58 as an issuance cost to additional paid-in capital in 2023. **Å** On February 20, 2024, in connection with the Purchase Agreement, the Company issued the Series A Warrants to purchase a total of 415,468 shares of the Companyâ€™s common stock at an exercise price equal to \$1.2705 per share. The Series A Warrants are immediately exercisable and expire five years from the date of issuance. The fair value of the Series A Warrants on the grant date was \$0.61 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.24%, dividend yield of 0%, and risk-free interest rate of 4.3%. The Company recorded the fair value of these warrants of \$254 to additional paid-in capital in 2024. **Å** 13 **Å** 8. Commitments and Contingencies **Å** Sales Representative Agreement **Å** In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the â€™Representativeâ€™) received exclusive rights to market, promote, and distribute The Catamaran System in the United States and Puerto Rico. The agreement is for an initial period of five years, and automatically renews for an additional five years unless written notice is given by either party prior to April 27, 2023. The agreement provides for a bonus to be paid to the Representative upon an acquisition or IPO. In May 2021, the Company entered into an Amended and Restated Exclusive Sales Representative Agreement (the â€™Restated Sales Agreementâ€™). In connection with the amended agreement, the Company paid \$500 cash and issued 53,757 shares of common stock to the Representative, for which the Company recorded a combined total of \$880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October 2021, the Company issued 4,445 shares of common stock with a fair value of approximately \$333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 31,235 shares of common stock to the Representative in accordance with the anti-dilution provision, fully satisfying the Companyâ€™s obligations. **Å** The Restated Sales Agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the Restated Sales Agreement as long as the bonus paid to the Representative is at least \$6,000. **Å** On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the â€™Termination Agreementâ€™) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative \$1,000 in cash; and (ii) the Company agreed to pay the Representative (a) \$85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal \$3,600. In the event of an acquisition of the Company, the Company will pay the Representative \$3,600 less previous amounts paid pursuant to clause (b) and clause (c) above. The Company recorded a charge of \$1,000 for the payment to the Representative in the fourth quarter of 2022 and expensed the \$85 per month charges as incurred over the six-month period. For payments under clause (b) and clause (c) above, the Company estimated the fair value of the liability using level 3 hierarchy inputs based on a Monte Carlo simulation of future revenues with a 25% quarterly estimated standard deviation of growth rates and a 10% probability of dissolution, discounted at an estimated discount rate of 15.4%. Based on the Companyâ€™s fair value analysis, a total of \$2,611 was charged to sales and marketing expense in the consolidated statements of operations and comprehensive loss and recorded as accrued commissions in the consolidated balance sheets. A reconciliation of the liability under clause (b) and clause (c) for the six months ended June 30, 2024 is as follows: **Å** Balance at January 1, 2024 **Å** \$2,377 **Å** Amounts paid during 2024 **Å** (252) **Å** Accretion **Å** 185 **Å** Balance at June 30, 2024 **Å** \$2,310 **Å** **Å** 14 **Å** **Å** Per the terms of the Termination Agreement, the Company ultimately expects to expense \$3,600 under clause (b) and clause (c). **Å** Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the â€™Consulting Agreementâ€™). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Companyâ€™s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement. **Å** The term of the Consulting Agreement was from October 6, 2022, until October 5, 2023, when it terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company paid the Representative a base consulting fee of \$700 per year, payable in monthly installments, along with additional compensation of \$62.5 per quarter, if certain sales targets were met, for four quarters; along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services. **Å** Litigation **Å** In the normal course of business, the Company may possibly be named as a defendant in various lawsuits. **Å** 9. Concentrations of Risk **Å** Credit risk **Å** Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable. **Å** The Company maintains cash balances at financial institutions located in California. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. **Å** The Company grants unsecured credit to its customers based on an evaluation of the customerâ€™s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses. **Å** 15 **Å** **Å** ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS **Å** You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and the other information set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024. In addition to historical financial information, this discussion and analysis contains forward-looking statements that reflect our plans, estimates and beliefs. You should not place undue reliance on these forward-looking statements, which involve risks and uncertainties. As a result of many factors, including but not limited to those set forth under â€™Risk Factorsâ€™ in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2024, our actual results may differ materially from those anticipated in these forward-looking statements. See â€™Cautionary Statement Regarding Forward-Looking Statements.â€™ **Å** Overview **Å** Tenon Medical, Inc., a medical device company formed in 2012, has developed a proprietary, U.S. Food and Drug Administration (â€™FDAâ€™) approved surgical implant-system, which we call The Catamaranâ„¢ SI Joint Fusion System (â€™The Catamaran Systemâ€™). The Catamaran System offers a novel, less invasive inferior-posterior approach to the sacroiliac joint (â€™SI Jointâ€™) using a single, robust titanium implant to treat SI Joint dysfunction that often causes severe lower back pain. The system features the Catamaranâ„¢ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Published clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the SI Joint. **Å** With an entry similar to the SI Joint injection, the surgical approach is direct to the joint. The angle and trajectory of the inferior-posterior approach is designed to point away from critical neural and vascular structures and into the strongest cortical bone. Joined by a patented osteotome bridge, the implant design consists of two hollow fenestrated pontoons with an open framework to facilitate bony in-growth through the SI Joint. One pontoon fixates into the ilium and the other into the sacrum. The osteotome is designed to disrupt the articular portion of the joint to help facilitate a fusion response. **Å** Our initial clinical results indicate that the Catamaran System implant is promoting fusion across the joint as evidenced by computerized tomography (CT) scans which is the gold standard widely accepted by the clinical community. We had our national launch of The Catamaran System in October 2022 and are building a sales and marketing infrastructure to market our product and address the greatly underserved market opportunity that exists. **Å** We believe that the implant design and procedure we have developed, along with the 2D and 3D protocols for proper implantation will be received well by the clinician community who have been looking for a next generation device. **Å** We have incurred net losses since our inception in 2012. As of June 30, 2024, we had an accumulated deficit of approximately \$62.5 million. To date, we have financed our operations primarily through an initial public offering, private placements of equity securities, certain debt-related financing arrangements, and sales of our product. We have devoted substantially all of our resources to research and development, regulatory matters and sales and marketing of our product. **Å** 2024 Series A Offering **Å** On February 20, 2024, we entered into a Securities Purchase Agreement (the â€™Series A Purchase Agreementâ€™) with certain investors (the â€™Series A Investorsâ€™), pursuant to which the Company agreed to sell, issue and deliver to the Series A Investors, in a private placement offering (the â€™Series A Offeringâ€™), a total of 172,239 shares of the Companyâ€™s Series A Preferred Stock (the â€™Series A Preferred Stockâ€™) and warrants (the â€™Warrantsâ€™) to purchase 258,374 shares of our common stock, par value \$0.001 per share, at an exercise price equal to

\$1.2705 per share for an aggregate offering price of \$2,605,000. Under the Series A Purchase Agreement, each Series A Investor paid \$15.125 for each share of Series A Preferred Stock and along with their shares of Series A Preferred Stock, received Warrants equal to 15% of the number of shares of our common stock initially underlying such shares of Series A Preferred Stock. In connection with the offering of the Series A Preferred Stock, the Company exchanged the Notes (as defined below) for 84,729 shares of Series A Preferred Stock and Series A Warrants to purchase 157,094 shares of our common stock. There are a total of 256,968 shares of Series A Preferred Stock outstanding as of June 30, 2024. 16 A Reverse Stock Split A On November 2, 2023, the Company effected a 1-for-10 reverse stock split by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The reverse stock split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the reverse stock split into one share of common stock. No fractional shares were issued in connection with the reverse stock split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the reverse stock split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the reverse stock split. Components of Results of Operations A Revenue A We derive substantially all our revenue from sales of The Catamaran System to a limited number of clinicians. Revenue from sales of The Catamaran System fluctuates based on volume of cases (procedures performed), discounts, and the number of implants used for a particular patient. Similar to other orthopedic companies, our revenue can also fluctuate from quarter to quarter due to a variety of factors, including reimbursement, changes in independent sales representatives and physician activities. A Cost of Goods Sold, Gross Profit, and Gross Margin A We utilize contract manufacturers for production of The Catamaran System implants and Catamaran Tray Sets. Cost of goods sold consists primarily of overhead related to operation personnel and facility costs, costs of the components of The Catamaran System implants and instruments, quality inspection, packaging, scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. We anticipate that certain of our cost of goods sold will increase in absolute dollars as case levels increase. A Our gross margins have been and will continue to be affected by a variety of factors, including the cost to have our product manufactured for us, pricing pressure from increasing competition, and the factors described above impacting our revenue. A Operating Expenses A Our operating expenses consist of sales and marketing, research and development, and general and administrative expenses. Personnel costs are the most significant component of operating expenses and consist of consulting expenses, salaries, sales commissions and other cash and stock-based compensation related expenses. We expect operating expenses to increase in absolute dollars as we continue to invest and grow our business. A Sales and Marketing Expenses A Sales and marketing expenses primarily consist of salaries, commissions, stock-based compensation expense and travel and entertainment expenses of our sales and market personnel along with commissions paid to our independent distributors. We expect our sales and marketing expenses to increase in absolute dollars with the increased sales of The Catamaran System resulting in higher commissions and salaries, increased clinician and sales representative training, and the cost to complete our clinical study to gain wider clinician adoption of The Catamaran System. Our sales and marketing expenses may fluctuate from period to period due to timing of sales and marketing activities related to the commercial activity of our product. A 17 A Research and Development Expenses A Our research and development expenses primarily consist of engineering, product development, regulatory expenses, and consulting services, outside prototyping services, outside research activities, materials, and other costs associated with the development and refinement of our product. Research and development expenses also include related personnel and consultants’ compensation and stock-based compensation expense. We expense research and development costs as they are incurred. We expect research and development expense to increase in absolute dollars as we improve The Catamaran System, develop new products, add research and development personnel, and undergo clinical activities that may be required for regulatory clearances of future products. A General and Administrative Expenses A General and administrative expenses primarily consist of salaries, consultants’ compensation, stock-based compensation expense, and other costs for finance, accounting, legal, compliance, and administrative matters. We expect our general and administrative expenses to increase in absolute dollars as we add personnel and information technology infrastructure to support the growth of our business. We also expect to incur additional general and administrative expenses as a result of operating as a public company, including but not limited to: expenses related to compliance with the rules and regulations of the Securities and Exchange Commission and those of The Nasdaq Stock Market LLC on which our securities are traded; additional insurance expenses; investor relations activities; and other administrative and professional services. While we expect the general and administrative expenses to increase in absolute dollars, we anticipate that it will decrease as a percentage of revenue over time. A Gain on Investments, Interest Expense and Other Income (Expense), Net A Gain on investments consists of interest income and realized gains and losses from the sale of our investments in money market and corporate debt securities. Interest expense is related to borrowings. Other income and expenses have not been significant to date. A Results of Operations A The following table sets forth our results of operations for the periods presented (in thousands): A Three Months Ended June 30, A Six Months Ended June 30, Consolidated Statements of Operations Data: 2024 A 2023 A 2024 A 2023 A Revenue A \$901 A \$743 A \$1,620 A \$1,176 A Cost of goods sold A \$431 A \$549 A \$680 A \$1,029 A Gross profit A \$470 A \$194 A \$1,191 A \$164 A Operating expenses A \$2,186 A \$2,829 A \$3,909 A \$4,401 A Research and development A \$708 A \$901 A \$1,193 A \$1,377 A Sales and marketing A \$1,448 A \$1,883 A \$2,331 A \$2,829 A General and administrative A \$412 A \$3,711 A \$4,011 A \$4,112 A Total operating expenses A \$4,342 A \$5,513 A \$7,955 A \$9,355 A Loss from operations A \$39 A \$37 A \$66 A \$93 A Interest expense A \$ A \$ A \$ A Other income (expense), net A \$ A \$ A \$ A Gain on investments A \$ A \$ A \$ A Interest expense A \$ A \$ A \$ A Other income (expense), net A \$ A \$ A \$ A Net loss A \$(425) A \$(577) A \$(457) A \$(775) A Comparison of the Three and Six Months Ended June 30, 2024 and 2023 (in thousands, except percentages) A Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin A Three Months Ended June 30, A A A A 2024 A 2023 A \$ Change A % Change A Revenue A \$901 A \$743 A \$158 A 21% Cost of goods sold A \$431 A \$549 A \$(118) A (21)% Gross profit A \$470 A \$194 A \$276 A 142% Gross profit percentage A 52% A 26% A 26% A 26% A Six Months Ended June 30, A A A A 2024 A 2023 A \$ Change A % Change A Revenue A \$1,620 A \$1,176 A \$444 A 38% Cost of goods sold A \$680 A \$1,029 A \$(349) A (34)% Gross profit A \$940 A \$147 A \$793 A 539% Gross profit percentage A 58% A 13% A 13% A 13% A Revenue A The increase in revenue for the three and six months ended June 30, 2024 as compared to the same periods in 2023 was primarily due to increases of 7% and 19%, respectively, in the number of surgical procedures in which the Catamaran System was used. A Cost of Goods Sold, Gross Profit, and Gross Margin A The change in cost of goods sold for the three and six months ended June 30, 2024 as compared to the same periods in 2023 was due to increases of 7% and 19%, respectively, in the number of surgical procedures performed. Gross profit and gross margin percentage for the three and six month periods ended June 30, 2024 as compared to the same periods in 2023 improved due to the absorption of more production overhead costs into our standard cost, operating leverage created due to lower relative fixed costs and higher revenue associated with the increase in the number of surgical procedures. A 19 A Operating Expenses A Three Months Ended June 30, A A A A A 2024 A 2023 A \$ Change A % Change A Research and development A \$708 A \$901 A \$(193) A (21)% Sales and marketing A \$1,448 A \$1,883 A \$(435) A (23)% General and administrative A \$2,186 A \$2,829 A \$(643) A (23)% Total operating expenses A \$4,342 A \$5,513 A \$(1,171) A (21)% A Six Months Ended June 30, A A A A A 2024 A 2023 A \$ Change A % Change A Research and development A \$708 A \$901 A \$(193) A (21)% Sales and marketing A \$1,448 A \$1,883 A \$(435) A (23)% General and administrative A \$2,186 A \$2,829 A \$(643) A (23)% Total operating expenses A \$4,342 A \$5,513 A \$(1,171) A (21)% A Research and Development Expenses. Research and development expenses for the three months ended June 30, 2024 decreased as compared to the same period in 2023 primarily due to decreased professional fees (\$141), payroll expenses (\$29) and stock-based compensation (\$19). Research and development expenses for the six months ended June 30, 2024 decreased as compared to the same period in 2023 primarily due to decreased professional fees (\$279), payroll expenses (\$111) and stock-based compensation (\$25). A Sales and Marketing Expenses. Sales and marketing expenses for the three months ended June 30, 2024 decreased as compared to the same period in 2023 primarily due to SpineSource transition fees in 2023 (\$260), decreased payroll and employee expenses (\$165) and consulting and professional fees (\$102) partially offset by increased commission expense (\$108). Sales and marketing expenses for the six months ended June 30, 2024 decreased as compared to the same period in 2023 primarily due to SpineSource transition fees in 2023 (\$690), decreased payroll and employee expenses (\$312) and consulting and professional fees (\$197) partially offset by increased commission expense (\$153). A General and Administrative Expenses. General and administrative expenses for the three months ended June 30, 2024 increased as compared to the same period in 2023 primarily due to increased legal and professional service fees (\$215), insurance costs (\$93), bad debt expense (\$36) and stock-based compensation (\$25). General and administrative expenses for the six months ended June 30, 2024 increased as compared to the same period in 2023 primarily due to increased insurance costs (\$191), legal and professional service fees (\$93), bad debt expense (\$46) and stock-based compensation (\$22). A Gain on Investments, Interest Expense and Other Income (Expense), Net A Gain on investments for the six months ended June 30, 2024 decreased approximately \$28 as compared to the six months ended June 30, 2023 due to interest on our investments in money market and corporate debt securities. We did not have significant investments in corporate debt securities during the first six months of 2024. Interest expense for the six months ended June 30, 2024 related to our convertible debt. Other expense, net was related to foreign exchange losses on the liquidation of our Swiss subsidiary. A Liquidity and Capital Resources A As of June 30, 2024, we had cash and cash equivalents of \$2.0A million. Since inception, we have financed our operations through private placements of preferred stock, debt financing arrangements, our initial public offering, additional stock offerings and the sale of our products. As of June 30, 2024, we had no outstanding debt. A 20 A As of June 30, 2024, we had an accumulated deficit of \$62.5A million and expect to incur additional losses in the future. We have not achieved positive cash flow from operations to date. Based upon our current operating plan, our existing cash and cash equivalents will not be sufficient to fund our operating expenses and working capital requirements through at least the next 12 months from the date these consolidated financial statements were available to be released. We plan to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. We continue to face challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to (a) the uncertainty of future revenues from The Catamaran System; (b) changes we may make to the business that affect ongoing operating expenses; (c) changes we may make in our business strategy; (d) regulatory developments affecting our existing products; (e) changes we may make in our research and development spending plans; and (f) other items affecting our forecasted level of expenditures and use of cash resources. A On February 20, 2024, we entered into the Series A Purchase Agreement with certain investors, pursuant to which we agreed to sell, issue and deliver to these investors, in a private placement offering, a total of 172,239 shares of our Series A Preferred Stock and warrants to purchase 258,374 shares of our common stock, par value \$0.001 per share, at an exercise price equal to \$1.2705 per share for an aggregate offering price of \$2,605,000. Additionally, on February 20, 2024, the Series A Investors agreed to a complete prepayment of our obligations under convertible notes (the “Convertible Notes”), including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at \$1.2705 per share and the Convertible Notes were cancelled. The Series A Warrants are immediately exercisable and expire five years from the date of issuance. There are a total of 256,968 shares of Series A Preferred Stock outstanding as of May 14, 2024. A As we attempt to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our

sales and marketing efforts, research and development activities, or other operations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, and collaborations. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans. Due to the uncertainty in our ability to raise capital, management believes that there is substantial doubt in our ability to continue as a going concern for the next twelve months from the issuance of these consolidated financial statements. **Cash Flows** (in thousands, except percentages) **The following table sets forth the primary sources and uses of cash for each of the periods presented below:**

	Six Months Ended June 30, 2024	2023	\$ Change	% Change
Net cash (used in) provided by:				
Operating activities	\$(4,758)	\$(6,752)	\$1,994	(30)%
Investing activities	\$(119)	\$5,798	\$(5,917)	(102)%
Financing activities	\$4,371	\$4,665	\$(294)	(6)%
Effect of foreign currency translation on cash flow	\$464	\$124	\$340	283%
Net (decrease) increase in cash and cash equivalents	\$(460)	\$3,723	\$(4,183)	(112)%

The decrease in net cash used in operating activities for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023 was primarily attributable to our decreased net loss of \$1.7 million, adjusted for decreases in non-cash stock-based compensation expenses (\$42), in addition to increased accounts payable (\$316), partially offset by decreases in accrued expenses (\$313). Cash provided by investing activities for the six months ended June 30, 2024 consisted primarily purchases of property and equipment (\$119). Cash provided by investing activities for the six months ended June 30, 2023 consisted primarily of the net sales of short-term investments (\$6,010) to fund our operations, partially offset by purchases of property and equipment (\$212). Cash provided by financing activities for the six months ended June 30, 2024 consisted primarily of net proceeds from the issuance of Series A Convertible Preferred Stock (\$2,437) and from the issuance of common stock (\$1,934). Cash provided by financing activities for the six months ended June 30, 2023 consisted primarily of the \$4.8 million, net of relevant expenses, received from our registered offering in June 2023.

Critical Accounting Policies, Significant Judgments, and Use of Estimates Our management's discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported results of operations during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from three other sources. Actual results could differ from these estimates under different assumptions or conditions. For the six months ended June 30, 2024, there were no significant changes to our existing critical accounting policies from those disclosed on our Annual Report on Form 10-K.

Off-Balance Sheet Arrangements As of June 30, 2024, and December 31, 2023, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk Not required under Regulation S-K for "smaller reporting companies."

ITEM 4. Controls and Procedures. **Disclosure Controls and Procedures** We maintain disclosure controls and procedures that are designed to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the rules and forms promulgated by the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and President and Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosure. Because of the inherent limitations to the effectiveness of any system of disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been prevented or detected on a timely basis. Even disclosure controls and procedures determined to be effective can only provide reasonable assurance that their objectives are achieved. As of June 30, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and President and Principal Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) pursuant to Rule 13a-15 of the Exchange Act. Based upon that evaluation, our Chief Executive Officer and President and Principal Accounting Officer concluded that our disclosure controls and procedures are not effective at the reasonable assurance level. Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties. Therefore, it is difficult to effectively segregate accounting duties which comprises a material weakness in internal controls. This lack of segregation of duties leads management to conclude that the Company's disclosure controls and procedures are not effective to give reasonable assurance that the information required to be disclosed in reports that the Company files under the Exchange Act is recorded, processed, summarized and reported as and when required. To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over our Exchange Act reporting disclosures. Changes in Internal Control over Financial Reporting There have been no changes in our internal control procedures over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during our fiscal quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. The retirement of our Chief Financial Officer and his transition to a CFO Advisor effective July 31, 2024 did not significantly impact our internal control over financial reporting for the fiscal quarter ended June 30, 2024; however, if we are unable to hire a replacement in a timely manner, changes in our internal control over financial reporting will be implemented to ensure reasonable controls over financial reporting for the quarter ending September 30, 2024.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS None.

ITEM 1A. RISK FACTORS As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. In any event, there have been no material changes in our risk factors as previously disclosed in our Annual Report on Form 10-K filed with the U.S. Securities and Securities Exchange Commission (the "SEC") on March 29, 2024.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(A) Unregistered Sales of Equity Securities None.

(B) Use of Proceeds Not applicable.

(C) Issuer Purchases of Equity Securities None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES None.

ITEM 4. MINE SAFETY DISCLOSURES Not Applicable.

ITEM 5. OTHER INFORMATION On July 23, 2024, our stockholders approved, among other things, the following: (i) the terms of (A) our Series B Preferred Stock, (B) the warrants to be issued on the issuance date of our Series B Preferred Stock and (C) the amendment to the terms of our Series A Preferred Stock to decrease the amount of the conversion price thereof, in each case, to comply with Listing Rule 5635(d) of The Nasdaq Stock Market LLC; and (ii) amendments to the Tenon Medical, Inc. 2022 Equity Incentive Plan to (i) increase the total number of shares of the Company's common stock subject to the 2022 Plan by 1,100,000 shares and (ii) permit the issuance of equity awards to individuals and legal entities.

EXHIBITS

EXHIBIT INDEX

Exhibit Number

Description

31.1* Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer and President of Tenon Medical, Inc.

31.2* Rule 13a-14(a)/15d-14(a) Certification of the Principal Accounting Officer of Tenon Medical, Inc.

32.1** Section 1350 Certification of the President and Chief Executive Officer of Tenon Medical, Inc.

32.2** Section 1350 Certification of the Principal Accounting Officer of Tenon Medical, Inc.

101.INS* Inline XBRL Instance Document

101.SCH* Inline XBRL Taxonomy Extension Schema Document

101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TENON MEDICAL, INC.

Dated: August 13, 2024 /s/ Steven M. Foster

Steven M. Foster

Chief Executive Officer and President, Director (Principal Executive Officer)

Dated: August 13, 2024 /s/ Jay D. Hanson

Jay D. Hanson

Director of SEC Reporting and Compliance (Principal Accounting Officer)

25 649-5760 1.02 2.24 3.28 7.50 12.15 13.05 33.01 37.49 26.55 false --12-31 Q2 0001560293 0001560293 2024-01-01 2024-06-30 0001560293 2024-08-13 0001560293 2024-06-30 0001560293 2023-12-31 0001560293 us-gaap:SeriesAPreferredStockMember 2024-06-30 0001560293 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001560293 2024-04-01 2024-06-30 0001560293 2023-04-01 2023-06-30 0001560293 2023-01-01 2023-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2024-03-31 0001560293 us-gaap:CommonStockMember 2024-03-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001560293 us-gaap:RetainedEarningsMember 2024-03-31 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001560293 2024-03-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2024-04-01 2024-06-30 0001560293 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001560293 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2024-06-30 0001560293 us-gaap:CommonStockMember 2024-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2023-03-31 0001560293 us-gaap:CommonStockMember 2023-03-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001560293 us-gaap:RetainedEarningsMember 2023-03-31 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001560293 2023-03-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001560293 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001560293 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2023-06-30 0001560293 us-gaap:CommonStockMember 2023-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001560293 us-gaap:RetainedEarningsMember 2023-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2023-12-31 0001560293 us-gaap:CommonStockMember 2023-12-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001560293 us-gaap:RetainedEarningsMember 2023-12-31 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001560293 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001560293 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2022-12-31 0001560293 us-gaap:CommonStockMember 2022-12-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001560293 us-gaap:RetainedEarningsMember 2022-12-31 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2023-01-

01 2023-06-30 0001560293 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001560293 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001560293 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001560293 2024-05-06 0001560293 srt:MinimumMember 2024-01-01 2024-06-30 0001560293 srt:MaximumMember 2024-01-01 2024-06-30 0001560293 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001560293 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001560293 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001560293 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001560293 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001560293 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001560293 us-gaap:ConstructionInProgressMember 2024-06-30 0001560293 us-gaap:ConstructionInProgressMember 2023-12-31 0001560293 tnon:CatamaranTraySetsMember 2024-06-30 0001560293 tnon:CatamaranTraySetsMember 2023-12-31 0001560293 us-gaap:EquipmentMember 2024-06-30 0001560293 us-gaap:EquipmentMember 2023-12-31 0001560293 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001560293 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001560293 tnon:LabEquipmentMember 2024-06-30 0001560293 tnon:LabEquipmentMember 2023-12-31 0001560293 us-gaap:OfficeEquipmentMember 2024-06-30 0001560293 us-gaap:OfficeEquipmentMember 2023-12-31 0001560293 tnon:ConvertibleNotePayableMember 2023-11-30 0001560293 tnon:ConvertibleNotePayableMember 2024-06-30 0001560293 tnon:ConvertibleNotePayableMember 2024-01-01 2024-06-30 0001560293 tnon:ConvertibleNotePayableMember us-gaap:SeriesAPreferredStockMember 2024-06-30 0001560293 tnon:ConvertibleNotePayableMember 2024-02-20 0001560293 us-gaap:WarrantMember tnon:ConvertibleNotePayableMember 2024-02-20 0001560293 2014-02-18 0001560293 us-gaap:SeriesAPreferredStockMember 2014-02-18 2014-02-18 0001560293 us-gaap:SeriesBPreferredStockMember 2014-02-18 2014-02-18 0001560293 2023-05-04 2023-05-04 0001560293 us-gaap:CommonStockMember tnon:AttheMarketOfferingProgramMember 2024-01-01 2024-06-30 0001560293 tnon:LincolnParkCapitalFundLLCMember 2023-07-24 2023-07-24 0001560293 tnon:LincolnParkCapitalFundLLCMember 2024-01-01 2024-06-30 0001560293 tnon:LincolnParkCapitalFundLLCMember 2024-06-30 0001560293 tnon:EquityLineOfCreditMember 2024-01-01 2024-06-30 0001560293 tnon:PurchaseAgreementMember tnon:SeriesAPreferredStockAndWarrantsMember 2024-02-20 2024-02-20 0001560293 tnon:PurchaseAgreementMember tnon:SeriesAPreferredStockAndWarrantsMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:CommonStockMember us-gaap:IPOMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:CommonStockMember 2024-02-20 2024-02-20 0001560293 tnon:ConvertibleNotePayableMember 2024-02-20 2024-02-20 0001560293 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-06-30 0001560293 tnon:MergerTransactionMember 2024-06-30 0001560293 tnon:TwoThousandAndTwelvePlanMember us-gaap:CommonStockMember 2021-04-30 0001560293 tnon:TwoThousandAndTwelvePlanMember us-gaap:CommonStockMember 2021-07-31 0001560293 srt:MinimumMember tnon:TwoThousandAndTwelvePlanMember us-gaap:CommonStockMember 2021-08-31 0001560293 srt:MaximumMember tnon:TwoThousandAndTwelvePlanMember us-gaap:CommonStockMember 2021-08-31 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember us-gaap:CommonStockMember 2022-01-10 2022-01-10 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember us-gaap:CommonStockMember 2022-02-02 2022-02-02 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2022-01-10 2022-01-10 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2022-02-02 2022-02-02 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2024-04-08 2024-04-08 0001560293 2024-04-08 2024-04-08 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2024-01-01 2024-06-30 0001560293 tnon:UnderwritingAgreementMember 2022-04-30 0001560293 us-gaap:WarrantMember 2022-04-30 0001560293 us-gaap:WarrantMember 2022-04-30 2022-04-30 0001560293 us-gaap:MeasurementInputExpectedTermMember 2022-04-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember 2022-04-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember 2022-04-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-30 0001560293 us-gaap:WarrantMember us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001560293 2023-06-01 2023-06-30 0001560293 us-gaap:WarrantMember 2023-07-16 2023-07-16 0001560293 us-gaap:MeasurementInputExpectedTermMember 2023-06-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember 2023-06-30 0001560293 us-gaap:WarrantMember 2023-11-30 0001560293 us-gaap:WarrantMember 2023-11-30 0001560293 us-gaap:WarrantMember 2023-11-30 0001560293 us-gaap:MeasurementInputExpectedTermMember 2023-11-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember 2023-11-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember 2023-11-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-11-30 0001560293 us-gaap:WarrantMember us-gaap:AdditionalPaidInCapitalMember 2023-11-30 0001560293 tnon:PurchaseAgreementMember tnon:SeriesAWarrantsMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember 2024-02-20 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:MeasurementInputExpectedTermMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:MeasurementInputOptionVolatilityMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-02-20 0001560293 tnon:PurchaseAgreementMember us-gaap:WarrantMember us-gaap:IPOMember 2024-02-20 0001560293 us-gaap:EmployeeStockOptionMember 2023-12-31 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001560293 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001560293 us-gaap:EmployeeStockOptionMember 2024-06-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001560293 tnon:SalesRepresentativeAgreementMember 2020-04-01 2020-04-30 0001560293 tnon:SalesRepresentativeAgreementMember 2021-05-31 0001560293 tnon:SalesRepresentativeAgreementMember 2021-05-01 2021-05-31 0001560293 tnon:SalesRepresentativeAgreementMember 2021-10-31 0001560293 tnon:SalesRepresentativeAgreementMember 2022-04-30 0001560293 tnon:SalesRepresentativeAgreementMember 2022-10-06 2022-10-06 0001560293 country:US tnon:TerminationAgreementMember 2022-10-06 0001560293 tnon:TerminationAgreementMember 2022-01-01 2022-12-31 0001560293 tnon:TerminationAgreementMember 2024-01-01 2024-06-30 0001560293 us-gaap:FairValueInputsLevel3Member tnon:TerminationAgreementMember 2024-01-01 2024-06-30 0001560293 tnon:ConsultingAgreementMember 2022-10-07 2023-10-05 0001560293 tnon:ConsultingAgreementMember 2023-10-05 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure EX-31.1 2 ea021094901ex31-1 tenon.htm CERTIFICATION EXHIBIT 31.1 A CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 A I, Steven Foster, certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of Tenon Medical, Inc.; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrantA's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A A (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A A A (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A A A (c) Evaluated the effectiveness of the registrantA's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A A A (d) Disclosed in this report any change in the registrantA's internal control over financial reporting that occurred during the registrantA's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantA's internal control over financial reporting; and A 5. The registrantA's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantA's auditors and the audit committee of the registrantA's board of directors (or persons performing the equivalent functions): A A (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantA's ability to record, process, summarize and report financial information; and A A A (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantA's internal control over financial reporting. A Date: August 13, 2024 A A s/ Steven Foster A Name: Steven Foster A Title: Chief Executive Officer and President A A (Principal Executive Officer) A A EX-31.2 3 ea021094901ex31-2 tenon.htm CERTIFICATION EXHIBIT 31.2 A CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 A I, Jay Hanson, certify that: A 1. I have reviewed this Quarterly Report on Form 10-Q of Tenon Medical, Inc.; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrantA's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A A (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A A A (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A A A (c) Evaluated the effectiveness of the registrantA's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A A A (d) Disclosed in this report any change in the registrantA's internal control over financial reporting that occurred during the registrantA's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantA's internal control over financial reporting; and A 5. The registrantA's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantA's auditors and the audit committee of the registrantA's board of directors (or persons performing the equivalent functions) A A (a) All

significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2024

/s/ Jay D. Hanson

Name: Jay D. Hanson

Title: Director of SEC Reporting and Compliance

(Principal Accounting Officer)

EX-32.1 ea021094901ex32-1

tenon.htm

CERTIFICATION EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Steven Foster, the Chief Executive Officer of Tenon Medical, Inc. (the "Company"), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Report") of the Company fully complies with the requirements of Section 13(a) and 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2024

/s/ Steven Foster

Name: Steven Foster

Title: Chief Executive Officer and President

(Principal Executive Officer)

EX-32.2 ea021094901ex32-2

tenon.htm

CERTIFICATION EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Steven Van Dick, the Chief Financial Officer of Tenon Medical, Inc. (the "Company"), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Report") of the Company fully complies with the requirements of Section 13(a)/15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2024

/s/ Jay D. Hanson

Name: Jay D. Hanson

Title: Director of SEC Reporting and Compliance

(Principal Accounting Officer)

EX-101.SCH 6

tnon-20240630.xsd

XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)

link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)

link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Alternate 0

link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)

link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Unaudited)

link:presentationLink link:definitionLink link:calculationLink 995306 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)

link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Organization and Business

link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Summary of Significant Accounting Principles

link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Fixed Assets, Net

link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Accrued Expenses

link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Debt

link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Leases

link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Stockholders' Equity

link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Commitments and Contingencies

link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Concentrations of Risk

link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies)

link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Summary of Significant Accounting Principles (Tables)

link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Fixed Assets, Net (Tables)

link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Accrued Expenses (Tables)

link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Leases (Tables)

link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Stockholders' Equity (Tables)

link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Commitments and Contingencies (Tables)

link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Summary of Significant Accounting Principles (Details)

link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Summary of Significant Accounting Principles (Details) - Schedule of Dilutive Common Stock Equivalents

link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Fixed Assets, Net (Details)

link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Fixed Assets, Net (Details) - Schedule of Fixed Assets, Net

link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Expenses

link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Debt (Details)

link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Leases (Details)

link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Leases (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases

link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Leases (Details) - Schedule of Future Maturities of Operating Lease Liabilities

link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Stockholders' Equity (Details)

link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Stockholders' Equity (Details) - Schedule of Stock Option and Restricted Stock Unit Activity

link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense Recognized

link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Commitments and Contingencies (Details)

link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Commitments and Contingencies (Details) - Schedule of Reconciliation of the Liability

link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information

link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7

tnon-20240630_cal.xml

XBRL CALCULATION FILE EX-101.DEF 6

tnon-20240630_def.xml

XBRL DEFINITION FILE EX-101.LAB 9

tnon-20240630_lab.xml

XBRL LABEL FILE

Total current assets

TOTAL ASSETS

Total current liabilities

Total liabilities

Class of Stock [Axis]

Total stockholders' equity

Balance Balance

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

Gross Profit

Total Operating Expenses

Loss from Operations

Total Other Income (Expense), net

Net Loss

net of debt discount

comprehensive loss

Balance (in Shares)

Balance (in Shares)

Equity Components [Axis]

Net cash used in operating activities

Net cash (used in) provided by investing activities

Net cash provided by financing activities

Net (Decrease) Increase in Cash and Cash Equivalents

Cash and Cash Equivalents at Beginning of Period

Cash and Cash Equivalents at End of Period

Organization and Business [Abstract]

Summary of Significant Accounting Principles [Abstract]

Antidilutive Securities [Axis]

Fixed Assets, Net [Abstract]

Long-Lived Tangible Asset [Axis]

Fixed assets, net

Accrued Expenses [Abstract]

Schedule of Accrued Expenses [Abstract]

Total accrued expenses

Accrued expenses

Debt [Abstract]

Leases [Abstract]

Schedule of Supplemental Balance Sheet Information Related to Leases [Abstract]

Total operating lease liabilities

Present value of operating lease liabilities

Schedule of Future Maturities of Operating Lease Liabilities [Abstract]

Total lease payments

Stockholders' Equity [Abstract]

Number of Shares Subject to Outstanding Stock Options, Beginning balance

Number of Shares Subject to Outstanding Stock Options, Ending balance

Weighted Average Exercise Price per Share, Beginning balance

Weighted Average Exercise Price per Share, Ending balance

Number of Outstanding Restricted Stock Units, Beginning balance

Number of Outstanding Restricted Stock Units, Ending balance

Weighted Average Grant Date Fair Value per Unit, Beginning balance

Weighted Average Grant Date Fair Value per Unit, Ending balance

Statement of Income Location, Balance [Axis]

Commitments and Contingencies [Abstract]

Schedule of Reconciliation of the Liability [Abstract]

Balance at beginning

Balance at ending

Concentrations of Risk [Abstract]

Assets

Current assets: Cash and cash equivalents

Accounts receivable, net

Inventory

Prepaid expenses and other current assets

Deposits

Operating lease right-of-use asset

Operating lease right-of-use assets

Deferred offering costs

Liabilities and Stockholders' equity

EQUITY

Current liabilities: Accounts payable

Current portion of accrued commissions

Current portion of operating lease liability

Operating lease liability, current

Convertible notes payable and accrued interest, net of debt discount of \$0 and \$77 at June 30, 2024 and December 31, 2023, respectively

Net of debt discount (in Dollars)

Accrued commissions, net of current portion

Operating lease liability, net of current portion

Operating lease liability, noncurrent

Commitments and contingencies (Note 8)

Stockholders' equity: Series A convertible preferred stock, \$0.001 par value; 4,500,000 shares authorized at June 30, 2024 and December 31, 2023; 256,968 and 0 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively

Stated value (in Dollars)

Preferred stock, par value per share (in Dollars per share)

Par value (in Dollars per share)

Preferred stock, shares authorized

Preferred stock shares authorized

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, \$0.001 par value; 130,000,000 shares authorized at June 30, 2024 and December 31, 2023; 3,780,827 and 2,600,311 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively

Common stock par or stated value per share (in Dollars per share)

Common stock par value (in Dollars per share)

Common stock shares authorized

Common stock shares outstanding

Common stock shares issued

Issued shares (in Shares)

Additional paid-in capital

Accumulated deficit

Accumulated other comprehensive loss

Revenue

Cost of sales

Operating Expenses

Research and development

Sales and marketing

Sales and marketing expense

General and administrative

Other Income (Expense)

Gain on investments

Other income (expense), net

Net Loss

Per Share of Common Stock Basic (in Dollars per share)

Diluted Weighted-Average Shares of Common Stock

Outstanding Basic (in Shares)

Diluted Consolidated Statements of Comprehensive Loss: Unrealized gain on investments

Foreign currency translation adjustment

Stock-based compensation expense

Release of restricted stock units

Release of restricted stock units (in Shares)

Issuance of common stock and warrants, net of issuance costs

Issuance of common stock and warrants, net of issuance costs (in Shares)

Other comprehensive income

Issuance of common stock, net of issuance costs

Issuance of common stock, net of issuance costs (in Shares)

Issuance of common stock

Issuance of series A convertible preferred stock, net of issuance costs (in Shares)

Cash Flows from Operating Activities

Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense

Depreciation and amortization

Provision for losses on accounts receivable

Amortization of operating right-of-use asset

Increase (decrease) in cash resulting from changes in: Accounts payable

Accrued expenses

Operating lease liability

Cash Flows from Investing Activities

Sales of short-term investments

Cash Flows from Financing Activities

Proceeds from issuance of Series A Convertible Preferred Stock, net

Proceeds from issuance of common stock, net

Gross proceeds from sale of common stock (in Dollars)

Effect of foreign currency translation on cash flow

Supplemental Disclosures of Cash Flow Information

Non-cash investing and financing activities: Preferred stock issued upon conversion of debt and accrued interest

Reclassification of deferred offering costs to additional paid-in capital

Interest expense

Issuance of series A convertible preferred stock, net of issuance costs

Accounts receivable

Inventory

Prepaid expenses and other assets

Purchases of short-term investments

Purchases of property and equipment

Proceeds from issuance of common stock and warrants, net of issuance costs

Deferred offering costs

Series A Convertible Preferred Stock

Series A Preferred Stock [Member]

Series A Convertible Preferred Stock

Common Stock

Common stock [Member]

Common Stock [Member]

Additional Paid-In Capital

Additional Paid-in Capital [Member]

Accumulated Deficit

Accumulated Other Comprehensive Loss

Organization and Business

Summary of Significant Accounting Principles

Schedule of Dilutive Common Stock Equivalents

Antidilutive Securities

Excluded from Computation of Earnings Per Share

Fixed Assets, net

Schedule of Fixed Assets, Net

Fixed assets, gross

Accrued Expenses

Schedule of Accrued Expenses

Accrued compensation

Other accrued expenses

Debt

Leases

Schedule of Supplemental Balance Sheet Information Related to Leases

Schedule of Future Maturities of Operating Lease Liabilities

2024

2025

2026

Cash paid for operating leases

Remaining lease term - operating leases (in years)

Average discount rate - operating leases

Stockholders' Equity

Schedule of Stock Option and Restricted Stock Unit Activity

Number of Shares Subject to Outstanding Stock Options, Granted

Weighted Average Exercise Price per Share, Granted

Number of Outstanding Restricted Stock Units, Granted

Weighted Average Grant Date Fair Value per Unit, Granted

Weighted Average Exercise Price per Share, Released

Number of Outstanding Restricted Stock Units, Released

Weighted Average Exercise Price per Share, Forfeited

Weighted Average Grant Date Fair Value per Unit, Forfeited

Schedule of Stock-Based Compensation Expense Recognized

Total stock-based compensation expense

Commitments and Contingencies

Schedule of Reconciliation of the Liability

Accretion

Concentrations of Risk

Less: accumulated depreciation

Less: imputed interest

Number of Shares Subject to Outstanding Stock Options, Released

Weighted Average Grant Date Fair Value per Unit, Released

Number of Shares Subject to Outstanding Stock Options, Forfeited

Number of Outstanding Restricted Stock Units, Forfeited

Amounts paid during 2024

Outstanding restricted stock units [Member]

Outstanding stock options [Member]

Stock Options [Member]

Outstanding

warrants [Member] Warrant [Member] Common shares convertible from preferred stock [Member] Construction in progress [Member] Catamaran tray sets [Member] IT equipment [Member] Leasehold improvements [Member] Lab equipment [Member] Office furniture [Member] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Research and development [Member] Sales and marketing [Member] General, and administrative [Member] Statistical Measurement [Axis] Debt Instrument [Axis] Class of Warrant or Right [Axis] Trading Activity [Axis] Credit Facility [Axis] Short-Term Debt, Type [Axis] Agreement [Axis] Sale of Stock [Axis] Business Acquisition [Axis] Plan Name [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Measurement Input Type [Axis] Geographical [Axis] Fair Value Hierarchy and NAV [Axis] Price per share Reverse stock split ratio Percentage of valuation allowance in deferred tax assets Depreciation expense Debt instrument principal amount (in Dollars) Purchase of warrant Warrant exercise price (in Dollars per share) Exercise price (in Dollars per share) Interest rate Default interest rate Maturity date Warrant term Operating lease term Operating lease costs Preferred stock, designated shares Percentage of gross proceeds Common stock sold Weighted average price (in Dollars per share) Net of issuance costs (in Dollars) Line of credit (in Dollars) Closing price of common stock (in Dollars per share) Conversion rate description Purchase exceed amount (in Dollars) Purchase of shares Percentage of outstanding shares Net proceeds (in Dollars) Issued offering warrants Common stock exercise price (in Dollars per share) Aggregate offering price (in Dollars) Conversion shares Description of series A preferred stock Equity percentage Percentage of shares issued to stockholders Deemed liquidation percentage Increased percentage of deemed liquidation Transaction excess amount (in Dollars) Number of shares of common stock reserved for issuance Options were cancelled Fair value vested issuance (in Dollars) Purchase of warrant shares Weighted-average grant-date fair value of options granted (in Dollars per share) Fair value of warrant Issuance cost (in Dollars) Expiration date Fair value of warrant grant date (in Dollars per share) Fair value of per warrant grant date (in Dollars per share) Fair value price (in Dollars per share) Daily return rate Short-term annual volatility Standard deviation Agreement term Agreement additional extension term Cash paid Equity ownership percent Fair value Bonus paid Payment amount per month Net sales percentage Sales percentage Net sales amount Amount paid Payment to company Growth rates of fair value of liability Dissolution rate of fair value of liability Estimated discount rate Ultimately expects to expense Consulting fee Additional compensation payable per quarter (in Dollars per share) Basis of presentation Going concern uncertainty and liquidity requirements Notice from Nasdaq Use of estimates Reverse Stock Splits Income Taxes Net loss per share Recent Accounting Pronouncements Not Yet Adopted Minimum [Member] Maximum [Member] Convertible Note Payable [Member] Series B Preferred Stock [Member] At-the-Market Offering Program [Member] Lincoln Park Capital Fund, LLC [Member] Equity Line of Credit [Member] Purchase Agreement [Member] Series A Preferred Stock and Warrants [Member] IPO [Member] Merger Transaction [Member] 2012 Plan [Member] 2022 Plan [Member] Underwriting Agreement [Member] Expected Term [Member] Expected Volatility [Member] Dividend Yield [Member] Risk-Free Interest Rate [Member] Series A Warrants [Member] Sales Representative Agreement [Member] Restated Sales Agreement [Member] Termination Agreement [Member] United States [Member] Level 3 [Member] Consulting Agreement [Member] Class of Stock [Domain] Statement [Table] Statement [Line Items] Equity Component [Domain] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Dilutive Common Stock Equivalents [Line Items] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment [Table] Schedule of Fixed Assets, Net [Line Items] Award Type [Domain] Stockholders' Equity (Details) - Schedule of Stock Option and Restricted Stock Unit Activity [Table] Schedule of Stock Option and Restricted Stock Unit Activity under its Plans [Line Items] Statement of Income Location, Balance [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Stock-Based Compensation Expense Recognized [Line Items] Statistical Measurement [Domain] Summary of Significant Accounting Principles (Details) [Table] Summary of Significant Accounting Principles [Line Items] Debt Instrument, Name [Domain] Class of Warrant or Right [Domain] Debt (Details) [Table] Debt [Line Items] Credit Facility [Domain] Short-Term Debt, Type [Domain] Plan Name [Domain] Trading Activity, by Type [Domain] Sale of Stock [Domain] AgreementDomain [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Business Acquisition, Acquiree [Domain] Measurement Input Type [Domain] Stockholders' Equity (Details) [Table] Stockholders' Equity [Line Items] Geographical [Domain] Fair Value Hierarchy and NAV [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Accrued commissions current. Accrued commissions non current. Additional compensation payable per quarter. The amount of aggregate offering price. Agreement additional extension term. Agreement term. As per agreement value to pay the representative in the event of acquisition net of previous amount paid. Class of warrants of rights grant date fair value of warrants . Percentage of deemed liquidation. Description of series A preferred stock. Dissolution rate of fair value of liability. Equity ownership percentage. Fair value of offering warrant. Going concern uncertainties and liquidity requirements. Growth Rates Of Fair Value Of Liability. Increased percentage of deemed liquidation. The amount of products net sales. Disclosure of accounting policy of Notice from Nasdaq. Payment amount per month. Payment to representative as per agreement. Payments for deferred offering costs. Percentage of commission to net sales agreed to pay the representative until aggregate amount paid. Amount of percentage of gross proceeds. Percentage of net sales of the product sold agreed to pay the representative. Percentage of outstanding shares. Percentage of shares issued to stockholders. Percentage of valuation allowance in deferred tax assets. Number of preferred stock, designated shares. Proceeds from issuance of common stock and warrants, net of issuance costs. Purchase exceed amount. Reclassification of deferred offering costs to additional paid-in capital. Tabular disclosure of reconciliation of liability. Number of restricted stock units released. Weighted average grant date fair value per share, released. The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares. The risk-free interest rate assumption that is used in valuing an option on its own shares. The number of shares under options that were released during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Shares of issuance of common stock and warrants, net of issuance costs. Weighted average price under the program common stock. Agreement. Amended and restated exclusive sales representative agreement. Catamaran Tray Sets Consulting agreement. Lab Equipment Member Sales Representative Agreement. Series A Convertible Preferred Stock [Member] Termination agreement. Two thousand and twenty two equity incentive plan. Underwriting agreement. Agreement Additional Extension Term Convertible Notes Payable, Current Stockholders' Equity, Reverse Stock Split Weighted Average Price Under The Program Common Stock Payment To Representative As Per Agreement Lab Equipment Member Use of Estimates, Policy [Policy Text Block] Assets [Abstract] Commitments and Contingencies Series A Preferred Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Common Stock, Value, Issued Earnings Per Share, Diluted Retained Earnings [Member] Schedule Of Reconciliation Of The Liability Table Text Block Series AConvertible Preferred Stock Member Lessee, Operating Lease, Remaining Lease Term Reclassification Of Deferred Offering Costs To Additional Paidin Capital Growth Rates Of Fair Value Of Liability Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Weighted Average Number of Shares Outstanding, Basic [Abstract] Operating Lease, Payments Series B Preferred Stock [Member] Weighted Average Number of Shares Outstanding, Basic As Per Agreement Value To Pay The Representative In The Event Of Acquisition Net Of Previous Amount Paid OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Description Of Series APreferred Stock Increase (Decrease) in Prepaid Expense and Other Assets IPO [Member] Other Nonoperating Income (Expense) Agreement Term Statement of Stockholders' Equity [Abstract] Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Percentage Of Shares Issued To Stockholders Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Proceeds from Issuance of Preferred Stock and Preference Stock Debt Conversion, Original Debt, Amount Dissolution Rate Of Fair Value Of Liability Concentration Risk Disclosure [Text Block] Equipment [Member] Research and Development Expense [Member] Income Statement [Abstract] Stock Issued During Period, Shares, New Issues Lessee, Operating Leases [Text Block] Equity Line Of Credit Member Convertible Preferred Stock [Member] New Accounting Pronouncements, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Additional Paid in Capital Operating Expenses [Abstract] Supplemental Cash Flow Information [Abstract] Earnings Per Share, Basic Warrants and Rights Outstanding Net Cash Provided by (Used in) Operating Activities [Abstract] Two Thousand And Twenty Two Equity Incentive Plan Member Assets Liabilities Research and Development Expense Accrued Commissions Current Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Termination Agreement Member Construction in Progress [Member] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Debt Disclosure [Text Block] Minimum [Member] Common Stock, Shares, Outstanding Additional Compensation Per Quarter Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retained Earnings (Accumulated Deficit) Increase (Decrease) in Inventories Depreciation Net Cash Provided by (Used in) Investing Activities Schedule Of Stock Option And Restricted Stock Unit Activity Abstract Payments for Other Fees Warrants and Rights Outstanding, Measurement Input Debt Conversion, Converted Instrument, Shares Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Unlabeled Abstract11 Payments to Acquire Property, Plant, and Equipment Stockholders' Equity, Policy [Policy Text Block] Unlabeled Abstract12 Unlabeled Abstract10 Payments to Acquire Short-Term Investments Warrants and Rights Outstanding, Term Preferred Stock, Shares Authorized Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Standarddeviation Preferred Stock, Shares Outstanding Property, Plant and Equipment, Net Prepaid Expense and Other Assets, Current Stock Issued During Period Shares Issuance Of Common Stock And Warrants Net Of Issuance Costs Stock Option, Exercise Price, Increase Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Increase (Decrease) in Accrued Liabilities Income Tax, Policy [Policy Text Block] Maximum [Member] Fair Value Of Offering Warrant UNITED STATES Common Stock, Shares Authorized Short-Term Debt, Percentage Bearing Fixed Interest Rate Property, Plant and Equipment, Gross Catamaran Tray Sets Member Employee-related Liabilities, Current Operating Lease, Liability, Noncurrent Interest Expense, Nonoperating Deemed Liquidation Percentage Other Accrued Liabilities, Current Operating Lease, Weighted Average Discount Rate, Percent Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Warrant [Member] Schedule of Accrued Liabilities [Table Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Accounts Receivable, Credit Loss Expense (Reversal) Equity Ownership Percentage Stock Issued During Period, Shares, Purchase of Assets Sale of Stock, Consideration Received on Transaction Class of Warrant or Right, Number of Securities Called by Warrants or Rights Leasehold Improvements [Member] Payment Amount Per Month Proceeds from Sale, Maturity and Collection of Investments Series APreferred Stock And Warrants Member Restricted Stock [Member] Operating Income (Loss) Selling and Marketing Expense Net Cash Provided by (Used in) Investing Activities [Abstract] Lincoln Park Capital Fund LLCMember Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Purchase Agreement Member Operating Lease, Liability Underwriting Agreement Member Stock Issued During Period, Shares, Restricted Stock Award, Gross Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Convertible Note Payable Member Significant Accounting Policies [Text Block] Debt Instrument, Interest Rate, Stated Percentage Other Income and Expenses [Abstract] Sale of Stock, Price Per Share Common Stock [Member] Unlabeled Abstract3 Unlabeled Abstract2 Unlabeled Abstract5 Schedule Of Fixed Assets Net Abstract Unlabeled Abstract4 AOCI Attributable to Parent [Member] Unlabeled Abstract1 Statement of Cash Flows [Abstract] Unlabeled Abstract0 Class of Warrant or Right, Outstanding Gain (Loss) on Investments Unlabeled Abstract7 Measurement Input, Risk Free Interest Rate [Member] Operating Lease, Liability, Current Unlabeled Abstract6 Lessee, Operating Lease, Liability, to be Paid, Year Two Common Stock, Capital Shares Reserved for Future Issuance Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unlabeled Abstract9 Unlabeled Abstract8 Debt Instrument, Unamortized Discount, Current Noncash Investing and Financing Items [Abstract] Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Arrangement by

Share-Based Payment Award, Options, Expirations in Period Class Of Warrants Grant Date Fair Value Of Warrants Purchase Exceed Amount Sales Representative Agreement Member Loss Contingency Accrual, Provision Schedule Of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Accrued Bonuses Liabilities, Current [Abstract] Net Cash Provided by (Used in) Operating Activities Stock Issued During Period, Value, Conversion of Units Measurement Input, Option Volatility [Member] Increased Percentage Of Deemed Liquidation Preferred Stock Designated Shares APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Released In Period Stock Issued During Period, Shares, Other Office Equipment [Member] General and Administrative Expense [Member] Operating Lease, Right-of-Use Asset, Periodic Reduction Loss Contingency Accrual Two Thousand Twelve Plan Member Lessee, Operating Lease, Term of Contract Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Percentage Of Gross Proceeds Equity, Attributable to Parent Measurement Input, Expected Dividend Rate [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Nature of Operations [Text Block] Going Concern Uncertainties And Liquidity Requirements Policy Text Block Accumulated Other Comprehensive Income (Loss), Net of Tax Statement of Comprehensive Income [Abstract] Revenues Share Price Other Expenses Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value Restricted Stock Units (RSUs) [Member] Operating Lease, Cost Class of Warrant or Right, Number of Securities Called by Each Warrant or Right General and Administrative Expense Earnings Per Share [Abstract] Depreciation, Depletion and Amortization Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule Of Stock Based Compensation Expense Recognized Abstract Unlabeled Abstract Common Stock, Par or Stated Value Per Share Related Party Transaction, Amounts of Transaction Earnings Per Share, Policy [Policy Text Block] Common Stock, Shares, Issued Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Amended And Restated Exclusive Sales Representative Agreement Member Loss Contingency Accrual, Payments Weighted Average Number of Shares Outstanding, Diluted Gross Profit Agreement Axis Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs Property, Plant and Equipment Disclosure [Text Block] Selling and Marketing Expense [Member] Accounts Receivable, after Allowance for Credit Loss, Current Lessee, Operating Lease, Liability, to be Paid Share-Based Payment Arrangement, Option, Activity [Table Text Block] Percentage Of Valuation Allowance In Deferred Tax Assets Line of Credit Facility, Average Outstanding Amount Share Based Compensation Arrangements By Share Based Payment Award Options Released In Period Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Equity [Text Block] Stock Issued During Period, Value, Restricted Stock Award, Gross Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Debt Instrument, Face Amount Sale of Stock, Number of Shares Issued in Transaction Assets, Current [Abstract] Series A Warrants Member Cash Net Sales Amount Of The Product Property, Plant and Equipment [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Notice From Nasdaq Policy Text Block Liabilities, Current Operating Expenses Increase (Decrease) in Accounts Payable Consulting Agreement Member Statement of Financial Position [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Proceeds from Debt, Net of Issuance Costs Schedule Of Dilutive Common Stock Equivalents Abstract Cash and Cash Equivalents, at Carrying Value Accrued Liabilities, Current Other Current Assets [Text Block] Aggregate Offering Price Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] Measurement Input, Expected Term [Member] Servicing Assets and Servicing Liabilities at Fair Value, Assumptions Used to Estimate Fair Value, Discount Rate Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Daily Return Rate Common Stock, Conversion Basis Increase (Decrease) in Accounts Receivable At the Market Offering Program Member Cost of Revenue Proceeds from Issuance of Common Stock Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Deposits Assets, Noncurrent Class of Warrant or Right, Exercise Price of Warrants or Rights Condensed Balance Sheet [Table Text Block] Deferred Costs, Noncurrent Preferred Stock, Value, Issued Liabilities and Equity Lessee, Operating Lease, Liability, Undiscounted Excess Amount Debt Instrument, Maturity Date Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Nonoperating Income (Expense) Share-Based Payment Arrangement, Noncash Expense Percentage Of Outstanding Shares Percentage Of Net Sales Of The Product Sold Agreed To Pay The Representative Percentage Of Commission To Net Sales Agreed To Pay The Representative Until Aggregate Amount Paid Payments For Deferred Offering Costs Preferred Stock, Par or Stated Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Merger Transaction Member Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Stock Issued During Period, Value, Other Operating Lease, Right-of-Use Asset Assets, Current Inventory, Net Accrued Commissions Noncurrent Equity, Fair Value Disclosure EX-101.PRE 10 tnon-20240630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 13, 2024 Document Information [Line Items] Å Å Document Type 10-Q Å Document Quarterly Report true Å Document Transition Report false Å Entity Interactive Data Current Yes Å Amendment Flag false Å Document Period End Date Jun. 30, 2024 Å Document Fiscal Year Focus 2024 Å Document Fiscal Period Focus Q2 Å Entity Information [Line Items] Å Å Entity Registrant Name TENON MEDICAL, INC. Å Entity Central Index Key 0001560293 Å Entity File Number 001-41364 Å Entity Tax Identification Number 45-5574718 Å Entity Incorporation, State or Country Code DE Å Current Fiscal Year End Date --12-31 Å Entity Current Reporting Status Yes Å Entity Shell Company false Å Entity Filer Category Non-accelerated Filer Å Entity Small Business true Å Entity Emerging Growth Company true Å Entity Ex Transition Period false Å Entity Contact Personnel [Line Items] Å Å Entity Address, Address Line One 104 Cooper Court Å Entity Address, City or Town Los Gatos Å Entity Address, Country CA Å Entity Address, Postal Zip Code 95032 Å Entity Phone Fax Numbers [Line Items] Å Å City Area Code (408) Å Local Phone Number 649-5760 Å Entity Listings [Line Items] Å Å Title of 12(b) Security Common Stock, par value \$0.001 per share Å Trading Symbol TNON Å Security Exchange Name NASDAQ Å Entity Common Stock, Shares Outstanding Å 3,951,767 X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a quarterly report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef - Publisher SEC - Name Form 10-Q - Number 240 - Section 308 - Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef - Publisher SEC - Name Forms 10-K, 10-Q, 20-F - Number 240 - Section 13 - Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition ISO 3166-1 alpha-2 country code. + References No definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef - Publisher SEC - Name Exchange Act - Number 240 - Section 12 - Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef - Publisher SEC - Name Exchange Act - Number 240 - Section 12 - Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef - Publisher SEC - Name Securities Act - Number 7A - Section B - Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name:

dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:)

dei_EntityFileCategory Namespace Prefix: dei_Data Type: dei:fileCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: [\text{\\\$} Cash and cash equivalents \$\text{\\$}\$ 1,968 \$\text{\\$}\$ 2,428 Accounts receivable, net 679 518 Inventory 609 554 Prepaid expenses and other current assets 831 389 Total current assets 4,087 3,889 Fixed assets, net 904 961 Deposits 51 51 Operating lease right-of-use asset 525 646 Deferred offering costs 439 798 TOTAL ASSETS 6,006 6,345 Current liabilities: \$\text{\\$}\$ Accounts payable 1,111 433 Accrued expenses 932 808 Current portion of accrued commissions 1,089 470 Current portion of operating lease liability 271 256 Convertible notes payable and accrued interest, net of debt discount of \$\text{\\$}\$ 0 and \$\text{\\$}\$ 77 at June 30, 2024 and December 31, 2023, respectively 1,173 Total current liabilities 3,403 3,140 Accrued commissions, net of current portion 1,481 1,999 Operating lease liability, net of current portion 290 428 Total liabilities 5,174 5,567 Commitments and contingencies \(Note 8\) Stockholders' equity: \$\text{\\$}\$ Common stock, \$\text{\\$}\$ 0.001 par value; 130,000,000 shares authorized at June 30, 2024 and December 31, 2023; 3,780,827 and 2,600,311 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 4 3 Additional paid-in capital 60,003 55,894 Accumulated deficit \(62,475\) \(55,073\) Accumulated other comprehensive loss \(46\) Total stockholders' equity 832 778 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 6,006 6,345 Series A Convertible Preferred Stock \$\text{\\$}\$ A Stockholders' equity: \$\text{\\$}\$ A Series A convertible preferred stock, \$\text{\\$}\$ 0.001 par value; 4,500,000 shares authorized at June 30, 2024 and December 31, 2023; 256,968 and 0 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively \$\text{\\$}\$ 3,300 X - DefinitionAccrued commissions current. + ReferencesNo definition available. + Details Name: tnon_AccruedCommissionsCurrent Namespace Prefix: tnon_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAccrued commissions non current. + ReferencesNo definition available. + Details Name: tnon_AccruedCommissionsNoncurrent Namespace Prefix: tnon_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred \(and for which invoices have typically been received\) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + ReferencesReference 1: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \\(c\\) -\]\(http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: <a href=\)](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <a href=)

Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 12: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible

Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details> Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(17\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(10\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(10))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1+Details> Name: us-gaap_DeferredCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(17\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details> Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2>: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(6))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details> Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))) -SubTopic 10-Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(26\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(26))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(23\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(23))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15): <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(14\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29): [http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(d\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30+Details](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30+Details) Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(25\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(25))-Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(23\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(23))-Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(32\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(32))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details) Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8): <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12):

1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 21: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementOfClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Net of debt discount (in Dollars) \$ 0 \$ 77 Common stock par or stated value per share (in Dollars per share) \$ 0.001 \$ 0.001 Common stock shares authorized 130,000,000 130,000,000 Common stock shares outstanding 3,780,827 2,600,311 Common stock shares issued 3,780,827 2,600,311 Series A Convertible Preferred Stock A A Preferred stock, par value per share (in Dollars per share) \$ 0.001 \$ 0.001 Preferred stock, shares authorized 4,500,000 4,500,000 Preferred stock, shares issued 256,968 0 Preferred stock, shares outstanding 256,968 0 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAmount of debt discount to be amortized within one year or within the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1> + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_PREFERREDStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PREFERREDStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_PREFERREDStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPREFERREDStockMember Namespace Prefix: Data Type: na Balance Type: na Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Á Á Á Revenue \$ 901 \$ 743 \$ 1,620 \$ 1,176 Cost of sales 431 549 680 1,029 Gross Profit 470 194 940 147 Operating Expenses Á Á Á Research and development 708 901 1,377 1,735 Sales and marketing 1,448 1,883 2,829 3,909 General and administrative 2,186 1,732 4,112 3,711 Total Operating Expenses 4,342 4,516 8,318 9,355 Loss from Operations (3,872) (4,322) (7,378) (9,208) Other Income (Expense) Á Á Á Gain on investments 39 37 66 93 Interest expense (34) Other income (expense), net 7 (56) Total Other Income (Expense), net 46 37 (24) 93 Net Loss \$ (3,826) \$ (4,285) \$ (7,402) \$ (9,115) Net Loss Per Share of Common Stock Á Á Á Basic (in Dollars per share) \$ (1.02) \$ (3.28) \$ (2.24) \$ (7.5) Weighted-Average Shares of Common Stock Outstanding Á Á Á Basic (in Shares) 3,749 1,305 3,301 1,215 Consolidated Statements of Comprehensive Loss: Á Á Á Net loss \$ (3,826) \$ (4,285) \$ (7,402) \$ (9,115) Unrealized gain on investments 3 16 Foreign currency translation adjustment 13 46 12 Total comprehensive loss \$ (3,826) \$ (4,269) \$ (7,356) \$ (9,087) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5> + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B ->

Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of realized and unrealized gain (loss) on investment. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 3: [http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_GainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1) + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 23: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type:

xbxrl:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbxrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbxrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbxrl:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbxrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbxrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(a\) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1) + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbxrl:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11> + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbxrl:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbxrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)

10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 21: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 23: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - \$ / shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Á Á Á Á Diluted \$ (1.02) \$ (3.28) \$ (2.24) \$ (7.50) Diluted 3,749 1,305 3,301 1,215 X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2): <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Convertible Preferred Stock and Stockholdersâ€™ Equity (Unaudited) - USD (\$) \$ in Thousands Series A Convertible Preferred Stock Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Balance at Dec. 31, 2022 \$ 1 45,843 \$ (39,492) \$ (100) \$ 6,252 Balance (in Shares) at Dec. 31, 2022 \$ 1,123,680 \$ \$ \$ Stock-based compensation expense 2,094 2,094 Release of restricted stock units Release of restricted stock units (in Shares) \$ 38,695 \$ \$ \$ Issuance of common stock and warrants, net of issuance costs \$ 1 1,643 1,644 Issuance of common stock and warrants, net of issuance costs (in Shares) \$ 1,000,000 \$ \$ \$ \$ Other comprehensive income 28 12 Net loss (9,115) (9,115) Balance at Jun. 30, 2023 \$ 2 49,580 (48,607) (72) 903 Balance (in Shares) at Jun. 30, 2023 \$ 2,162,375 \$ \$ \$ Balance at Mar. 31, 2023 \$ 1 46,883 (44,322) (88) 2,474 Balance (in Shares) at Mar. 31, 2023 \$ 1,125,128 \$ \$ \$ Stock-based compensation expense 1,054 1,054 Release of restricted stock units \$ \$ Release of restricted stock units (in Shares) \$ 37,247 \$ \$ \$ Issuance of common stock and warrants, net of issuance costs \$ 1 1,643 1,644 Issuance of common stock and warrants, net of issuance costs (in Shares) \$ 1,000,000 \$ \$ \$ Other comprehensive income 16 16 Net loss (4,285) (4,285) Balance at Jun. 30, 2023 \$ 2 49,580 (48,607) (72) 903 Balance (in Shares) at Jun. 30, 2023 \$ 2,162,375 \$ \$ \$ Balance at Dec. 31, 2023 \$ 3 55,894 (55,073) (46) 778 Balance (in Shares) at Dec. 31, 2023 \$ 2,600,311 \$ \$ \$ \$ Stock-based compensation expense 2,052 2,052 Issuance of common stock, net of issuance costs \$ 1 1,803 1,804 Issuance of common stock, net of issuance costs (in Shares) \$ 1,123,439 \$ \$ \$ Issuance of series A convertible preferred stock, net of issuance costs \$ 3,300 254 3,554 Issuance of series A convertible preferred stock, net of issuance costs (in Shares) 256,968 \$ \$ \$ Release of restricted stock units Release of restricted stock units (in Shares) \$ 57,077 \$ \$ \$ Other comprehensive income 46 46 Net loss (7,402) (7,402) Balance at Jun. 30, 2024 \$ 3,300 \$ 4 60,003 (62,475) 832 Balance (in Shares) at Jun. 30, 2024 256,968 3,780,827 \$ \$ \$ \$ Balance at Mar. 31, 2024 \$ 3,300 \$ 4 58,969 (58,649) 3,624 Balance (in Shares) at Mar. 31, 2024 256,968 3,726,974 \$ \$ \$ \$ Stock-based compensation expense 1,034 1,034 Release of restricted stock units Release of restricted stock units (in Shares) \$ 53,853 \$ \$ \$ Net loss (3,826) (3,826) Balance at Jun. 30, 2024 \$ 3,300 \$ 4 \$ 60,003 \$ (62,475) \$ 832 Balance (in Shares) at Jun. 30, 2024 256,968 3,780,827 \$ \$ \$ X - DefinitionShares of issuance of common stock and warrants, net of issuance costs. + ReferencesNo definition available. + Details Name: tnon_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts Namespace Prefix: tnon_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8): [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9): <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12): [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 14>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15): [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17>: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph \(c\)\(3\) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 6)

Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A> + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of preferred stock and warrants for common stock issued. + ReferencesNo definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference> 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) \$ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash Flows from Operating Activities Á Á Net loss \$ (7,402) \$ (9,115) Adjustments to reconcile net loss to net cash used in operating activities: Á Á Stock-based compensation expense 2,052 2,094 Depreciation and amortization 189 60 Provision for losses on accounts receivable 46 Amortization of operating right-of-use asset 121 111 Increase (decrease) in cash resulting from changes in: Á Á Accounts receivable (207) (373) Inventory (55) (155) Prepaid expenses and other assets (442) (325) Accounts payable 678 362 Accrued expenses 385 698 Operating lease liability (123) (109) Net cash used in operating activities (4,758) (6,752) Cash Flows from Investing Activities Á Á Sales of short-term investments 6,503 Purchases of short-term investments (493) Purchases of property and equipment (119) (212) Net cash (used in) provided by investing activities (119) 5,798 Cash Flows from Financing Activities Á Á Proceeds from issuance of Series A Convertible Preferred Stock, net 2,437 Proceeds from issuance of common stock, net 1,934 Proceeds from issuance of common stock and warrants, net of issuance costs 4,808 Deferred offering costs (143) Net cash provided by financing activities 4,371 4,665 Effect of foreign currency translation on cash flow 46 12 Net (Decrease) Increase in Cash and Cash Equivalents (460) 3,723 Cash and Cash Equivalents at Beginning of Period 2,428 2,129 Cash and Cash Equivalents at End of Period 1,968 5,852 Non-cash investing and financing activities: Á Á Preferred stock issued upon conversion of debt and accrued interest 1,186 Reclassification of deferred offering costs to additional paid-in capital \$ 130 X - DefinitionPayments for deferred offering costs. + ReferencesNo definition available. + Details Name: tnon_PaymentsForDeferredOfferingCosts Namespace Prefix: tnon_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from issuance of common stock and warrants, net of issuance costs. + ReferencesNo definition available. + Details Name: tnon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts Namespace Prefix: tnon_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReclassification of deferred offering costs to additional paid-in capital. + ReferencesNo definition available. + Details Name: tnon_ReclassificationOfDeferredOfferingCostsToAdditionalPaidInCapital Namespace Prefix: tnon_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to,

currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionOriginalDebtAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1:

Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireShortTermInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Business 6 Months Ended Jun. 30, 2024 Organization and Business [Abstract] Á Organization and Business 1. Organization and Business Á Nature of operations Á Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran[®], a SI Joint Fusion System (the “Catamaran System”) that offers a novel, less invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (the “FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct. Á Principles of consolidation Á The condensed consolidated financial statements of the Company for the three and six months ended June 30, 2023 and as of December 31, 2023 include the accounts of its wholly-owned subsidiary, Tenon Technology AG (the “TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. In 2024, TTAG was dissolved and, as such, the financial statements for the three and six months ended June 30, 2024 and as of June 30, 2024 only include the accounts of the Company. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Principles 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Principles [Abstract] Á Summary of Significant Accounting Principles 2. Summary of Significant Accounting Principles Á Basis of presentation Á The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”). Á The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company’s audited consolidated financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 29, 2024. Á These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022 included in its Annual Report of Form 10-K

filed with the SEC on March 29, 2024. Â These condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements and, in managementâ€™s opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. Â The Companyâ€™s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022. There have been no material changes in the Companyâ€™s significant accounting policies during the six months ended June 30, 2024.Â Going concern uncertainty and liquidity requirements Â The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Companyâ€™s ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued. Â Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. Based on the Companyâ€™s expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of June 30, 2024 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Â Notice from Nasdaq Â On May 7, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (â€œNasdaqâ€) stating that for the 30 consecutive business day period between March 25, 2024 and May 6, 2024, the common stock of the Company had not maintained a minimum closing bid price of \$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the â€œBid Price Ruleâ€). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until November 4, 2024 (the â€œCompliance Periodâ€), to regain compliance with the Bid Price Rule. Â If the Company does not regain compliance with the Bid Price Rule by November 4, 2024, the Company may be eligible for an additional 180-day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. Â If the Company cannot regain compliance during the Compliance Period or any subsequently granted compliance period, the common stock of the Company will be subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel. Â The notice from Nasdaq has no immediate effect on the listing of the Companyâ€™s common stock. The Company is currently evaluating its options for regaining compliance. On December 21, 2023, the Companyâ€™s shareholders approved an amendment to its Certificate of Incorporation to provide for a reverse stock split in a ratio ranging from one for two (1:2) to one for fifty (1:50) at the discretion of the Companyâ€™s Board of Directors. Â Use of estimates Â The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, allowance for credit losses, and stock-based compensation. Â Reverse Stock Split Â On November 2, 2023, the Company effected a 1-for-10 reverse stock split by filing an amendment to the Companyâ€™s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The reverse stock split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the reverse stock split into one share of common stock. No fractional shares were issued in connection with the reverse stock split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the reverse stock split. The authorized number of shares and the par value per share of the Companyâ€™s common stock were not affected by the reverse stock split.Â Income Taxes Â The Company accounts for income taxes utilizing ASC 740, â€œIncome Taxesâ€. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Companyâ€™s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Â Net loss per share Â Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that certain potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Companyâ€™s weighted average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive. Â The Company had the following dilutive common stock equivalents as of June 30, 2024 and 2023 which were excluded from the calculation because their effect was anti-dilutive:Â Â Â June 30, 2024Â Â June 30, 2023Â Outstanding restricted stock unitsÂ Â 136,690Â Â 93,156Â Outstanding stock optionsÂ Â 72,563Â Â 96,934Â Outstanding warrantsÂ Â 2,388,068Â Â 2,009,600Â Common shares convertible from preferred stockÂ Â 2,625,016Â Â â€”Â TotalÂ Â 5,222,337Â Â 2,199,690Â Â Recent Accounting Pronouncements Not Yet Adopted Â In November 2023, the Financial Accounting Standards Board (the â€œFASBâ€) issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which increases the disclosures about reportable segments including more detailed information about a reportable segmentâ€™s expenses. This guidance will be effective for the Company for the fiscal year ending December 31, 2024 and the interim periods thereafter, with early adoption permitted. The guidance will have no effect on the Companyâ€™s results of operations as the changes are disclosure related. The Company has elected not to early adopt. Â In December 2023, the FASB issued Accounting Standards Update 2023-09, â€œIncome Taxes (Topic 740) - Improvements to Income Tax Disclosuresâ€, which requires additional tax disclosures about a reporting entityâ€™s effective tax rate reconciliation as well as information on income taxes paid. This guidance will be effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent +Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fixed Assets, Net 6 Months Ended Jun. 30, 2024 Fixed Assets, Net [Abstract] Â Fixed Assets, net 3. Fixed Assets, Net Â Fixed assets, net, consisted of the following:Â Â Â June 30, 2024Â Â December 31, 2023Â Construction in progressÂ $718Â Â $602Â Catamaran tray setsÂ Â 538Â Â 538Â IT equipmentÂ Â 56Â Â 56Â Leasehold improvementsÂ Â 15Â Â 15Â Lab equipmentÂ Â 14Â Â 14Â Office furnitureÂ Â 9Â Â 9Â Fixed assets, grossÂ Â 1,350Â Â 1,234Â Less: accumulated depreciationÂ Â (446)Â Â (273) Fixed assets, netÂ $904Â Â $961Â Â Construction in progress is made up of reusable components that will become reusable Catamaran Tray Sets. Depreciation expense was approximately $86 and $35 for the three months ended June 30, 2024 and 2023, respectively. Depreciation expense was approximately $173 and $60 for the six months ended June 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: <a href=)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1)Reference 4:

noncompliance with debt covenants. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1) + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] Á Leases 6. Leases Á In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancellable operating lease expires in June 2026. Operating lease costs for the facility lease were \$73 and \$73 for the three months ended June 30, 2024 and 2023, respectively, and were \$146 and \$146 for the six months ended June 30, 2024 and 2023, respectively. Á Supplemental balance sheet information related to leases was as follows: Á Á Á June 30, Á Á December 31, Á Á Á 2024 Á Á 2023 Á Operating lease right-of-use assets Á \$525 Á Á \$646 Á Á Á Á Á Á Á Operating lease liability, current Á (\$271) Á (\$256) Operating lease liability, noncurrent Á (290) Á (428) Total operating lease liabilities Á (\$561) Á (\$684) Á Future maturities of operating lease liabilities as of June 30, 2024 were as follows: Á 2024 Á \$154 Á 2025 Á \$310 Á 2026 Á \$144 Á Total lease payments Á \$608 Á Less: imputed interest Á (47) Present value of operating lease liabilities Á \$561 Á Á Other information: Á Cash paid for operating leases for the six months ended June 30, 2024 Á \$148 Á Cash paid for operating leases for the six months ended June 30, 2023 Á \$144 Á Remaining lease term - operating leases (in years) Á 2.00 Á Average discount rate - operating leases Á 8.0% X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders' Equity [Abstract] Á Stockholders' Equity 7. Stockholders' Equity Á The Company's current Amended and Restated Certificate of Incorporation dated February 18, 2014 authorizes the issuance of 130,000,000 shares of common stock and 20,000,000 shares of preferred stock, both with a par value of \$0.001 per share. With respect to the preferred stock, 4,500,000 shares are designated Series A Preferred Stock and 491,222 shares are designated Series B Preferred Stock. Á At-the-Market Offering Program Á On May 4, 2023, the Company entered into an Equity Distribution Agreement to establish an at-the-market offering program, under which the Company may sell from time to time, at its option, shares of its common stock having an aggregate gross sales price of \$5.5 million. The Company is required to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares and has also agreed to provide the Sales Agents with customary indemnification rights. During the six months ended June 30, 2024, 1,033,592 shares of the Company's common stock were sold under the program at a weighted-average price of \$1.83 per share with aggregate proceeds, net of issuance costs, of \$1,834. No shares were sold under the program during the three months ended June 30, 2024. As of the date of this report, the Company may not sell additional shares under this program. Á Equity Line of Credit Á On July 24, 2023, the Company entered into a purchase agreement (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC (the "Lincoln Park"), under which, subject to specified terms and conditions, the Company may sell to Lincoln Park up to \$10 million of shares of common stock from time to time during the term of the Purchase Agreement. On September 22, 2023 (the "Commencement Date") and on May 10, 2024, the Company filed registration statements with the SEC covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement. Á Beginning on the Commencement Date and for a period of 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company's discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to \$10 million of shares of common stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, direct Lincoln Park to purchase on any single business day on which the closing price of its common stock on The Nasdaq Capital Market (the "Nasdaq") is equal to or greater than \$1.50 up to 10,000 shares of common stock (a "Regular Purchase"); provided, that the Company may direct Lincoln Park to purchase in a Regular Purchase (i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least \$15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least \$25.00 per share. In no case, however, will Lincoln Park's commitment with respect to any single Regular Purchase exceed \$500,000; provided, that the parties may mutually agree at any time to increase the maximum number of shares of common stock the Company may direct Lincoln Park to purchase in any single Regular Purchase to up to 100,000 shares or any number of shares that shall not exceed 4.99% of the then outstanding shares of common stock. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to our common stock. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of the Company's common stock immediately preceding the time of sale, as determined under the Purchase Agreement. Á During the six months ended June 30, 2024, 89,847 shares of the Company's common stock were sold under the program at a weighted-average price of \$1.113 per share with aggregate net proceeds of \$96. No shares were sold under the program during the three months ended June 30, 2024. Á Series A Preferred Stock Á On February 20, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors, pursuant to which the Company agreed to sell, issue and deliver to these investors, in a private placement offering (the "Offering"), a total of 172,239 shares of the Company's Series A Preferred Stock and warrants (the "Series A Warrants") to purchase 258,374 shares of common stock, par value \$0.001 per share, of the Company (the "Common Stock") at an exercise price equal to \$1.2705 per share for an aggregate offering price of \$2,605,000. Á Additionally, on February 20, 2024, the Investors agreed to a complete prepayment of the Company's obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at \$1.2705 per share and the Convertible Notes were cancelled. The Series A Warrants are immediately exercisable and expire five years from the date of issuance. Á The Series A Preferred Stock is convertible, at any time, at the option of the holder into shares of Common Stock. Each share of Series A Preferred Stock shall be convertible, at any time after the date of issuance, at the option of the holder thereof (or, upon a Required Conversion (as defined below), at the option of the Corporation), into that number of shares of Common Stock determined by dividing the Stated Value (as defined below) for such share of Series A Preferred Stock by the Conversion Price (as defined below). Á Stated Value means for any share of Series A Preferred Stock, an amount equal to the product of (x) \$15.125 multiplied by (y) the sum of 1 plus the product of (A) 0.06 multiplied by (B) a fraction equal to the number of days that such share of Series A Preferred Stock has been issued divided by 365. Á Conversion Price means (i) for the shares of Series A Preferred Stock issued on the Closing Date, \$1.5125 and (ii) for each share of Series A Preferred Stock issued thereafter, an amount equal to the greater of (x) \$1.5125 and the average of the VWAPs for the 10 Trading Days prior the issuance date of such share of Series A Preferred Stock, in each case subject to adjustment as set forth herein. On any date that ten out of the last 15 daily VWAPs of the Common Stock is 250% higher than the Conversion Price on such date, then the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock. Additionally, on and after the time on which the Company has \$2.25 million in revenues in any single financial quarter, the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock (a "Required Conversion"). No dividends are payable on the Series A Preferred Stock. The Series A Preferred Stock will vote together with the Common Stock on all matters other than as required by law; provided however that any additional shares underlying the Series A Preferred Stock as a result of the anti-dilution provision described below shall not vote on an "as converted" basis and shall only vote when issued upon conversion. Notwithstanding the foregoing, the vote of an individual holder of Series A Preferred Stock (and underlying Common Stock) shall be capped at 9.99% (or 4.99% if selected by the holder). Á The Conversion Price is subject to anti-dilution adjustment as the result of any subdivision, combination of shares or recapitalization, stock dividends, stock splits and similar transactions affecting the Common Stock. In addition, the Series A Preferred Stock will have weighted average anti-dilution protection providing for adjustment of the Conversion Price in the event of issuance of, or commitments to issue, Common Stock for less than the Conversion Price then in effect immediately prior to such issue or sale (a "Dilutive Issuance"), subject to customary exceptions; provided however the anti-dilution for Dilutive Issuances shall not be operative until the stockholders of the Company have

approved the terms of the Series A Preferred Stock. Upon any liquidation or winding up of the Company (a "Liquidation"), the holders of Series A Preferred Stock will be entitled to receive in preference to any other class or series of the Company's equity securities the greater of (i) the Stated Value plus accrued and unpaid dividends and (ii) what would be paid if the Series A Preferred Stock plus accrued and unpaid dividends had been converted into Common Stock. A consolidation or merger of the Company or sale or transfer of all or substantially all of its assets, or any transaction which results in the stockholders of the Company owning less than 50% of the equity or voting power of the surviving entity (excluding the issuance of Common Stock in any financing transaction unless more than 50% of the Company's shares are issued to one stockholder or a number of stockholders who act as a one group) shall be deemed a Liquidation (a "Deemed Liquidation") with respect to the shares of Series A Preferred Stock of any holder who opts to have such occurrence treated as a Deemed Liquidation; provided that if the liquidation preference payable on a Deemed Liquidation is less than 110% of the stated value of the Series A Preferred Stock, the dividend rate on any accrued and unpaid dividends payable with respect to such Deemed Liquidation will increase to 10%. All liquidation preferences payable in respect of a Deemed Liquidation will be payable in shares of Common Stock based on the closing price of the Common Stock on the date of such Deemed Liquidation. Consent of the majority of the holders will be required to (i) amend the Certificate of Incorporation or Bylaws of the Company so as to adversely alter the rights, preferences, privileges of the Series A Preferred Stock, (ii) create any new class of shares pari passu or senior to the Series A Preferred Stock or increase or decrease the number of authorized shares of Common Stock or preferred stock, (iii) pay or declare any dividend on Common Stock or other junior securities, or incur indebtedness in any single transaction in excess of \$1 million or (iv) redeem, purchase or otherwise acquire any share or shares of preferred stock or Common Stock (other than (a) the repurchase of shares of Common Stock pursuant to a written benefit plan or employment or consulting agreement, or (b) the repurchase of any equity securities in connection with the Company's right of first offer with respect to those securities contained in any written agreement with the Company). A Voting rights A The holders of vested shares of common stock are entitled to vote on any matter submitted to a vote of the stockholders and each such holder is entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock are entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock are entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company's Amended and Restated Certificate of Incorporation, as amended. A Equity awards A In 2012, the Board of Directors of the Company (the "Board") approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two to four years and have a 10-year expiration date. In April 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 662,516. In July 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 737,516. In August 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan from 737,516 shares to 799,266 shares and approved the form of a 2022 Equity Incentive Plan. A On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan. A Option Exchange A On April 8, 2024, the Company issued an offer to holders of outstanding stock options to purchase an aggregate of 90,987 shares of the Company's common stock to exchange their options for a lesser number of new restricted stock units ("RSUs") to be granted under the 2022 Plan upon the terms and subject to the conditions set forth in the Offer to Exchange Certain Outstanding Stock Options for Restricted Stock Units (the "Offer to Exchange"). The Offer to Exchange expired on May 6, 2024. A total of 27 eligible participants participated in the exchange. The Company accepted for exchange options to purchase an aggregate of 83,391 shares of common stock of the Company. All surrendered options were cancelled effective as of the expiration of the Option Exchange, and immediately thereafter, in exchange therefor, the Company granted a total of 41,698 new RSUs under the 2022 Plan. The incremental fair value of the new RSUs that were vested at the issuance date was \$32 and was immediately expensed. A summary of the Company's stock option and restricted stock unit activity under its plans is as follows: A A Number of Shares Subject to Outstanding Stock Options A Weighted Average Exercise Price per Share A Number of Outstanding Restricted Stock Units A Weighted Average Grant Date Fair Value per Unit A Outstanding at December 31, 2023 A A 102,089 A \$42.54 A A 76,916 A \$69.50 A Granted A 66,967 A \$0.87 A A 119,351 A \$1.00 A Released A A A A (57,077) A \$32.05 A Cancelled or forfeited A (96,493) A \$43.27 A A (2,500) A \$2.91 A Outstanding at June 30, 2024 A 72,563 A \$3.12 A A 136,690 A \$26.55 A The following table sets forth stock-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023: A A Three months ended June 30, A Six months ended June 30, A A 2024 A 2023 A 2024 A 2023 A Research and development A \$358 A \$378 A \$725 A \$750 A Sales and marketing A 34 A 58 A 77 A 116 A General, and administrative A 642 A 618 A 1,250 A 1,228 A Total stock-based compensation expense A \$1,034 A \$1,054 A \$2,052 A \$2,094 A At June 30, 2024, there were 54,173 shares available for issuance under the 2022 Plan. A Warrants A In April 2022, in association with the Company's initial public offering, the Company granted to The Benchmark Company, LLC and Valuable Capital Limited warrants to purchase a total of 9,600 shares of the Company's common stock. The warrants were immediately exercisable at an exercise price of \$50.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was \$27.50 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 62.55%, dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of \$264 as an issuance cost to additional paid-in capital in 2022. A In June 2023, in connection with a registered offering of stock, the Company issued warrants to purchase a total of 2,000,000 shares of the Company's common stock (the "Offering Warrants"). The Offering Warrants were exercisable upon issuance and will expire five years from the date of issuance. Per the terms of the Offering Warrants, the exercise price of the Offering Warrants reset on July 16, 2023, to \$3.146 per share. The fair value of the Offering Warrants on the grant date of \$3.164, or \$1.58 per warrant, was calculated using a Monte-Carlo simulation to estimate the final exercise price, which is considered a Level 3 fair value measurement, using as inputs; the starting value of \$3.00 per share, the Company's VWAP on June 16; an assumed daily distribution of returns; a mean daily return of 5.18%; a short-term annual volatility of 100% and a standard deviation of 6.3%. The model used Black-Scholes to then calculate the estimated fair value of the Offering Warrants, using an estimated time to maturity of 4.9 years, a risk-free interest rate of 3.99% and a long-term volatility of 60%. A In November 2023, in connection with the issuance of the Convertible Notes, the Company issued warrants to purchase a total of 45,000 shares of the Company's common stock at an exercise price equal to \$1.94 per share. The warrants expire five years from the issuance date. The fair value of the warrants on the grant date was \$1.29 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.89%, dividend yield of 0%, and risk-free interest rate of 4.41%. The Company recorded the fair value of these warrants of approximately \$58 as an issuance cost to additional paid-in capital in 2023. A On February 20, 2024, in connection with the Purchase Agreement, the Company issued the Series A Warrants to purchase a total of 415,468 shares of the Company's common stock at an exercise price equal to \$1.2705 per share. The Series A Warrants are immediately exercisable and expire five years from the date of issuance. The fair value of the Series A Warrants on the grant date was \$0.61 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.24%, dividend yield of 0%, and risk-free interest rate of 4.3%. The Company recorded the fair value of these warrants of \$254 to additional paid-in capital in 2024. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 705 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies [Abstract] A

Commitments and Contingencies 8. Commitments and Contingencies

Á Sales Representative Agreement

Á In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Sales Representative”) received exclusive rights to market, promote, and distribute The Catamaran System in the United States and Puerto Rico. The agreement is for an initial period of five years, and automatically renews for an additional five years unless written notice is given by either party prior to April 27, 2023. The agreement provides for a bonus to be paid to the Representative upon an acquisition or IPO. In May 2021, the Company entered into an Amended and Restated Exclusive Sales Representative Agreement (the “Restated Sales Agreement”). In connection with the amended agreement, the Company paid \$500 cash and issued 53,757 shares of common stock to the Representative, for which the Company recorded a combined total of \$880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October 2021, the Company issued 4,445 shares of common stock with a fair value of approximately \$333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 31,235 shares of common stock to the Representative in accordance with the anti-dilution provision, fully satisfying the Company’s obligations.

Á The Restated Sales Agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the Restated Sales Agreement as long as the bonus paid to the Representative is at least \$6,000.

Á On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative \$1,000 in cash; and (ii) the Company agreed to pay the Representative (a) \$85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal \$3,600. In the event of an acquisition of the Company, the Company will pay the Representative \$3,600 less previous amounts paid pursuant to clause (b) and clause (c) above. The Company recorded a charge of \$1,000 for the payment to the Representative in the fourth quarter of 2022 and expensed the \$85 per month charges as incurred over the six-month period. For payments under clause (b) and clause (c) above, the Company estimated the fair value of the liability using level 3 hierarchy inputs based on a Monte Carlo simulation of future revenues with a 25% quarterly estimated standard deviation of growth rates and a 10% probability of dissolution, discounted at an estimated discount rate of 15.4%. Based on the Company’s fair value analysis, a total of \$2,611 was charged to sales and marketing expense in the consolidated statements of operations and comprehensive loss and recorded as accrued commissions in the consolidated balance sheets. A reconciliation of the liability under clause (b) and clause (c) for the six months ended June 30, 2024 is as follows:

Á Balance at January 1, 2024

Á \$2,377

Á Amounts paid during 2024

Á (252)

Á Accretion

Á 185

Á Balance at June 30, 2024

Á \$2,310

Á Per the terms of the Termination Agreement, the Company ultimately expects to expense \$3,600 under clause (b) and clause (c).

Á Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement.

Á The term of the Consulting Agreement was from October 6, 2022, until October 5, 2023, when it terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company paid the Representative a base consulting fee of \$700 per year, payable in monthly instalments, along with additional compensation of \$62.5 per quarter, if certain sales targets were met, for four quarters; along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services.

Á Litigation

Á In the normal course of business, the Company may possibly be named as a defendant in various lawsuits.

X - References

No definition available.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X - Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContentReference>

2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference)

3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContentReference>

4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference)

5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference)

6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent>

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R16.htm

IDEA: XBRL DOCUMENT v3.24.2.u1

Concentrations of Risk 6 Months Ended Jun. 30, 2024

Concentrations of Risk [Abstract]

Á Concentrations of Risk 9. Concentrations of Risk

Á Credit risk

Á Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

Á The Company maintains cash balances at financial institutions located in California. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

Á The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses.

X - Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/275/tableOfContent>

+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X - References

No definition available.

+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm

IDEA: XBRL DOCUMENT v3.24.2.u1

Pay vs Performance Disclosure - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Pay vs Performance Disclosure

Á

Á

Á Net Income (Loss) \$ (3,826) \$ (4,285) \$ (7,402) \$ (9,115)

X - References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection v-Paragraph 1>

+ Details

Name: ecd_PvpTable

Namespace Prefix: ecd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X - Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference>

2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference>

3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference)

4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference)

5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference)

6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference)

7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference)

8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference)

9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference>

10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference>

11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference)

12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference)

13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference>

14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference)

15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference)

16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference>

17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference>

18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference>

19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference)

20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference)

21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference)

22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference)

23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference)

24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference)

25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference)

S99-1AReference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37>: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22))) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual

tnon NoticeFromNasdaqPolicyTextBlock Namespace Prefix: tnon_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-20>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-19>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-17>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-9>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-28>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-1> + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477968/946-235-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-1> + Details Name: us-gaap_StockholdersEquityPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Principles (Tables) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Principles [Abstract] Â Schedule of Dilutive Common Stock Equivalents The Company had the following dilutive common stock equivalents as of June 30, 2024 and 2023 which were excluded from the calculation because their effect was anti-dilutive: Â Â June 30, 2024Â Â June 30, 2023Â Outstanding restricted stock unitsÂ Â 136,690Â Â Â 93,156Â Outstanding stock optionsÂ Â 72,563Â Â Â 96,934Â Outstanding warrantsÂ Â 2,388,068Â Â Â 2,009,600Â Common shares convertible from preferred stockÂ Â 2,625,016Â Â Â â€”Â TotalÂ Â 5,222,337Â Â Â 2,199,690Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fixed Assets, Net (Tables) 6 Months Ended Jun. 30, 2024 Fixed Assets, Net [Abstract] Â Schedule of Fixed Assets, Net Fixed assets, net, consisted of the following: Â Â June 30, 2024Â Â December 31, 2023Â Construction in progressÂ Â \$718Â Â \$602Â Catamaran tray setsÂ Â 4538Â Â 4538Â IT equipmentÂ Â 56Â Â 56Â Leasehold improvementsÂ Â 15Â Â 15Â Lab equipmentÂ Â 14Â Â 14Â Office furnitureÂ Â 9Â Â 9Â Fixed assets, grossÂ Â 1,350Â Â 1,234Â Less: accumulated depreciationÂ Â (446)Â Â (273) Fixed assets, netÂ Â \$904Â Â \$961Â Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses (Tables) 6 Months Ended Jun. 30, 2024 Accrued Expenses [Abstract] Â Schedule of Accrued Expenses Accrued expenses consisted of the following: Â Â June 30, 2024Â Â December 31, 2023Â Accrued compensationÂ Â \$311Â Â \$334Â Other accrued expensesÂ Â 401Â Â 474Â Total accrued expensesÂ Â \$932Â Â \$808Â X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Schedule of Supplemental Balance Sheet Information Related to Leases Supplemental balance sheet information related to leases was as follows: Â Â June 30,Â Â December 31,Â Â Â 2024Â Â 2023Â Operating lease right-of-use assetsÂ Â \$525Â Â \$646Â Â Â Â Â Â Â Operating lease liability, currentÂ Â \$(271)Â Â \$(256) Operating lease liability, noncurrentÂ Â (290)Â Â (428) Total operating lease liabilitiesÂ Â \$(561)Â Â \$(684) Â Schedule of Future Maturities of Operating Lease Liabilities Future maturities of operating lease liabilities as of June 30, 2024 were as follows: 2024Â Â \$154Â 2025Â Â 310Â 2026Â Â 144Â Total lease paymentsÂ Â 608Â Less: imputed interestÂ Â (47) Present value of operating lease liabilitiesÂ Â \$561Â Cash paid for operating leases for the six months ended June 30, 2024Â Â \$148Â Cash paid for operating leases for the six months ended June 30, 2023Â Â \$144Â Remaining lease term - operating leases (in years)Â Â 2.00Â Average discount rate - operating leasesÂ Â 8.0% X - DefinitionTabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SECReference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-3> + Details Name: srt_ScheduleOfCondensedBalanceSheetTableTextBlock Namespace Prefix: srt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Tables) 6 Months Ended Jun. 30, 2024 Stockholders' Equity [Abstract] Â Schedule of Stock Option and Restricted Stock Unit Activity A summary of the Companyâ€™s stock option and restricted stock unit activity under its plans is as follows: Â Â Number of Shares SubjectÂ Â to Outstanding Stock OptionsÂ Â Weighted Average Exercise Price per ShareÂ Â Number of Outstanding Restricted Stock UnitsÂ Â Weighted Average Grant Date Fair Value per UnitÂ Â Outstanding at December 31, 2023Â Â 102,089Â Â \$42.54Â Â 76,916Â Â \$69.50Â GrantedÂ Â 66,967Â Â \$0.87Â Â 119,351Â Â \$1.00Â ReleasedÂ Â â€”Â Â Â â€”Â Â (57,077)Â Â \$32.05Â Cancelled or forfeitedÂ Â (96,493)Â Â \$43.27Â Â (2,500)Â Â \$2.91Â Outstanding at June 30, 2024Â Â 72,563Â Â \$3.12Â Â 136,690Â Â \$26.55Â Schedule of Stock-Based Compensation Expense Recognized The following table sets forth stock-based compensation expense recognized for the three and six months ended

June 30, 2024 and 2023: [A](#) [A](#) Three months ended June 30, [A](#) [A](#) Six months ended June 30, [A](#) [A](#) 2024 [A](#) 2023 [A](#) 2023 [A](#) Research and development [A](#) \$358 [A](#) \$378 [A](#) \$725 [A](#) \$750 [A](#) Sales and marketing [A](#) 34 [A](#) 58 [A](#) 77 [A](#) 116 [A](#) General, and administrative [A](#) 642 [A](#) 618 [A](#) 1,250 [A](#) [A](#) 1,228 [A](#) Total stock-based compensation expense [A](#) \$1,034 [A](#) \$1,054 [A](#) \$2,052 [A](#) \$2,094 [X](#) - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies [Abstract] [A](#) Schedule of Reconciliation of the Liability A reconciliation of the liability under clause (b) and clause (c) for the six months ended June 31, 2024 is as follows: Balance at January 1, 2024 [A](#) \$2,377 [A](#) Amounts paid during 2024 [A](#) (252) Accretion [A](#) 185 [A](#) Balance at June 30, 2024 [A](#) \$2,310 [A](#) [X](#) - DefinitionTabular disclosure of reconciliation of liability. + ReferencesNo definition available. + Details Name: tnon_ScheduleOfReconciliationOfTheLiabilityTableTextBlock Namespace Prefix: tnon_Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Principles (Details) - \$ / shares 6 Months Ended Jun. 30, 2024 May 06, 2024 Summary of Significant Accounting Principles [Line Items] [A](#) [A](#) Price per share [A](#) \$ 1 Percentage of valuation allowance in deferred tax assets 100.00% [A](#) Minimum [Member] [A](#) Summary of Significant Accounting Principles [Line Items] [A](#) Reverse stock split ratio one for two (1:2) [A](#) Maximum [Member] [A](#) Summary of Significant Accounting Principles [Line Items] [A](#) Reverse stock split ratio one for fifty (1:50) [A](#) [X](#) - DefinitionPercentage of valuation allowance in deferred tax assets. + ReferencesNo definition available. + Details Name: tnon_PercentageOfValuationAllowanceInDeferredTaxAssets Namespace Prefix: tnon_Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-4> + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsiarySaleOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Principles (Details) - Schedule of Dilutive Common Stock Equivalents - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Schedule of Dilutive Common Stock Equivalents [Line Items] [A](#) Antidilutive Securities Excluded from Computation of Earnings Per Share 5,222,337 2,199,690 Outstanding restricted stock units [Member] [A](#) Schedule of Dilutive Common Stock Equivalents [Line Items] [A](#) Antidilutive Securities Excluded from Computation of Earnings Per Share 136,690 93,156 Outstanding stock options [Member] [A](#) Schedule of Dilutive Common Stock Equivalents [Line Items] [A](#) Antidilutive Securities Excluded from Computation of Earnings Per Share 72,563 96,934 Outstanding warrants [Member] [A](#) Schedule of Dilutive Common Stock Equivalents [Line Items] [A](#) Antidilutive Securities Excluded from Computation of Earnings Per Share 2,388,068 2,009,600 Common shares convertible from preferred stock [Member] [A](#) Schedule of Dilutive Common Stock Equivalents [Line Items] [A](#) Antidilutive Securities Excluded from Computation of Earnings Per Share 2,625,016 [X](#) - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fixed Assets, Net (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Fixed Assets, Net [Abstract] [A](#) [A](#) [A](#) Depreciation expense \$ 86 \$ 35 \$ 173 \$ 60 [X](#) - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fixed Assets, Net (Details) - Schedule of Fixed Assets, Net - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross \$ 1,350 \$ 1,234 Less: accumulated depreciation (446) (273) Fixed assets, net 904 961 Construction in progress [Member] [A](#) Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross 718 602 Catamaran tray sets [Member] [A](#) Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross 538 538 IT equipment [Member] [A](#) Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross 56 56 Leasehold improvements [Member] [A](#) Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross 15 15 Lab equipment [Member] [A](#) Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross 14 14 Office furniture [Member] [A](#) Schedule of Fixed Assets, Net [Line Items] [A](#) Fixed assets, gross \$ 9 \$ 9 [X](#) - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A> + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -

Subparagraph (SX 210.7-03(a)(8)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5:

(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(a\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: [http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(d\)](http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a)) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock \(or preferred stock redeemable solely at the option of the issuer\). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + References](https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + References)Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(21\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21))) -Publisher FASB -URI https://asc.fasb.org/1943274/2147487777/944-210-S99-1 + Details Name: us-gaap_PREFERREDStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtPercentageBearingFixedInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\) \(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) (2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=tnon_ConvertibleNotePayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPREFERREDStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases \(Details\) - USD \(\\$\) \\$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases \[Abstract\] Å Å Å Operating lease term 2026 years Å 2026 years Å Operating lease costs \\$ 73 \\$ 73 \\$ 146 \\$ 146 X - References](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=tnon_ConvertibleNotePayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPREFERREDStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Details) - USD ($) $ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases [Abstract] Å Å Å Operating lease term 2026 years Å 2026 years Å Operating lease costs $ 73 $ 73 $ 146 $ 146 X - References)No definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + References](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + References)Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases \(Details\) - Schedule of Supplemental Balance Sheet Information Related to Leases - USD \(\\$\) \\$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Supplemental Balance Sheet Information Related to Leases \[Abstract\] Å Å Operating lease right-of-use assets \\$ 525 \\$ 646 Operating lease liability, current \(271\) \(256\) Operating lease liability, noncurrent \(290\) \(428\) Total operating lease liabilities \\$ \(561\) \\$ \(684\) X - Definition](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Schedule of Supplemental Balance Sheet Information Related to Leases [Abstract] Å Å Operating lease right-of-use assets $ 525 $ 646 Operating lease liability, current (271) (256) Operating lease liability, noncurrent (290) (428) Total operating lease liabilities $ (561) $ (684) X - Definition)Present value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - References)No definition available. + Details Name: us-gaap_OperatingLeaseLiabilityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + References)Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + References)Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + References">http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Details) - Schedule of Future Maturities of Operating Lease Liabilities - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Schedule of Future Maturities of Operating Lease Liabilities [Abstract] Å Å Å 2024 $ 154 Å Å 2025 310 Å Å 2026 144 Å Å Total lease payments 608 Å Å Less: imputed interest (47) Å Å Present value of operating lease liabilities 561 Å Å $ 684 Cash paid for operating leases $ 148 $ 144 Å Remaining lease term - operating leases (in years) 2 years Å Å Average discount rate - operating leases 8.00% Å Å X - Definition)Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References)Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: \[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \\(a\\)\\(1\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - References\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - References\)No definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References)Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + References](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + References)Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 +](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 +)

of rights grant date fair value of warrants . + ReferencesNo definition available. + Details Name: tnon_ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants Namespace Prefix: tnon_Data Type: dtr:perShareItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of deemed liquidation. + ReferencesNo definition available. + Details Name: tnon_DeemedLiquidationPercentage Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionDescription of series A preferred stock. + ReferencesNo definition available. + Details Name: tnon_DescriptionOfSeriesAPreferredStock Namespace Prefix: tnon_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFair value of offering warrant. + ReferencesNo definition available. + Details Name: tnon_FairValueOfOfferingWarrant Namespace Prefix: tnon_Data Type: dtr:perShareItem Type Balance Type: na Period Type: duration X - DefinitionIncreased percentage of deemed liquidation. + ReferencesNo definition available. + Details Name: tnon_IncreasedPercentageOfDeemedLiquidation Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionAmount of percentage of gross proceeds. + ReferencesNo definition available. + Details Name: tnon_PercentageOfGrossProceeds Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of outstanding shares. + ReferencesNo definition available. + Details Name: tnon_PercentageOfOutstandingShares Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of shares issued to stockholders. + ReferencesNo definition available. + Details Name: tnon_PercentageOfSharesIssuedToStockholders Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionNumber of preferred stock, designated shares. + ReferencesNo definition available. + Details Name: tnon_PreferredStockDesignatedShares Namespace Prefix: tnon_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionPurchase exceed amount. + ReferencesNo definition available. + Details Name: tnon_PurchaseExceedAmount Namespace Prefix: tnon_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares. + ReferencesNo definition available. + Details Name: tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation Namespace Prefix: tnon_Data Type: dtr:percentItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price under the program common stock. + ReferencesNo definition available. + Details Name: tnon_WeightedAveragePriceUnderTheProgramCommonStock Namespace Prefix: tnon_Data Type: dtr:perShareItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionDescription of basis for conversion of convertible common stock. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockConversionBasis Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAverage amount borrowed under the credit facility during the period. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityAverageOutstandingAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OptionIndexedToIssuersEquityLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 850-SubTopic 10-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3> + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_Data Type:

sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemBalance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1:

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(v)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. +
ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2+Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense Recognized - USD (\$) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Schedule of Stock-Based Compensation Expense Recognized [Line Items] Á Á Á Total stock-based compensation expense \$ 1,034 \$ 1,054 \$ 2,052 \$ 2,094 Research and development [Member] Á Á Á Á Schedule of Stock-Based Compensation Expense Recognized [Line Items] Á Á Á Total stock-based compensation expense 358 378 725 750 Sales and marketing [Member] Á Á Á Á Schedule of Stock-Based Compensation Expense Recognized [Line Items] Á Á Á Á Total stock-based compensation expense 34 58 77 116 General, and administrative [Member] Á Á Á Á Schedule of Stock-Based Compensation Expense Recognized [Line Items] Á Á Á Total stock-based compensation expense \$ 642 \$ 618 \$ 1,250 \$ 1,228 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForFees Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscount rate used to estimate the fair value of servicing assets and servicing liabilities. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 860 -SubTopic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481229/860-50-50-2 + Details Name: us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=tnon_SalesRepresentativeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=tnon_AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=tnon_TerminationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=tnon_ConsultingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details) - Schedule of Reconciliation of the Liability 6 Months Ended Jun. 30, 2024 USD (\$) Schedule of Reconciliation of the Liability [Abstract] A Balance at beginning \$ 2,377 Amounts paid during 2024 (252) Accretion 185 Balance at ending \$ 2,310 X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LossContingencyAccrualDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow reducing loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualPayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualProvision Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration EXCEL 51 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$L#!0 (+V+#+5D'04UB@0 +\$ 0 9&J C4')O<!.087!P+GAM M;\$/V./0L',1!\$!IQO;=!P4)B0-!2L+(/>QLOD!1#LD)~!OCG!CVX>;QA&WPIG M*N*!#BV&5(C(I(/ !47BK9.7;=N')=HI6 Y #OGDK7A.YNJQ<&4GPZ4A!0W J=0U[R;UEA 6#MI7E!+ P04 M" "JBPU9CG?=\$=N\ K @ \$0 &108U[R;WIS+V-O&ULS9+/ M3L,P#=(?!>7>NDFG";*N%Q GD)"81.(6)=X6K7FCQC*=V).6K1."!^ 8~Y?/ MGR4W.DH=\$KZD\$#&1Q7PSN.YGJ>.&8BB1,CZ@\$(EFC MVB.(JE#0U)&D8)6,2%R-K~&*D3@<KIC#<=JP&UL[5!;<]HX%[0K]X9_9M"8V@;:T\$W!E=MNTF83M M3A~\$%5B-;EDD81_ OTV23J;/ 0LZ?O.14?GZ#AY^XN8NB&B)3R M>+ !J06N!+3+ MUES@6QH0J!<ZM-O=5H11;~\$81V1@<?XSL\$%05%;U!M.4.? @5RU2-9.;! M\$U!<1)KF(M+Y,7VMX*9< !.ATR@6XP&U@<YNO!1.6HCA5,+P&IG/U9K MQJ"22("R7V4!;I)J/3%0@R#3LZG5C.=GSVQ.V?C,K;=#1M&N#C7@XML02 MBW A(5M>5 TR M6!IVULS2 Y9>?* RUE!K9';O=05SP6.XYB1~QL4\$UFG2&98T1G*=D 4. #?3 MT4Q0?*!MHK@PI+27)~6SRFU4!H(FLB!J)4>"(<7K;YH) M5Z%82=\$!<!!&N#<<<~9ST6S!IZ5&T?95O- ICEU!5 9<8WS2J-2S%UGB5P&M MG#P=Q+>E L08:7)82J3E~34@3 BNEVOZKR2.FJW"\$2M"/F9 M-AIRM1!MG&IA&!!\$!>1>=\$2M!6:PUDSY@R.S- D77.U!\$.9\$)>-T(^(8LZ+ MD!& 'H8X2IKMHG&8!V>7L-)P>B"RV;JN'Z&U3-L+([W1]072NO)/J< Z3T M!Z;.60FJA%9GZJ'~ZH'C(*)?&Y'C|E>G@*Y;.&O%"N@GL!]'- *K^<+ M.7N@<^E[!GT;2MSAD6R4)RU3393>~\$ M\$Y!&V[I4 5*E?>EKJDHN*Q;Y.FOH70+>+Y% GM,T+>T.WF)&Y M"2-D&_ #^>G%>!KB.=D\$N7V85VWGV- '1^~?4;[C]SR6<<?([J(A)J&F;_ # M0X=Y!>~89Y7&4#04;6RL)"Q&MV"XU \$!L!.ID8~V!@X.O40+R4&5&5& RNO MHGQ,C\$7H<.>77% CT9+CVZ9EM6ZO*7<9;2J2.<[!F!-G]K<9;^!51W/55OR ML+YJ];053L ^6:W(GPP13A8+\$DACE!>F2J+S&S.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X\$G:V#P(RN;JY7JIE,6>F\M\M# DL6XA9N1)-7>W5YNTB42J(P# 4A M%W+<C^~3:G>U HL@6V\$5\$)DU1?~0XG!/>3-R0A)J?>.NVB8+A=OB5,V[!&KXF M80\$O>+FZ=>? VU!4;/074;SHYG@'K. MYA.L0A2!~P7V#BH 1JV*~N4J]/~26<.[!H&8@F S6VZ3VW>_?2K6J5D*Q\$ M2P=V!Y(&XQ);#1? CQ1BK~;QK<;.0QY@%CS#*%F.^~!9H.;J6+K#F-"F! MU4#EY/OJ4#6CV#30,9FV-J/D3@H\W/O#;#"Q[!A[8N 5!+ P04 M" "JBPU9O8"1/5;& "X(P &'AL+W=O&W!<?;0F6!@2\L&EM!VMU!<#+2>~VLI+; ME=J7LAT[M?<Z)P>?S1J]NYY&MDR^+WD#W)G6-DK<QP M30<7 6G/<>4B\$7,5T."ZG^/S&-19)1T M';X5HKWR-TW@!066 3(SK/T4,D OT0T1FIJ]VCQJH8 M:J!J. [J,RL,C8R> MSR.9 45;/~#80 JY50(+H)U">(PR? 3YZ(B=@>P60 1 LB G#+=+!%G@!JL9 MS4N6V3JGBDY!/"PCRMUU,2/T2>>J+5%GT @M?Q UV6LD!D6Z S @K^DB;'R4. M\$"(T%(>#PZ2!M#A%U;~*OBN&7)N)F>6Z-WSO4J4UJ%KI)(S)B^]]>U?@I= M*1+!>OVU5EDL_9)F8'Z0&^JSTYX>>9>P1];_ @_@'CL_V?R^D=<@KJ/V 1!2 MK3?OVR8S4D'L5\$J(+NV&8+9;~2RF1VBK% M Z-VAN7J]L8- 6TQ0!>=FW;7>~ZRUJ)T&@<3#6AJEQR2P#/=>D'6BI<17~DLP^&U#0>+ MM31U7J)HZ;M8\$;YD!>6 2AFDYZ[O**Y4IHC9@/S/M?6G2JL_.Z>7H?11A+XP M*M"EOFC,K[!8G44XK*W"6S _MCT:CU+&F&YSJ3\$0QJZY64!@F8^!NIIGF M+Q3?*/6 E=IK Q7Z8) MM@!OV"J42J<3A>8TMH[7/4+W%_.~7>?+LZOO-GU M J;:>X=6NUV@#JY8!&T4MCU=^6ND=?~!J1K^RZMA6,IQ#P;.~38M?KL M@GJ!P4 8QI;^YV48,31/XPJ,K M0+>=FN SJ?/@="F]X:@<JYD&#WQD)=L%ND=?~!#&B'1#/"*YT*2763 U "Z63~^(M =3S551W;I/WB7R!ZGYAM=P%~\$*D#1;. 7MOOW,>F[V&J^T"V;." M%31AF^6VDU+A-T? Y.%EESN3:F'%&MZ%HKUZ)4S\$1AS^I^+<8LBW5/C#4VL M\$~^>F5KRA>:/VJMPB2 M)PF+JM^>2/.*6JA(VHB%3611M0T^PM^+<@VIRBK@YO\$FE;W2&JUN=5U@&U M(=974!XLT=90Q4ZD3\$3N5KCUSIJ^IGC^E5L>PW#67Z)-5W)IBX=BV5BMF(C#D M)=J5H56EWOH:V.UUP4ID8J42"-2*NW=LEX+B6 M3MV*E5RGR7QJN^929YJ[54Z<K]J[OTN\$005'R:Z0"JW0BH71J]LLX\$HJ7- MNT?@W= Y>FUUU@4N14[N3#S7"/LA5K6NO4+UCTB%-%Q?S09.U9 7<~3N_-M#?ZD5G3?ZU";A4R#7ONVNG).Z("JW(BH79J[!4\$5Z5;Y\$F+Q!>(A6S\$~%K@VK M;EA)PV:L:6RAN/ U^WT OB11BE#/'SB'CH.12;K91UUK)70!7&X?7"[\DC# M9)"M85 BQY90>[1F_&KZZO"BW0B+7YIUU:VI@!JMY[BVSO +I)E#QUV+<@VYJ\$6:YEF79D<@W).DRBOEMM29MEFCU+>+ZGY1,UJSV M(K;4H<[A1/^ZR+>?Y">~*[*=@@]<1YGAVM&R_ K^GD.U/3\$ 4&[6F?X# M4\$!L#!0 (+V+#+5G/T(O)CKP8_.< 8>+&PO=VJR:W-H965T&ULO5EMZ,X\$XK5K9;4I[!PT\$T!=(ZJ);J.C;IG>XC!:=! M"YC%)FWOU!<8)@!X9JW55JR!MX>;>8>S;_>G#ZXQ@=>?4K0!>=\$K%?7Y7F/JA+>M O=I'V0' V%+>.'57 2TMK5Z**RY8.EZ."!(XVSU/WA>3\36 .QT#~#K >2M M ^SU@&KF!BMD55B7@0C&IP5!0H6T!7 RHJ];:C1\$V=R<;>B@=>+LQC!<C"Y9% ML@T0G#63R/LI"BJ73.T;?]+>BC&.Y1!H?H?GJ)/AU1@9!\$.0C (T.T.P06SSU?/AW/ J7.CI!M]1&QB*9?F4?>DE#&(ZKX?;N M_(CT5J)X*4OFSNZ.B+ J;"11P#C\$?Z^>9.7#T#N2..~9Y\$~S'FPI3HLE M!8T ? L!#ZT07W9Z<[<1JU["N CBX O\$*P.N4! 5G&RR"!X+6KN'(UKT\$) MLK Q&6(JME& M;63\$=DESQF/JA(TT.=!)"9#39 82MAE8L(Z3;G!;!B+>E%!@651(.CUD\2 M3J)9U/*%64J@<ANNOFCH#&L;_>@PF4_YQ22\$S;* XD\J!Q 92N!/TDH=W> MUQHC;J11;~#N(96QR@R;3Z 55H5&-7&K<C!>:QLQ^!T UW *MMJ\$ MH\$D*J1;W4E=\$-5V,Q5FYS)65')>C8'9;J' M'+(TC;GL% 2@5!;"EJ]L0J?*:P.U U983~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~N9Y=7TW1Y-LEFLYN M+W[!>GMS>?5JNH%]P0]]>POI2M\$3<^N]J4JZ'Z^<X&4A6U6%&HYZ'P3-"V MJKTK-@U Q0A:TS:WJZW[^ *V.PF++~;J?R7OV7E]U[!O;NQ;+!O-@J=. M@< K ? (Z 3KYT.FY_YD-H67KXC9>]=>OZGSC05E _W[;5EK F27N!AML?72Z MW_Y^XK]J^<@W?<@V3KR8\$;7J]IJQ/^N!>+U_3@J7Y5X8(&D)G2 ./!&4C0 M]8G/R%5_U!S_U!+ P04 " "JBPU9Q>SO33T# #W"@< &'AL+W=O M4^6V<6L+M-9O(RG F#&+<KH')JG^>@+G42R23;W _\$@<U@-4%~>V? M;2;D^+M]ZK7WM,~N^~#7[3X\FEE1#7J).V*9R?>V",9K&G%\$S>Y^QD.0T.; M+Y5"\$(&H\$T;6"N!\$SFA-YFP] M44-G\$R5W1-EHS&8'KC9.C6Z8L-NX- JO,M29V5R#~#<C;(&C+3G+J;("54 M!\$6-K\$F^<"5AG#*?D9D5\$).~82GE^!<I;0)Z73<3FTRWY1)@>?2RTE1D M>N(<1+2XW;=>YK&#&B4! _J)Q('GTD41(<~? R\ E2E=(.N +>2Q+6YNH MK4WD@U.Y/L:NBTBN;~%8&9QG!)COO6Q7]; M[352WUW+4-7R1)&IF4M1>WX&K9 _J]7X]#%GK&FA;~^(<B'R)31_U@('EHV# <30Z8#Z.BY@B,394Y.XN3= MQ\$SKJK \$R96PQW%G84 <9M <9C' "FU6W89J?H M'V_O157M2EJ\$S|EJZ^3^?4ZN:O!H^=J_.QK!,MQ>]!AV:E#~#Z\$?;IEFH1 MO3!, [I/Q 7)W;G:SG<[! :#MA5=2D 4R!G<(<+>?978(<%O5&V8D1(3#&F7! MWOC?J]CYEU1,C2W=064F#QQXW\$%D'LH&X/6UE.9U8L^!5EW)A]02P.\$% M @08L- 6=9E.RZ/> @2\$!@ IX;"JW;WQD2EX<^>Q\$;2B7ZF?>#N!MI!Q>C.=BL.%Y M(L[9EA;J/R0&T2J4X>BRVGR;(2RK,Q<1 Q G^=I,9I>5M=N^~22[626%026 M(I(+X1_ZS9>[P:X=-3A8 I>B/+~^JY399TSJ]J[>W7)V _UJ6:4X+D;(" M<JZ&EWCBY@!\$4~%#VEC^+H&J54^AC!4IZ&6U.Z)~*+6;I(U.^>SFB6 ME9K4_OYNE(X.Y:"Q)=(V/MJ4Y!69AT302.L=1!G1?>V?&T,<22@J," I!\$@NH#7/<V B M NYS5 _>^Y*TP;@8KZN.9>+6Z>R&1ZR=DCXB5;.2L/MR7MTLI>:5\$&RIWD MZK^IDI/3&2N6RNTUB>218YF23^OZN9J]16#(BMT(G.D9N.L)~N1\$H5IM< O)SN[QOD1\KQOVL19ZL=4.L"G 9%>?>=(5X MXA _/L^>N(1.? [5H _J]=8B7T\$K?6Z/OG?@>N6T#177Q 6#D9\$=^GJ" MKJZ5>;"R,A)>B&VRH%@T<^MF _I!J]GQ8"UJ)J 4JP+I!]>3@R_~^V@F)O#<+<F9N8K!G'XH!D X) ^@ M^KZ)>=O\$RFW&A)QSD4@R"J";26GQR^MCGZ@O.S.2+<(8FQ@J]U@B&8.R2""?H" M@ZK5X\$M>M);SE:IA/CYK]V]Z.Q_#B(T_B9F,C3^0<Z" F"Q\$SH!>9LT=20 M8HWBKJNRXH1.)(9,D,JFP^I+IY(6<<1X<\$1X7D"4\$30MA417R!D;~&MF7Z MAMP1+G\$0.*\$6ZD)ZHQ>4D3^>FJZ5QEAY_UB!A8BQ MYH!P1B>2XQ_S C]!F M- (VFZ@)3W!;;&GOE8#<@/!#AAX>@P'F\$ /0!<C M~WKTFR9C[!OF]MOL\$S]N[S72&ILL]M(XZD*15!>P*!;)(KFV,3GSUQ/M?W MKJ8U:MO860'6]/.7_-Y8J? 8T^K^C8CV.Q* SV&K N^Q^+F6F+3<[M?<?{6N MY=I>+&EL[Q*]>~!^#?0!9EDS3K6J,6I"\$M+Z^<C*@R;UW8=NY8GOM^AN5U+>F.MD UH#0)VJTA&#(#S2#C1.0*PP'.E@: 11CWE?>V:~61M=((\$46WRL%WFX33 ML^<^!P[;6+&OM&2D[0B2I] MS2\$8.3?NP 86=4+XO"Z/+>OJ9S3>OP%!\H@(!<:0:17HF+&)MZE\JX- JFP^J M+1*6)=?;1 @<^&ZNUH^<3MV~?>C,T'8'=75%NESJBA_ZZ)JB9.T M(P^QCQ6BEQC6FXL+T!2#C@Z~L!J]BT>2EO75>WH0.RC0UGCLYB3PLGR% Q MAV! ,8=<0#&8'W/M9G+2S]/#0<6ITF6 _BMV/VE!&?=\$=XPKNI@18J\$FFQ^!8D3PJ1?5+YN5?N]H!\$F@5F M!<@;@E!<1#>JOCPN0M)CH'8Z/>9!!:=W-9J5P7/NZL F\$=^3T!) M<8TB" M8<3ZF3QD>OL^/UJ6W T(1VQ6R?B5YN'KX/NZ>BNO7; !%S.,7) CB(C^ M^J!57W\,\3[AZ[00*MKM91S'B@Y@K[OI\$SLFWU OV12TYSKF=4U98T<#8 M9B;(\$!EIK9(+*+& 6")2H?614426-[4J]=!OQD/2;J! MF&?27,FF74L\$E=2;P18PY*~H?<6CJL- GFZ_UY^OT#P!;!O /YS(P0- M('ANA+ &E;EVK=24;D\$5C0;~XC0WLHJDNB\$Z!HWU8H1ZD]D2^J0A3D5C7B1X MZ1 075F>L80JW,5PWK =E"1!2;Z5(*@5TEHH3US[.E4- \L.R%DI,9%8A,0;&89O*4G)&WQ"8R1;.,?RV?WS#YS !=UW\$/(?'?B\$ _KQ92"7S _?W4=+=4T6=)/I;V)?EC2&H84-M)D&LP8K>O7'/G8]=7Y-LLEKDDU?B6SO1(+V1)(C[- &997J)W&G>~?2 14 M64=G;L Q1O9ZMPZ=F7G1N]SWFGIUX>3W>D;M-TPZ0UB(9.NT)#N#<X4L%ULIP M)YQ _7PXT/OD^<L[X8&#B;?<0 4=3IYJ\$Z>~? CG(-8F;DH2&E& MPX(K#1FF>+!>]@CM@<_7G/MO1@=H?U@BOU!+ P04 " "JBPU9V%{Z6\$) M^*50 _'AL+W=OK,MZR72~R?R?M;HIG _\ _WEP^9ZH=- Z8SU')>O/T _FFVEXOW(6V80_1(T^YD^<_LJ9! M5LV+([1L M>+>6EM]H<6'LLIW;6%>@UV2'7]&WJ]. "M G8\$"I"U A (&'2A MZVP)4*\$'&)/AM 5,L_-0&JRU@36VW15.PI[!<0LX3;_.O=N&QHNJZ;.JR)<T MHK;FM!J#\$[/!(DM61&5*)>U/4= W.;9AB<6VVC4YFGR2J]>J]BO _@ M&5>56OYU_<F1W57R.67;4455A2-31Y_U:~L_3-TPTKRE]~T]]?<K6M"MUUGRI8W&A3^<=N,4/> 7AC7T>ST.L6YB6;J^E2];>+G; M7) ^60*8&K>- PIE(YM8':G7M_34MW12W[!BH^Q^&_%>3VIGY54N)] _^/IBG?#*5^<#.;,OZBKW18CX M!D@:A8"[%O]F4&YH"3.&-'(^4THGH;U,8F\$C.B1..%+I7C"M4S M93 _M\F4;JR*)ZPF^;_[&ARRIP,N!\$CDCFD@<#XGC(W\$")\$[XNO;~\$N9J3]<^JBS A(5L%F;.*?<T<1)I;.\$L M#M^U@.==%?%S>Y@JZ5&ZW_X3(8CKU,6\$!)BQ\$

```

@05R9GW*F;4R9XZ;@Q,BWW4LR AU:G?777%OBIMP'S):F:~N. M&? ?SA%{AH#16J<#/#=S11^8T 4D0.<9[~P(U:~BRU)]ZTX-As^J{RUU4MSXJ M+4"EA5BT?
EYTVITABR(F);KBHM:PQI MF12(XB)DYXH7JL(F)J DM3XJ?1#K2<#+#WQ[L82EQ096#;$,8AGBE=F[Q*-B MU&2' E1:~B7KIT0QAEJ5>H2B5&
G.~+)>]~K0BBQ19<1R~WV'PK%QZJ[; MJ4K&~V4E;M7H1YPS%6U& ^5FY,U' A00B?2I9T(LA5IE>+~#ZJ^~79+< MOQU^U1.O#JA?
51:@$H+L6CJ].@$.+/*5A@MEP@K<#SBSN^9@-4+5FQ*11 M@ 4*X7H/70Z7W1Z%E'K M6?.$235LSI$/(+4+"1C@0(B2U>+&+9XN4=KT0)EI6T2M;.FD2771.8%#
GE8 M()J PAAQ16D2RU/XZJ?OK.#5Y/-7HY#96K4G?#**YVIG$5:9+4(AHD30)FH#0) MV4C2GJ& T*V23ZH(B%YV_&N]MU-8!!1 0&D2U:/V2@M0:~2$6K9J7G6Y&INEF
MPED.]1 FM+1(=6=[R]Q LQI6F:YTN@HP6UJ6!EJ?#YYG1EDHT9T, M1=0RU(23WCQ|O7Z$#*$.>+<06J>1(1TWQ73KHJ)("5%J>1)0OG1:=D$;62=8D MJ4.&8%
((( JZN(A%QF&)I4UB@<*S> :!VPA.YI^C3###!f6%.C,?/-!@ M?)^K2V?+L4XU88%~N-X#8@+1="~%RF2YTH7Z@|C9!|@<-%(0DZ|H%*~>9T*E
M1:BT$$(O63Y)=>+R+3M:R^?>Z?>.RQO W19 9D!1:7B%142ZFZ5==OSBP.G"B2 M|C|Q@>ONP0%0;6H-W6.BG2YU;U;H04ES!I@V<./X5EWN;N3>=4&D^ M*MBU
I858M'X6=9(454M2D)V15#-G7/RQ0!X6R.<^!5B@>J'4XUJ2ZJ|O>O M|JR25 M|Q?T6GBG2$5FV XK2EK=L#*%=.96=N5=5W:E@~F2YN8H18>J)JLXIY-E MARX=ZN).!Z-
J'6S"GOFXNPS%!UP^ \ ^.^.[N$NGRAGH<"Y46H~"~+%H_XIU( M1M4BV9IGKZ":=O9I[L3E,4&<(T, MV,$[3W4]9^)^F+O E19BT8X17YV]9^)^2RG?
(W7Q)LE+V0/ZV'. DYKZI|UWS5;W~#F7I:~23%<@~9B7 7 MO<~+~*7F8%;J3#2:~59ZG;EY8A$T624,U,%F^NV:U;G-F-R43J;Q72FSQG MZNF29_+Q?((
'SP">B(=5L0)&B[U>~^!WWQ=O=HJX&J5>4J^S0@M9G,67YX+ M?I9%WQ: L A3$>J&<4 >+>.XDD4*1>I$@BLM,YGS=S W M|QCG@6D8CN4173^0!ZBX1B=?
[9]!>B14/T>X;G;QYB]X@4: _5G^C69J MLY$!9:~**E07)8H2 ~*?HD"||Z2_/0|OC1Q11^19Y#NN2!!W^MBG>[QJ] MOR0BLO?/U>N^TP <6F>9.G^T+~M-I=*YNCW-
5>.B.(I7=Al+&S@WJR5J7F_ M5@O(3 6:)?QJ M$8<[7E@/7I//^)](LOY",YVTM 7"<~@GE?7;&E$GM#;(< M.7$C;=29+H.3;)"GH^TN>H 5'.Q;~4:~US#&@?K5M NS:3R
J5$~.KD5C@V!C-UDXJ]L;E# M7GUGUBYWM 8A MOR;~^N?2=FM9R!$TU;A M?9ZT2GM*1QJ;|CQ8|&%)B]5DQ<9Z;YS&X@QCA=0^_X;C916897S-1/1
MINB[WFCWUUCKNML/K(VO M.TOGI =>P]@X2^06GMKPJ]>>./NFV>=>@G>)-0-9# [R&*~&*1MEE[E6D@EV
M+S)A .I$2WJ~3&@/J,JFO<@;5@2AVGRVWMDC1=UEPN^73<~>.';~=[ITV MACQ;I M;9>~^H66QCJ AX&>?>1^0 TEH*!~.?:9=QMS?0*M9HN,JAA#81
M3LQZXPJZ?)4$%;E'.S' O M:MB3A5E+ZRULHO;|D6X|JLQ-K&YOW+P,8MU6MISXK@GB5&C8E83:M6~) MU1O>6N1;7MS=/J45>3E1D-EJ-
H6LUGO8M(0+SELR_U!% SV=B^V^7+4 M/?>QO.TGH>%R$N9RV&,DG*=5"H36&@!MS/QCBM( +JPOSY;F)("F!Z!6%ER
M1=SY#VSXWMFMKS="768G;V+O+3"VP _%Y[K,8];>=T$Y+6KK1J>A^A!^2$~M;XEG4 MMJ~W4>~VMY70<~1^J147#1I+WD!1BN0)&9AP,JMV
M|7N>0EJVM|M5ST1T3C$;G7,1QNQ0<-BPV;~Y+K*Y0<[?Y#~CCCLVG$7-T2 M6Q!;/>#>D3$SLEO=+~+M;J3TC1^I;M;A@>8J)"%S!+> B"*PDXC~.(M+129
M>@/H*~@2D|6JUEATK,%H8W.H&=&$0S@QFZ4@|P@/QWH'GDQZ]N%T)T# M;~^~^R+H9O:V((L6K>~$B|W/_ DIFTD1GT)9GQW)+YK$D S>;M5W
M3E HBZPPY?>F).MMO&B;~#?3FJ"LS,ZU^T,8V^$3!N90<~RXP,M|J U M6|DNQ>~QDOR.P~I76C&7/@~^E="B6AB6>2>;=SYX8-II+>?2*(~+X@Y M5P NPZII
[B2H _J6ZT WEZ3Y$;MY?X]K!-NX*!;(P?V!)&5~&~"R^C] M%+~K|B-K>6|DVGVGQ;Y R&=KCA+N;(&V^EE_YQWZ@ M2^J J02P$% % M @O8L-638.O&<|!O @PL
@ _I$;JW;W]KU>~%2VE9<D-R;7B M?GW/D^M91FT#>=&*Y%$G+FO)QOG;T.I5^3OE;^AM%O&6!~ID&6JA^A[VIE M<;>ROA(12I>A-HK422ER@S&P^&
@26T6I.P.ZG%6BU4 %?>P&R.NK!O-VEGR:G7:G8^&SJ8L MGP3^T+H3J|OX3J1^T|I87^XO3J!~!~D9 L"GSUMUKHQA0$JQK;79W;EDQ?W
M6^N7?7;~$LA1J(3GOSIRYB=>HJ|"%A5J|Q)=IMP&5M;~ 9GGOFI?~.9-G^C|R) M|D17MPN^P&85QJ!N+&C/R)1#$|6Y[GJ5AC?^D4;V MP&G+25E$CU;
O3C[XM?~ZG]~%IL@6=-8$B(1P,H@PST(#V9HZRZ;~SYAZIY^= MC66@7VRABH7Z^!#~81MOL9V-7S3XJ;)%F@Q|~I.ZR 8F^QBG21|DQ^E7Z:
M+T/TJ") GPH|6YT^9;96|YBC40|K3+MHB*~>GNK/7KT;OALOSHCHJ|K9^&6TC73915^WN0U5O06E @&=G4Y[N&4L^W^KE?>/(Q#HX MZ!AA&A)P(&%)HFZJ|D|(DA
1DQF$|X;+23|D|SYN72>9>>+ [N&;>X8U>MGM1025^4$97054&68 3L4;=8C)B|?2XKJ^GR+>S^HIWMR458BHZ^Q~N+ETZ523Z7 AF3?,"XTUS&ZJ MW-
JW>3^?12-.8A*1(Q0&RN8PH7Z4E~W];L;)E8WWB;?<OQ+3%~ETN2090 <; MMRKV:~9J^_YIRU8$1CP7G+P _P_17&=T2H+~^QKTLJ54C|QYE8J]4EYJ
M^8'U8V,V5D>MPA&~.~CI770-~.L,BY5@89$28XZJ|F4KK89^1K80V+3 M.E,940^3@>X>=52Y,4~R#H?($@JB1N^O3R2Z?I&@M@L5+7)KO@~PK>TD7"
M3C.GPJT,OPJG6^RT16XO;~.SD44.EOV6EY2B96J981!!OT=-98N<@<71N[H M=N1/DH@>~71(53;~DU@|12F*7+6A)2NX<~A]P^?E2M,Z8^Y_YA|VA79S,~^V_K0>~%IL-
JP^09|FAL#GQA+V M;P%(9+ M;~.JK5IR#PV2X&V72L;)&4TBGHI^A^1V>^PFT 1QE$P&.)J82NE%CP^M^0%
M42GT9S>0=S&M7:~)3YD48ONSEW/ M10W;|MOTD#%0JCQ$8J?~(H1H*J] MOJ5^X;~7;F]#(/'E~M-T&Y^V/W85&EKLGLXSA!W;][3SD M$~@C~^URR
M|ZJ K1JE;JA&~JUNGYQTF@>Q&VNVNW7ICS +I$Z;_J^_K$62|0$JL^ M^~!>=OJGEOQ?1W;FHM701C|TER;SY5D YROGXJ;#G;O[ME 4$#!10 ( M
+V+~5DD=5W!T@X IPH 8 >K>PO=VJR-W-H965T&UL MK5I;<JNX%7[GK|XVQU|1%UL1T|MQG^V6W3;K)NG&RG^T^D#1$ (2-B3!$*E M|;_O=PY $11E)
[OMBTV1P;~M="OMB8^K~==~779>77N|V7NKJG?>Q3>=J MD^9L^E7BR=+4A7X36^~.~54K7F&F(C^>329GQX74Z<~&K%WSONG|UPC0NUZ6Z
MKH5MD&6VJ]M-JA MHE;+EP?>T2V>O3V@|+ A^%JXV-X&5J)LCF^_UXF|TF!|~#E!>=I(PH2 V|5EG9@4@;ZTP1-H.70I?>O|P+>H|VG$>V#~+>V,MS^<(N7PC
MG7SUHC8;4=J4*~+%I5W@SE=DE^N7(VG&OOLRU56M|J(MCAQ-IWW$;J+ VU&S1PG^K2G^8CX9B=ED=O(O7DG ISIS^VXH M 7RZLJ^~'_JFG^7
```

ABPMF,FP+H3V3\ D MY8W\ Q50^QW0&#S[F5ABZ8LX"-&.AWBRG-UEZ'S/JXZ22&D1ZC@V1[I#W:RR7 M]/G;&SC1G79":.=LX7ND=\$\$\$V^TN>94?>BH.X",,j8Iu0#90MD=>+ X*A\$ M0\$T>HP>+IM9;PIR YU&X!>:!MU4BY40+ZH!>Z<0\$#1YSZ@+!1<5*N'DV.DL5E MJ);.\$70P\$*3KBJ9@^40?#;.*3,D'52T@TEML! ,U\$XWO-63#J]?BL6KIVX1< M .j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|JBZ&0?R*H%J|XZ<=> -V.PPY M[CO &VG1U DIBEN&JNA, "DU7L>\$O;A>D;F??[Z@ _&9H" *TRH2,6, + ^ _M8 Q04Y\$%G&I;E[WIUQ<27.2\ _<.#]0>@9AHK5Y(Q+%TH64V&DPJ)U8"E M!M!A\$;B0,\$F\$G'7VP;JH;38;,@HFI^9KR\$Z(VZV.QYQERRHF2+<@&[-39\$+ MMQKLY!L7)GJ][L1JH3S M))56JWE/DX&?>|QB)C%>7401OL4111? <#JAE5XU!K:3M.PS28;>V"3HHEI M8SB# 0FX5Y.VQVQY&LX;BP67&.W&3^46<*&M\$PP:E/U8ULG<94QBMRA4I6R!>0. M*C#A.(8,K)%BX4J13@/R7(*E M59WB<#%0R&#TZ12]5<8P NE7*P"@ ^77PW+VY[D7>9T+CBM8(V)VVS.18F> MHE6FNX45^7<&0?ML<3ZXRU4V5W1(L:N?|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|BZ.IZMTJ\$4HN M*+>JB60K+T43*!YS.;0S7=>#TH\$9 3PS*E/*50QA9-J6&6=%6Y\$1EP[#G6 M3)K%866(MB%HO/N;@S7TJG.\$);. \$2 TM=6R7PT%T/DAKLLA[MDQ\$CE->A\$>::P.1Y? 7! A6YWSVG+SF4U+ V*39V.GL:/ (9 MXB;VETIF<^>T] ^VPS |&VL@AR%^K3C^0 _U-J6YZ\$TOE2BF4JOK**!)TJ MLG9#9EJ8C4P 4C2^E>+>\$DT9D-\$2\$M87D.K%P:D [E(SU2B1W+9W%J%K)4RR M08L:BS _&8/HEEOQ+>=JJOZJ \$@ N7.T#B-&#&J[R<.(3WUJ31MY#NL* 4J31 MS96>GY;JHC/L\$82, =*72 *D9T39V1,7K\$E@6!;>9\$EXFW7/Y M.RJL +H;OX:*C?@>@ QJG4& (/I'1348\$E/.6ZXQGLYO@GC'FA< %<F/<K M?%W60 5 E8YKO *IWF&#&OLQ2L(Y%VT" >#>0S?7/W13K^#9T#);/SHV 6SFEW MJM JMKEGG>(OVOQR7J)G8#0^E5N56^6GIZO>#ROB\$#KZCFBIXJ?;J))!9^4JF.>LPT|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j3=0WCU%#IMMP 76I7/62QD@ MP' \LHA51!2P>P7XG7BD/EI-#&#U2C;E)TJ;LX1.N6 _JMOUID>P>3.9YMF 7ML| QQALQ@2*WS.M.N.ZH;IQT61?|&D M'6-T1)SP(ZVHSZ3+8YA-P97A5IS7Q<#(Z M|IK=\$56U+IX)[VL]G2SV@ZJYW, 4<9J)U? :6.VGY#2? JQ2/1U^O^ID= MWG@T# _IR!1? <&8S'AY-OUI|C6L77PGQ(%JZC/L1T? [O7<^_HUZO@#+YE M.#JSBK^J)S3UUWV-W55 _?U@SG+!|416;.)NJS5 _J8N9V=1%6C J/(I?9G; M,J^J?>\$> _K6'4(!#X-U-N@<[<(\$N_& W> UO4\$!#!!0 (<+V+&5G,I? CT M6 D .D8 9>@PO=VJR.W-H965TJ(QUY\$5=B;WM^YU;P^9+D7;URM1X,M< MFPYJ(PK^P^XJ)D7RM5@/IR=>#M(WNB) [MM7 W;Z&O=>F4+>2C8;; WUBB \$LW#75X1&3X&2R9S45B"V;.\$ *9W- IT/Z7U M2L\$ I=C8UM;@,^SFT7J&+J E;_T@&^2521QHX?JW@>U""%&, WRN=O69+\$FS_ M760 F<=>OB3M B4SM[S1798N(.15.Y); XN*GJFI" 5ROJ?;/63K\$C M6EJG|TH8S(DLPE ^6L6A)7 Y" PK@3&WNZPD;?R%>X|;71&V9H;-31'JY5 M+PWC9\$%>78&7R7DW.W\$SG/I&5G&2RIJ _J+XN%*(%I/I?7 80M.;&K?=>=! MW?B NGV^6QJ6GEGTJ1MRPJ@6F?N+>Q?GQ4X;JTE76>321N?#J[R-V M3QN|I|>T _D!5=VW6?(_ ,%7X<^">|*X3C5\$KM;&%"@GTIV-W^2\$5107+< M4I""%2^V#)^%\$1F3A=-0S#Z.IJT\$(^ZXQ9^4%;_!B">M=2*4JZ* [X5TAN_42(WFJ)J0^R53MWO>C.A.D9R;)(2\$FN6(K8:3.F)Y<|P|?QB87J>HN#A1J5V+&^B142 _L MD|ID4+ 30J)05.LV1CHG'E9H" O:Y+>#?LT2UOY? 27.F,9Y+!|L38KJ|R M+6TV.HR7.JW, #W _J^3ML2BWW\$3B9#>#V06S2L[KD%JHSW-HI.HVG+J UI MBWV(=I?O-P%VM8\$J4J27?HNZ0?*@JN;P<F29J8Z1 0'-J%@'OW;_N|< M#9FX^UM=7 4 L=JM') _EW(2 ^XJ38^?Y%>E.(8Y=R109.^L/J)O4SDO" MJ|>G4D/J/@;J6^V6QI=+H*^7)WJL%429*G@Y1V44"V _M|J3I!+AJAYBH M'08TGUDYGAV+M<IG9\$SO^UER58<<5G^N5*# !BTFD|D|(\$O),6?%RBF&A?J M@8I(C=IPTM^CP \$^6IC)Z^X^EH[5]A15PEPD+8SK<A\$98=A/G1Q16V1J07 MW^J-UR M4\$96M B|CHJ+V|N7D#&8AP|SY@J1&G\$@=L 9BQ08DSNF+!>.G9S'P^&PS[IM MD^@=>=1WKJUI'E'ZK;\$ _5['K8RA&O'.Q)=7AJG|HVPYUJ? &#"A2LLP/OS:AYLR&3:5 MID.YE: A3(XA[M1/I&A6@784D" P"||"0LYOB):2CIW 2BTF@;FLR@SEL248DQQJV|@R:U;JG08O>V _"(I2'OAD120|_BL|FW M'D8Z=NW1UT@!7A,JOI="2194K3H4S1ZVH("GI23)(BT-40QML-#7:X82 M)-DG^&6EMCJRPJ-P+LW&=>XO!E\$W7C^K<^LD3J:BQ@|E0|BCPI+>5JS"0(J:T?T? P4,X4V3!|@;H.Z MDJ|= @I?9? JAS^Y?K?SZI:2>+CC&JY5..WQK1Q?#X:L0V2&+I|Z^K(T%9C MID,I)K99J;X3/(OV2>GU:89,22,DEPPE+AM<|I|B=Z\$C"\$T\$PT" ("6ETG+78 _1"G>E%3U=2W73I^%> _M*JQ[\$**N4%+I+E|M'EW.JA3Z MC8=M=;A>ZSJBQJDI>@8I;G6AQ1*ER(JQV=YQ/ PG'I ENI)=HL>" _SD: (%IZ? S?..HX1M?T? M83 @OAJ HHZ:90!\$S'LF7T>HHJ> M>QB8.KY9X9,19DGGO#J|X B<&IF(IM%W>1YF<@>(K7L'AX'ID;G4?OTA:Z>OUZ M5G? #2B12=<=> 0X<)> 9 WVW."9;F574\$56%+J0-E2QO;CK@Y!^I3R*F@U(47E.C'X'N 500W97J)\$2,.; & MN4J Q W08*L6\$S.J4Q@&+<^GXF1"(TBWJ)&6\$Z70^OH-?%R/Z;6U)UO# MJ14""9\$1R@=E"2CGGJ>=!%GLK[XI9U62JZCWW3 @ M3C,U1-6060>|P|7B"AAHWY;A(G6.>6J%9R 311.8*GE?>@JZT0=(I3=K M;OQ.I?C&HNILO^LJ<|<|Z? LX%0DB7?#9S7KBRJQ<^7OG+@J0[IW YU)P, 6X/M@<U< T; _V|< @_j0 M2Y%> @ 08L6;ZX>?>P 6 @ !D !X;|JW)WK&ULE5?;JLV\$|W7T&H0)ZR;=-\$MM XZ|8!T0|SC6|6'8 T6= M+2X4J|(H _LO=T?)BH(ZI0I@FS NOON^ _H+>=IYRP|@GBNC,5%4H907V<9 MJA|B;FKP=>A.QOE^ILK5;8:UUE\$S|DD X.JNDMLER'M? N_7-NFF"TA7LO ML^DJZO-W8-Q^D5PDQX4'O2T#>+V3+>2VW) CA6W905:9.U*(6NP*)V5GC8+>+5 MQ?7-C.VCP5|JC@8^U:2. ?\$DZ.%(ADS(3"@ B- (^MGI&HQA#+QO<=> _!L M #?PT6<^M#22X2U.W K(I2+Y'H1!6QD8I*#V.LG9ZC)*=>#"IMVU YW.5AX'U^L-ATCE.(NV44&3Y1O.YG^NW%YZM'8T'46KT M)G+;@Z=>=37YAN796@0U>.&#?"00K&61E _LUJF M8G6,1)ZLZUOZF+Y B%<OTH-4 V!\$ DAFM|' _LLOD#MD'1 M=AXID),?>W: MG^2C%R&3L-/+TPK>1#PK("P-BT(O):S.ZT8768J|MZJDEQ*%&8<:O _"(3R M1.O&(1(>Z<)&E7WJ4G\$G+756KJ7(P6C8 8YB38?UTSVH0P*DAI)|@3<> ;8GDVY5|37|+>2^KQAXSV.\$>46*W X(C;K,X)YM!|!4 M\$W(9X9Y^W>O[N'7'SZC(^T4DCP-CM^OBU?JN,*S1'9+>ROVS)0HG,P3 MAQIU|&MGM-*T5KC.\$:GIQWP/LB2+YQB MD|O5 MG<J6^<6^B F9JM|) V6;Y?&F.TI? MSZ(2W)V\$EP=W&PO=VJR.W-H965TQW>VJ|J(P&R!U^HL2R8#NY4M4(BYGF4)YQBM@>F?|14F4 M-L42RTH R2RH+>#OND<=&LJ<+.*"N8@C7JN).I@+).NR)J @5?CQW/V3AN MZ#7QH'C9>+N 5U5|V|M\$G#G'DM\$2F2*>(O&+L7J/C6A&BMF|J@RYD|> MVSIL :>J +|%^"!I!X1Y T*URJ\$+2!K<*@=(^C4<9+5Q?Q(DCP=+(F&C- M9A.V^A-MZT69>2>W2NA=JG\$J(GM)H#L^*.98"2JA,RYK >@4W=TFZ/CH M!!TARM"OG->2L\$Q&6&EMPX#35F72ZJA|=JTS9Q#9JQ#>+>?(8/SR QSKG M+G% D.C\$TCXO69G* (= UPYJ|S3/V# K2^3 UV905=XH1=^J@L'S16UY! MWV4W=&\$ G>EM(UF1%;..EX2Q J<^.; ^A^Z.O>T>Y(EITDV>R-RG3L)NSL M#"/ 60N&(I+P\$= ^J2GO3=0T,QM!1F)*SBT^*#T9XM5W@GJC00OQCL1B4J MD>>AZ^>J\$S7JB/GO>U>3^J|J2^6(1T%\$J6J9JIYEIWF\$S7MLF^|S^|T=3K M|2=Z.C7*)F^&L9571^PIDZB A99RSIYUPQ3-N@&Q2O;#^>YTMW5+G,J84&8 M +V_X%MQM#Y0S>XU'U! P04 _"JBPU9Y+>L0\$0" *|@& 'AL M4W=OGV0\$3XJ(^.C? U)P>59 MX15:UPO25UD)58C40, W3W(A*ZS- 5!:_jB5@XI(JYH=1,K3+F7QFYM(J-8 M-JI!#AN\$5-56+ZN@>(E#XHVJX)*6%j6V'WX:U|B I) _ZHIT,|^G\$H!5U1P M)M^O.0.5XL9K;>!? PDJ|G8R1K60GQ+.=K\$BK!58&3\$K"Y|>\$>.&.@H &J M8WKJEC;Q=RD?WUFUIV6,=&8+HT67B?? 0@1PW3&.%X1MT|4PM+Q,N2LZ M+V11PIEC="BZ1^045Y!&S&R+ YOC'K|<^CWBH^?S>=>|9!& ME">J|D(GFX;I?F<WU-MM'2BUO!)OYBO%|R&F6^YS7NW^=4. ^PWS+WHYY TAPIDJ;J@OIEH MN&Y;1.; _JIEVU AK=^@+^G*&G;.0F-1C-S>N4;>=>K)UK4KMOLA#;JRPV+ M|L _0;JUP(?9S8#?K?3 H'4\$M#!I0 (+V+&5FV6979/J AK 9 M>+&PO=VJR.W-H965TJ|HPB MZR5^RXMG*?MYJ.Y?72FYN;^P'1D(2&!)O"M*S^<GMV 9'03M.Y|!8DD/L M=A> [SSZ|Y*NUJ3J;I5] W1=Y:5?+JY;O3@ ^MNE2%=(.S4J5N#(W52\$=OE+>M8|NJE,QX49\$23T:CT^>^Z0+@!A7 =E=OC^URW6I;BIAZZ^0U>.-RLWZ|<^X MH/GA@UXL? UP?|EJ)1?J5KEJYL*WXY;.*9DN5&FU^46EYJ|H8LOWHQQ @ M FUFU5K&WT69,K.F, TY5WV^F!\$&JE|+^>^C M 4>GIZ(MM+;.%&Q>^ATZ? +>^> (^_YZ)Z%|D|!@PGK|C5C+M+)RU>568N*|H8T'L"F MfHHITLZE5M7X.K.G=EY:~F+ITN^>+>Y#K5R@|;\$...)1A| ^IjV.'|6C1 M<1\$SO &B)X^>|/A6_F(MK? BAS\$2VO?X8.K:Z3AI=WT\$V'OOQ7LO?>#000J'D M^1YYT|V*8;_QJQ>EGNM4D\$>JYJTF>I5KJXSXJ7.N@|I)-J M3 B-GO=O1)GUPJ|D|JEX? ('6LJN|4P>7WWXU1N WF/&+>J/NYF7;Z35HEQ@ MV:63%.YJ2NX5TJZDKVSQ<F03JPD15K3.+G M9Y*+4 %?%C(\$AK9I52WBDDQ4ZHD2M98=&J|KFQ-A^",<- BEJLGLWLLR (LZ MY^U9J|KXJ>O/M;TFB%;F+>OE\$D.=7WWYUJ|J.7 MMSJ|<Z?QRZ.AN+|BI.I).Y)7PX**K"/[# @W:~>#?^!E:2|@)U65 RR* M\$G9>=>A@E74CFW!A7&J=\$IFV;^UO#R.*D6 _)|@J03\$;FX|0CK0H:PB) 2IZ M _I=Z4Y=I3%6&>Q2 Q2WY>PCN51OU S M6:|I/TI-QI^>E86BHJ7)P'X|/36H8/" ;'QDB6I@Q4RS\$7.(9I@H)*U58@ MDH3,?D2UXK4#&J|MIYTIYV(KBEA)A*B1^MY90FLYBKGA MU3880I.YO8NF*08FJ;.(68+2G%M.XM|OIEZP+Q^X6Y\$9'K-V+V)WIER^D9J, MON\$>UJJ0&X#=->J|JLO>AAL;..|JHDLHJ@> -6 MWXO'LP.O\$FJ^FO^4.PIER=mn3S96RY,K097 5+H%2 ;=>AHW-J9;=>PYL M#H^5=YO? =7T _+P(KZIW)?6E/LQJ%-E5KKG+XJ|O<@ U^FVH0K@)|WDIYW)6A> SUW*FZX&IU1Z:24HWL1^2'D0 M^>6P9E9,N.;JL(5/8&U4*PD*F9J6>(FAD:BG|X@TWQ|< :ZY*UG&TFP) MNYISYPNRJ&2Q?^ 3>@+J,3 \$6MLB'H(Q58^&K M1B1STD^>@SF,HY^E-(9W M2K60U)*5-JEF*. HI5IF@ "AH,41T:N V(8IE4%?@?S1 CA-NC589K? 0#QQ M@R0< " P# ^JY6@RNTJ4WJF M,Y5KW|F F 3-16MLX1LND#|>=>S\$F&X1NX8|'BH1L.9XCJ>CXGJ(+9 M<~!%/A15LOLTDJ>^".FK:TP|@PAF1Q.DA8+UBK'.07DHS^*VO _M9!>D@Q*Z1)HY!WI23YT5-KGBN<^>Y!II&Y0C7 PF)#G2."A50LQ)RLI"% JN|@>SD^Q<|U.6VKR>E>GJOG\$J M|W;OIT8-.HTI.8J/GJT.O Q/4 MC@NO\$S^0^FIR<C?ZZTSZ6?BH)1KS _?WR>G>J|?25|KZFP;=>YB.^A MXOAFD@;*\$>;LIG"K&M6I9J\$A**H\$(B;T)+Q =E6E8*1J|Z(91P -FNCT MV'Q4.5W4A2 V1.K=\$A^F'HJ1G9#T^31H1J6XX&Q6QZY M&@>3^Q&WICHH HS,4)R'Z='A M].CPZFC[^-2.2 B\$#Z#E0'J&N=*IRO@3B'6%Q: A6<*&MD-2VL4C'INH)APV7>U#8R.%T9@|N#>VCRPQWM>X1\$V;JY93,|C|(.GD5QV&(+YPCFT&RY>6NVVPQ|TT"Z MCJ)=X(E8^M2 ^+!I2.E5AY9H*Y8^0Z+N+NM(T#GR022.8&|..-X5J)Q M^3'H.X" 6AR9JN|GZ9J7RJC7E.%W1R^*M0D4Z+>S3S13-GP-LBD=D6<@^2V M24>3\$ZZI6>+PBM84?S!R/L@&)=4C9NLE\$G&B@SW>+NV&G-GU=UZ4\$DH8|H MCR.'?N\$86U\$LOG&L+!|(MP#BM J|J> ^8FCY21B+C C^C"J[G9I=^"93X=2& MXLHEGD JOCT,6:E*2ZNJEN#3XYF3Z&V0IQILCGH)MDJ54T" RGV M+I6'R*8 M.RJJC6;| MW\$(O: K)9!+ZR4&O!IPY2-Y"=R\$8+2@YM\$0F6<5,1YL>LU2K)XJ2D2K)!" (^<^<+>#?TI<^E5N;<3A^6 ^.;>#Z#F;MGT| M1(W|JR\$5RL.MUVSWABD+UUI^VA(G;GL/L)QUA^LUDUX9-OFQ3.E/KOWM;T MVR3PF?ON4<^V^?U8YI=P&TAYL=U(X#&TRTT2(451^5M^>+>4(L9XIH;? MCTM)W|KQ+>U^HJ9^2*H!IDZ\$2V58;#S#<#>M3I3V31UD21KQ.\$RJM:*&Q MD0J|K>E_IUHA,ZY\$D?Z!)? P+*AY|)01^N2YX^N+>8+=;ID(J.-ONHQIC^5P?|H27Q?Z(L)2SF;0! =R^G^9GO@|;^/S?&|T?0A)YXGE+25= M;XSNE=+>^)*.*%RQ0F/2 3L)#IXO@9 _%L\$/IZ@&(.K18N#3E|M7A1J| MD3<^*ZJ);^Z^7CFXE<=M.[S5N5R3>ST5A&:-\$^C2J|XCY5?2N&#>G.1E#A M#M10;.TU=;9X,3>#STI|H;M>| M|P8Y(M- PH);.J7.2@FE&J&K\$WORDNT1| E?J|U>|J|?8 MOICL>C@>D_ 5V.T|W""% D@G9U>RW.GH|&3&%->LCY.X61623.8*| MEXJN,A2 _&L;6!1+;L0FNV#)J21+>+>6S9B#&E,8VCSU5^7V0TV*YJ|M'ILY:O MAJE=)W#U>JBP94ON2>?FB=7SOPP35W20VDJ+79P|XHM&30>@JQM(=O^P)AZJK&I|H+P-N6Q M)_TJ M.AB4K

HKRP;WJ1:WLBDBW=2R^+QDRX!#0+/[PX,%(5P*TB"E.S%:&XK>' MNW"L%)%3>T+;:]3V1%*7V.X.&3^1<:17AU [0RT\XB?9\W>*MO':<:C[BV6 MT?>X1FO,Q\I>W=5]>[KJ]QT[0]M2Z?JES^<:;V7H7>[UO]=1% LO\I\J/R MT1214+V\TCQSPY#7Y*E]6X0-.N\ [LH[SAS'O#O3L :NF#31(-NL4ATN>.*NE MP.PP.1\W#WIK>=>Q1>?>. #9 >[646V]W<:;]UO>:~>[JGO;@E9RS!T]5Y8KMZ68<= ML2?I\W[V]5Y87CR3S-!EP+=>^02K0G+G+S?J?G\Q(RD&;& M1LX'7268>SA'Z6K5-9A?/[4"4"~*~>K04Y@'G/Y)?SP7?"4%BI\BWZ.* M,1V&I[G, L(3LZZJ7A10)%1 (=0%LT9M\1J D6S0SW^>)&K?>H1?0B::V) M(S2?)>WZ.CB]&F+Z6;IG@XO\ZW\F@'STY^>GP]& MI^>X-I=#\$Y'H^1Z^Y BV&K=P<("TG\X\1^2YR'CR,OEJH,Z&4PF\$#I\ MPQWCBPM6-1J\$12 :C; &2&5]J' "TR4QI"~>[?]&WJ\F. QL9R.G%>~>LD7R MY'WOHD3=4JLZ<="ATOC2,3,3/QT<[YX<->WAU>ZJ4A\X?M]216G%Q[C3>FR%O M\JVQT-D#GLV^>Y>^8H?O?>3P#?>HJV3.*O,~MH,GX;O3#UKALTQ49 IYWZ]\$\$7 MK1=%2TG%L=L=426ZK^O0%Q T3N9A:H6 .813R^YU ;J,'JMWVZ\NJT=K?J M5V- D=4'Q5[D:HEZ^'9R8H^NF HLS*W#< @.0J2P,%> O8L-6?>- KP6 P 1 8 !D !X; \JW;W)K M&ULK551;JLV\$[WKSBOH^!>B1+MF*GMH\$D;\$.#M?K4V? 8P([F&F3A18E1)*DK 824K3J ZZJ2#S\JON^<.)JU2;JULC.GAI MI+>+KJ'NO4D2RVM\F+W2+2KZ4FG3,>FV2>V- MS&E.R.>P>K?<@MFL->9K?>H=3J.II&QXVO8E\ [OY%L5BW,XQ=G^V#(2L944K1 MH+)*~S18K;Z\%XO2N?>C%>[>]J2 M>B"2]>V &8V4/OIT743 %*G7;~XKV6?XO2U>MH\$4&)%>ND^ZK\W^'OSJSC M<2M>Q<(^Z+~"AGG6X.P.2@661XLY=#4X)%NE/K#O#01?T#1Y0?FV&E M= >>Q.T3140S2]>I\$H?RM9>BHHSFVVPV& KF KJDI4@C\EX)9SW2DGU!X> MCMQ\!+5AY5\!B8H.* M *\$F/5J4I'Q\>J02+>I\!IZ- CXPFS'PT1>4<3>Y7;JY9,OG;.+>UN2L9P1WQ9?I(9)4JCL<~ B M8IG^,H^G\^J5Q.'G6R' PG46SXLO.'IF#&1J9W&^6,1L1:15FB\ C M(DTGA,2,15;UC,8)ZKH&A:ZIZA<~,HK^XR.9Q.BW@9M%-LW>3QZU8Q^F M<981?Y- 'M/E,D@<=>[V2D]H1H-F^>AYZ=>(0V3<4?P3\Y?K@&L S,WM\ MB4NL^#22\NIY8<9.9!A.MV\$.[2C]J1.6?U&T@'>EYI[8Z&]QA_3O)>+ M P04 " "JBPU9 PL-1LX" *]>@ &'AL+W=O>[V<=>U.53KQ163Z M1#8H:~>3JF2&IFKEZ4H4QNGLO~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~Z5\X&HSI4<3=Q7Z?ZB2~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~HL\~#MSJQ?>#&KV1?>.'>K\J C7-XA:EQ^*PY4&8CMY=#6< M7H^>=O3?XG>=>[>1W55D\<5-/A7S^&K^>.>@1C\T\>102\$<\$>XN&,>VI# M\7A1O\ HM9.6%3-XH\0? O+>[>32]H. JX5J4N/L="C";Z&Q\JL\$VX? J MNC96EBTS,2BY#< VU\$S<D>,>A<Q12SSL\BPP_>L6,ZWWH\TUH,FIE^>J MB1R7+BE+JVF7DYJ=W"))M.# S%8"S=DLM@3JMN)U W =-(W^*X4]+N#>PD M^RQ>^>=IF64^AA=IYV OJ1R^*D-(DS3KP1JW^D<=>=2O\|VIEK^8B^N4 MQ@>1J689P^V^J^K;>+>425;U 8K3X&S:MAGOS803K^69=Z[LE7;2B%>@AJ \NZ MJ@>12T5LFX\H)M<2W\I\AEP152J\Z@>@NP^H^4YH2YH6\J\K\@>D?>@I M+>P.X7L47H33Z3,>#J-LHO?>3<N41\1) (IK+>=>H830\J[F,NK2>K\>EJ MJ @>:+=Y+M3FHFJ8,P.M@>7 /K1^X2\^EDZJ9 /RDE7;WAR=+3Z\KJTR&G34P+BM@? % MKH&M:TUPAVC1PA)BR\?>+A\H71J=QW1VLBE^B=&CN,6 1)M7G<8\7^7< MKJZ^X3ASPS%E/=&#'(99UIQK0^f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~(,TL29^>EMDXD>Y8Q3^X2.DY2.O><=>Q^>W^>V^>M\W?>B=4,5B\I.#N:@>M.#?>:GCI>F\X(DP1^>U8NN2-1G5,Y+>EY0K^>4YL\FB1->M0B,8A620PEG@Q)YGH@>[WXX\

[illegible]

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

[Accounting Principles \(Details\) Details](#) [http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciplesTables 26 false false R27.htm 996008 - Disclosure - Summary of Significant Accounting Principles \(Details\) - Schedule of Dilutive Common Stock Equivalents Sheet](#) [http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable Summary of Significant Accounting Principles \(Details\) - Schedule of Dilutive Common Stock Equivalents Details](#) [http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciplesTables 27 false false R28.htm 996009 - Disclosure - Fixed Assets, Net \(Details\) Sheet](#) [http://www.tenonmed.com/role/FixedAssetsNetDetails Fixed Assets, Net \(Details\) Details](#) [http://www.tenonmed.com/role/FixedAssetsNetTables 28 false false R29.htm 996010 - Disclosure - Fixed Assets, Net \(Details\) - Schedule of Fixed Assets, Net Sheet](#) [http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable Fixed Assets, Net \(Details\) - Schedule of Fixed Assets, Net Details](#) [http://www.tenonmed.com/role/FixedAssetsNetTables 29 false false R30.htm 996011 - Disclosure - Accrued Expenses \(Details\) - Schedule of Accrued Expenses Sheet](#) [http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable Accrued Expenses \(Details\) - Schedule of Accrued Expenses Details](#) [http://www.tenonmed.com/role/AccruedExpensesTables 30 false false R31.htm 996012 - Disclosure - Debt \(Details\) Sheet](#) [http://www.tenonmed.com/role/DebtDetails Debt \(Details\) Details](#) [http://www.tenonmed.com/role/Debt 31 false false R32.htm 996013 - Disclosure - Leases \(Details\) Sheet](#) [http://www.tenonmed.com/role/LeasesDetails Leases \(Details\) Details](#) [http://www.tenonmed.com/role/LeasesTables 32 false false R33.htm 996014 - Disclosure - Leases \(Details\) - Schedule of Supplemental Balance Sheet Information Related to Leases Sheet](#) [http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable Leases \(Details\) - Schedule of Supplemental Balance Sheet Information Related to Leases Details](#) [http://www.tenonmed.com/role/LeasesTables 33 false false R34.htm 996015 - Disclosure - Leases \(Details\) - Schedule of Future Maturities of Operating Lease Liabilities Sheet](#) [http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable Leases \(Details\) - Schedule of Future Maturities of Operating Lease Liabilities Details](#) [http://www.tenonmed.com/role/LeasesTables 34 false false R35.htm 996016 - Disclosure - Stockholders' Equity \(Details\) Sheet](#) [http://www.tenonmed.com/role/StockholdersEquityDetails Stockholders' Equity \(Details\) Details](#) [http://www.tenonmed.com/role/StockholdersEquityTables 35 false false R36.htm 996017 - Disclosure - Stockholders' Equity \(Details\) - Schedule of Stock Option and Restricted Stock Unit Activity Sheet](#) [http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable Stockholders' Equity \(Details\) - Schedule of Stock Option and Restricted Stock Unit Activity Details](#) [http://www.tenonmed.com/role/StockholdersEquityTables 36 false false R37.htm 996018 - Disclosure - Stockholders' Equity \(Details\) - Schedule of Stock-Based Compensation Expense Recognized Sheet](#) [http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable Stockholders' Equity \(Details\) - Schedule of Stock-Based Compensation Expense Recognized Details](#) [http://www.tenonmed.com/role/StockholdersEquityTables 37 false false R38.htm 996019 - Disclosure - Commitments and Contingencies \(Details\) Sheet](#) [http://www.tenonmed.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies \(Details\) Details](#) [http://www.tenonmed.com/role/CommitmentsandContingenciesTables 38 false false R39.htm 996020 - Disclosure - Commitments and Contingencies \(Details\) - Schedule of Reconciliation of the Liability Sheet](#) [http://www.tenonmed.com/role/ScheduleofReconciliationoftheLiabilityTable Commitments and Contingencies \(Details\) - Schedule of Reconciliation of the Liability Details](#) [http://www.tenonmed.com/role/CommitmentsandContingenciesTables 39 false false All Reports Book All Reports](#) [ea0210949-10q tenon.htm tnon-20240630.xsd tnon-20240630 cal.xml tnon-20240630 def.xml tnon-20240630 lab.xml tnon-20240630 pre.xml](#) [http://fasb.org/srt/2024](#) [http://fasb.org/us-gaap/2024](#) [http://xbrl.sec.gov/dei/2024](#) [http://xbrl.sec.gov/ecd/2024](#) [true](#) [JSON 58 MetaLinks](#) [json IDEA: XBRL DOCUMENT](#) [{"version": "2.2", "instance": {"ea0210949-10q tenon.htm": {"nsprefix": "tnon", "nsuri": "http://www.tenonmed.com/20240630", "dts": {"inline": {"local": {"ea0210949-10q tenon.htm"}}, "schema": {"local": {"tnon-20240630.xsd"}}, "remote": {"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/irrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024 def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024 lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024 pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"}}, "calculationLink": {"local": {"tnon-20240630 cal.xml"}}, "definitionLink": {"local": {"tnon-20240630 def.xml"}}, "labelLink": {"local": {"tnon-20240630 lab.xml"}}, "presentationLink": {"local": {"tnon-20240630 pre.xml"}}, "keyStandard": 212, "keyCustom": 40, "axisStandard": 19, "axisCustom": 1, "memberStandard": 27, "memberCustom": 18, "hidden": {"total": 126, "http://fasb.org/us-gaap/2024": 116, "http://www.tenonmed.com/20240630": 5, "http://xbrl.sec.gov/dei/2024": 5}, "contextCount": 179, "entityCount": 1, "segmentCount": 48, "elementCount": 619, "unitCount": 4, "baseTaxonomies": {"http://fasb.org/us-gaap/2024": 590, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1}, "report": {"R1": {"role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": 1, "firstAnchor": {"contextRef": "c0", "name": "dei-Documents", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"p": "div", "body": "html"}, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true}}, "R2": {"role": "http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets \(Unaudited\)", "shortName": "Condensed Consolidated Balance Sheets \(Unaudited\)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 2, "firstAnchor": {"contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"td": "tr", "table": "div", "body": "html"}, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true}}, "R3": {"role": "http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets \(Unaudited\) \(Parentheticals\)", "shortName": "Condensed Consolidated Balance Sheets \(Unaudited\) \(Parentheticals\)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": 3, "firstAnchor": {"contextRef": "c2", "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"td": "tr", "table": "div", "body": "html"}, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true}}, "R4": {"role": "http://www.tenonmed.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss \(Unaudited\)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss \(Unaudited\)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 4, "firstAnchor": {"contextRef": "c6", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"td": "tr", "table": "div", "body": "html"}, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true}}, "R5": {"role": "http://www.tenonmed.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "995304 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss \(Unaudited\) \(Parentheticals\)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss \(Unaudited\) \(Parentheticals\)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": 5, "firstAnchor": {"contextRef": "c6", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"td": "tr", "table": "div", "body": "html"}, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true}}, "R6": {"role": "http://www.tenonmed.com/role/ShareholdersEquityType2or3", "longName": "995305 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity \(Unaudited\)", "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity \(Unaudited\)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 6, "firstAnchor": {"contextRef": "c53", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {"td": "tr", "table": "div", "body": "html"}, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true}}, "R7": {"role": "http://www.tenonmed.com/role/ConsolidatedCashFlow", "longName": "9953](#)

[http://www.tenonmed.com/role/AccruedExpensesTables", "longName": "995310 - Disclosure - Accrued Expenses \(Tables\)", "shortName": "Accrued Expenses \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.tenonmed.com/role/Debt", "longName": "995311 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tenonmed.com/role/Leases", "longName": "995312 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tenonmed.com/role/StockholdersEquity", "longName": "995313 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tenonmed.com/role/CommitmentsandContingencies", "longName": "995314 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tenonmed.com/role/ConcentrationsofRisk", "longName": "995315 - Disclosure - Concentrations of Risk", "shortName": "Concentrations of Risk", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": \["td", "tr", "table", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c6", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmtdFlag", "p", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c6", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmtdFlag", "p", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tenonmed.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy \(Policies\)", "shortName": "Accounting Policies, by Policy \(Policies\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciplesTables", "longName": "996001 - Disclosure - Summary of Significant Accounting Principles \(Tables\)", "shortName": "Summary of Significant Accounting Principles \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["p", "ix:continuation", "ix:continuation", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["p", "ix:continuation", "ix:continuation", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.tenonmed.com/role/FixedAssetsNetTables", "longName": "996002 - Disclosure - Fixed Assets, Net \(Tables\)", "shortName": "Fixed Assets, Net \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.tenonmed.com/role/AccruedExpensesTables", "longName": "996003 - Disclosure - Accrued Expenses \(Tables\)", "shortName": "Accrued Expenses \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \["p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" \] }, "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.tenonmed.com/role/LeasesTables", "longName": "996004 - Disclosure - Leases \(Tables\)", "shortName": "Leases \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,](#)

"tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R28": { "role": "http://www.tenonmed.com/role/FixedAssetsNetDetails", "longName": "996009 - Disclosure - Fixed Assets, Net (Details)", "shortName": "Fixed Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R29": { "role": "http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable", "longName": "996010 - Disclosure - Fixed Assets, Net (Details) - Schedule of Fixed Assets, Net", "shortName": "Fixed Assets, Net (Details) - Schedule of Fixed Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R30": { "role": "http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable", "longName": "996011 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Expenses", "shortName": "Accrued Expenses (Details) - Schedule of Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R31": { "role": "http://www.tenonmed.com/role/DebtDetails", "longName": "996012 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c86", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c86", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R32": { "role": "http://www.tenonmed.com/role/LeasesDetails", "longName": "996013 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R33": { "role": "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedToLeasesTable", "longName": "996014 - Disclosure - Leases (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases", "shortName": "Leases (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": null } , "R34": { "role": "http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable", "longName": "996015 - Disclosure - Leases (Details) - Schedule of Future Maturities of Operating Lease Liabilities", "shortName": "Leases (Details) - Schedule of Future Maturities of Operating Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R35": { "role": "http://www.tenonmed.com/role/StockholdersEquityDetails", "longName": "996016 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c92", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c92", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R36": { "role": "http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable", "longName": "996017 - Disclosure - Stockholders' Equity (Details) - Schedule of Stock Option and Restricted Stock Unit Activity", "shortName": "Stockholders' Equity (Details) - Schedule of Stock Option and Restricted Stock Unit Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R37": { "role": "http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable", "longName": "996018 - Disclosure - Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense Recognized", "shortName": "Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense Recognized", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R38": { "role": "http://www.tenonmed.com/role/CommitmentsAndContingenciesDetails", "longName": "996019 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c164", "name": "tnon:AgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "c164", "name": "tnon:AgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"] , "reportCount": 1, "baseRef": "ea0210949-10q tenon.htm", "first": true, "unique": true } } , "R39": { "role":

monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "AccruedCommissionsNoncurrent", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions, net of current portion", "documentation": "Accrued commissions non current.", "label": "Accrued Commissions Noncurrent" } } }, "auth ref": [] }, "us-gaap AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable": { "lang": { "en-us": { "role": { "totalLabel": "Total accrued expenses", "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": ["r36"] }, "us-gaap AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses [Abstract]" } } }, "auth ref": [] }, "us-gaap AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses [Abstract]" } } }, "auth ref": [] }, "us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable": { "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable": { "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth ref": ["r28", "r128", "r438"] }, "us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth ref": ["r15", "r16", "r50", "r134", "r435", "r453", "r454"] }, "us-gaap AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.tenonmed.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth ref": ["r1", "r10", "r16", "r345", "r348", "r387", "r449", "r450", "r749", "r750", "r751", "r759", "r760", "r761", "r762"] }, "ecd Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth ref": ["r675"] }, "tnon AdditionalCompensationPerQuarter": { "xbrltype": "perShareItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "AdditionalCompensationPerQuarter", "presentation": { "http://www.tenonmed.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional compensation payable per quarter (in Dollars per share)", "documentation": "Additional compensation payable per quarter.", "label": "Additional Compensation Per Quarter" } } }, "auth ref": [] }, "us-gaap AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth ref": ["r45", "r596", "r866"] }, "us-gaap AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.tenonmed.com/role/ShareholdersEquityType2or3": { "http://www.tenonmed.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "verboseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth ref": ["r463", "r759", "r760", "r761", "r762", "r813", "r867"] }, "dei AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)", "documentation": "Additional Securities. 462(b)" } } }, "auth ref": ["r731"] }, "dei AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b), File Number" } } }, "auth ref": ["r731"] }, "dei AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Additional Securities Effective. 413(b)" } } }, "auth ref": ["r729"] }, "dei AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth ref": [] }, "ecd AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth ref": ["r688"] }, "ecd AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth ref": ["r688"] }, "ecd AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth ref": ["r688"] }, "ecd AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth ref": ["r688"] }, "us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": { "http://www.tenonmed.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth ref": [] }, "us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth ref": [] }, "tnon AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "AggregateOfferingPrice", "crdr": "debit", "presentation": { "http://www.tenonmed.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price (in Dollars)", "documentation": "The amount of aggregate offering price.", "label": "Aggregate Offering Price" } } }, "auth ref": [] }, "ecd AggtChngPnsnValInSummaryCompstnTblForPlblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForPlblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth ref": ["r722"] }, "ecd AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "

"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r688"] }, "ecd AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r695"] }, "ecd AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r642", "r653", "r669", "r695", "r704", "r708", "r716"] }, "ecd AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r714"] }, "us-gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r319", "r320"] }, "tnon AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restated Sales Agreement [Member]", "documentation": "Amended and restated exclusive sales representative agreement.", "label": "Amended And Restated Exclusive Sales Representative Agreement Member" } } }, "auth_ref": [] }, "dei AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r645"] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r182"] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r22"] }, "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "label": "Schedule of Dilutive Common Stock Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r22"] }, "dei ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r339"] }, "tnon AsPerAgreementValueToPayTheRepresentativeInTheEventOfAcquisitionNetOfPreviousAmountPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "AsPerAgreementValueToPayTheRepresentativeInTheEventOfAcquisitionNetOfPreviousAmountPaid", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount paid", "documentation": "As per agreement value to pay the representative in the event of acquisition net of previous amount paid.", "label": "As Per Agreement Value To Pay The Representative In The Event Of Acquisition Net Of Previous Amount Paid" } } }, "auth_ref": [] }, "us-gaap Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r79", "r89", "r129", "r158", "r185", "r189", "r195", "r196", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r340", "r342", "r365", "r430", "r502", "r570", "r571", "r596", "r617", "r782", "r783", "r827"] }, "us-gaap AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r124", "r136", "r158", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r340", "r342", "r365", "r596", "r782", "r783", "r827"] }, "us-gaap AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "tnon AtTheMarketOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "AtTheMarketOfferingProgramMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "At-the-Market Offering Program [Member]", "label": "Atthe Market Offering Program Member" } } }, "auth_ref": [] }, "dei AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r645"] }, "dei AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r630", "r633", "r645"] }, "dei AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "presentation": ["http://xbrl.sec.gov/dei/2024", "localname": "Auditor [Line Items]"] }, "auth_ref": [] }, "dei AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r630", "r633", "r645"] }, "dei AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r630", "r633", "r645"] }, "dei AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": ["r727"] }, "dei AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r711"] }, "ecd AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r712"] }, "ecd AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r707"] }, "ecd AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r707"] }, "ecd AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r707"] }, "ecd AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r707"] }, "ecd AwardTmgMnpiDiscTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r707"] }, "ecd AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r707"] }, "us-gaap AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable", "http://www.tenonmed.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "ecd AwardUnderlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUnderlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r710"] }, "ecd AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r709"] }, "ecd AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r708"] }, "ecd AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "label": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r207", "r208", "r209", "r210", "r211", "r336", "r584", "r585"] }, "us-gaap BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r31", "r32", "r207", "r208", "r209", "r210", "r211", "r336", "r584", "r585"] }, "us-gaap BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": [] }, "dei BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r633", "r645"] }, "us-gaap Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r90", "r432", "r474", "r497", "r596", "r617", "r744"] }, "us-gaap CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r19", "r126", "r565"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r19", "r62", "r154"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Net (Decrease) Increase in Cash and Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r62"] }, "tnon CatamaranTraySetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "CatamaranTraySetsMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "label": "Catamaran tray sets [Member]", "documentation": "Catamaran Tray Sets" } } }, "auth_ref": [] }, "ecd ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r686"] }, "ecd ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsVstInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsVstInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r681"] }, "dei CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r100", "r131", "r132", "r133", "r158", "r176", "r177", "r179", "r181", "r187", "r188", "r203", "r231", "r233", "r234", "r235", "r238", "r239", "r268", "r269", "r271", "r274", "r280", "r365", "r458", "r459", "r460", "r461", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r489", "r511", "r529", "r544", "r545", "r546", "r547", "r548", "r740", "r755", "r763"] }, "us-gaap ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r29"] }, "us-gaap ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrant

exercise price (in Dollars per share)". "verboseLabel": "Exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r281"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.tenonmed.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of warrant", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of warrant shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r281"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issued offering warrants", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "tnon_ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrant grant date (in Dollars per share)", "documentation": "Class of warrants of rights grant date fair value of warrants.", "label": "Class Of Warrants Of Rights Grant Date Fair Value Of Warrants" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r687"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r687"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r41", "r83", "r431", "r488"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r70", "r221", "r222", "r551", "r771", "r776"] }, "tnon_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares of common stock reserved for issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockConversionBasis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion rate description", "label": "Common Stock, Conversion Basis", "documentation": "Description of basis for conversion of convertible common stock." } } }, "auth_ref": ["r133"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common stock [Member]", "netLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r608", "r609", "r610", "r612", "r613", "r614", "r615", "r759", "r760", "r762", "r813", "r865", "r867"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock par or stated value per share (in Dollars per share)", "verboseLabel": "Common stock par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r44", "r489"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails", "http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued", "verboseLabel": "Issued shares (in Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r44", "r489", "r508", "r867", "r868"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.001 par value; 130,000,000 shares authorized at June 30, 2024 and December 31, 2023; 3,780,827 and 2,600,311 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r44", "r434", "r596"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r692"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r691"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r693"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r690"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r17", "r141", "r143", "r149", "r426", "r442", "r443"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://www.tenonmed.com/role/ConcentrationsOfRisk"], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Risk", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r66"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress [Member]", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] },

"tnon ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ConsultingAgreementMember", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Consulting Agreement [Member]", "documentation": "Consulting agreement.", "label": "Consulting Agreement Member" } } }, "auth_ref": [] }, "dei ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": ["r633"] }, "dei ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/IMG, etc.)" } } }, "auth_ref": [] }, "tnon ConvertibleNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ConvertibleNotePayableMember", "presentation": ["http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Convertible Note Payable [Member]", "label": "Convertible Note Payable Member" } } }, "auth_ref": [] }, "us-gaap ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"] }, "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "terseLabel": "Convertible notes payable and accrued interest, net of debt discount of \$0 and \$77 at June 30, 2024 and December 31, 2023, respectively", "label": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r36"] }, "us-gaap ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Common shares convertible from preferred stock [Member]", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r268", "r269", "r271", "r612", "r613", "r614", "r615"] }, "us-gaap CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] }, "parentTag": "us-gaap GrossProfit", "weight": -1.0, "order": 2.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] }, "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r52", "r158", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r365", "r570", "r782"] }, "dei CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r230", "r780"] }, "us-gaap CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r230", "r781"] }, "dei CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Conversion shares", "label": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \\\"Part noncash\\\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": ["r20", "r21"] }, "us-gaap DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock issued upon conversion of debt and accrued interest", "label": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \\\"Part noncash\\\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r20", "r21"] }, "tnon DebtDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "DebtDetailsTable", "presentation": ["http://www.tenonmed.com/role/DebtDetails"] }, "lang": { "en-us": { "role": { "label": "Debt (Details) [Table]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r14", "r35", "r36", "r80", "r82", "r159", "r241", "r242", "r243", "r244", "r245", "r247", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r265", "r574", "r575", "r576", "r577", "r578", "r594", "r756", "r772", "r773", "r774", "r822", "r823"] }, "us-gaap DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/DebtDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument principal amount (in Dollars)", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r241", "r373", "r374", "r575", "r576", "r594"] }, "us-gaap DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.tenonmed.com/role/DebtDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r38", "r242"] }, "us-gaap DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.tenonmed.com/role/DebtDetails"] }, "lang": { "en-us": { "role": { "label": "Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r159", "r241", "r242", "r243", "r244", "r245", "r247", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r265", "r574", "r575", "r576", "r577", "r578", "r594", "r756", "r772", "r773", "r774", "r822", "r823"] }, "us-gaap DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://www.tenonmed.com/role/DebtDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r130", "r574", "r817", "r818"] }, "us-gaap DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r14", "r159", "r241", "r242", "r243", "r244", "r245", "r247", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r574", "r575", "r576", "r577", "r578", "r594", "r756", "r772", "r773", "r774", "r822", "r823"] }, "us-gaap DebtInstrumentUnamortizedDiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountCurrent", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals"] }, "lang": { "en-us": { "role": { "terseLabel": "Net of debt discount (in Dollars)", "label": "Debt Instrument, Unamortized Discount, Current", "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer." } } }, "auth_ref": ["r821", "r822", "r823"] }, "tnon DeemedLiquidationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "DeemedLiquidationPercentage", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Deemed liquidation percentage", "documentation": "Percentage of deemed liquidation." } } }, "auth_ref": [] }, "us-

gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCosts", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Deferred offering costs", "label": "Deferred Costs, Noncurrent", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer, classified as noncurrent." } } }, "auth_ref": { "r78", "r745" } }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": { "r657", "r658", "r672" } }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": { "r745" } }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://www.tenonmed.com/role/FixedAssetsNetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r7", "r27" } }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": { "r7", "r185", "r193", "r196", "r570", "r571" } }, "tnon_DescriptionOfSeriesAPreferredStock": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "DescriptionOfSeriesAPreferredStock", "presentation": { "http://www.tenonmed.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Description of series A preferred stock", "documentation": "Description of series A preferred stock." } } }, "auth_ref": { "r7", "r185", "r193", "r196", "r570", "r571" } }, "tnon_DissolutionRateOfFairValueOfLiability": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "DissolutionRateOfFairValueOfLiability", "presentation": { "http://www.tenonmed.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Dissolution rate of fair value of liability", "documentation": "Dissolution rate of fair value of liability." } } }, "auth_ref": { "r7", "r185", "r193", "r196", "r570", "r571" } }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": { "r657", "r658", "r672" } }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing. This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.'" } } }, "auth_ref": { "r633" } }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentFinStmntErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntErrorCorrectionFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": { "r630", "r633", "r645", "r696" } }, "dei_DocumentFinStmntRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntRestatementRecoveryAnalysisFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to u00a7240.10D-1(b)." } } }, "auth_ref": { "r630", "r633", "r645", "r696" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt.'" } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": { "r630", "r633", "r645" } }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "r631" } }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": { "r619" } }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": { "r633" } }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": { "r633" } }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth.'" } } }, "auth_ref": { "r631" } }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During

this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period" } } }, "auth ref": [] }, "dei DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report.'" } } }, "auth ref": [] }, "dei DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth ref": ["r673"] }, "dei DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-O, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth ref": [] }, "dei DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth ref": [] }, "dei DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth ref": ["r622"] }, "ecd DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth ref": ["r150", "r165", "r166", "r167", "r168", "r169", "r170", "r174", "r176", "r179", "r180", "r181", "r184", "r334", "r338", "r352", "r353", "r427", "r444", "r567"] }, "us-gaap EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth ref": ["r150", "r165", "r166", "r167", "r168", "r169", "r170", "r174", "r176", "r179", "r180", "r181", "r184", "r334", "r338", "r352", "r353", "r427", "r444", "r567"] }, "us-gaap EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth ref": ["r150", "r165", "r166", "r167", "r168", "r169", "r170", "r174", "r176", "r179", "r180", "r181", "r184", "r334", "r338", "r352", "r353", "r427", "r444", "r567"] }, "us-gaap EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement_Parentheticals"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth ref": ["r150", "r165", "r166", "r167", "r168", "r169", "r170", "r174", "r176", "r179", "r180", "r181", "r184", "r334", "r338", "r352", "r353", "r427", "r444", "r567"] }, "us-gaap EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth ref": ["r22", "r23", "r183"] }, "us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "label": "Effect of foreign currency translation on cash flow", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage: held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": ["r366"] }, "dei EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)", "documentation": "Effective after 60 Days, 486(a)" } } }, "auth ref": ["r735"] }, "dei EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)", "documentation": "Effective on Date, 486(a)" } } }, "auth ref": ["r735"] }, "dei EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)", "documentation": "Effective on Set Date, 486(b)" } } }, "auth ref": ["r736"] }, "dei EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)", "documentation": "Effective on Set Date, 486(b)" } } }, "auth ref": ["r736"] }, "dei EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)", "documentation": "Effective upon Filing, 462(e)" } } }, "auth ref": ["r736"] }, "dei EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 462(e)", "documentation": "Effective upon Filing, 486(b)" } } }, "auth ref": ["r734"] }, "dei EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)", "documentation": "Effective when Declared, Section 8(c)" } } }, "auth ref": ["r738"] }, "us-gaap EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "parentTag": "us-gaap AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable"], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": ["r36"] }, "us-gaap EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"], "lang": { "en-us": { "role": { "label": "Schedule of Stock-Based Compensation Expense Recognized [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, "us-gaap EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "label": "Outstanding stock options [Member]", "documentation": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth ref": [] }, "dei EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth ref": [] }, "dei EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth ref": [] }, "dei EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth ref": [] }, "dei EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth ref": [] }, "dei EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth ref": [] }, "dei EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth ref": [] }, "dei EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth ref": [] }, "dei EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode",

"presentation": [{ "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth ref": ["r621"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth ref": ["r625"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth ref": ["r621"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Domain", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth ref": ["r621"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth ref": ["r737"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth ref": ["r621"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Incorporation Date Off Incorporation", "documentation": "Date when an entity was incorporated." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Information Former Legal Or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Information Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth ref": ["r726"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth ref": ["r725"] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listing Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listing Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listing Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listing Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listing Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listing Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listings Exchange Axis", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth ref": [] }, { "http://xbrl.sec.gov/dei/role/document/Cover" }], "lang": { "en-us": { "role": { "label": "Entity Listings Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are

used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r645"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r621"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: USD." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r621"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r621"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r621"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-O/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r728"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "documentation": "Equity Awards Adjustments, Footnote." } } }, "auth_ref": ["r679"] }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table." } } }, "auth_ref": ["r721"] }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "documentation": "Equity Awards Adjustments." } } }, "auth_ref": ["r721"] }, "ecd_EqtyAwrdsInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForApblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table." } } }, "auth_ref": ["r721"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityTable2or3", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r11", "r122", "r145", "r146", "r147", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r186", "r204", "r205", "r212", "r282", "r329", "r330", "r331", "r332", "r333", "r335", "r337", "r338", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r377", "r387", "r441", "r449", "r450", "r451", "r463", "r529"] }, "us-gaap_EquityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Fair value", "documentation": "Fair value of the entity's equity." } } }, "auth_ref": ["r814", "r815", "r819"] }, "tnon_EquityLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "EquityLineOfCreditMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity Line of Credit [Member]", "documentation": "Equity Line of Credit." } } }, "auth_ref": [] }, "tnon_EquityOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "EquityOwnershipPercentage", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Equity ownership percent", "documentation": "Equity ownership percentage." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "documentation": "Equity Valuation Assumption Difference, Footnote." } } }, "auth_ref": ["r689"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "documentation": "Erroneous Compensation Analysis." } } }, "auth_ref": ["r638", "r649", "r665", "r700"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "documentation": "Erroneously Awarded Compensation Recovery." } } }, "auth_ref": ["r635", "r646", "r662", "r697"] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "documentation": "Executive Category." } } }, "auth_ref": ["r695"] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)", "documentation": "Exhibits Only, 462(d). File Number." } } }, "auth_ref": ["r733"] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d). File Number." } } }, "auth_ref": ["r733"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r254", "r284", "r285", "r286", "r287", "r288", "r289", "r354", "r355", "r356", "r357", "r358", "r361", "r362", "r364", "r389", "r390", "r391", "r575", "r576", "r581", "r582", "r583", "r588", "r590"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r254", "r284", "r285", "r286", "r287", "r288", "r289", "r355", "r356", "r357", "r358", "r362", "r391", "r575", "r576", "r581", "r582", "r583", "r588", "r590"] }, "tnon_FairValueOfOfferingWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "FairValueOfOfferingWarrant", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Fair value of offering warrant.", "documentation": "Fair value of offering warrant." } } }, "auth_ref": [] }

"*ecd ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt*": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r642", "r653", "r669", "r704"] }, "ecd ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r642", "r653", "r669", "r704"] }, "ecd ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r642", "r653", "r669", "r704"] }, "ecd ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r642", "r653", "r669", "r704"] }, "ecd ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r642", "r653", "r669", "r704"] }, "dei FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": ["r632", "r656"] }, "dei FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd FrValAsOfPrYrEndOfEqtyAwrdGrntdInPrYrYsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdGrntdInPrYrYsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r684"] }, "us-gaap GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Gain on investments", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": ["r56", "r58", "r739"] }, "us-gaap GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap OperatingExpenses", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r54", "r513"] }, "us-gaap GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"], "lang": { "en-us": { "role": { "terseLabel": "General, and administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r54"] }, "tnon GoingConcernUncertaintiesAndLiquidityRequirementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "GoingConcernUncertaintiesAndLiquidityRequirementsPolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Going concern uncertainty and liquidity requirements", "documentation": "Going concern uncertainties and liquidity requirements." } } }, "auth_ref": [] }, "us-gaap GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r51", "r52", "r88", "r158", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r365", "r569", "r570", "r764", "r765", "r766", "r767", "r768", "r782"] }, "tnon GrowthRatesOfFairValueOfLiability": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "GrowthRatesOfFairValueOfLiability", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Growth rates of fair value of liability", "documentation": "Growth Rates Of Fair Value Of Liability." } } }, "auth_ref": [] }, "us-gaap IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "IPO [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei IcfrauditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrauditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r630", "r633", "r645"] }, "us-gaap IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r213", "r219", "r220", "r359", "r360", "r363", "r446", "r448", "r514", "r563", "r589", "r837"] }, "us-gaap IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r219", "r220", "r359", "r360", "r363", "r446", "r448", "r514", "r563", "r589", "r837"] }, "us-gaap IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r144", "r323", "r324", "r325", "r326", "r327", "r328", "r457"] }, "us-gaap IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r6"] }, "us-gaap IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r6"] }, "us-gaap IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r6"] }, "us-gaap IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in cash resulting from changes in:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r742", "r753"] }, "us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and

assets classified as other." } } }, "auth_ref": ["r6"] } }, "tnon_IncreasedPercentageOfDeemedLiquidation": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "IncreasedPercentageOfDeemedLiquidation", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increased percentage of deemed liquidation", "documentation": "Increased percentage of deemed liquidation." }, "label": "Increased Percentage Of Deemed Liquidation" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual" } } }, "auth_ref": ["r642", "r653", "r669", "r695", "r704", "r708", "r716"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r714"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r634", "r720"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r634", "r720"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r634", "r720"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement", { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r192", "r752"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r135", "r566", "r596"] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": ["r658", "r659", "r660", "r661"] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": ["r674"] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r674"] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r674"] }, "tnon_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "LabEquipmentMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Lab equipment [Member]", "documentation": "Lab Equipment Member", "label": "Lab Equipment Member" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r69", "r385"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": ["r618"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.tenonmed.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r826"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable", { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r384"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable", { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r384"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable", { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r826"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r384"] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term - operating leases (in years)", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r386", "r824"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.tenonmed.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r825"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.tenonmed.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r376"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r35", "r36", "r37", "r39", "r40", "r41", "r42", "r158", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r341", "r343", "r365", "r487", "r568", "r617", "r782", "r827", "r828"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", { "parentTag": null, "weight": null, "order": null, "root": true }] }

"presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS'2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth ref": ["r49", "r84", "r437", "r596", "r757", "r770", "r820"] }, "us-gaap LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth ref": ["r37", "r125", "r158", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r341", "r342", "r343", "r365", "r596", "r782", "r827", "r828"] }, "us-gaap LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth ref": [] }, "mon LincolnParkCapitalFundLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "LincolnParkCapitalFundLLCMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lincoln Park Capital Fund, LLC [Member]", "label": "Lincoln Park Capital Fund LLCMember" } } }, "auth ref": [] }, "us-gaap LineOfCreditFacilityAverageOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAverageOutstandingAmount", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit (in Dollars)", "label": "Line of Credit Facility, Average Outstanding Amount", "documentation": "Average amount borrowed under the credit facility during the period." } } }, "auth ref": [] }, "dei LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth ref": [] }, "us-gaap LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r223", "r224", "r225", "r228", "r321", "r573", "r778", "r779"] }, "us-gaap LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ScheduleofReconciliationoftheLiabilityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth ref": ["r223", "r741"] }, "us-gaap LossContingencyAccrualDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of the Liability [Abstract]" } } }, "auth ref": [] }, "us-gaap LossContingencyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualPayments", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ScheduleofReconciliationoftheLiabilityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Amounts paid during 2024", "label": "Loss Contingency Accrual, Payments", "documentation": "Amount of cash outflow reducing loss contingency liability." } } }, "auth ref": ["r777"] }, "us-gaap LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/ScheduleofReconciliationoftheLiabilityTable"], "lang": { "en-us": { "role": { "terseLabel": "Accretion", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth ref": ["r777"] }, "srt MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciplesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth ref": ["r101", "r103", "r105", "r106", "r108", "r120", "r121", "r224", "r225", "r226", "r227", "r290", "r321", "r358", "r394", "r445", "r447", "r455", "r479", "r480", "r535", "r537", "r539", "r540", "r542", "r561", "r562", "r572", "r579", "r586", "r590", "r591", "r592", "r593", "r606", "r784", "r829", "r830", "r831", "r832", "r833", "r834"] }, "ecd MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure", "auth ref": ["r687"] }, "ecd MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth ref": ["r687"] }, "us-gaap MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividend Yield [Member]", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth ref": ["r816", "r817", "r818"] }, "us-gaap MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected Term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth ref": ["r816", "r817", "r818"] }, "us-gaap MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputOptionVolatilityMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected Volatility [Member]", "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth ref": ["r816", "r817", "r818"] }, "us-gaap MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-Free Interest Rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth ref": ["r816", "r817", "r818"] }, "us-gaap MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth ref": ["r356", "r357", "r358", "r590"] }, "us-gaap MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth ref": ["r356", "r357", "r358", "r590"] }, "tnon MergerTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "MergerTransactionMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Merger Transaction [Member]", "label": "Merger Transaction Member" } } }, "auth ref": [] }, "srt MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciplesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth ref": ["r101", "r103", "r105", "r106", "r108", "r120", "r121", "r224", "r225", "r226", "r227", "r290", "r321", "r358", "r394", "r445", "r447", "r455", "r479", "r480", "r535", "r537", "r539", "r540", "r542", "r561", "r562", "r572", "r579", "r586", "r590", "r591", "r592", "r606", "r784", "r829", "r830", "r831", "r832", "r833", "r834"] }, "ecd MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth ref": ["r707"] }, "ecd MtrTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth ref": ["r715"] }, "dei NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth ref": [] }, "dei NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth ref": [] }, "dei NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth ref": [] }, "ecd NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth ref": ["r688"] }, "us-gaap NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.tenonmed.com/role/OrganizationandBusiness"], "lang": { "en-us": { "role": { "terseLabel": "Organization and Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth ref": ["r91", "r99"] }, "us-gaap NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued

operations. *Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.*" } } } , "auth_ref": ["r153"] } } , "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } } , "auth_ref": [] } } , "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } } , "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } } , "auth_ref": ["r153"] } } , "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } } , "auth_ref": [] } } , "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } } , "auth_ref": ["r62", "r63", "r64"] } } , "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } } } , "auth_ref": ["r53", "r64", "r85", "r123", "r139", "r142", "r147", "r158", "r163", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r178", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r334", "r338", "r353", "r365", "r440", "r510", "r527", "r528", "r616", "r782"] } } , "tmnon_NetSalesAmountOfTheProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "NetSalesAmountOfTheProduct", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Net sales amount", "documentation": "The amount of products net sales.", "label": "Net Sales Amount Of The Product" } } } } , "auth_ref": [] } } , "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"] , "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } } } , "auth_ref": [] } } , "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } } } , "auth_ref": ["r658", "r659", "r660", "r661"] } } , "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c) File Number" } } } } , "auth_ref": ["r732"] } } , "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c) File Number" } } } } , "auth_ref": ["r732"] } } , "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } } } , "auth_ref": [] } } , "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } } } , "auth_ref": ["r687"] } } , "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } } } , "auth_ref": ["r642", "r653", "r669", "r695", "r704"] } } , "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } } } , "auth_ref": ["r678"] } } , "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } } } , "auth_ref": ["r677"] } } , "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } } } , "auth_ref": ["r695"] } } , "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } } } , "auth_ref": ["r715"] } } , "ecd_NonRule10b51ArrTrmmtFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmmtFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } } } , "auth_ref": ["r715"] } } , "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } } } , "auth_ref": [] } } , "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } } , "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] , "lang": { "en-us": { "role": { "totalLabel": "Total Other Income (Expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } } } , "auth_ref": ["r57"] } } , "tmnon_NoticeFromNasdaqPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "NoticeFromNasdaqPolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"] , "lang": { "en-us": { "role": { "terseLabel": "Notice from Nasdaq", "documentation": "Disclosure of accounting policy of Notice from Nasdaq.", "label": "Notice From Nasdaq Policy Text Block" } } } } , "auth_ref": [] } } , "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"] , "lang": { "en-us": { "role": { "terseLabel": "Office furniture [Member]", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } } } , "auth_ref": [] } } , "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } } , "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] , "lang": { "en-us": { "role": { "totalLabel": "Total Operating Expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } } } , "auth_ref": [] } } , "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] , "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Operating Expenses [Abstract]" } } } } , "auth_ref": [] } } , "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] , "lang": { "en-us": { "role": { "totalLabel": "Loss from Operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } } , "auth_ref": ["r88", "r569", "r764", "r765", "r766", "r767", "r768"] } } , "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/LeasesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } } } , "auth_ref": ["r381", "r595"] } } , "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Future Maturities of Operating Lease Liabilities [Abstract]" } } } } , "auth_ref": [] } } , "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable"]

"http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating lease liabilities", "terseLabel": "Present value of operating lease liabilities", "label": "Operating Lease Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r379"] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liability", "negatedLabel": "Operating lease liability, current", "label": "Operating Lease Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r379"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "negatedLabel": "Operating lease liability, noncurrent", "label": "Operating Lease Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r379"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r380", "r382"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "verboseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r378"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating right-of-use asset", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r754"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.tenonmed.com/role/ScheduleofFutureMaturitiesofOperatingLeaseLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r383", "r595"] }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityLineItems", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Stockholders2019 Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Business [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.tenonmed.com/role/ScheduleofAccruedExpensesTable": { "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r36"] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r2", "r441"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r4", "r10", "r76", "r140", "r143", "r169"] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on investments", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r137", "r138", "r202"] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": ["http://www.tenonmed.com/role/AccruedExpenses": { "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ultimately expects to expense", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": ["r54", "r55"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Other Income (Expense)", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Other income (expense) net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r59"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r687"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 171 or Item 181 specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r633"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r640", "r651", "r667", "r702"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r643", "r654", "r670", "r705"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r643", "r654", "r670", "r705"] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance

"Disclosure" } } }, "auth_ref": ["r676"] }, "tnon PaymentAmountPerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PaymentAmountPerMonth", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Payment amount per month", "documentation": "Payment amount per month.", "label": "Payment Amount Per Month" } } }, "auth_ref": [] }, "tnon PaymentToRepresentativeAsPerAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PaymentToRepresentativeAsPerAgreement", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Payment to company", "documentation": "Payment to representative as per agreement.", "label": "Payment To Representative As Per Agreement" } } }, "auth_ref": [] }, "tnon PaymentsForDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PaymentsForDeferredOfferingCosts", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "negatedLabel": "Deferred offering costs", "documentation": "Payments for deferred offering costs.", "label": "Payments For Deferred Offering Costs" } } }, "auth_ref": [] }, "us-gaap PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForFees", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Consulting fee", "label": "Payments for Other Fees", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r61"] }, "us-gaap PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "negatedLabel": "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r60"] }, "ecd PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r686"] }, "ecd PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r686"] }, "ecd PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r678"] }, "ecd PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r695"] }, "ecd PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r688"] }, "ecd PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r677"] }, "tnon PercentageOfCommissionToNetSalesAgreedToPayTheRepresentativeUntilAggregateAmountPaid": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PercentageOfCommissionToNetSalesAgreedToPayTheRepresentativeUntilAggregateAmountPaid", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Sales percentage", "documentation": "Percentage of commission to net sales agreed to pay the representative until aggregate amount paid.", "label": "Percentage Of Commission To Net Sales Agreed To Pay The Representative Until Aggregate Amount Paid" } } }, "auth_ref": [] }, "tnon PercentageOfGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PercentageOfGrossProceeds", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of gross proceeds", "documentation": "Amount of percentage of gross proceeds.", "label": "Percentage Of Gross Proceeds" } } }, "auth_ref": [] }, "tnon PercentageOfNetSalesOfTheProductSoldAgreedToPayTheRepresentative": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PercentageOfNetSalesOfTheProductSoldAgreedToPayTheRepresentative", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Net sales percentage", "documentation": "Percentage of net sales of the product sold agreed to pay the representative.", "label": "Percentage Of Net Sales Of The Product Sold Agreed To Pay The Representative" } } }, "auth_ref": [] }, "tnon PercentageOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PercentageOfOutstandingShares", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding shares", "documentation": "Percentage of outstanding shares.", "label": "Percentage Of Outstanding Shares" } } }, "auth_ref": [] }, "tnon PercentageOfSharesIssuedToStockholders": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PercentageOfSharesIssuedToStockholders", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares issued to stockholders", "documentation": "Percentage of shares issued to stockholders.", "label": "Percentage Of Shares Issued To Stockholders" } } }, "auth_ref": [] }, "tnon PercentageOfValuationAllowanceInDeferredTaxAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PercentageOfValuationAllowanceInDeferredTaxAssets", "presentation": ["http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciplesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of valuation allowance in deferred tax assets", "documentation": "Percentage of valuation allowance in deferred tax assets.", "label": "Percentage Of Valuation Allowance In Deferred Tax Assets" } } }, "auth_ref": [] }, "dei PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "us-gaap PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812"] }, "us-gaap PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812"] }, "ecd PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r679"] }, "ecd PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r724"] }, "ecd PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r678"] }, "dei PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r619"] }, "dei PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r619"] }, "dei PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r626"] }, "dei PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r628"] }, "dei PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r619"] }, "dei PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r619"] }, "tnon PreferredStockDesignatedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PreferredStockDesignatedShares", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, designated shares", "documentation": "Number of preferred stock, designated shares.", "label": "Preferred Stock Designated Shares" } } }, "auth_ref": [] }, "us-gaap PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals"] }, "auth_ref": [] }, "http://www.tenonmed.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value per share (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per

share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r43", "r268"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r43", "r489"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred stock of shares", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r43", "r268"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r43", "r489", "r508", "r867", "r868"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A convertible preferred stock, \$0.001 par value; 4,500,000 shares authorized at June 30, 2024 and December 31, 2023; 256,968 and 0 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "verboseLabel": "Stated value (in Dollars)", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r43", "r433", "r596"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r748"] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds (in Dollars)", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": ["r152"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock, net", "verboseLabel": "Gross proceeds from sale of common stock (in Dollars)", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "tnon_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts", "crdr": "credit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Proceeds from issuance of common stock and warrants, net of issuance costs", "documentation": "Proceeds from issuance of common stock and warrants, net of issuance costs.", "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of Series A Convertible Preferred Stock, net", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Sales of short-term investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": ["r18"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Fixed Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r385"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.tenonmed.com/role/FixedAssetsNet"], "lang": { "en-us": { "role": { "terseLabel": "Fixed Assets, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r68", "r94", "r97", "r98"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable", { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r69", "r127", "r439"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "label": "Schedule of Fixed Assets, Net [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r385"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable", { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "totalLabel": "Fixed assets, net", "terseLabel": "Fixed assets, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r385", "r429", "r439", "r596"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.tenonmed.com/role/FixedAssetsNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fixed Assets, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r8"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r69", "r385"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Provision for losses on accounts receivable", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r151", "r206"] }, "tnon_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PurchaseAgreementMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement [Member]", "label": "Purchase Agreement Member" } } }, "auth_ref": [] }, "tnon_PurchaseExceedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "PurchaseExceedAmount", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase exceed amount (in Dollars)", "documentation": "Purchase exceed amount.", "label": "Purchase Exceed Amount" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":

"Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r676"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r676"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r101", "r103", "r105", "r106", "r108", "r120", "r121", "r224", "r225", "r226", "r227", "r283", "r290", "r315", "r316", "r317", "r321", "r358", "r392", "r393", "r394", "r445", "r447", "r455", "r479", "r480", "r535", "r537", "r539", "r540", "r542", "r561", "r562", "r572", "r579", "r586", "r590", "r591", "r592", "r593", "r606", "r610", "r775", "r784", "r817", "r830", "r831", "r832", "r833", "r834"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r101", "r103", "r105", "r106", "r108", "r120", "r121", "r224", "r225", "r226", "r227", "r283", "r290", "r315", "r316", "r317", "r321", "r358", "r392", "r393", "r394", "r445", "r447", "r455", "r479", "r480", "r535", "r537", "r539", "r540", "r542", "r561", "r562", "r572", "r579", "r586", "r590", "r591", "r592", "r593", "r606", "r610", "r775", "r784", "r817", "r830", "r831", "r832", "r833", "r834"] }, "tnon_ReclassificationOfDeferredOfferingCostsToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ReclassificationOfDeferredOfferingCostsToAdditionalPaidInCapital", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of deferred offering costs to additional paid-in capital", "documentation": "Reclassification of deferred offering costs to additional paid-in capital." }, "label": "Reclassification Of Deferred Offering Costs To Additional Paidin Capital" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r635", "r646", "r662", "r697"] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": ["r619"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction excess amount (in Dollars)", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r33", "r388"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r322", "r563", "r570", "r835"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.tenonmed.com/role/ScheduleOfStockBasedCompensationExpenseRecognizedTable"], "lang": { "en-us": { "role": { "terseLabel": "Research and development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r636", "r647", "r663", "r698"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r637", "r648", "r664", "r699"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r644", "r655", "r671", "r706"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.tenonmed.com/role/ScheduleOfDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding restricted stock units [Member]", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r22"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.tenonmed.com/role/ScheduleOfStockOptionandRestrictedStockUnitActivityTable", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units [Member]", "verboseLabel": "Restricted Stock Units (RSUs) [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r46", "r73", "r436", "r452", "r454", "r462", "r490", "r596"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r122", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r204", "r205", "r212", "r329", "r330", "r331", "r332", "r333", "r337", "r338", "r344", "r346", "r347", "r349", "r351", "r375", "r377", "r449", "r451", "r463", "r867"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r86", "r87", "r148", "r158", "r185", "r190", "r191", "r194", "r196", "r197", "r198", "r200", "r203", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r365", "r428", "r570", "r782"] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Concentrations of Risk [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r715"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r715"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net of issuance costs (in Dollars)", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock sold", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "tnon_SalesRepresentativeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "SalesRepresentativeAgreementMember", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales Representative Agreement [Member]", "documentation": "Sales Representative Agreement." }, "label": "Sales Representative Agreement Member" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.tenonmed.com/role/AccruedExpensesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.tenonmed.com/role/ScheduleOfDilutiveCommonStockEquivalentsTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS

Calculation [Table]". "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Dilutive Common Stock Equivalents", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r22"] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": ["http://www.tenonmed.com/role/LeasesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": ["r743", "r758"] }, "tnon_ScheduleOfDilutiveCommonStockEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ScheduleOfDilutiveCommonStockEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Dilutive Common Stock Equivalents Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"] }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r30"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r30"] }, "tnon_ScheduleOfFixedAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ScheduleOfFixedAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fixed Assets Net Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.tenonmed.com/role/ScheduleofFixedAssetsNetTable"] }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r8", "r385"] }, "tnon_ScheduleOfReconciliationOfTheLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ScheduleOfReconciliationOfTheLiabilityTableTextBlock", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Liability", "documentation": "Tabular disclosure of reconciliation of liability.", "label": "Schedule Of Reconciliation Of The Liability Table Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option and Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r75"] }, "tnon_ScheduleOfStockBasedCompensationExpenseRecognizedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ScheduleOfStockBasedCompensationExpenseRecognizedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Based Compensation Expense Recognized Abstract" } } }, "auth_ref": [] }, "tnon_ScheduleOfStockOptionAndRestrictedStockUnitActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ScheduleOfStockOptionAndRestrictedStockUnitActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Option And Restricted Stock Unit Activity Abstract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r620"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r624"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r623"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "(15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r629"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r102", "r104", "r107", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r198", "r199", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r476", "r477", "r478", "r536", "r538", "r541", "r543", "r550", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r564", "r580", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r607", "r610", "r786", "r836", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] }, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] }, "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "verboseLabel": "Sales and marketing expense", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockBasedCompensationExpenseRecognizedTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing [Member]", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r54"] }, "tnon_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Series A Convertible Preferred Stock", "documentation": "Series A Convertible Preferred Stock [Member]", "label": "Series A Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "tnon_SeriesAPreferredStockAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "SeriesAPreferredStockAndWarrantsMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock and Warrants [Member]", "label": "Series A Preferred Stock and Warrants Member" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Series A Convertible Preferred Stock", "verboseLabel": "Series A Preferred Stock [Member]", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r746", "r747", "r785"] }, "tnon_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "SeriesAWarrantsMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Series A Warrants [Member]", "label": "Series A Warrants Member" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Series B Preferred Stock [Member]", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r746", "r747", "r785"] }, "us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Estimated discount rate", "label": "Servicing Assets and Servicing Liabilities at Fair Value, Assumptions Used to Estimate Fair Value, Discount Rate", "documentation": "Discount rate used to estimate the fair value of servicing assets and servicing liabilities." } } }, "auth_ref": ["r597"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] }, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"] }, "lang": { "en-us": { "role": { "negatedLabel": "Number of

Outstanding Restricted Stock Units, Forfeited". "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value per Unit, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Outstanding Restricted Stock Units, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value per Unit, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Outstanding Restricted Stock Units, Beginning balance", "periodEndLabel": "Number of Outstanding Restricted Stock Units, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r304", "r305"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant Date Fair Value per Unit, Beginning balance", "periodEndLabel": "Weighted Average Grant Date Fair Value per Unit, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r304", "r305"] }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Outstanding Restricted Stock Units, Released", "documentation": "Number of restricted stock units released.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period" } } }, "auth_ref": [] }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Weighted Average Grant Date Fair Value per Unit, Released", "documentation": "Weighted average grant date fair value per share, released.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value vested issuance (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r311"] }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Daily return rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Daily Return Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value price (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term annual volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation": { "xbrltype": "percentItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Standard deviation", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Standarddeviation" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "label": "Schedule of Stock Option and Restricted Stock Unit Activity under its Plans [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options were cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r303"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares Subject to Outstanding Stock Options, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares Subject to Outstanding Stock Options, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant-date fair value of options granted (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r310"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares Subject to Outstanding Stock Options, Beginning balance", "periodEndLabel": "Number of Shares Subject to Outstanding Stock Options, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r296", "r297"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price per Share, Beginning balance", "periodEndLabel": "Weighted Average Exercise Price per Share, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r296", "r297"] }, "tnon_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReleasedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReleasedInPeriod", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares Subject to Outstanding Stock Options, Released", "documentation": "The number of shares under options that were released during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price per Share, Forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price per Share, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r300"] }, "tnon_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReleasedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.tenonmed.com/20240630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsReleasedInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.tenonmed.com/role/ScheduleofStockOptionandRestrictedStockUnitActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price per Share, Released", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Closing price of common stock (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expiration date", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r587"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtPercentageBearingFixedInterestRate", "presentation": ["http://www.tenonmed.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Default interest rate", "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate", "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r35", "r772", "r773", "r774"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r34", "r772", "r773", "r774"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.tenonmed.com/role/SummaryofSignificantAccountingPrinciples"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Principles", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r65", "r155"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r627"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet", "http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r100", "r131", "r132", "r133", "r158", "r176", "r177", "r179", "r181", "r187", "r188", "r203", "r231", "r233", "r234", "r235", "r238", "r239", "r268", "r269", "r271", "r274", "r280", "r365", "r458", "r459", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r489", "r511", "r529", "r544", "r545", "r546", "r547", "r548", "r740", "r755", "r763"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3", "http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r44", "r47", "r48", "r122", "r145", "r146", "r147", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r186", "r204", "r205", "r212", "r282", "r329", "r330", "r331", "r332", "r333", "r335", "r337", "r338", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r367", "r368", "r369", "r371", "r372", "r373", "r377", "r387", "r441", "r449", "r450", "r451", "r463", "r529"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Geographical Axis", "documentation": "Information by geographical components." } } }, "auth_ref": ["r102", "r104", "r107", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r198", "r199", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r476", "r477", "r478", "r536", "r538", "r541", "r543", "r550", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r564", "r580", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r607", "r610", "r786", "r836", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024". "localname": "StatementLineItems", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"
"http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/ShareholdersEquityType2or3"]. "lang": { "en-us": {
"role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r160", "r161", "r162", "r186", "r377", "r395",
"r456", "r475", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r503", "r504", "r505",
"r506", "r507", "r509", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r529", "r611"] }, "us-
gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract",
"lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "documentation": "Statement of Cash Flows [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of
Financial Position [Abstract]", "documentation": "Statement of Financial Position [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement"] }, "lang": { "en-us": { "role": { "terseLabel": "Consolidated Statements of Comprehensive Loss:",
"label": "Statement of Comprehensive Income [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders'
Equity [Abstract]" } } }, "auth ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementTable", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"
"http://www.tenonmed.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": {
"role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income,
financial position, cash flows, and shareholders' equity." } } }, "auth ref": ["r160", "r161", "r162", "r186", "r201", "r377", "r395", "r456", "r475", "r481", "r482",
"r483", "r484", "r485", "r486", "r489", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r509", "r512",
"r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r529", "r611"] },
"ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Stock Price or
TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth ref": ["r639", "r650", "r666", "r701"] }, "us-
gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock and warrants, net of issuance
costs", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "documentation": "Value of preferred stock and warrants for
common stock issued." } } }, "auth ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": {
"role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares
equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth ref": [] },
"tnon_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri":
"http://www.tenonmed.com/20240630", "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock and warrants, net of issuance
costs (in Shares)", "documentation": "Shares of issuance of common stock and warrants, net of issuance costs.", "label": "Stock Issued During Period Shares Issuance
Of Common Stock And Warrants Net Of Issuance Costs" } } }, "auth ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3", "http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": {
"terseLabel": "Issuance of common stock, net of issuance costs (in Shares)", "verboseLabel": "Issuance of common stock", "label": "Stock Issued During Period,
Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth ref": ["r11", "r43", "r44", "r73", "r458", "r529", "r545"] }, "us-
gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesOther", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel":
"Issuance of series A convertible preferred stock, net of issuance costs (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number
of shares of stock issued attributable to transactions classified as other." } } }, "auth ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Purchase of shares", "label": "Stock Issued During Period,
Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a
business combination." } } }, "auth ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Release of restricted stock units (in Shares)", "label":
"Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited
as a result of Restricted Stock Awards." } } }, "auth ref": ["r11", "r73"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "negatedLabel": "Issuance of series A convertible preferred stock, net
of issuance costs", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion
of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth ref": ["r11", "r44", "r47", "r48",
"r73"] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": {
"terseLabel": "Issuance of common stock, net of issuance costs", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock
issued attributable to transactions classified as other." } } }, "auth ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit",
"presentation": ["http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "terseLabel": "Release of restricted stock units",
"label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued
during the period." } } }, "auth ref": ["r11", "r43", "r44", "r73"] }, "us-gaap_StockOptionExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockOptionExercisePriceIncrease", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] },
"lang": { "en-us": { "role": { "terseLabel": "Common stock exercise price (in Dollars per share)", "label": "Stock Option, Exercise Price, Increase", "documentation":
"Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
} } }, "auth ref": ["r281"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquity", "crdr": "credit", "calculation": { "http://www.tenonmed.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet",
"http://www.tenonmed.com/role/ShareholdersEquityType2or3"] }, "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' 2019 equity", "periodStartLabel":
"Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes
temporary equity and equity attributable to noncontrolling interest." } } }, "auth ref": ["r44", "r47", "r48", "r67", "r491", "r508", "r530", "r531", "r596", "r617",
"r757", "r770", "r820", "r867"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedBalanceSheet"] }, "lang": { "en-us": { "role": { "terseLabel":
"Stockholders' 2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth ref": [] },
"tnon_StockholdersEquityDetailsScheduleOfStockOptionandRestrictedStockUnitActivityTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.tenonmed.com/20240630", "localname": "StockholdersEquityDetailsScheduleOfStockOptionandRestrictedStockUnitActivityTable", "presentation": ["http://www.tenonmed.com/role/ScheduleOfStockOptionandRestrictedStockUnitActivityTable"] }, "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) -
Schedule of Stock Option and Restricted Stock Unit Activity [Table]" } } }, "auth ref": [] }, "tnon_StockholdersEquityDetailsTable": { "xbrltype": "stringItemType",
"nsuri": "http://www.tenonmed.com/20240630", "localname": "StockholdersEquityDetailsTable", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Table]" } } }, "auth ref": [] }, "us-
gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract",
"lang": { "en-us": { "role": { "label": "Stockholders' Equity [Abstract]" } } }, "auth ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.tenonmed.com/role/StockholdersEquity"] }, "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]",
"documentation": "The entire disclosure for equity." } } }, "auth ref": ["r72", "r157", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277",
"r278", "r279", "r282", "r350", "r532", "r534", "r549"] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityPolicyTextBlock", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy"] },
"lang": { "en-us": { "role": { "terseLabel": "Reverse Stock Splits", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth ref": ["r9", "r533"] }, "us-
gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityReverseStockSplit", "presentation": ["http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesDetails"] }, "lang": { "en-us": {
"role": { "terseLabel": "Reverse stock split ratio", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split
arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } },
"auth ref": ["r74"] }, "us-gaap_SubsidarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidarySaleOfStockAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"] }, "lang": { "en-us": { "role": { "label": "Sale of Stock
[Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth ref": [] }, "us-gaap_SubsidarySaleOfStockLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidarySaleOfStockLineItems", "presentation": ["http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesDetails"] }, "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting
Principles [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information

associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [] } , "tnon_SummaryOfSignificantAccountingPrinciplesDetailsTable": { "xbrltype": "stringItem", "nsuri": "http://www.tenonmed.com/20240630", "localname": "SummaryOfSignificantAccountingPrinciplesDetailsTable", "presentation": ["http://www.tenonmed.com/role/SummaryOfSignificantAccountingPrinciplesDetailsTable", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Principles (Details) [Table]", "auth_ref": [] } , "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosures of Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]", "auth_ref": [] } , "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List Table", "auth_ref": ["r694"] } , "tnon_TerminationAgreementMember": { "xbrltype": "domainItem", "nsuri": "http://www.tenonmed.com/20240630", "localname": "TerminationAgreementMember", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Termination Agreement [Member]", "documentation": "Termination agreement.", "label": "Termination Agreement Member", "auth_ref": [] } , "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount", "auth_ref": ["r686"] } , "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group", "auth_ref": ["r693"] } , "us-gaap_TradingActivityByTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingActivityByTypeAxis", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Trading Activity [Axis]", "documentation": "Information by type of trading activity.", "auth_ref": ["r77"] } , "us-gaap_TradingActivityByTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingActivityByTypeDomain", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Trading Activity, by Type [Domain]", "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).", "auth_ref": ["r77"] } , "ecd_TradingArrAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement", "auth_ref": ["r714"] } , "ecd_TradingArrByIndTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual", "auth_ref": ["r716"] } , "dei_TradingSymbol": { "xbrltype": "tradingSymbolItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange.", "auth_ref": [] } , "ecd_TrdrArrAdoptionDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date", "auth_ref": ["r717"] } , "ecd_TrdrArrDuration": { "xbrltype": "durationItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration", "auth_ref": ["r718"] } , "ecd_TrdrArrExpirationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date", "auth_ref": ["r718"] } , "ecd_TrdrArrIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name", "auth_ref": ["r716"] } , "ecd_TrdrArrIndTitle": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title", "auth_ref": ["r716"] } , "ecd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available", "auth_ref": ["r719"] } , "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date", "auth_ref": ["r717"] } , "tnon_TwoThousandAndTwentyTwoEquityIncentivePlanMember": { "xbrltype": "domainItem", "nsuri": "http://www.tenonmed.com/20240630", "localname": "TwoThousandAndTwentyTwoEquityIncentivePlanMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "2022 Plan [Member]", "documentation": "Two thousand and twenty two equity incentive plan.", "label": "Two Thousand And Twenty Two Equity Incentive Plan Member", "auth_ref": [] } , "tnon_TwoThousandAndTwentyTwoEquityIncentivePlanMember": { "xbrltype": "domainItem", "nsuri": "http://www.tenonmed.com/20240630", "localname": "TwoThousandAndTwentyTwoEquityIncentivePlanMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "2012 Plan [Member]", "label": "Two Thousand Twelve Plan Member", "auth_ref": [] } , "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails", "http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "auth_ref": ["r339"] } , "country_US": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.tenonmed.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "terseLabel": "United States [Member]", "label": "UNITED STATES", "auth_ref": [] } , "tnon_UnderwritingAgreementMember": { "xbrltype": "domainItem", "nsuri": "http://www.tenonmed.com/20240630", "localname": "UnderwritingAgreementMember", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Underwriting Agreement [Member]", "documentation": "Underwriting agreement.", "label": "Underwriting Agreement Member", "auth_ref": [] } , "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change", "auth_ref": ["r713"] } , "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.tenonmed.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "auth_ref": ["r24", "r25", "r26", "r92", "r93", "r95", "r96"] } , "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "auth_ref": ["r682"] } , "us-gaap_WarrantMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.tenonmed.com/role/DebtDetails", "http://www.tenonmed.com/role/ScheduleofDilutiveCommonStockEquivalentsTable", "http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Outstanding warrants [Member]", "verboselabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "auth_ref": ["r608", "r609", "r612", "r613", "r614", "r615"] } , "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Issuance cost (in Dollars)", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "auth_ref": ["r816", "r817", "r818"] } , "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrant", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "auth_ref": ["r816", "r817", "r818"] } , "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.tenonmed.com/role/DebtDetails", "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in PnYnMndTnHnMns format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days.", "auth_ref": ["r816", "r817", "r818"] } , "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "auth_ref": ["r175", "r181"] } , "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "auth_ref": ["r174", "r181"] } , "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": ["http://www.tenonmed.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Shares of Common Stock Outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "auth_ref": [] } , "tnon_WeightedAveragePriceUnderTheProgramCommonStock": { "xbrltype": "perShareItem", "nsuri":

<http://www.tenonmed.com/20240630>, "localname": "WeightedAveragePriceUnderTheProgramCommonStock", "presentation": ["http://www.tenonmed.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average price (in Dollars per share)", "documentation": "Weighted average price under the program common stock", "label": "Weighted Average Price Under The Program Common Stock" } } }, "auth_ref": [] }, { "dei": "WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r730"] }, { "ecd": "YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r680"] } } }, { "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214747401/830-230-45-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } ZIP 59 0001213900-24-068416-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-068416-xbrl.zip M4$#!0 ( + V+ +5G&M* KIMP -18^0 7 96$P.C$P.30Y+3$P<5JT M96Y0:BYH=& WL06MSXD86, R=7Y+3N^Z L E2U&UKQ;?7ML5T L ^~ M+B$E1'M.'HB5A% WKWW,R=061?2'9# 1TX5!EIQSRW, G ?SIE&7AIJf8,^ MU JNGQO 3:~&N&XJJ/ UOI!>ES/KZ^NY#>=8LF12RUB6, K7P^L L H ^~ M^D^I'X:NADOP+9&XJ?6X% G1WX1J711$#&0ID-BX2ZM8GYE_K3OO MB7I'W:MVJ=OFRKOVY134SBTJGS!+O^='S B6IP,%*I&7PP A'^T3>I'W'FJ MV#?'A/('^W5@N+58E-H-ILM)OJX?I$A/OI)#UBSHKX0 MURUYI?>U5SYB:2$A4V+U#FUR(U)I0 &7-; (L&=>2.F.IVSNW1! ?>SXTN M#(=<I<E505!1'5X'D?>VO/I X.5:4-B:'I4:IL(S13D871) 2-V%NO! M(E,~!VC.GSW:NIV#,. $!5J!>I723Y+R+XBO# M4Q701,2) >6^WMJ!% V>HJ!>W:P<6 +$D+0 MW0D+V+ZUDJ30 J27-56G^>~>H0!>Y* I7WQ@/!VIH@89&(!* -I-9Z?>MS> M%U?U1Z?OD 7CY1 3D9O:XN/UY< FZ>:JX?^:~*W+I?Y= &1 ^>DTN!FY MOWEIO+FI?9OI N?X16!WMf^W=TV:E? GE^>@6G4!PS>XUY2: C IIP07B13 ME7#1$UET5M^K8L+2R&VJ?@616'F%1 ?@IEYW8YAZ?) (3i:3 025 KJ@NC2? MYLZ Z^<G^D?>U:W69G(U%- IY OC3:2.4 ~#2$IK V''JPRM+Q' BSH^<A$ M+MD<AB MD26N1$ U-H4' J^ZABCC2>^~^N'F#K2? VZOK*Y*0A71JY71#1$~^FPIJTY MHI+9!H4Q= [#IPSE6E>NX+8000/KHf N+TF~:$!1 K-OWY5+5G2 @70.0K? M6.$#!$Z06-V4V:O UT24?/FO+EA)H/M.[>?D?6'B?*-5'LR.%>4)5=-M MGBG#EG.F=#.%)(!? 9)>I>QK>:I-W@&U7I-G@&ZV^EX-N^F L>33PON^>3UX>M J1 MWS7 IV N XAM$,%?WTIC3#H8RA,X+M)+LL<~!&LJ;D?>IY=DILW9JA#KQ%<+Y!H5Z8?A!8$^&I@&: &MNO:~5)=HVN8+I2?H6! IJ=-Y?2A:@IS<?Z?8% M5!~^CBI BG)=@VA M3HPL3UH$!DBUH+^ZE2E'E'UHM#H6D6? UOQD7.9WJBA;TDC2<I6F+22%17_K M0%2X: RO:=&O1.OI5.NI.5:24$3P2'M'D 9*#T@BK14 M'RMK>3PFU'W)/Tf.T:16X&-98:V2.Q)?1R1EFGV^OV^YU^:O''-/B/R?@E M!+1HIJEGCU 6+DL98Q#?) (8IHR.YI)14+465$>P@?>'DY1^+VJ0X=&F6S&+? M5 JD2?D SK:-Y-YFZ1R?<9?0>~%4@IIO$A /?ZL6X$3 MLRWF2$&VA ZY-(P%G)FI@5IEVC.U!OZ/I?T9N@?@E? +PSGXQ?62TM^NC.X9% M2I5LPJ2/I(02A57!&O:=3^UV.UU01M3M2J1Z I(012)33%VYU&
```

HZSOIY6W<w>H2\$(4:..9.O#Y\$XCD02=AX.70N+JOK&5R/(1C.M)3\N26MF4#H\$(F)5WC@/(5?M.3"BXKG:9RT@!>&C&2 PKA 5*~W\$2K: MOS/MTB7W1K#D.3R5G0S61ACNB15L=K&Q3\$=*7Y*H>UD56L\5.64@0V*N**C MZ,F4&G+ +8& JC15H2NF.92/0-9V.NJ.F4D1C:XIZ+0L:0' O'6!|I6|W4 MF.JOG.8J\$YJ+Y=Y@0E. 6X217U. (<0&8I23*4.DR 10|LPA4&Y&VPN#M=[2Z \$M. +2M2V1L.I2:4|1:3. C)*758K@=IH#4J|COO=U=TT5OC4M1|RB*ZD*W\$- D:..:DE95AO|W= 1.NM\$O^78281NK|O%(<2G.)3%F@UL8VO|W! ML+*=>F*TW*^U-BD*H5.55DMNG7466\$.\$!\$QSC%5KB53Y|8@=U=1:T%L8K3 MBN\$5.] +RG1|:3Z^S23^CH&M|N*61@B.RAV&9. (<7)EMT*Q?>U2A2%(<F Y M+R-^<D ZI:H<1S: >#>0-9|>=+YJ3: ?B#N9# =ZJ|!C22Z&QUHD\$X#RKN6|M|MTW2? J9C14Q#&^L<169?F|@G|UE: I\$5|>#>1'>SN|>Y:P2|I|JH5ET E| MQ|<^G.A.3|R|@&6=1|T|S: >XQ?L>2^<W8R W|R|>?YJ23CVROR^1^W^3| MN MV?>WP& VV:IOH*MG6+*=|Q.&N|SFGPU.3NH/G+NZ-K:YPD/9T|G\$7G>* M|QON90ESVY7|61T\$6L-D.^XD?:<?7..0.7H(EV|F<1^9K-P#E%:+|EW+ MWHAW.3A0>^J- >+>|> G0#Q5G6N|O4 FDWRS6:1HG<2| SH^@|6Y|G|<1' %!<4&>5@08| =>Z2-ZPN021ONDW 8>S?QXHC:HBN":C)PIG4>TJ55 'M.1 PGLIK|/ =>MG3123.95"B|GRK"6P4Y\$5\$#P86 M#U6R-F7K-GOM*^<5*|>= X:O5 2|9V4:4| I M+U-(F TP47EJOX4C^> ((@>2>3%|B/8|5&Q/NIWXL/GU8>-H<"B(MK^A2D^ M+V:H/DP^AX|A|<=\$B >Y|X9|H^AC3Z2%Q.R6K"<=Y|^493 1S#<=31WT|(| M:)^FA=^L D/89P2FCG(+M8 <=2>=>SUZZ>X-1Z26#6WH.1|N8D%<5*P5 MDR^GH3|ZU43| [KUI3 O/ R|L|&|X|M^A(1-W MWTU|C"<S|J|/M-BB|NX6S94(N.L|M^|IGRC^4:***:18'.&Q|JGRZ^OGK MR16 <X<9\$YV. ^HC|T2P2JFCV0?7219\$Y@|LCF^LP.FW(TVTA^S6H NFS^ MI:R&ZRH^NU|D0|ISDD^L:P.Z15GDG@NE:J3U|."H7|B.4:VU#5D5#X73.M.1| (US7G|Q:A^RO5*19 L\$%VRES55YORP|G*ZU0|?#>|> Y8.V/ XE:KA+7#^>-SP%|' M|0&.:.SOW%|^*= T?MKM2WR:U93F/5BYH\$|S\$7Y@SU&AW3E+A8"?P? GCBW>= M.1|TW18+N2?GC^?|B|<=|N@ AOO^4193MG02^2HXC<=C=|OX^|Q|6=<M^NGO:R| MH#BK69Z:QCOQVEPPH7W>.M^UO? <N:5|XCM8(R|.)BSE?700|I7H5?>@JUL?|>=FV6\$5Z:X.M|TP-MZPH(V6N|.)GEZPUV^H^<K|U<@1F:1:|>@^?N?>|P|J.OO^ Y1=GKMD MY&B5MX9NN^9@<H|>60|%-59<|/|<|<|CYE|Q:T^U\$:*GPH4%T:|IOXFT^ M/3|Y|U%HO2+G5E7RS(*V@^WD3U&|/=<EM&-N|PUN|?H \$U-ZO%|L:~?W9? MA=<6E-Q:0A^T2G275SV4:2 ZG0R|>13D<2TEFF>TXW>B^OMS.1#5FM|1%T. M|X:|XH|^?|1EE@<B?&F\$GLZ|8MR|&1CKW8B|) ^Y|VGM|T2VW6NSYN^V6= MX%-<0@E 9L|>=<40DG\$|> QD<?T02|> -3D<CWO?>Z\$W%:K?SY1#6IW .|D7NP^A.99|CBJ-^>@|J.M. K:MA#^VTV|JL9B#\$|DJA9U+L.C.W|LQOXLOOX/A^46R5|DW+%^U|4V5L%|J M'6HVI&|@%9A08#OS9*2P14:"U6PXA42EMCZX3S|699:"|L| MYKE@|Q|F9^+|1TR2SOXYH120\$XZ2%Q/X% H\$>0&5YH8<9F?>= 2|4U|H|E^>|> M4^ZTF\$HLIF^O4GWT3 8|59|C<1^1.ZFZL^>VK?T^1N:5LVZC%|I|^Y.J.BREY MGEQBY7LH0SSH8WTOQ?>S25GY+B O6DAU+O2Q|SFMOYA|W4RY3 B|DXZM3MOB(LUUD32L\$H8U)KOV3 9#BVD+6#H.U:LE5\$U6HUO 1:1*|<=<@%+&K+4XM\$#82|+= T56?Y@=> 0TH551|JU^TESM8C1^R4U|@|^ZN+|C3: @S|T02 M14OR^V^* Z96P.|I 90^NC>Q<^#H/4 LPU0\$Y^OS |13 3+>@^O%??BHK KGOP@N|A^?>0#2:PVTOS|4159&^?>Z.G.M^F=4|3M5T\$9K8+>=D\$.30|NA7+>=TZS35-19%K=R^F (= +%5|1&9^ZH.K|O6:4%46X8KZ4^9 MHCADM\$- :G8\$59(O|E:ZV8F|4Y *\$*5 5R5\$%P QW0\$03^Z>F|I|(RH= PHA| ^J.Z4.UOZ|VW:J8CWE| MY.1&1-3+|^M+|QF.HS510|JP M'59HW^OK:TZ:|Z2Z09ES\$S?< C65Y.5|J M\$B|L.G%<95@P|F2K.#|<=U9QY>\$4|SQ9.1N|J|A|/|> W> W4E|HJM?2|GPU?T:D|J|^|PTD:F|Z=W:(4 MEWRV6VS*3C|5P7KB*Y79VW97R1- PH^9|>ODBG+2% 67KD#<=0| L&G|J M5R7|7-NZ: =DB19:|B.3M UD=BM|&8|N|>^T/CBOP MWL@<+R O\$*L. @>Y |NA|DDO7?7K>U?WP3|>- .WDP M2<2|>W|9^!>+DC\$>2^A|O|J C8B\$2UFZ(ZAV=9EM#<2|16.S\$Q|X|Y2N|>|P MX^M@0&A.)|Z|<L-9&+Q|L3|H|SWZ+<=U95+>.>S.K2B.T4\$Y|J|4^6=^V M.L=Z.ORH|&8:W3|<?>7VL*7*98 M\$>O>+2^C|4|!>^FJ31^4|>+*E|?>E#9 M>.:9\$Q.)LO|VRI+VFK|>+BKJ|E2^DJZ K'.BZHP^A.3|/A<C|YS#97^D U M|J#\$<S^K=<JM+> @>Q|>T|MARU|ZY0%)*CK/GWQO<3Q23CG|B M|>@GP&T|7|S1 MX^Q-4ZWRLYPWQX>:WDT=5(2C /KG&C^1 VINT|0%)*XF MEU^"||76WB.03|6|R8|10&105+074RDU|A|OXE=Z:Z|Z|E:G2#(I4=8V M+BFP=|H:U: FL55?@0=BI=1^<E-L&#&P@>Q7|LL|6N>GPZ4|=3D.LAR M #G%|4M10|88CVA(OCIF|<^40SMUE3%|O&RV:|@5/3\$1J|D2: 5 MA6994UW|B|LLCM@25:T|JP*15OY4|Q.ML3@XZ^ I.6=A8T^A.3=^A@C^Y M|C197>BK% VHL0.Q7DR|98VE^L|J|^<O:~<8>?>D195N8FYYN%T9VR^D8G M77^V MCG610V|@>^X|F7>Y|M|PY**IM3 DTA@:1*9MK|I1RX9U.L&B:~&L M|:YGV V^U!>52U|V43U@>AYBN .A+>#8E|WH\$D|FZ.G&R D%\$<3|PL MACM^: %X+&|>Z8^S907L7Y|C5|OC.V6429<M^>?>DKL^W "H.Z^*P*G|<=OW? +Y%>ZXRDJ33F11*%>5U.U<46A6W/W: +.O| M>GZ^<FFZ7F8X.)BXYB3C768|JSL>V\$MXYMUV00G2S.M|FX|J5=MQ=<R B M6O^EF64\$98C^1^0%7. :F.N6BGR9Y|JYQ\$X:XO^44^>U>UGHY|2P84 M|:VO>NN YV|2NWS 5A=|T*|I|V|DQK|P-7|<=N|A|R<2STOSS4#AG:(H MO\$Q.IXS-7-IOL^AU XJ\$^LU:U>+! :JWB|V^EAU=+|/+X?H5^W|6D|59|M.+3S+20. \$GOL^|>OZ8 X45\$^U|I37%715N2 R=89-K|J-M|^20 Z|J|I M+&|J@^<31Z0H|MF2K.LV0WFCK%\$%5#%HPF4AGZ. J^R*^J-H<.WSOH(|=<P M|J.9.KF7SD84/F(8Y|J5JCMX<^<^1-@>820)|DF=4XO|I-IW|&+W06P.*7L T886<+&(\$<2^<P^BYS^OL4|KMS) M\$|U|^1+&9\$@>GMW=WO|GE8+V^8E|>I2\$N@<18Y9&X\$|<|>^|RX&@2M M|YAM@|J85|J|/ ^# T1^O1+P^N%? ^AH|(?| (NC MOX-|6-MKFJ3W^<1^>=Z|<40Q>+>|D|J|C|K<A^9A&^U0|>VGE>:JH|' Z.M \$^T^O|W

M<54R;JDVZ \$0Q-16!(U@?^LF^*^.=6MP W\1?"?%==&9>^>)OBO\$C.\$HY?IY-ACKTJ\$E-?<%B 1M@E[+Z@H M2SB>.0:JZ6]@P8"6P[+XV: KZ8OUC\$G<"1 \$S=JA;BW+&N5?1W].>..GFH4S*\$G5UKH(C8EM %>/(=<#5.6 B#>Z(UB@13XTT\$%UUN8 M#1;+LC)Y: F*#N+&WGF"RCV]IP5!7- L"" Z&I^MKV4"~KW0FA1.5V=CO7007?A#> MCNLS\$3\$22=Y1-%GLG 4I2:>UW FW4W EWMV#7WLVTWNNM)%-ARS)#@1=2; M8B"DOEABK- WW.0Z\$~J@:\$54G .A.RX+PE8Q1@ZC2V?<FQ701D"~#8N3K*P2M?<3B4/F4 QX-PJD HEBG<>02WI(>L1.8?JCO^N.F:S0ZEKYORI^3 M*U5:(D.M>H7S M 3ZG3UFU]8>E>E.C 6M86T -7\]"<I M.ZT?"PIFS&+K+S1T9?BFN4L OB-/9:T."A"]\$H9:1M).Z):J2>E@%?&4MXU^> .OR609/GK"SZR:S8!IFRG9,H"SWK2>9ME./:6F"DW MAJ]=A@/M:/XY52H8W\$:*60+2X.OI^D.3NZ=S?W-(VVB%SO .3.2)IW CXLYP# MYXT.F=8VR30LJ.ITI7621.2_Q>5P:J O1I#K YP"NHG#*YAM%V*13^M"TBZ? MU3"MR4(19HL7(CD3CCZS+NX@ #7-F3W \$CWO:VLAR>[?J8"G^A8-OW"HI^" M^~F"O*?/..G^+ 4\$PU*1.0R0PZ"GM\$%Q4I3>5BUU LE:MK(74 %QW:KWO:HI^"@GGM.MML:XAE 5 V3D@SILJ^0P^Y:AVBU1@?D>D&[7T85.Y111/7I.1\$)I]N10.1 MQX T&KUA _B2_2%8+M3T*XL:.\$B\4:K&S [*#\$ LTP1VLV(I2OLF#<6>X.* MH+=3' 7%1K>7=7SZD<1K B8N!%O<:PW2GUE/K=S.5Z.HZ)|+Y0\$83W<.1T M>S!H" FFI):1M?JMBD"ZCY 6A&&C%Q%1.-OXN 4G:XJ5=E3V&T(K7A%.*^155&<+>+Q?1.8170I0>XH(Y4CAW"7 M1TJ&8.+DMEV)^R^TJQSU%/C..DRJ^N?Q\$>JBR*

U^_9/5WR9^*V*W# 44 MR*WA.)'/8" |K@|~39 NFH,S/D/0'EX02,PS#~W E(A 7Z8JH AIGOL,ZP1+ MK'^S&=@8D4I.AUKH9D0P5626F,V Z(V&2L&IE5?P!:@R O9'II@1DH(B;M"IB#~0Q>\$8, 1#W P4>WBK|RP>#322^CA^>^U.G(SIJ)O1CP5KXW1KG+&1M-85^@P"]/-JGEF WX Z^08@9T & GA.'@/N%5-W: 68NIT.3IJ_&H64G(? M<.479^4\$CW YXK)Y)IIPDN.1<=Z%SO2?9\$G64Z*2Y_.F '7FKSP5B1L.S1 MIH4<7^H7Y=N498JIEKD>:FZ2SM3C>V+@+HCF1N05MH M5&'- Z9CF9C.&FA@Q65L6(\$:H:./4><1.EG"2K 1 MEE]JR. NB^&B.8"%C3\$|QB(97CRU\$+L\$8G3#F78GX-MFZW0LR+6 RF.N-4 M^C4NKGUR*3X\$WO9."W|@K6A#_0. <1+&^+R0L%MAQ^<6+|^~E.*E!MC:YS@ M 8AEI?BVD:6'PI3|NFJ.D *1YFB^OL9YP.3140?3SMSL:JB+M#04;.M:FT+M.155W11XRA8P(@?> W6/XPK'NH+&@:P9HT^<[36M^~.@O9ML.-%G=5AYG.@O9ML.A M.JZ).M41=9^>Q6H>.@G"]O?#7F16TAI@PQD'M%QDSKV11(=L:~5\$S23+= M:4=;T#\$%I53PIUA.31I@=WV@J2E9Y)2O4R *0KKW*6=G5I.13L F.DFG3=% M9D:Y2DOWPN)#KYP"Y\$7Z-W1"8^1B1-9X M/K-CXF@/@'!=@_JHU:TD=0I:QX7<_? (5JF?Y.FY1#1_&8RL*6&Z?>?T M?|K'O=KR1P=^Y"LPCL.I?E+93K(XJLW<%0#ZSW5I?>S9H?AS8?G(MZR+LQ -6JF0X1.Y1R \$J!>E.?E2!/R'O- PP4E9>H9J7QV@.V54 809V M8I|W<@73<+X"V3MD5(HKJ4>=>3HYI)Q_>.&\$S"(#(A9+&. KOE8-15ZGL M\$W4M3CJ03.M13.VZWA62#1.1%P55HBD MQ=00"UM:AIG_U9+Z\$#_.3=D:0K=.#.\$W&D(3@VA"VDI(O6<&9&+WY: @3WF.MV1"3Y8L(L%Y:*\$J|L+T/TAOD[V+B.#@OD^ S@E? 64)7I2&!#7\$B.-L\$) L2/TZ|3).2LAUA MEOHSA*XM#?0.M1"ZMISSY4T.WY44?<(K1O MC16E#M1QOF-2+12TBD6+&J14&E411OGX_X B@2T6LJ MQ%>R|(&B9,VE-@-/>? F F%@/@F2&63.W^~U123<3".Z"PRGQ|>XSK.%9".V#0M XZ2^0Z0Z|M=@?%:IVQ@M.M.I\$^H+&WPLI@/"N ^"EJEG6W?2? *5WY@*^IULV MW.MNZM#E1.115/ERNI.D62C.9-W NJ|(BEDW&EC^D^M#MOZF= 312SMGTIG21.MA8D9I/2I|>@^~XTM)LL).%TIRIC^57@ 6LZ05BL2.L^!I2_1 (V-Y M<%- UJ8>FG1_0TUSH3-DU1B<3/CZ4JR8#<#~.1G3VFY1O?>9YCU:YSW/LIK MV8OIQ9^BF6@19E?.\$16HZ9B|/\$F/U7#I*>S2H2FFI>5N.X>P.6WR<&~.1I.TY M|MT?SQ> -6@^+^"ATQ9076<1V-0J&B MR^H"~2J<5>L851YUJE:~8L+1LC=>1R^PFFE%."HQB-M^6W#7WA=L:1?3 M./"/H14-IX1 =PJM&T56PQGT@& (GRU)866LT2\$ RKR392ZML\$T9MC#~ MPVFEZU+0&F2QM9U@P.O.#.1.4I(0)YI-V9X:>+X@IPW+DC7^48K.+IA3CC4.MW#CD 22^Y\$<9 I ^~&#JGE? HC'^H3A\$&|XVB+4\$|<#=#/0-MOMJ9^H3U=A M9P6=U0).%Z.O."S@|V L2S.527I0I+1@PGY+|. '@A.YOU3N? @^W+ACW*GP M|B|4A'F.JS14IUC7>5Z _AFED)NEK\$ J|J&@%@LTIKIDR@>D.M2PUSJUSMR9\$-9\$HE.GU:2=>[RYIN]"3'3'ZKAB.OEA.^E-OV7LZ'< ^Q1('M%1%7^*3)10VH>73>33..1CE4 92&RN^N V&\$&4^" @ OEF9X.B|I MJ1UR/8SN3L.G.CC:~T>=B7XA((O2G*RI:UJBBOL1)-L151CF\$)#1'RN\$0_I^ M4MK69/2L:2>4Z2P3(12.IXN6I7F24^V+2D:5& (GO+TIV^1|_ 7N^<V14 4 MU.1W05&1FO NK=N>V>.E.WY"P=|^I]J>1:1.GD95(>9. *#E^G8365E#@U(^I ML.4P^698Y?>-F1=(#14N0Q7)>E.)I^&TRD9EH8+M8(? P072-ACV"1WD9.8 MJ9F@-1&K.\$WE=N9L^KIG(BB%N%N8E)+.)N|US@PD0T+5V5W0D(M&.\$S)@QN=9.1%JWUUIOR^-.15TW^1D-CYTLB=5I M|A@=DQ\$5J:RO? 7IU7LNMK=EL6FSK E&EG6U|@>|JLX1%"D8SU.^2I*IR<.9 MUK7Z1^+M+M^E>F.GI^V'FBX7H~CEI)X-G-Z#1YOM"XXI.KQ1U6GR^VIM3EUF Z(3RYQSE1)M+^1%"FW:~SV>WQ <~1F2NS.C-9A?>1+T.R^F SUUKSR1V_10SE3O(GZP M3=8^BSGX@OUV:TY89@ SK#D.8#T@8fKO 5)C)W3)58KDROY.Z.S^YIO M.#.JT:(#E)Y3V AB80>|>~.13MTW^4CBRG=QAT6L47IFBA|F.JUJ^NT2D@I|3 M>?>GCJ|'0UC|J|H(Z9)3|N|J|0ML|13V56|PQ0I|J|YR2C5|=F1_76F>1/X? D9Z1^<KID"89.IK1^@Z/ HW0.G.T M_5X2*HBPL7YYG M.CW0N.1B(NG="I'N:(XOEO.30-/8P9B2=MB.-OV"W9>A=05TMZ"V|>J7. M" W.L.D.2H6U0|4C:H * (|=ZJOR645=VPC34@U".D=OF+&W M(VU)E= PLFUK^P29C1CVZTYG703=7+1%4F1518V+XFM2O\$F+& M|J-WCV+KYE589"?3.OTR#W2WHU3:1%D6I|R|@>2(7& M3C+&1|_ P7 M|>[HXG5^2M72I|N|JCP?>D^M Q|12@IC:W2*OP|D1^=3>|@8Z>ERS=>984.Q1L1N MZ01)0BHRIT.Q+P|ZT\$=>=M.O:1CBZ90:K+G|J5EE? Z"WPMa=1M+&E^UTXX=9Y6X9FOA-@ (L0W%M4W(OW> M|N@>CML:~@U<+&TC+Y\$*\$Z.F+M129R&9QJD?TSLA@X0: E>N1.WEN.Y3" M6&902- 4LH3NLCPOX73<YD"3./W*93.IV7=H R.YMM|WR|A.A:6M|OJ(6 ML^YN^<=92B(TIT"0=I=K=&+&MA"*JP*G8T|MNQ/(ILUVCK^S^<=6PU1W.RJ MMG.KY.OZ5@NN# ZL>N|IMPZHVIUMIM M|WODOD|MZ>3J|^*1@J05DEW3FS:Z ZV^8ZX=V9O ZMR.OXZ\$TT0QO-N&KB0)IQS M|HN\$|^|N|'KV.'TO M_". E)KVP:D6PCF=8XC.>OVS%&_.2RG>6>1#Z.\$S.INV&LJ6^1I4V#B(XH2@VKOUYDI@E7#80G.DO515GK6L: M:0&1TB16HIT=@|JLP V2IRI3184|=Y\$LI- =UL>@XU|OQB;2;JC/P?|YH-K%Q."#?H?XIZ6V(F"G<5KT5?SVV2=N>UJLX. M>_UJ&:<|<N1^TPD83I^32VFA8J'5R"81OGV|)=|J3/ RO^|10+EI8- *?W-S M|9V\$9PG> Q1\$?3C?1TD&S|@RAJZ1^1Y3H12'NG" M=IHNBYOU-XYLX| WLVAYKA&UPW:H5Z;KK8H:HE56H@SUS;YNH|<_ \$S MIA4PI>+Z\$G;T0CWI|KL.ZRCK6U:9^V)=S|D1FRU^ES|I0"1LP"&X?9#7D.- MOPF&J20|5U5#0=U5I+C.%^M(4+V)AHU6/EA |J.V.KJLLVS81:(6 M+Q8&9I1+@&SW%OE"D>GVV-74.(IJCU**1L2+PH~=.THV?)9#.0\$YG>JFNN MI&?'L|J12%7711+DAL3T:4@0"MACL^@H1/8PV=16JW _H@&B9+^\$ MH^D0 M/O:3.R*COYI;TIZRO&Y@P9NLR.^YI_ MW3.IQ(TND WLIZ2=MSXVWSWG)#_ SFFD T.>E)ID>4:N8O' -6P7).BRHF#81 M0XD|>WT*.X((O%N>AF^2)8:WGZK/L(>^1QG+1\$=KEMY79V&B)|= MGSLYP%~UC\$<."?3T#L;DMZI=6JQS>&^JTR_KG.^MB(V/R7E=M? 5UD8UUB M>V%#;4IO=#A%<~@!*"94I?1-I1:)%UM51SS;G|?^Y8A+PS.MRI|I>H3 MC=0"NG%RIY'SFFOEN0YH'UTB+WOST=R \$Z70)U("=R=.G9E@PIE.=+&=9JZ5T\$&4^V\$V)9C>0^~M^..ER:0)05)1TW T%W19+^18|PORV6OX;WE7."1:NLQI'B8D5BW/XI"Y2 M4&|&V|JP- 2DAODLZ?>CCH|L.B?N|:WN#9F%UIG^@%\$&S^'6(2IM^~0G7U|5= 49=1A/M ML+ZG OKLV99N<71^~1G%:YO)1G4&I E'1:GTT&\$:4^M2*C4\$FCPF%P MI=IY^XO"13\$<|YI|0A#U1V1V)CHQU)2I3CVCRX^X|B|6VK?3=V@.+&V3Y26 MW> 71V-EG2|IIEV.R:RF?9- M'HS02\$MSL'B@H^U23B#TZ?E#(PUC8D0: MIXCC@|I|<I0K=W=O@SGZF1"MA4U^HZ?BGF9GH/9/Y94 VO#&8.H@N|GJY>34 M1)? L9BOYL2AGGS|LIFA+&7)LLS7/X:NX:18\$-N:AE; #HZ I^-IPI'\$S+O# MG2.E(3GQD^6(Y.@D8.N@J8BTEA-L2&H-@TJ|BTEJ(B575U*W" ^6T-X M&S5PIN62BCH0XE-1&VLJ|@N?YHOA-&^S^*=FX)G?3NBI#7W+&|MM|HLOQ" M%94.+HGFF7&G04 -.3F)5) UC:9IIMK^V> MV3TW;IP0(&Q- "XF5A&WFK _RLZID\$A@(@/0\$W).3ANQOJBHS^|Q4.2E3A"U)=#Y6%0Q^U2E,8R+Z84A.X(M%RT).79:MC>0)@ EWT39S?F2<:E3B8W^G1SVBIS^F- U"RO.PYY *3N&= /ION\$X MW3I\$55A.12;@G"TT"(RF+Y)4X(%E#LKAH01)DP?*1I.C.|0ILRLD5%F= ME15+|@3+N? =7A9MZI'K36T'GND(C.WC#F/XV8^:MC@|S'ZI&#>2@CAT54>49V MR.34(W(<#1AKW#4LY_5XZKU^P+V#>K^C\$CL1|4P2PE(16.ANZ>Z\$N?V%|5 W996%V.@AX9N>ZH(9)O|H.C MLZ."PP:1UK:O#BU5FE&I) +&KJ.:9!NKA")U2V5>S0JGW(O' =(LIZI M'516^LVU.'8LV193) (TW8.'5O3.EI&AAL8T^=2KOSK(|^VYO^1O.Q30CD MGSD)CH9/APCOZO./\$4(I+GDCDE(7<.P16X9BP1BK5FHOQFPT61R).C.1@ MO# [H\$K180^*E1#87#Y\$SGD)2M'(## 1\$V1/0SB+!^EQ4KI7 BVP&@&6R1)@ M^UR4IK%SGO^ 9W |V:D+VR|H%72IU2MLRQ.C7TIT+Q4.F:.\$12H MO9R_QOYI+&I69@RH#7@!R9("4L+ M^0\$PW&JCI/Z#)-3I/GB-TR10/42#KE^%G MUHV9YTEFD4)G?&AU;IS9%"X-TA>C6P340 _196.!@JSR#1D2X5^0+L37 M.1#I*P>*^YP)*3I)U)UFZM08NP0/_L4<=MRSSIF08K1I^B9+|Q-^I MVOB\$Z04*\$97(24)=|T|\$7G4Q8PEEC=3SHVYU)UZ|4YY*.DWWL|KA|I/@O MB/SJ.(%LYZ^FQMN^ 4%L^N -M^_.#1NYR&HJSQ MV@XN46G^COD9F AU|6(O=G-IHQ=>J)>H%M9+&(%0F88JXS (8..U3.Z@A#) ML_ (4J|4XKR%A2I%|;"S91"*LDAE*\$SF*G!#1+.#A:S*6&BPFY(7.18+. M"J 04:200RYG\$P?%? YB'1 JBW\$W(SA7.S1-Z#1X@MX4YE3=U@JCK)105TV\$ ME1N1/GG99\$N@/L/J3.5A^>1%#B|K+Z;<13BBT3^*?SRIR=L:7QJ.8=S2 MTY?PD1!" (O.M+Z\$G>1H03(GV+.:<5E6&R&="B7@><+>.C20.N2!<..M.-S9.)D^WZ^<(NMYYG^4.C"E|^#7F^ 28 MX1|JEXPI0=D.YQ@#JA.24FBV M=5'Z^~.J30IJR)|1V5C0DLC^DU.Y6)B^L3M/7.=Y=.F|E93XL8N|ZUZO^ M?>9ILNKDI M:~%IS:70I(=9X)10&I23>BNQN.4B8\$QPIE5V9@24<+&R71\$F&:8ER/\$S+&#(6 MZG@EIK^TB'6PO'HPE|@>%5@D(IUX7^ K3+ERN:~*ER- OG\$#E:@WTO^&85%\$ MRC^*F7167X>#6^0DV#;O&MB3LS1+|NDS^~PJ|3I^<=3EKS'M/E3^2GRG MPE|<=72)15 Y3=3 (PM3%K@K0T)3|NOP7KE2IMZPD\$=Z:X D=(?69&+=SM(2HF<4RC9QK^G#H)1^#Z<@&SW\$25=2.HKY+|J9P&G6E#BN1@=R743:\$*OXOZ MJ22'SY\$^S^WD<~F9=0@Y(4I77P%WZ.#L&K8Q.W.9I(#&_.1Y?"PM4NJ.#K&M.20<5N/B).M^U..5PV.FE-C=K9:=61|/@:CUXRI/2Y4E2#X'23:AB|' M8M\$INL)C1|LW&|LO>~M5@>7.72.90QJ ^J&@%X#H!UJ_06 U1:N09@<^U4 M9^?W L1.4:92I\$=2|V4X80I30-(YI)-FI-CB@OX)CU>@7V2(J)G2W\$O M2-S30D2:09&92#GP(@XMM#T16'B20.A>?>@UO B1QKOE7+CK(K\$^9 C.M#A.S40|~*805WA(U16.GU.77=W4:41 JV>J..1LZPD9^5.Q%Y:YQ72 M&#V)*?FYI%")0S2.D|&#BR.(#UF(DQK1>C+DP)8+ .+%H _IMT- 'M1.UC:0F MP7^-RHQU-E311\$B^3.OPIIKX 5XH(|U(WEMI+^P.M*HP4^PL\$6> (O(89^=CM|W|B>\$":.A+I| IW>I^A_9NHK=D8^F@345P<7^& M(LN28WT<1@~R"W|SU@I7=A&F&B~?+4R5U162<6.VKT3YSPQA@Q.87\$06 MPC" 7I Q(K<6:13FZPD4*\$S#%\$|S|=WY:ALLJY(-7_VR#M%)L5DL+&F.MZEHT5YL%0XF^N183N).QI.O56KAB:~?1.46I\$<+J4|LOTEPU-9) M/HVFW _ABJ=.RPLH|J2'=s87>\$B(DG:0D*7Z4"1;UL:80K=5THK4: M%:TEA85%7T'18CD^1)P3")D&VSJ3P N%"@5NL#E.-YKIQZ0KG3E:LAK1Y: M M8KT7|7#^L'D|A6V%EQP0|ID."M^~@..AH*7PK\$YI97Y|!*BN989I=RN=2T/DRIJLIQ<20%CU3BR4+ GZ*205\$E66>T1" OY8Y0 M 5ODE9@ICS4S:BT1&6Z>0).%>10N.D5LE>|.1*#GCCO)4S+&KIML:262 M%UKNAVJ25JAIOITFM&C@^2B(3A1OBHYZ)=U60 1J0S.S+T8V'7 VV=(OP: M|'G0K(1EWJ4ZV|?QKC?>+S\$Y 5PTG&.8Y502.6-DS/ZI^QXRA+Q:YV3=V|DG+&Z16Q^NCCK3XRJQ@.V@%W@PF\$@H-HM MUO 2IU1I:C79.T=4#1K|X8? N8(\$96D)C@>IAIS0S) W@9(NY47TL9BZUJI MUD(8IAA.45)G>4D>90QUZ=>+APZ2K0P5Q(I>G|=)%#S)/PIGWG; M0:J|IE WOVF9(38M%T)E(I/MZ8F ARB21^P^X7J2RX&0#00#>E.7CD M#1|D|@GI^*8^P.C1.ONT^I?D."CK34A954@BUODT9K HTGIC I^Q T*D\$ MY!^17JX &I3 D*(1K/2^16BT G45A# F^J_|RWSN~NTL|R6W>2>.0=Q/M.ZD>|DXVG7>R8M)(+&C?I8\$KL:~8HJ3#R.BAIX6RZ.=?E;Q MYBM%6&7SPUD'Z ""DODIK30+9@0QT415&L:~4NWX"QQ-1%COJWH_Y16R.I) Y>^JR<:28 B/K(ZXA_M_O43V/EI_QG?4OGQ U|ZA8/9W+6D#POG+&624^%~MH2<+&CX-VPO8R M38XR?>6AD41K1Q&QZ|MGMV\$UAX8LVFMEUB\$Y0'IB9QR^AHMLL6UC%)I1 M^*9:LO2CW&^ZQX\$BG.BQF324)2R8=5 2257_NNA_5-Y2EOIE>B&Q1^~1) M5NKALP LH\$S"SBW17 M:~G-8+&LMK.SK08UMK(6TO 8I? _3=5^H.MB'I?<=J5KN/R|'C?E+=I^Y1 MM5(O56NGI6|JC<1O7=|C&U^B"PB3S%=U7+XP>&X98T|@PO.G-"VWKO^3K-/VK M*(L8S#SSO)'VE./4+ [AHL|DO:E66^<(UW642)IE(2.LLHYF7U5+E-Y@>@|6DA+6SW#?@)^ ^)_IR H2:~SVM:M6?>+0L)PPF|0&IE7P>X^B+ MFTD)OME=2T& <21S2@L1^H^S.SRL:~YQETI%#AT7BTEN"15+1<8XCF8RR2.F MK903QBI0Q27G1P+Q53#.#=1.IGC(FH&ABFI^2OXH52R<^1N|^26^*DE M<=7 /:~C27U)1H^6*IWZ4|4X:XO^&U9&=>J780TGO9/IME 1I:LY80>=<= MK5Q=S/53(V^M4%_QKGA.U?_KP6.7O?HXJ|J42*\$|OL.GV|1|@UBK V&2GFM MG|>+O&A&D&W:~GI+549@4I&IR'3:1>JKL:GZL|^LZX:QEKLEJ9+TI^Q(U^M\$>~J5>W#60MX47-Y+&ZGEI:C.S4^RYD2 E/KH#3XH<^JU4P9I|/ _J_YIC.M|15>~IYPSB^5733UIJE9GMY6:~GOJCOFPOFJSU@&D^M6 HX0R1I)D3FA M#1381(KYN=?AY=L-(+L+095:RUL|JZW9P.2<)ONJ.#1^ISQ?&^~M.T M:R|RW^JL^R1+M:~\$IY>N2L&B/GE!AT="X2@20EHPZC: VPRO :J) MUD\$**184U-W>_~D12>%/L|D16B-Y3RLG1&ACJL1C19J\$IED6MDLPSNB_&5 M>R|>=V/A1 7Z-AW@8IWD+ X>+P^X X?(Y&?QL\$^~D M2+<~*F M&:>8E+^3_ E785JGM-)YA-3AX<\$!:: (3|SI|>="5OGXDHFG/M\$PX\$.H50EH|HYN6(C|JT+E M#G:EDZ1+KRLV:1B_H T& C?:\$+VN?3AKU\$M^YXM")L6I^R:"K0?PRJ^1U^TJ MTMZ*1?R- _HJ|9#7<11P_@OMQO M^P^X|8YI_ **D?OER3NXH+*2@O^T^W4I8@ZQSS9JY<~.#A<~(VM=KUV2VM M>70"Q (%Q@=)@M33^K; [H0LFP^4:~#&M%\$;H6D(((XT.38)@04O+LWMF@H MR=BCXB^F5YT|I)X=O_KA4W 9I|QJZ0-B _\$LG=G/U#H4A|LL^G51K:X.>\$&I M':O/B%-U:%?0" (UTYSA4GBX#P= 9%HX<6KQ M6\$MY.F+SPUD3I.1X1L&L^&74.QWQ.AB@N_P4R\$LC-6+M%1)(MCI D<6>~M|_O))-H38|DN8|+*7I@XZH#)J|

#.N#K0D4D:8H2Z^(\ MM0K7ZWP014[E]GPO)6E+T&LZAGS.Q<9GLI:;%H83F 4NJTJ8:H:0 S.B^HSP(0U" M"XB810Q>W\$*N+ ,TK|M&JKB0V%>QQ%<
<8LBC.&A9O>J/,U A30K6EXE?ATKEF..2" M- W=1^6/MIJK:0:7I/ @ZS4<+F+UIV-PU+TG2KZP+T:4<94M_U2REN#59/6
M\$X:.\$!IKU#^58B0.HKA>G8/XKN)ZW QHP/&HE+4\$TT!36I8ZUO"Q:>=L"P/SI MR^V>6L(EF!FI4:4!61W.BF:U([@O#W=1,X M5A_3@LSNF. &L'0-?^S:
&H=46\$71%/4ZMB0QJO:Z1^@+W#/@I3E>R#+ M= .?&TTTTPA'R/GY\$6'C/CNN'2D&W)AZT!IMBR8-DI'3) #H!@|PB@KZ8-JWF8
M\$D!4031/XF&99@KIV3A#N6^!<+ BDO!90A1N#M#@/?2!QE,"!RC9CGN,>?& M\$7-3C#@^'W5HL)FS=LAJF=
I!>6D P=>4H*IP#FDKX7/P7Q0?#DJICVLA*O*.M.\$ZUWY!#;:"!ZN7X+=A+"%7-ZIK:S@U-WL_9@5Y>CM^4Z'15.NQGOC'68:5 MU-:PBC9_1NRFG<
JIL(:QG%>V-B2F1:Q/!"6"Y@UCK:9& MJEZB99SD/IEO^C:AJ@WUK9IH!S+A=EBQGI0_BXVL&IK.\$"E"801M>T:QP7K MLP/JB>L:\$WNR!,"Z!V5(#V-
*9XK:9S4!Q93V>*1Z8D+Q!45)4M9>=HXC M*4W.9RU7\$1A/@(IM3SYXINHP!<@!8:3="!%64JDYLD7WP3UNWE:3AC?M\$(@
ML_9&7N3W:~12"EMH;I2PDCDFY.C >#7*60@E!JY!SALI V"!+V^3ISL MJ12B S0P-25*6V!RE&M!92973=,68C5(4/LIC^Y!U!97.\$UP%YB+T!IQ
M(IP!"T3.F)74R77J,S;D^K9 B.BKC5*!68"Z6Q-EVPO!|C:7CYJTT*0BNA MC_VTBAFG"WU>JA"P7JZ+AGK>O!++*%\$5:OXHBMER!1WV*XS2QVO5<,I!|VX
M06-B8CQ>L!>_M\$VG=2 N QMU5/J>=LY3>IYR@=J-4C_H0-QA5TO/H:A5V/UDS M_QVO7L^J_!+50AUOECCMR82)7IM!815*R4\$Y3FI-
+AZF0TKGX\$P":N9PIO M\$)JY=L>6RWBY^\$+ Z^!S0<+ \$FL R\$!ISM/V-0_UHQ3J2(/!>2\$TBE M+ Q9J&T8:73R5A.06LT\$S/ M+X!ID_HX&
<&).Z!>-7L J3= IPPT-PX"0:0)3WT4CQ%|B(H\$9&9!JNL: ^O>3 MK@&W UX!(C+NVTF!|8A*L-&0G6\$A)(7E >+!PEQN2/B7!|+!|JH>E3;VI@ M#N?TW1-
"%2Y"/K60XRQT=CR:ZIRITUY\$3U*N:0K@TOFI1^6E:E:9#PB6Q\$ M3?>@-E'120"&OLK/&WLEY,I!8(G>|AXOC%\$ M28C+?K.I.8!UN.=MN|&A@LOO3=
[#K|:PHV:U#N:O":B-(2!\$JEQCEHT^RG M"110:#V XB,8^1)WYIG!>=<=9! /74JK?:T\$=MX#;8L:04:WVLG>?EFP!6 M'OOS>ONGE;E!B!\$-
%6IKZ!IPPM4V_!13P 2XG)+4+U&AB99 *.@H%EMV M_X!Y6VRPI!Q\$S084@6H!AP!(8WM,IEN09J!L(4I0J9\$3818!S!CTS-9.H7+
MRE'@NGS5T6=4U69?%LQ6I@Q9YV9\$RSTHU60V!C=(G7^~!JX\$YH!\$ _PH3\$^! M3Q1:*K80K+;BB"P0.=MKJ/CGNO>|B6V>O2A6CD MM*()^OB9-
6=;*UEIU4QJW4!L1!>4G.LHAC+>V2D2I!>_G_!>L!>#0H-!>9H?IXN:YV&VIN!J!#0!L|K|JTB/0U*.PZB M;.&O2DE7-) '\$\$9)WW38IET<-
|I=@L|EHL M#M'^7W>!:20 F:~%F5FUSU;0H M-EGD5JOT9|BHFH/VF2Z2J.1.R88)>2GG4TOYFI+NTJTW+2I< F!I4KR>X7V?<=5XQ\$37! MEXKD->)Y#
2";R5H>*=ZBYA\$!Y:0HEXLA#(N,>.@T!@2QC,AJ44@^HKOF M4I/KE!|B&PL LTI(8CTR: %@M%*UEIX.-@&R\$K^1Z+V!A:.09(0#"@RCV1
M>:7J:@IC9(T\$M6W_!H@PP/7LXT8!<|(PF/L5_0/4!&64Y!^!A!!'=N-C MDI!"H!GX.RAE7@7\$@CI=A9+@0:*F+;|9YQ Q!+F ^% 4VT6!|%=5W%6LK^C(
M<:0I:5N;F3W:~!"/L!KHM*MIJ <>P>~R.5!&4V<3DL#V@S-M0E+X!J MH.H<80:)Y&3!|LA3IK0^A6M!@DKI<F4J4<^G"TOI9)Z M9I!%?
|\$:EY\$P=HV:(\$V-9Y*H%&%W-C>|T^<\$I2-SZE!DY- !I:=0+=HC_7CA M":LKG)"4/OZ?*"C U0_K-D)=XVF.6G.^+!-/A&I5- &5:~\$T!#T0<^+ZL3 M>MX4
83)"BC7>~4)A&2& .<C>6A2)T+X>KVI+J64WH@3HM@1N!IGN0!)_H MK9_R(9JLZW@QO#)>J_8#HN7.=/LB7!2JTGZCPX_KZ@0I(!*=)JW&V<
M1#=#X;8-GOLH+>(CMCIZ!2M*MIK.N#-G4!A@JE*X.&OBX*1KVJ8X!|V>E M15!:=H:XJ!E5RPWKDIG\$A!&@&#T&ZYEP2
%7&X%0.7"0EH#>0/8B&@&R! M.2!K!\$5@.EC1Q:J!J3LO.U!UXZQ L>+>T\$J4_T !P!2<0K=X58)GH&3&P*# MTIYEXDW%*C>.:E#=#%^EAYX4U3IOU4
R5R36462>7&|AC&KR?^0@|(+R M%Y'=DTOCUS9!=(G^NAUTPA,I)&|='ZIQ8CIC+X^RYH&Q/@N.*CD:1 RMG+^X MI@?4BVDUE LGDXU\$13U.13-BR[K;
|/C*4W):~N^IL!Y=*)0C(!I%90:LR1M,1!9QO-::3:1?|(9XJAUN^8'F:PP M_ !JL!I8T+X*!|. **7W"1#>+~#135!<5.1J3C190U13N&E:91=(61'6+9I=I=
MEG#^I(L7N#&|:(+X=GO!UJ!|C.N&@QL;B-597&+HG^8U^!U!5N>3:CGC4D@1MW5KXIE4)9G6*~2F!N(4J3YH?3XJ32TA
M!9&R'(FWD8HUQT4ON#XV%L!\$%G&O?(-O.8" 9#POBP_NL8S1@=?#5R/9Q M*#4|JMG1S4&^J:>=>HGK='6+~#% OV0#*"<~9TIG5^
%E*~DXM!NP>TICLE M12VX@8 H84J!<=>JHU=X<00W8)-T!~:ALV!6A"#E+>ZOB+T+CHBY^#@AZY<57D4K44,YQV-/NM(OLGW!DDXS:CT5%6?4J
M!3!8=5YIG!@6*H*R&NMB!P>QTQIO8UCAC!\$E>% #!|IG?(TTV3QDBX)!<~#7 MAH+MMO.Y!JFEFBA7BJS<|FU^9YX5^C^A+FA\$"#A\$""
(95)\$ _JLLX_CJ?W3 MVETD/SE_F2BM0R9^/!. _2LC\$WT F?LS46#WE/KM1WIF)D3WU&@IY8^B5O,SN5>""^5&Z(YTSN_P\$6Z!|D*^#AQJ77;<.:>-ODC
M^.:T10+1G|B1'=>FCZ65^A!|IC6\$2 F=|DEB Q(Q)ADM&0!+X@|5CY%G3K M923*#TV2!V4^L3CITC.ZS2!7G7O_ 9BPITY!L-NFW 3T O7_.EN^FP AJN:
M-OV+K0>|G:=R* F^_O7<@E#0:H<^"5,P(5!>P/<KXJL7?|S!^\$3VWULC N MZ2?%+>DM!|DBX30/4(??3U)T#GG+?~|R>:W-:(\$<=/(|H-!C!O!Y""9O
M-AM\$&S28!>|?%#1+Y2L3?>ZNIZRQO-XON:QI=X:*7IQ!KQ!"G-(!T^6 MK1*~. _?U3ZAG-07C
U"W#&_ HDS.IF!F#X0A!+H&58.\$1N\$<#P^|K+^*K17UT9QBG/O> M!+|/+U*M:8U:~\$FVL4A56IRD#_Y@H!6I6I!Y!|=0)ZZM/U!N\$M7H!;8J.*1 MJ'+!-
CH/^N@T#D^&_&2&N!N-NW!|WY2504KGB2&V#P<^OND&O C-D?T(OR M*\$*C?V#=#S0O(!E_C,K)F\$TDP(HD^*C%|J-T43-50>_S/O5+>^T @0T%D
M^Z@95/OQD0F=OYO!F!FEWFI90!A9.4/5E^*(^>O4".OP.9CLX#>78CE8&*M"94 G<E\$EY# N:2\$#QWW) #<6%L-EY@Y@YTB1S7>=>I@=|&
O89H.O=W" M&7A>M_<,W!;VV&"VC71Q=(GR8XQ.O+;+~\$M1H+ZL?M5MG:4S HYMF<+X2E\$ MDI\$J&O%2QV/A=?S4 |B3!0#|RL1(XAZT
3A!>PR=F4N=R7X; ^\$O_K8% M"7#_#~#~.PZ(C%\$)TYEUL.O:~LXQLX+K<@ MDX@.03B0G0K5D-!D* YDNWFW) C3.W=.#>1.YD&IN^XX_ ;P
M<U!|HWN9#&_..U_ ^7~H!Y>~\$?7-YV!/^O M_~!JN!B^E^YQIRX=N7! R M>GMW>=+~+QZ2SIL?39G!|80QM.?<
8PO0OG6>U4AH2.E0P!7%V5^.. /L.DHI M_|,|U#|B7)POV^G,|!| OJ!|C! (CP MO5QGPHW!F6EQS)+@O%A)3/ABLP M*X70R1 C\$N_!VH9XTOREP5578
X"0\$ ^! M&Q:O-VE*\$3AT.M-F/A4\$A&?XZ.>"H!+;:-B&Y!L2?_?W(\$M!8^GA9Q"/\$TL MH2AE8\$K"* W9T5,/"\$!7!3ADN\$G5-HM?1ZKZ\$82AW(OH
M@<%12@OZL^@|4E23\$.!F!H5CG.=R0P?5*HA2FN;|0C4)XC\$ IQ&Z%/!_4.M;9D^0 4.8DP40>C|F!03&F0ULF|G80?7<|&6#P40VBV.I,\$F(PS!|IN
M8\$+0@4ILT?P^TA";H>H_OST'D#%PVZ2%#XYNI8I_U8?&|S2?&K\$S)TLY" MZ!B"FL45>PIWU4?I04FDAV51K.907^U8&&D.7\$A4?_NFIAS(>C)
<@/8<< MP^A46&~!A&T^675!0MZ!XW7CQF4..MN^9B(AHYT^HO.).2)E>N42CM.@ MFHE\$^Z9?8\$.A!%:M:|52ZIRI!#D
N0&=E@9NFC>VE&|JXJ!X==S)"GVII16K(5^41!.(?>OP3CJ!|6UE#>PJ M:T5:5%;ZJ?5GY2: 4W!UW>C6F78!5XGUDMI:18=2QII>4>33O!@YI-
ZSPDM |+WG.B!VU/ HJVS8BJ!A O M?7+O/Y914VEG.8&XZ>OV^9X*~!"DX-L6#T 8GW@#X#).2:~\$4 Y&F^M^N!S^M!(HDT^|@JX_ 33\$!S48!S.MB^E8!SF
S>|& *J!"OOC&|73"J8(@8Z63; MBP8JH"#SY@|O*!00!9|^9J8W(J-H)!E@).|9#_H.>AR56/SLPWT35;G P M%BA \$Q: 8?K(W/E;R;PM#OLS>|H P7T4H/?
P&=>M92-?>=>7PT!H (MAJ M#M:R@5!)>K|M&8&B\$B#VW-Z)O^6D+7S^97W5<14W!>7#Y1X8_G!|^AV3=^%7Q_JWFF@ M0<^+U!EEQ.L<(Q90Y.
(F/&L< K8H\$FZXQ\$SR^S^T2P95 MU(ODM0^C:ZB>M9@.(@A@CP^B6<|!-U;Y>GJNO&_2."KB14=,~X4J=5)A
M'DXEWEN1TY+!9Z.%="GP\$_.!XGD2!S^X&M!;N!HQ!|-D*:I6.P+!AO>%?WEAX!4JS= M&A#=#+|BZ \$D@88 PLJKP81FH-
65Y^@|EJZ!H\$=J%JOSSNDY\$FL2B;H2!A7V M=IV^WD'\$=J6F" %\$\$.TIXG9X\$%KPP?7RLDTAEL28 OJ: LRE+@|JYXR("B6N4K_J)(O\$)
MSK<8<3M4=3GN(OOCH4!|IFG#%@) (=G.F^F"=GJUIR7W0N64N<3PA(U! M:CX9)"B\$4:F!|>+K6R>BA8Z?#>R %4_!M-1Q^S7??X)L|
|@GLPE3P.GT4 M.25H!J.K 'SQWT7:70F!|S/30^?E R:; &U>+H4=!) XS>=SC5L^_0!RZQ M+H6.1@JAYAKP
M.J2:IV%PF301G|DUB7M(AA4(3IUDH\$&)G3U4:IZ5;JRM!S.^RW!<126_9D=2!AZUG42Y)2!909&:SYP#8T. @8B>)
MY)!S+R^L!S6A2KG!\$K\$|LR1!+RR O/3>JE5?~8(I^K_#H6!5JK3GD299 M=JY!K9TZT2J9G=|SV\$R<P>#|LW#V^W M^6EAP;+@V&^&%DF?
Z>J^VA#(15HWP7N8-\$%-5\$43*(~3K:*X\$9^4_@ (M\$SO!Z9P; RD^W8NE9MS36L<#<.. (K^U>F\$7HFIC!A2K\$"+O MZ 78*Z_?<
4%#="DV0MS6#T9+|VTUZ%6WX&|#~.P#G!^DSC3F5F+4U)5(*Y M#PQ8PL6>M#9IM(YMA\$!5)!_1_P.@#TM:-M4:(W!>_N^EB^M!|=8J6%U2
M.JLM2Z7J0!T23>9X-)S+!F7<%8>Z9ZE~*#S^OR>A!|!^FYHHP=N\$^M!M MN:7) K!#?&|IR.0^N^4KD!) DDA; &Q*O'D!#W*~ M#U_!>@-O058<M-
S_6P2^2J^LL+>+!819N@!U!2&."2X3J(71B-DB5^6EG M.7K!&I:1%N%\$!"QI7EFIC|UMIMMX8^GE!@-I35!> ">RIX\$3X&G^Y!WTA.E
M/D: ...5Q\$EU4":."NRD|=8QO90!&D139 JE6KB", +XB;8.X)^42K+P^M/ M#BH DB* U\$A8GE.N^EV4M?~\$5XE_HGI,00PK\$DO6+^YA"P6US""72Q^888<
M.S0HG=H\$63."@6/S9K"P"!D4BK&N45^HB5S!A:P406XTON@.80 MCM/V5.Q!76) H2C)G>L3) 1!^VB?~6W9G>=|P\$7N.-CG^!|I-|5@^BC_6UJ MC/Q&=|
<-O/CHH^0TM%FA"U:Q:Q=|SCTI|@YAE)(#_1.#^OLJ\$!4;2D MR(#T!>8!N3Q6LFY>~9@> (LO8!Y/G^X">0).R+>^LP25%)ILWC:4@U.
M^6ICQ1@^!&P-C" WG2!B.V4ZL_51U25B(XXFX6KNQ!+>ZAQ4-J^P4V="!< MG@9O"3550=TBJW! +>(8G^)^W9X |B9W.TPGM.LRW=9C8Q>
(VPA7(E#^E%P"

%M\$PN< 1P0A@ M.#)|-KI#\$4*+>OU6R/&W\$#0.E/D)1&|M|AD:)TKCW!FT3!CWJGV:1A@ "WN(M>D')=HH!7!329D=M,
(/)>4.CYR:7G8WVVO4%Q/OEK!/:~3'(=)U!+!& M.%!@US;|!|6XC|2AT Q\$!> B!_Q?AA=I9\$IF+2E201T7V4LG3^6_U-5! MLUSBIJRABY(1BR.6L S7XV
2:"?H!<0=0%U7NGNB7KD|!|P&A!&,<|C: P(!I^F!\$2W(OT|3#=#W4F M!M16"!1NDOB" 1+^BMAT!Q 5C\$79K\$59:ZOH\$3/RJO!#F8^E2+M^?3?<
MZ./L8.ON.%PWR2; @?M8:4>~68 C\$B\$#9T(DD=?<|I!TQA!O!K+!-W M1B+>=>DD924V&7A^#S.)!IR\$ _E\$C7 SRL^IQ(I\$2Y0\$Y9+0\$!1VLB1\$>A
M!AZI1W;2380:F5TV0CXN!5)!GFEK\$2!|WE.AR!7HF.^R(E>|BU!/>C6^~ M9>E:BH;HJU#DNI\$0+H1*%7D!\$!+O(2S)*
M_E9L5@E9=BDH!^*OYJH84!L3RA.D!C^3DPR& H57 YYNUL&X\$5E!P&Q> MDAXI^EOKIV0 OQJ!J^Y. PN?G+&|G>V9ZP=#=L!#?|+*B Mkt?
KET/7!W!Z5!8A=O(+F3R&!) T_Q(4Q!SNT^A\$9N-JB;G93 |K MP88!T;W^OI>|H^PFH7Z<8Y".99V2!2BI&^LZGV\$Y\$+4A&A^D_P4 MY+RR,S<
|+V">/TE\$.44LO)IA8-"6T803"?4/Y!-RZ#, 78XZO*"^F5%LJ-D MX&E_O>DSIW+?X |RM_#)!&"(E!Q!|=|AWCDX!#)MGGO+8RS5E47N!ODJ8 MH(!E%LS-
-OC_LUQ?3:AI\$W/YT ROR^!E\$G04IOWT!N6M/%3! R_ MUXF00X\$5^5F&X&7RJUD^4V.BW\$=V6.930:56TCWMMQOB^YAE^3="J XKDN=M2."GM!S^D'
HC3+D41CD82!D12W)!BSLR:OZ8LODQ!6%&M?>P>45+>9^P!7^G\$W.80).OQHGH.R8 M7\$+|S!UPL|@-Y!|FL&AEIM!PQO4&^V^!RV"TG6&~;
Y^SVU\$M.O1173.UN M49)'MSFI4\$!_1@W=)JX_7Q*~5X2;9(6BA"633OI@OD4@J |<=3^>~>I M4XT&BBVVVFR@^&2@%<
<|YX>Q@A^U\$!F!&|I!+>W!4!9(JZ>4E2&7^4#AL% M.6MW79WV>-L_?P=|S3&JX;">12LH9 M.LA6RJ=F5JRT8\$2E!87^3KUUC^!V6IU!T^0KA^HH-I:~?<
CC^>M08VG.@:U\$*15: M..~W!|VT:HVLR^EE8DVH!|. @<05Z7BA5^YV>QIPU.II+M70:MR0!VM)=J5U9 M;W^+2J5?1?5?TFZ+~+2|?5@)9#DV8%XFZA:
M%~X^V4PN_ F\$&HIPT_LXW5!/>0%OP6!>LO895!LH;C!K2K2J!&^#M!M M.^N9!^5\$WJ^9(U7UU<|!65>2!J!9E2^;UR\$4Q^!_E\$^
M_U3WLWHM!P?QZ^MQ?2\$N3@XLN0+QI M.G6A:HY#N?9A.SG=3^Z2^W=5KIV7\$#NMF!|=J!7A3!+M9MY(8QJ M(R!#VEHK+S1:BU>|YI9IILFOW.<"
|7@WR>FR^9K!Q TWKW^J:ALM>M>~WW MYP;I!W!5IKQ>L7W!H^&INXYU6NQ^~R MKIG?P2Y!>=I6^6JN!^S!.PF^RPU.
S77^0HWMX^RQ@X!@^/"D" #. 76N=G- MMDPTDCTMMYXB!L)~N^!ZLARIH7O.X.@4.1J?8!@DHEX"! OJC:MK5!) M;H\$2+=OI&O/WW.S!JO?
&3J!^*OVJ7/OT^%5W3K=59SC27=, #R!89T)AB5F2(MWIO8C9VHKE.O!(<^@C4Q2F2,<0GTM)X!|PIK5+WC:9^9PR:GTU1/E-21=;_<
M+Y3U_!J8_9+^4FSO^6V1!>@GWRE-ZG95?7?>Y^E=|N(?!%=-82FM^B(JR=M^NQNQNM\$YU)3TPH50N^TP4>Z^KU^ ^FWT:NZQT/U9U!>MH?U-
GW7Y^YTS9BQ!_ MN-\$3T!&|V!|JYH8 WPR2NP^3EP^3ELR-MCID: MQ?2?>9FUQ_X69_A \$XKR\$!DOEF\$&OKQI?^9Q.IM@OY^&^W08F_RI/ OI
M#A!N?^FXM!^L4@^XR+M!>??C ^SX_>|I?/!OK^MO+36KR!4=S(VGN*3% M3:Y!|+Q>CW^@XOBX:OYYP!^|K7<>|W3A=ZD?7?
P:J5!>#EKJWAZ=|#~+W=| MGM_!RIU+>V>| HZIW/75X&F+20962.XJ\$ZZA>_@/4L^QU I6_@/ 4 GOFF#IFO MUTBJ!_#4^E43P#>~0!4\$GCXT!J:~G.N!\$!<
|J>#M9^+I!3=0^+ 6 %CN@ M:3>M^VDJ?UC"6=@BFP>MGZ\$)B6%>@T.U1X/NX!+>_I6<~&Q@&C>T9_#.# MA5Z?S=X\$ _2!>|W582K?5AXGG&T-?<
PM9_7*1^A(FW2)R@2%52:4>~MLHXCI M^KF=&CJF6(1^!NF BA@ B60KX^"O6P#&QY^A5^<(^ W E\$S^P2O)!F7& M8-OKT^LY+5V1P^XZ?<
&~>M=SW!\$VZ!&3#!W74..!_7&/201B!-G0^X012!\$! MA2/@|V!|O!Y+4CLR!^ ^OB+~B\$!|N93FO!HZ1LZAWHCHPWPSQ4CSG.W!+ M^!J!>=<
WSG)Z)SRNO!&N^C!P!W^?NE+>|Q3>7FD-9/+>0@2|BUI =Z3?7=USWQ^+LNTHO)I0\$3) WYFXI7SFJU_+0JS>N>0W5.0%Z#<
|XRAI!>^N)Y6:L7^QIPW M<O!&SG6&#_YE20V!&^!ZZHB_~88U\$UN-2K)BIY@42IU!D^<V=O3^VE+ M9U+|EJW_KFS '3R0!<~<^!&K!&_<
|KM".<~W4KN1E M+T=;J1^OA-N%\$SM%A.'@Q=Z:|!D:> >@5LKM;1WWPBO^H!ROS<OK\$\$\$!R_V
MQC9V!Z2:XXZ4>^O^;9=|0&Q!&_!T^W4U!@Y4R0_!F^NDU=|=I:59I(12A\$; MX9_!|Q2J9.V>H!|YNJOYI3?I0W6+U^?T?Y3E"=\$ZM\$!Z^%3D#P_~QP:6

[illegible]

[CLS/V=+O_&18+P;^)=O==J@40Y?3JF5%.^T Y>TTYK8PJ*32M M<|/!=N+XASX1YFAEQ%LX#O6:3J]-O%H@X^>G3DVY 9PR UW8/M=Y*6G/-GB+67A6M/6U4UW JH8U>UKAW T/MP(&>+&4V&ID_).YJZJL?/CA:FI(1JLT_2N'IIMU<_J=<30IT MOYM%?29ISJ?LP3UO^N:6;>8N7J5UGF+/-VT.%HJ?IC(I(O=MIP7I'-N/VT M9%:IKT U0P1J|I7'^^4^S|>HM%.X*YU...KN7QR_>)%8ND(5)UM5E::%MSI*ZBU:EQ?F'^ZJ?P<4?OD\$Q16EC_S_(HO3>I|U>@TUX#)%\$S#<5185U MZ.RN94W*(S*GWZ?-MVZT^W+M;2J8?VBRJ'^^L(*ZQ4LLPC(=66)10H36A3%#:6)=1<W/3?%96+10#17J M=MI>:I7'^^H/RB+I32B'M;2.4.2AC6I'M7?H'MJ=)I3AE7U/J^B.T,15E8 MAU'AW::9HK2PU:(C-U8R1.G19?0.W+;94E%A#%\$Z,64LN52)12291N>N<M79LFELU;9+GK*(OG-LEORA>%9@I@RB<ZV8M%.7BS/33FHF<Z_8M%0CJS= M3.FH<(I%81%1CBSL3.FH<I'-G'65OU1)Q+VP.MH9A9B7PY'E3R#1.24 MG1VY7+G::W5'^^N'S7?Q1+9P5UB:P|O6|Z+>N%XP6X)KF&^6-PODWQA+F#1TL+DZP*._%I-R M1A1V?|O|VU+8RAFRW7J^V&|A/I|O:U5<@<R J71N|=OM|OE3P@KG<=L' M,BJM0@:9K92D<UG8+?>NLP'^^I_4-/!NM(+^NLF*20#YTP<*ZVLK M@'D3Q.HK>NF20.QV@65A_7"H^>6P#5>W/Z_:%IFYI|OZM@U<=I(C^*?M^M^P^KX'^^A^NM(F?OL*ITD^N5.)FOOM*LPG>1/+RBLI^>U.U,7/+NC9%K M>/%X3U|JE9FR*^L(@&J3;Z:1;6/U@Y\$=G*C6R2J1I%M:15P@L1JXPX7'9 M*SR%_U>X<Z*IN8AOP-IPULAXIA? !6 *M9XTI(OUZ.+=\$\$5AW7V%X @1MOJY5,N/KA?7990V+63;S:176|587+>97M4J1K-L A:Q:M.TF?&?1D:N8# M1BO->1%76&17?E\$W:|B@KRTRLB#VU4_6D5SK%|X|?#180AO@/DZJ-GLZ=:M#_.19VS|33MX>9R-TCXMH671A+SU+N^.(^OLYJ^M^HLWQA+|U=<^X|E< MK<*ZOJYT U^M:&YTGPSUIA& 2+V+N:KD@ \$^N' A MIJ6:[MROO:&US+#+3%70UK)A-7RHD0V^|J|(#MTM|1ZN29<2MIA6:7.*JZS M|AIP5 \$W_LAZ|9QOL|/O+O%-^J^I^K9R|Q|OH?SI)?>W|O:JUO,>_B+U=ME<^<Q<@IPY6.\$|I4IRXU4V#%_|R.AR18?&*C\$B|MPB2IUX86^S^L^IT2\$TY_M J6\$=>*24Z^5.2\$X=UH8CF^9|62_/TD\$172%6^<^)|SB^_W9|AL?^?#;T/MT,M^<GL|S|I?|I3|@LV=.)W|_U|+ P04 " "JBPU9YLF\$<3@ "E(P M&P &5A,(Q,0,DT.3 O97@S,2TO7W1E,FJN+FAT;>U:WT_2!|!^1_6^%=M:9(A"91I*&FD0-Q) I1\$S_MX19>)W087M>|3LCJ|22-KO%#SDJH>G>|@#Q M>G9F=N<=:V:7-1^Y:VUO-IWZ|@|_2|U|SCW6I^>XNWM>|U|_2R1X5=M|5_>.<|L.1.LGS(@>L|13.<10(8<\$NW1%>OWMQUNVUSYG_V3|+G/7|C\$ M":_C*M>|JCWJ7_UJ7T1L_2|3^=>ZOOQ/<KW?Y7JUQ^+E/FM?L7;GLA?X MG9?WZ@IQH6@=U0|I8L|G|GUVU^Z?M" JI_+SN?|E>ZM|J M^KPWK|I|G|Z?4 M1L;39T;+W\$H7TD;1<:>8W> A00:&8?7SYN=89..==F(CP4QA06#B8BP M.JG9OY(76_9R7V1J(P16\$HTNVMI1GW(U,O^T2&L0BDBF//>_PH-GL_9EM8G)XP\$ZY1B2POG3*KC,U240T%)X+3>\$"BG8R939W@IAG*(=50%+RA,4|O%#15"H-|K)W1'(1"BTYL641%)^+6|X2?&6 1O M8#(A^B0:\$(CL<+5%)(9YL52|1L+AB,F2P743\$0A*BU8 DNE3@2/9R9D M\$VE&6*+>16@D).LY?%,1"|48TR(VF^X^XB)=^M&E:1L6RPQ|I00M@NAM;\$_MIGA?+G(+>8^X49"DDOUI@O M|KIC0AE^F3R_/F#IK9"^O374IWH?|\$5QI-64\$|L>BBVF6|\$8Q^+O<+)(+B MP3@>_SBD'I\$B4@B(>#>HZD#A.E2|PCBBA4HJU.7JA01C6!;?YB 0RI(+N MWX0CG@T%:V/S|X-VO/0XY5):EB9PX:9(1%EU"C\$L@:_QMI=AIK@5%,\$0+O0TCYPN\$C9|B^A6RD)=Z|RE44_8".*PLN1*ER@(*P\$)CJ2VY04ID5@|U M6@M:7*60B3< KNJ40MP>A74MTDL|BH006B4RX1.8Z.M RDKR0M M12JEE^XPT ME9JJFV4:4NA94*E1PRH\$E^>IEP8G LRSJQ|*8X6KN1-P_X2S0B313JMJKS-16CBS\$^|X|HAG|G|>- MM:('+') 6-LVPS|:M8I?>D-18(N0&24;DM\$5^&V|L0RNVDLQ1'7Y5O9/MCE=) S2/?6|L'QO1/BX1_."14>|W M8R|VYV-106UW_/11@OUF^>=<<|)OZ#4C+B>UWDB(PM*\$5F6 MM@NH&2*(^U2*|3|3?RW@<O:0T0;L;U;W?SIG^WWW^L=)=\$T0Q:WF(\$S|IOKXD5'E&1|I1R<|XVCFCBN\$2TV!#K35!HCO|KJ'^C467H?23A(6M@N M4 6FTL2\$^\$M=Y0R|XFLIX:_%9F%IERI|_N4|I<0-FIK7('5&196"H%M N3SE:4H5U4ZFB5U,494|C(^K^Z)BXI|19HG:BKC=C)2CGY+@>"7D|2O |^ MZB+70'|KA?Y+NG\$=T.MT?*&4^HL'QIG9B-F/MIYO10.16|Q:Q6.%-SFO#PYBEC|E|G'I CLOH=>L;9:=5TI?29_>JU:NL^8MR0 MYU:\$^|OOY\$WZ?8ZV9>|_|+>^>:"|>7|QW|NAK^?^|U|+ P04 " "MBPU90)...!<"N(@& P& 5A.#Q|D.T3 Q97@S,2P2R7W1E:FJN+FAT M>U>@:6:1.#^>BG_P8K44R-M GF|PU%V@Y^\$H5A>W42C2|GS976_77BCW MZ^>9>PDD(82T2.1KEFPA178SXYG:SXP-M8O@P5|0>ZVMV?>^&3T5P>P66K M7JNX3|RME*|K9YWF%|8|OERVW|N.56K@L8-J9E@>@Z?9E9BRGDIXZKD^NN+ M7 YW,!#NT|==|H2GH|D^HZ1/64?>-|/%8CO HEZ.QV:G7SNJMSQ?MLW; MC@|V#VN5,IC=?4&#?Z0#G9V^D(U0I\$;D=E:-5B|HGI<?M#N7+!>OVVE>_M=M> 9.2M^Q^7N.J<OZ+5>1%9+WG4_3K2^O A9T6_398L^&|@<^W?+>=RM8W.IV@U7Q|K JMAHW64?X0(A90+|I;2^M.C58;7ZDECYI^&F XDQ#6/6\$YG#51.U=YLKU4-WJR20|2+>LP1B MDB&|>=9.P T7| 9U8G\$X5|Z180POV3&KE,UC44T\$IX+3>X^SBG82979W@IAG M5IA9/(8_W^9*3(=8)IQ(^)I&|<1E")52R'SD&9):RM#H DD M|)XX7J^>C+>^8QM BR0IIDBBB"& U^NDOYK3SJ&OZ\$S:OFJ|2V|>2UR3DL M<7KH,9*#FIY2>O7NM:...I2# ?BZ|7Q|PO<#|6|KW+_->WN6E62RG7J MH\$&\$&^W1)<2X|I)(S&U:LVEH2\$T41OPCY07FCM&Y7ME+U+>6C.IAKEA|29M|5|@N8C@K7S#IJOI9872?FO<->9 MJL.EK\$5(HKY:UE)5>B3)%# M 5AH(K4E-TB)U.JA3FM|B|O4FHN86V""7-6HJ3|D^77HI09P1:M81MD801P=: M1I+BD8@72FU:|>2ID)3=:>.H&TIM\$RHM(!#|M1+@S).22|B3@R.:5DG%E42 M(US-76X6<#40) B.O7@1G2YG#_JZ3X/62ABMO=:>Q?6/CP^V\$+PW9C0KR^MWLVI=&_0_@3&1\$V.?8/G(H&U U16<6%Y)<_SIU@9S-C^KV^K^TE"S_M+(3<K@ENM32V=KTK9Q02N09?<QMFQ&&8#2K@.WT1B)6|Q_#R7@C.EHB)(I.V MUJ\$52TEFI Z^>#9|>K:1+CPG(I)5..AVCTY_11^CTY^U^T|OZM9OF9_-N>:K6S+> M3PP\$&Q(Z(3Q0A7G8@TW8G|I^VJ#AXIO%A@AWF%;2=<|)#?2G 11\$6|3|C MNN3=!P%M4,NVS|Y9B;0G|^ 59O6&14Z17J|\$5|J0F2ALU_>EZ-(((OJ CAB< MFC?7-W6>R,B^4D26I>T\$2@=>=8)R9WQ^WOOA.T|8L6VGO7 ^S|WY+OW M|^4^)|CRULL9N^6Y?PNUC6QPA,J|KU6|L8WCG;J+SI/R7?^M. M\$5:P&81P4L:GMP.91|I(H8 T.BCY^JR1JIUD0|PF+>=3.G|^P^G?N6:>^_RI M\$|^E=9B#E#OD65@F14|L6H\$|^5.IE.5#P15.U2:BK/B;2?62Q6HF|8Z M5HPY^2VX E|4KOW?^H:UT3(W\$&_&_L.SCRV&^U|@WAV_X7^2IHQ^M#G= M&RAC5^+>R>9VB9C93|YO=>#F9^8BSF(2?;ARSQS?/8:JRUZQ5=L= =M-??>K^IJE7:|G.K|3JYX@F=@ZXAE|7A?P!%ZRW=F=#S<=>ZX\$T1O.S?71+ M^XEHQ|I2|5|4G%>|JM%OX#U)AQ^O58|>Q1==_IR007IR\$=UP_OOC1W/CM-MWE5(OSNAWYNX^Z0|U3^+U+ P04 " "JBPU9FRXW7|@< "O#& @P M& 5A.#Q|D.T3 Q97@S,BTQ7W1E:FJN+FAT;=U7;7:1.#^>S@S_88>99I(9 M7@R4SC509HPQ|10<+>RDWP4M@RZ&LF5Y23P^ MN|IKC|31D7_!>=KHS/7GN(OF_>^&3NCD>=|A=>X2AT60Y082_7|I=>XU8 M^GT^72050/B.9:|@U|^2.Rf:94<3 J9XW\$|!>-/6?>C>\$54;+D|I3+6&H-F-M;M&\$;|I+|I<8|>IF(/>5<&XO") E='^!|W;0=MH0 MN\$X18:<_L|H0X\$@=>@U=L2>PMVHJDC>6F,7^3.A3>R%&|26W/WLEZS M^6^&L5>190_|@SS>J8WPDUEDZ?&X4U=93H4&+> JPD+I2AU 9H|C62J M652017F\$1..9S(&O6404+6F@6MY4W|JF""VHP8RIK@86":73\$1.YFA^W_ MPMER|H-|P|<|RL&RSCF(5&C#^1WM^SB(Y58F.P==.\$NMO#1R&O\$Q9MV.G/H-RADNX(&=>6>1% M8|QM T%>^N14(<^E8LE0HU\$7/3*H=@K<^0^Q507V^8#("ACXB^T7#|JH M=L JO?Z^YM)Q7*E|(%B/,%<4|L)1Q3NNV2GZXP|BGGBNPQO.S8^I9+O=:M M^I3H""XN06^X|GBV0AP|(|M^1M6+9_NV |KH^\$S93^.#%|I9A^#.*X^P!^?62N#H^T.R>9N2?587&@>(|L1:=>YQOLP>?>H9G/I^ MU.XE2.S)W 7^G<1#WW:|O_ O&E:C/OV=>%JUGOS-8_TUDRU7@UA+57\$5"N M24+3C&%SAW^XIHU(I0#=>6M\$IA74E:FL6(VK)-92:|F|>?S&^>U|F&Q:95C MB-8>I|JSA&3Z;:=iK<^>I| G|I|=93%)/BQM(C_)CP:PE.@>\$KO^W.EG@Y MN\$-R^>_LDI^7&G:SSY9\$VZGAX+5|FEXR|_>HDI/15^QUM3X>WH+NS\$G M.99_@00M|>2_5D2KA_OM_>Y:8JDDCV62F_+T8@R|C_>ONX)XJ1X^#Q(I M^<3KF7?>O7=Q?A#>P9@N3*(KF;4>UCZV|^I_P2UN5^81ZKUAGT>7B:IV?Y M C4U;|4\$!#!!0 (+V+5DH=9-9U@_-T: 96\$P.C\$P.30Y M_#%E#>R,3>)>=&5N;VXN:1MW5=M|J1O(8(25%)\$X.E.H?71CF,5 M|8I4>4_-Q8Z1A+V:77:>+>9FT3H913+E%)I2(|>UJFIEG9F?YC3X|!O5 M:>4M1O|@OZ9@12.W)9^9^XVJF6S?""N0\$ N|FY^ONOX.H^ND:J(&|:FL< MWL-*>EOEA-!>ED<0.%473Y4KDA:(E< WX%>JLO|4\$?5(LD:(U3DJTWJCSR MQRWZ|O>P>T>^>V1FCV^+7_ M%<=>|N\$7A|8M+Q>=>?6(|@>=T_X+KMM^TV^>Y= M6-CM#XSFVQAB^6_YBV7@.G|HT|Z2#19|559>U.O67:@ MEWJ&<D53U@0/5T/>7P%>^>L|N^6.A H|X9B&56C^)/5_IAS+28:>+B^Y2IULZ3Z%LNAK;8IH3QSF4O MNFS^ADIZN|^2Y2B|I8?W=|N".B_N\$1FMZ|30\$KIID^):J=>,>X8==L0 M(*=?/W MKJ 9^I9+'7N2|I&NN(U!>M#6!_Z/M|U|<|J07=\$H_#\$<|<+ 5N" TU;&_J\$EL:C|C3I9 M|SZI^3AMF|^>6YV.P|M-BH_50_-747^>?/L%815PH.S5QD_UMJYQ66 MOA:Z|SA|N8)<|1W)37N%ZP%3RZ/O_AGLJXW6JAST@>YUC587^4C^I-E^1-ZPP%#DO^ZM7S|I^RCL MZ_3IGM5?>|>^U|+ P04 " "JBPU9W-D|SUM<|LV\$O|>7|SS=SEANN?HS6_R0:F1)3MU8EN.)=) M.YT.1\$(2\$@I4 5*6_.MO 9(2M) 7V7^8^K^T@.DLGL6S6.P^(/>F0N9J2TP MX12B)SN-U_4=#5|=,@>B.G.S<#78I@>1%Q7NM0A0N\$86XY3:=WB_>^>V?G#0289\$VSL:*7A+>_WK57<|Q=>CQ.8|1^KRTV MJ:U?U83|>.&P^+>X_X_-7|DQ^OX9^+T2_ME\$TTZ_563:P>|(8|JXC85/9U7^#(F_>E\$93?|79-0O6+>EREJO_>T|23S)/\$ M N1|&|5Y4!VKHL&38Z_?>=KIDN J&S&Y_Z_%S6!|OH!H|M9:NZU4#O) MZ4)"N8VHCG>?U?R@:<(^*66C6PP6^>^AJW@>^)W1LO?4>P4|11<^<^>=XK.E.M.Q903G8XFPC=1^7@>O|IC+!G;U%Y.VN.F4V@ MRPT^P3P+QVF%5Q>L(G-RPWDG=K:YUGSO^+IP_M@AZ:>^%W>Z^V:%)LUZ+>HDA^TI M.L5@>DPO|J|I#%?MWJGORD(|_>W_3|VW9|OU5OP*PS_1.3W5^D6.0/>O-16H7^W>J@>^_2M_!VU:D^5R2U:MAPHA73 MFXTO?>GLO&RRA>G^BEK^R4KHM\$S11K_>D(4\$U@U U9/3)|2JD076 M+BV>_9XKCC.X|IAV2_/LFR1924>0V08\$>AOE:0MA6O=>UY|G5|H\$O6|O M#SF?644GES.IM|74LT_-G?SC\$7HG^38NU0D:04BS!>O00SF|6H@X=F1B M|O:"8|R8+&17Z4-R%|>HG_|>C9./RYB^K9H&BWJ^+^/3X;I M<8=A^".H20Y 7U852ZMN+>@LTH@U:T#9)(<^|BEH|CE98|>6.62:UY^EC.BK^EN M.TJ3M^>Y.UZM@91\$+BHF|I^>N|S|QMER+N:8|B&^OLLS:KU^N:8)M^N:8)T74P45 M^BYZ>10>")|I@AH^>|>B16#BBE|IR|OBEJ|IR@S(I&TH|WMUJSL6CS|Y<_M-D(3|KQUUD|5J.5FYH#00|I|3)5:7^7F8S8LOD 6|12"M\$|(I(A<_100MU MN1RK^8VJ^\$!L@>=Y21\$|DY:#2\$TX=5/76<|>SQ>+>%HPEGO\$>N8&7L SE|O(EAV MA|IB\$H+HOP4_)S8CTICEIG^9ZX^XMC):Y\$|97_ML%K%>7*..42C;3--KVHVO|8SK8BDRJ;URVZE6?>(GG0F<)>A:(>1% 7BPDC^6@ MJ0Q5_2DH(DL\$)9?>ENO:#&DZ:O4Y&S29@2_FIR P>@8Q84.A^J^@HGD8E MS4NJ0EG+>_!+!!2JHRIJ^JZP_X&T|^+1^3P=U HU:KBA6>_#G081D3< M+CS7Z^9QG+>-16(1HM=>4-6Y3,=>GV^!>)(U|O1LLL|B^E4>D+A !?>(%\$-*M#1PXX5|YHHJG|3 M^"0<3/5 B9H^|,W^YQYQ^""L SOV<^432P\$|ND1VB9FJB M98S@OO|I|KN67^>^O?M|I|=>^MQ92|I|>Q<Q^>YO?)W>?>AW2%K^WYH?KD; MKKAYN-?Z^9|NV8|O^P|:794_M.N.G)|W|O|JB^5|I|W-180P8(AW|12| MNPLZ2/9-D_M^>^FH_A_N_|>=>+>_?/>N?>EQTIC|O#BJ|Y^I7OM3O J|=Y^X=T_+> MT.3UK=>:SN?I>=Y^N3R8?>KXY+|J|UY.IK|L|NWJ|I|WW?>|>PFE^>O^>N>=\$74Y^/H|F|^>GYY W-|K33|UETX+2UBU|_G^M^> MOO0-8_|>2RYMCX|7|I|U^F|<^K_X_0|I|I|W<M^>+>G>3Q>O|CJL|A|I|>C M\$2A688K-1YQ8OBW>O|2H>|9.DS)H!>F1?/6_'MR^BZK: USUYOO>EZLSAI M @H^SYOVXGN9HGH5^Q98\$DGB/(PF^W>+>V;Z^R)I-07Z|/N^CD2NX& MD?=-.8-)|4D3SVLG1_0#?>SQ?0%:SHB7=>=QBW9|O-HB-3(O^R)|AQ?I^>ML M|>12CA:5XV=2V@91M>2_UH-DO_43P|^I&EOXRMFRY\$36A>5#SYE\$ K#&MIG0=C\$5_IGULD^X9FR^R>SD<=>5#1B^>|9B|^%<=>9Z\$X\$^01KB&OG9_T\$2_Z86ND-|/O?A6X;DH_A*9G_-M+69K^I^*451I|I?>=6E14MQ^57\$7|M^O5WQ>+?1W&TU7B^YX5_(4A^"%4-JI M\$>88^K>-BA4MU E|>#>Y5+12A.SYK_#9LV7XN1|1^LUQ>15U&I&35E^S_M-9>Y:|I|@5H&M(Q0|7M4YUE|K\$6-5ST|MB&AQ12/4<*>L6X4:=0Q+GX|I|=|HRV:AC|IKNZ4/L&D7:ARIN^UY=1?O> M+7P2P.F/^2W.XX0\$=0_("(=K-ZI^TM>_>3&NKO01KV+@P|+ZD|DIU^E|8_"D|7&|@>=E?<6 MEDG-^*0^1.LEQO^|/13^>QXHT2JM HID^SA^HTBZG0^>X\$K6(JD)50A:UB^NR7 M4(718BH;E14_(_|^I^T)DSSR>|(I|D|= ML|N:=<39GT4@UB:Z^>@&G^>AZO=>E^U_1_4.H^P;N8MLI+>S|S|MERL+>S^>7| MREL+N7@>N7/7@>P>DKI|Q|AH?>?_M@OU+6XS2-F14HITD^/D*\$|LT;JQ.>@ M63K&|CIGUNRI7;65-6TZZYG-28F.I8RO&|22>V#G%NMY=U/VQ_!_X^G|O9*% M/4706ZR;"\$F^>Y^M-2)XN86AW#D/LWR+Q|Q^""TB<^>1N:W|<=>C|YI2+4|6 M33GKO+>D90#2|)ZWXKX?|60?8P|PHR1."/>%7MOA^>|<^<3/>VJO>9|4WQ0N12(I(G|X^XV#R< KOVU^AE^M_X(G675Q9|>|4|<0L81W(H|N(1N?1)^1J;SIS#_%^@%-47%|E@>HWZRW#?Z4 M1|0:\$0?&A|TB)YSJ3)-ZT\$^>^!4C|>_>.EN7\$?L2U1^8?J#EEI#(^/DM^M= R;^CKI3|B6?>L>20(I G^#!GRR.%1^4UP|B|E.P?0J3|E21M|G|F:6\$BIA)<|>X.I8^>@|/MEA3 M%_P.G@>(EL-6#_4PRP3|>+<3^K^NEDH?2HA;OK ZD^G|_R-Q=>#AE^5=-X|XANSE |DO%-ML_4<8P5GG^*9;K.M.FB)V(^>P3UHMG^|I2I8%3 MLW=1=29SDV#WQ\$1?>URXDOCKR06|MCQ>Q>G|X/5.P^>9V&B;B68^|I=K?2W M^>X^>_JE4#3%#>OW^Q:@OR+6?FIND|B(97MIAV+>V%GOW^>1QI-M?L&ZV|) MSOY\$* #O#>+P@|)?SEWU@_I_%F?T%>NJ0Q^>24^_|I|>8S<=>^3A?F/TP(O4H M6)2;.*>+6WQ#XE:M^S^J\$^J5E_<8#^>X689TKF90IDU_>R3UFXB114N0)3 MG^X)CE9\$^O3VT#85V^XWJ_>^L|I#?>E0L384/+>R=|IEKL?>

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|NZITJE7F?>?+D;CERZ@4&%Z(WI<6) T\A+C.R.] M4J5I10+8*15L.Z.#P\$)I'QIEE.H13/>6#7;@+AWH^A5J.4600..M6O>@R\N(QF)P(3+Y?I=44U5B0^UT/(2(0IU07I124@."W8P_99I@- 6.Q.UPB M:A8=F:]&I?8PC<0*104D%I- 'C:L@F1|>Q?W=*9?>|UAIWP-.?A2+|1054+4+|/-,0<3 M.2?2Y0>.>L&B'K7COVXPXK7I:IOE^AMSOI146=>8OYJCV SA#T+Q78.\$PT2 M-NP1*10|PL N./1504\$?;2.C#57Y(+>P QT2NTK2)2GN>62FV'D7\$HJ M2Y0DXN02C5B9F\$SNH&P./\$7G0X=X<7 1KDIHJ"IT"AT"? NW76X9K6) (T:6L4 MB:4O.>|D6!S:=I>|@CK^+M4'-U\XID.;%|XXOGLJU/"FB+8#86LB8M-D:Q M&(7(BW@>\$-8-TIO.._BN;D:W TFPP+XTZ@@OPF19^" < *C%Q1M -P>?7DE)@9B C>=U+1^R^<+&#!'J4(0F--)|B(V(MH)LM7.'36.\$S\$1) MMF\$.45+4>559Q(I.FIHP30Q2@WXE>(S14_10%~%1'I'H M#H:ZJ0S9T7.IE.-9306A''')->42)MKO C|'VBD@BIEHRMH1=.LKD<#IG15 ME^W-(@C|'8I'F1V4W'6.M<+@.POM.D'1Q 1/41G*6@W6#*\$ZB:O7LPEA^! MB24|XPA9Q X6%U+!=&C-N5 -:D/5T+%Y2>D&0B'8'(5-(M*.B:0+=)-KT%L M3H'XX\4B5?I.-4C2!^0D\$+C00<1'J:7? 6^<(XXU%16T*PBIQPLP7Y47%.A.* MD_2''<1^LXO@GO1|P&+)'0UH&XX@LJ7WQI=B.V^8NAI/RK\$^<DO..>&KBIV> M6IQT; [8=8MXA7D)BU7P5UUI^F">1I04S>BL_<S#2EDH+/TP:PL1.MHM; MKO3>0R0KVWF(D!)OKPP2115\$X6XH;.>|YFD6T!>XQFLD=-8D&90C(B\$1*\$ MDIRU5=CFXOF.YBDFE;J2<6UVX\$7R\$3K^F0G>2QP27LOBOD LTK^Y'QJR MBK)6Z^Q48MS-J;Y'+@2/FU.Y+^"3:- [C+|7E12MEC.&K8)Z|@#UT0:YI. MDFBR+9*OC\$R;3BAEGE|@C%Y.E^U\$F3:5CD*\$99V@\$ (N;... \$GCS9IAH+\$D;_ M6_ .B4.D\$!4G*/.03BYQ.Q%:=>|/- BSL;|?IXO/VV\^KY^#O:N^!|V|(W4:=FXLDI6|UY-JZHXRWUQBK_.#NK=>*Y+ MH_) :DITCH\$Z7X|@-^Q@|=W=WGO?Z7;QOWMIPV;C^-:MO7WT; |I>G>|"IH" M1#603M0&Z%VAG9OG_3QJ#;J1M@|<LOX'N VO^1^MQG;IS=>MILUSGFO.GUL M?^UZU.Z^MLWIC|OZB7JMUCO/%Y67V_90)S?I3_M|K|/LY.SKSO;U?|WYMBN MPNO)?LO&%1.AT1:T?V&=F^!'^7Q2-T9M.OKV@.H6/? Y3J7?.._B'1&Z;^M- M:03D+3OSZ;OU57W#(NOA2PNYI(B\4UC\X\A)2BM.09(RIB, ""|YRO.Q) MS+16K5HI('H4^A=H\$-?NK^*|BF U5WVWN- Z)3I|<~%1?T6)#K64I(R-34S MMS O6T2)Z\$D<4 4MA9YAPH1|Q%=>(\$FM;2 MFF;U M B D|' M+FH'^5=TIGU/L0- <0UDQ.+^V:|EN11&8:&UN+N6B0RHW@.ZKRS'fW1K8|EHJ MVYAOIRN"?0Z|*%.R| M2IU+D=Q?BE AN"ZK^VFONGK8W.;ZX+ (7X1+TA=&@|UJXD\$3D_PVX3YG51 M5K9I*.'Y1Z XG|>7_58L&\$KD<4 4T^Y^KB.IS 18?QT6CIO8".V+|O(G)ER+5 ^@ M\$E)G..6.60D6QOO.('&&6<9;9E? QZ2SYFM@M.GUA213U13PJ04.;59M0%I=GT>? M7OUR34.SQ_YG%8A19%@A^YBJA'Q6E1|6V7;|15RZ|@-QBY\$5IV4&=8TO 16 MWIRE@U.157#UIRM,NH H#YI.L PN>|LDIHT@|DW\$SR6>IIR:KI227R\$<7^"8Z MYOQ WPF\$.#WE7P^CF59A?D@05E3I=E.5+1.U@>|L\$C5.0V/QZ_9M|A4B \| MF5AV%FS(? 8J+/*Y_25PN|WB15 5G)._*C\$3EO68(PJ=>2=Z0<;&3&VSV\ (L7 MGC^XJ0^F+4R=O=QR9='AW|O?>KFT? ^5K%|_ 5NM8@Y^#*!IY Z2|17FGH= MPN5E/D)I)=_SE@C'3ZZ|G^U+;ZC%AO0+V17\$8BH.."-8.SWSE(C'9LD6<6-9 M?P\$Y?I(-5_T?>|1)"8H)K5F29K' O/Y/\$5<3+*E^<>+?%UHM!<*> MPN6!W!O2#Z2.+1-6V^BB&A\$%@B..0+>L-G^F4T?D\$ _115|ITIE|Q M1J5|6=1^Q@&Z^X.F@APL E'16XS^XKEC>?OP%02P.\$% @ 081-601O M O>|-@ 1\$1# 14 |T:FIN+3(P.C0P-C.P7VIE9BYX;6SM?5MSV\;R|OO^ M%=H^+^?4*D6^>^<2LXN2I0<1)*H14N\DEV\4A P!|&#@!8 4D)_ 9X9_ "I M8J|HYA^V^A)>#&\$|^+|G1Z>G+S|_ |U|L.EB0- N3^<.7KJ|Y^<~? Q^X2A'D MYQ=W-X>#FY|S|Q? |?V#O|C|_V|@QX3V*2>CD)|#NZ7?R2|I_&#PIN4R_ MQDDZ. R_>S_ '1P>3|X<>CH?|QV| ^IW.#U.2?|4QJX.#PD Y8^7F2 M\$C@;CPL CN?207NW;LC M_M255I.P18MTY\$='_ JP<~>|RSE'4CFO ^\$W MV&^U=<..V4>^KUX?OGGUS5.6K^9(OO/D^S+U_X|O|X@N%U'Q).%7N; & K1H1ZB9LI M^7>:1_5?2? GH?YI8.|CDW^A.6C)| (13@8)|XV? 0L2AYM8F|?P2E%4;1 MQ(O@SUS=>7%P/_ ^F&3;|/<|SK2%6|_O/293%^2=Q_*R\$^<#WT F<4XW MMZLT|C/VOCJ818^WQP" ^"Y| (.|@RDF>7^NIVXRE(#45?YV3X/3I@<29/G?; MCX\$1-"3WVK#P?I^">4\$| PS;*JAIL\|3|U) "V)&|_":?LJ\$TX^W.FNS.Z MKJD.8JN#FI2A.E(R|0W.9I22+D^RI+Q=9AJ.E"LV|^~75-LV|MMS5I2>_E_ MTN:09 1^C=|4A|?>|8^6+4<?>? FWC2;=>NSD!)1UYIF4VM_&!"W0K.93;KQ M#)A-MZ76#\$5|I#RLD2_4.6:S0I\$;<K1PVTPTCT@R'H:1/1^7A%#8HX8@VKA M16PBG+ VW\$:#@BVF=F616L^|I9! (.5E3:EM(90/MW44^!OY@ T.2>7E0 M)' \$S\$ _\$YK&K&C29I4M('Y|D2PA"H>3Y/R0>/_ C_ Z3LQJ_YBRC^Y-3 M O B| ^S B?|^5-E.*&#J +1#10WERNR99GH8^Q9= ?2>+=^FJIE2G08<1?2 MTJ1ISN&8(AHP^R=^ERORE5S3?R\$&B?22=^E#75?Q1MFC K=+*0DTI&^70E M/+9I4P^Y^V|D.1>J.^).AT6RG1I|B*^DVY_&!9L*.SX9SJCX#;FH9S:3X\$ M*(C-|J^IM D' -N<)%:BX60U1@+15./\$GS_J@S@XI33R96TCUY8^V1CEFO52 M7W>2@IN:ZJ^%7=^%Q|Q^<2%Q|NTDI\$C.C8FT?YBX.23^WJS|^~^<BCQR5WSG; M?GPWKW(.28I|4.D_OR>^X(FVW:8".N^* S(\$YG)9/4D- MT6T(MN)&+^/THAL.NR|U8RHG;4(*H?E#;Y0S8UVRO!|LO1I|HDP\$)7I3D M\$.#H1M^B=B=H1M^B?>|8E^? C'/#B>>|_ #7ZAJ\$SHZ\$SR%..*S16>E3L\$9U^*F10OK2&_KL|9AVN; MJE^L&%G-^RW+5".M!!H+&A87FSOP5)&B*2QSI_VA#28 <2-OU|NAA (S^B, M-P1N, (1^?KP^5EHDI;XX(H^3^|T)=|^*T/G+4EH51^VL^H1:9I3;P1_X>+ MUI+AA^2WBM/YR3QEP2R^*RQ/3|YDHC|>(\$X8>^AN^IF<)<^B8.B9D|U3 MNV 8Y^>=>FB|IT-&3^E)HG2&+H7:Z4I|GX;I E07>P M| R^LKO+HPASE4Y(V9@C;|A^V?<?<72|9H85=R|OVTW8S)GH9F|TWVG^#E8I M7:4)? GERZO(SS#> M|8B)O+J2DG+&+SSVK3(Z54IM9KHLA>4BRD^H4Q5UE M\$OLH2T1(NUD)J6+CG#6&22&2N>P;|6=9J3I=3B9Y|Q>56>; K +)>3ZA&? M%~"1#3^KI50<;D^2+>(PVG6;=|JQ.S=- Q&)WA3L^@6U'66# M<2W6"=>Q(B&T|IX5&48X7^D.GE?>DITZ<4_H&T1<^@S5TMAV^J\$^ZVHB#6(W:18%- |6^!L.G1: M\$!>QPODFWE.Q@3*|41^QAF M@|N+>=HOTQID>7PP&BMJ%;_ P_N|K:E^>VNX01M=)P^;72V&Y>|V_!@:1.2NY&SQXL(T+VEW^| @X#EYTY87?>7SB/82Y%P%SO03\$|76N^5.\$2^G006P8 M<@|WRPF(GZ^I|3>|J-C|KQ|FO-TQ M\$60MR&H89^WC^N136)NOTIE_/M^4^FENG6=4Z2OFI ^|SNR(I+WN.ZFP6 M\$G5|B-1+G-##RROPN\$F?&|L&|WR:ISR&4/FV1:P|TTT^E|+!|L6C|RR;|XO_M):%|OU.38;2+; |6^XFB>LOXQ0(G.#EA3I9)_ C30P0&8U6Z5=K0WZ\$1L@+>+3 M'D|9L^9F8)>\$^Y DY FE-W@>3TJ|Y#;="N=\$^D0\$B|J M O>3+AI0@CHAN- L9\$^LT14 EP.7)G%>2@.7ZK8=V* MK8(MS30^~@|@TWV62Y-Q20=<|3|I|@WH&Y|_9W559-ZG299=I4Y G=G|I>?P3|S2SL;|THX2UB^~^Y)2LF44I.MXJ1: MO>#.'C\$EIUN..8NDF*&E(O%YUFD5<|:OTA3\$G.HY;=0M6;QH-5+J+L ML1FL:V-0-8)MK |O+83OXI1X\$00\$^B6)F(2MC |WQ"|I|O_2_*-&M)?XPG= MK\$&7UQO|X MX+1%Q) Q(|7GB@=BQO2>Y|Q^|)+6E7\$H.3TMT02%1FE08C M>=>X%\$2M MF);=|AKJ^ASXJN<^T^\$PS^Y^#|M" (JO3EG^6^NM106/8E7>S<=%J/&J MC4^5N1|1T6|)^HW|+<4PM=)^D:HM6P%|E:0RG.AESZ.^23V0)S^NP(A9+M;.6%Q2);E:1 G11P4O66:6RH12T MV1|2I2VKY(D\$%A0;B: Z+@HKY+0K3I^Q5T%Y(^B^BQ6= C36|5H|X^7X8|NYILN3I8F_1\$T%0;&L M;V.RV22PMU0A1^RE(O.X T;J&^U.Q20+I36 M7GD2X+W#VH1|3^KMO|3UQ^*7W^%\$X Y>D:C.XK=CM@HH-V^*F.&8*+4&1^* MU Y5;)V@TX8SG5=A4X-8VCIE^ UR2T|/2^S9X|^ EQ+9X5(4SZ^"E: M+BEQO.ZFD.>:V:A+|7L9J9D0+I-ES>Q |TT|A1+I#^IHN|IGT.OG>93C|D MH|/@E6L^YAZPN%.1B27|G/7(8&UK/O|C:B\$7? 4E5K=KORA\$5U+ -/>6|S@ (M5U@B 0^C7:N8BF06+5|BFY_U/7|4|I|5|J2.+@QQ2=>-CV+DL<7#~<7=|Z@|SEBU8^2DNHDO&^|J M318AQ>)X>9>Q&.Q559V|GX>+&(|\$Y14L)K_73@0)SS=6A#^_%%.7XNBLI=H MM2^*Y4C^T<|||/\$? 1J1|^39QNS1I|K@/9JCFZL5A\$K9G09K|8S|UVTB+B|A M.5?2UC5N^|Y8@71#0BU>|^14Z|1^*/O|D4S+0SN;I%T%K^?T|K|(^7F+I MPH2.G=TRG^7L|G2Y^Y-|YUS3HG5M^RNU&OBM6R1^6^*W.KC:G|;^Y9HE M.8W&1 4&64:RNI@A%5T2)2IU" (.Y51^JOM(W2|DDA|J3XM_8N910(7L;J+N&| MB+S2M.5.|\$0^SMJ>0J5HJ\$B3<(&0^J=%TFGW|4.AE|T#4^4P|LV:59^-8/ MA."A.G);@O+@7*O 2%6?;HVV:N4^AA."SODTK53|T|IG?FJA^?I5J3^QX MKO:XI8|5<5>=>E%65^T1-I-D|JJK93B;.%Z-V^?>P=W^L^39)? MU(ZZA2=^@5;Q+DQ7LT J5#G^J^7PUOALBC%|^5=|LXNEUG70^G 71-TU45 M M^E;I|P>|(DHF|7<(DH1|BIY70B\$QID9_1U:KR(?/R5G9PR>N011^AY>\$R M3IT.J^F&S0SM@EIT56Z2_ ^|YF|^~.9+EMR2=(3)=BZ9+M^0%|S^>|ULT>X/M^C3I2;2+ZIBKXP9I7Z.F_0(166DEX_4DFN232UX?B=:"2QAQNU)F-1 (9M|5J;J_0164Q^4I&8_HOL|8&9;2^4I=4GGRZXD^? ^D73|@UM0Q^9L7^X|=U19>1^C_0969 MROY_X4;S@|HW@64^8X9|DFJD:7ZC BK5D>G:149D=07^7XT^W@K1C4 !2C MLK;CR??J\$AKOJ(4^MDGO=99A7T@-J-3TL0JDV3^~|"4HO>BZBW.XW&2SHJ> M/TA9CH4>Y1!! V2D3K52_LVUBU7>|.USC.5^<43>=>?&MIT^Y5.S^?Z^1 M^RM2U|4AN<|K;G2<+I1^S3P8P%7I^?9JB;GE_7CFZ@Q-Q^E&#".NKX^?"; M^>79>\$X|+G C<;M|JG-.I|A50=2RPWOF8A+UZP-3X&@U;UFA2|>.^HG7EPF MFGAQ<#S|PIBLI;WZQ=8)2#5B^*RK)11I;EBU>:M6? S.G; MKV|B^LAH7(9.4?K06^<(V |@V^~D%|FEZ7V^C1X..P_M8|RBZ^YK61B1=FBLE:2-|XTK5^%>W>TB9!U^F^6%L^1MI%D7C908).X+>+7|^V M#Q/BEEM^4-6M^<(NK^*P% (ZIDM\$2^9.W^\$)-1)=(5?&R^*M+&+QO|^"7ROI) MZ_5\$.KECV^%>16WJ|U<89M^>E-OB^C^~^~|JLZMI^\$8DET.P:W|>]>\$! M2#_7#\$TG^X@YO>MK9U9=.%50.3+?Q?VN8^Q\$V^>2)CF60E80ZUBO?6M@?%VM M3I?E;:4A^6|Q(1H:N8@851_G) M^?_U72,<>UF8C<8; Y= 82T\$3|JND:0Q1\$A1N\$|PN_*Y^F-FVLW^BY":@ & MU_3D12:3XEYOREQIC\$G(|@=JF;SXM;1%*6/1+I9<%WKJ6M^*: MPV^18T^*8&S^26I9GB7D='X- O#F9>#9XUL+|W^T4\$^EOL>WS+|N|^;7 MIXU) SUUTN2P\$=DL=Z^02TQ |NOEFT|CIGU2C^8:N5SN N1N7E/4&O MRW|Q+WQIR281|I6&=IQ@S^Y^&^W|^?U>BBXY^122PN\$C^CDK4-F5GMA-<)&Y^UC3|>?WQ2E MA^_5M.06/8|J^08F%>%^!^Z9C.QF? REC6N1KZ\$&L&AMC|IEV(OCHNR TP|18M.FM5T+RIE|NIPVQF MX.XK81?KID14KQ7>+B+@E%;_50P(MU|Q|9TL.>^1_P_L^L^KX2X=@ GU^G0.M ^'<LNM|KN9W^J)D2>@A.5V\$3)FW3740|>^X49GUXYO\$X6<2%5LBI1)&| MGJ? 3|B+VH@3+K4J|WW7_|DJE(X=NMMSIKR6DZ|<9E@|P.UOYWS+U+KCHMQK8 MI1EK^909 4=7^0^E9|QL^1UULJ8UNI&W=9|G('E.;SL-(W);RF|I0+!6I: M1B\$&8\$YHA-9TP)-#O)WSHJA|@4.+^LX%|J@;.*=5=.V=%G6HZ-&3.H&|/7 M0|VG?|Q|LV#P%.|9@I7..FX_5^I0|GAS23ZG1%+V1^V6^HHJJ LL^I^1 MG\$&CM)^&|&I8J|7TG_E8CAV>M5^Q>#>2%?Z2Q5M<34T<?1 M>4_&WC\$>^|Q@M^\$2%YDL^J^FW3C1V+ B^HY|Y6&@YCPCO579U^I IQOV|JO MG EK3Q0^71TIG;."VLI^ AE;H|P4M^*YIC.PZVL^#^|C8;=0L_LB; M^: M^H0U6_R@|I%1%K5^38D=2N_2COMJ409VOTX9Q|>#WD| (X+2RGF@9|Z|KSJR.R/H.U0^F(MGH0@=7/KL;7=:=J8^\$<\$J|BNWO M^I8^CN!;TJ&(QV^+Y^>+M^*V:R#BM8>6CA=^C^"T>(^N^A0LNA8R#G>M&W M- 311SH\$E.%|YI.=B-P6.CGI2^@|B2T2^JXE CSF\$YFDI(LPSJGB\$FY4H:M^NG;-LXHS^"UQV^<3|SLL;C^V4EP.2|ZME? RUO^S.T=WM5 M<|Q=FV. |M39>D.MA|^JOP:6."674>TB319\$B<(5&267T2J6#)|^|IY;M2^~^|>N\$>JKEJ^YIJ+9WU^A.E4W>SP.28^KHMI.N_K6BX^ 518S3R^ |MLWR2)MG.3JX%L2W<5^3^~^15|.->.|?S?3_1EY-@2IY2XA2A/23GJ2M;P:S M).W+MCC^24*|@JFM9=|E|S1^|81#;.\$=J^7F79+@W+RGGG|^15HZ4+.*N MBRCRN7^AMJ>82^SYPHO&N:40X:6CS4TL;4R(#>=4Z^E-@U#|L2NI74-&J7DD-B:0MYQZ<Z^|Z8G6M M07&1%_*DEKPQ2L\$SH&Q.H JJ- GVGFGH>QU.IOEH?<1?BF/^@J.M|P&:VAR MLJ^Y+@AA8.+>HJT|B).55IG3FVC1W6+9_ |KHZRF|85J|GN+4N&.OJ\$.*4 M^O80W@W^OA@^Z;C9L0/_ YJ5MSB1R5 |8S_.JZ_BP5I=64|DQ?>7\$^T2L.H.*|;|@Y^M+&B+>=U=2M(H@7YD.3Y%|T^P^H|IFYY=B.G.K<@CQ|I3H3AY.UCXD@~^NHN M;PIVQ? H5TEA7 |H3<<1KUXTUK=:#.#=-*B|.*;#SLU8+<#|OTJ2I;(W1R^ MX-U>C#MXL.OS.;GC&C Y|;?9#0(5J^RK05D3|Q|L^+<- **H9QP&+ZT&IYH4RIWQ^| M|)^AP? ^?#I| JSW_RW^8/ T1? 70D7^W.QVM^T@Z^OGCY2^X2;UP M0#|I27Y- WJ_OOO.GX|N|^F>V>?QS|L_XY?|N| L7^1^C|W7|S|_?H2 MOIY.WB^X=|H|?D?GCY2_9X1|XEBW>+IU|_?AY^<=B|_UOOR|/K|JEA M|:O|Z=C^?B-2XV.N_CIA|ODHS|_|C^O^FZ>GJR? ^OY?|S='WKN+J_N| MWIY|W|S^>|PGW|_|^|>3WJ_?YR;_FWIR| SXD_??MFJ_1T_P-6WYCS|OWEZ<7- &R;LL?CUS|=G6?)>O^A_NWK MYVW| M|^~OE^#DYNK@/T3.U9074VO1-(S4>1-"1PBP\$@N>O8N^YMT68W.A M2%K)P..5O^Y1Q_~^DY;L>I>#Y^I;=4 N6YXGTZ2Z DJS.@5 M74#@J9MV+NWSL&|ETXJQW^B^XVG7QS05WF)#|X%|+R-VZD7ERIV4H590IU MJDMM&L|JO^NWNPI+I9851>P|CALO6AR4GUI? 1N76|J^<|TG.Q=PYE^A M^H7DN_?>:ILAN;K|8L-.9WV/GN@|FSKWV1X^;JO=WU|_20^7XZ|_I>7Z&> MWIW.E^0B|Q M7H0(=+23KDG\$(K^N^=E4M^K&|)OH%N120N%)\$SKL=2H|^?F< MI+|A;BM6H#Z8C9W%|RL|@L JO7CJ>G=ZCCSZ7PIIU,I9V.EA5^IESMZ 4/C MTIF

!AF+SY(+ROA*I%K87>U2,Z2=\$Q"5A%B|T|UDAD^>T8U.5F)G>Q:RHEO MM&6V?7*0FDJ! *SQ|@TM)9C:HJ|!*/WT1W|>@::='LU<U.(O|J1Z1H M:4F1H-
W0*F+ 3 J^K EXWRZ+JB(4- J M(LF\$S\$WH&H J,OZ2M|Q(E91C+XZ?5%*MKN<*0|VD-\$LKL MFG +LSK6\$.S. @1'N|N:~X50&6NUU|S|R%>%|90
9U&"T&1AM?Q(76M1B MX3I S JN7:N>LS3_ZYI=U>DZF>D#-1&DOZW%KSD6DOJ2K(780589|S=@ 2ZO MMAI= UBL WO#U>3 M|J|2PTT|5U'7?
#4<|T:(NK |J+)|WC5-C:~|J>L D, M3\$*:XSDQ3@7+K D)TXXVANP)S*MX3+*B-|282U.8:8YGNM1V9Q_5=D91|4: -
M*Q\$9EV\$|VF:~&BPU>ZR8LU68^~|HLZ_|%F<*:ARB\$|MOH4'2;16C:-!P!U=2&W5,SW^4ZL1|7|(E D@YK% _SH1R<4KIM?A@GE(
M'E+B%YYOX'DWAG;|@>=5F6*UO-8'1L_')7|(M'DF(VICEC%"12XZ.EFH#|BU>|4D,K5N-D|S:~&"Q#(H9|H&|J)R*"X.*RA:G M:JL:9| ZB90*|J'.LSR47K-
.L_0=|>83A_L+ E*.(706PEB&ERME|".S%K* M3"E:2A8A|S4)32Q#3.PG|JH-BE5H>N2&I")|E=IZ2SD%B2%">+R8DD|2E/CH MU@QYE^
\$O(RX^CUA9:8;|F@L976%|&+*LOB_|JH(PQF+)|H&UIRND%G^X^ZAB92'2CA'9|M:|66HGT(U9W\$GZ>|@>)%T4D.%Z>>OZT^=U=:/M&|W\$Z,60 ;
#DE:8XF0\$?JUAZM_IB5?|U>|4("E*|8|W/G+5)JB+&Z^31G2A|G'59'NWE1?>I9L+Z01E77
M4L(N+4EK#2Z'4MF4QK:|4I+FMR2=L;FLZ1T3+PWC";^PK|+^C1@2+TG?#4& M5=W|'6"1?
Q|RMDLLA_|E!|REUEBO1";0"G:FU@&|=2'D|B9=VT4^78MF*CM MT:6CTTDO&|1L7?6NCR-8QS^1.3ZXF.4_|F|"(|L7)X+&EVGFS\$ EV:4D*H M%TI-
|2R9P-N.0%|J6M3|FSRZ2|DWE9.E9C<=&|MU?2D|GR3+~|D|5\$96G(9|PA=E M:8BU9B&B*O|4\$'6X|2OKY=J (26|ITDR>QGN8| MJPTFK)S5|BT1A;
(H*:\$HBCF|KJO:J&K*P\$W7(9|6?_3'U4U7/6W M|_\$.ZN5AMN2)>;V53M0. &>6|10%):(BGLS2R:44|8J"Y(SH^K+QEO7)|I< M'3FC68S:RB|>>3\$+HD-
08(VAW57|LM1|<36 TPB*2H(^B|J#8&=YM\$TTR9G:7#C MELMO4@27|RV(|4|9|"CEKR 33UVQ\$?PW|!5|_Q\$LEJ\$M/IGW-*(IDRK>_ M1RB|24:)
<8*4E'5'5'.D)'01=2HCXY56|OK\$(I30D6TNG?F4V'F3(6N6-56281HSU<^~|J|S2-FH0="OFE%(KJ#K,KA_/XZD M#N|U^~>6V|Y+ ,1G.=<:
PPF?2|MIU@_*|Y1|(JLM:~W5<~|JVP-~|U>Z F M:3R)2YVW=HH7\$HK\$-9|JH>_Q+0VM8H|JZT|RV?>\$S S(T&@|80LM\$H BZ M.^|:23\$'40 2BN:Q)|@K-
3(LR^@RB:WU)|7-(4,ITE*%W:6S6R;"C<|/IAB M14\$93@3<+@)|BL%LO.1^*|13K|3P+8Y)E Y^JERS<|S-Q\$D|E1|994K *O| MGWU=2+>(2Z0Z.?Z406Q7#-
M#~#8|0\$>97F|/32 M "ELHCEV#U7@|C@5\$^~Y(BK8=L|CY?KIY0=8?GLUE.. |3 +Y0ING7|JMW9.0N@T+CBK=TS |3:| WHR@N#|_C\$
M>PAS+|*&|2LVAW|6H6FOT6C:!!2VMI M:|H|IT 038UGK7L)MH=|0:50K:UO 356FPX.%838W|)TJRFOTOT.C1=>M|JBF M4A7*V'AC:~|
|)^\$IP8+&:&|O06V^_22M8I\$+E^=3|L%+Y%|-*8:01A(KM)D MDGJM0(LR %6#N+0-:J5K3.#E6B@9%|^C.F\$|4'G 'VHF?|=IGG::1KZ(48
MH%CN\$R\$W|Z|E9Z/F|S>|@XN+\$0".KQ|G|H+40:~S 5T* H|K|T8H2WPIKLLK?~WB_7U78.\$ M|2|KDN5IR-S?2&9W%)>+L^N8.A0UR6DZC.?#2M.K,5(-
'YMP-4 |J9VSS?VJU MZ%DW-|6ZZ.M*PE?&A7|D2R1>D#0|/R-?F>2\$2@:+0#0 63J 6^M=52|PA<:< M|J\$4Y|ISO^>C|YCGTRO-/X.WZ|51#HS
M386@AO|2@G74'ARE/\$0^X#W3KTC*YX+*0B%1M_H1B)=B2C:B'|I8X|VD&3A M)&:D"XG2LP0D0_1K?6F|HNR28+FR\$|0(#NC: A FZL4^~)=V?
P1.6BU|UO M1 1263>9BF1E 6B>A-*|V:9%DU5|U5)'RZCPM#(6Z.G278JAS|C:T%Y8 M^82#|AVMH9V%YJ0=GBFM5Y.M@JZQ3:+*V/A-W@DF!
S054|J|HF9G|L/; M*2F08H1Z4K#>#(=TYYZ\$UX&FB'D+LG9>E 14F(64"?>E7|.?A L2C':S.#5H
M|JTO+6N^K+I|IR>>+>6D+2|JME|7|CJ>9|E7LQ06V?|/Z|V6Q\$NH_ZUP0:O*)| M7.ES10*|4<~#|W05UI|1UPZS*V)|5WBQWPIG/
"I|E%2'D@NR2|_ \$WPU"RVB M|3TEZ\$*JKNUCN9Y|^_V A.65|N<=>|!^X+R:4|(-&|S9U21+[*Y|3)W:~|=O" M%|D B428#?=-541N-
'E|P|IPIOBW: 6&F)|5FF.Y|6|Z|F@%C MXG&4CM G&T|D(H%P'Z3N|>7>U=LNC&REUVDF3@JTN#8)|89X)CQ4*5P2N M8\$E-B*|-"16Y?MZ *D&L&
CM'ZD9.SN22M.AV.^=300+BI%B(MXBUTS)_2) M.O.P*Z*Y|Y&2KJ28M|L G*W|7|J\$|S^M+~:C8X\$K\$|:~*2|165=6\$ EHM#V..H M|J=|%>H2 _%H (0>
|/R:~P5HR6.#G MK|)&X\$E|L2O_FDSV\$VX_/75|60>L5|66F*N68 MKE@8=E2R(@MHZ>:|J6|8MTF|X|JQRT8R5.^8:(12Q2.Q'|="PY(9"2Y".L
MBXYH|B01\$J_CY_EFQ4C0|J%<_)QF=3@|ZE*P-1\$M9F|U<0~0#01P|U(ABIN.K)W%|V:ROF5#N&5^MP*WX^PU Z7|76|J0G%IKXFF0D
M79#>+&G(YOD|)950C&Q\$~58|GT\$6B?>M(XC2BR^#U1BE|O^MG|TT-8!SME MYWQ"881UP@PYXJ"11F5:~%WS+&=&K:K|5|5Y6%:1|F4AEUY|X
MN>D4VH43SF V/96|SDRHO /,0>ED- SB59201\$MSO|XI&:AWNDVR|IGW| 9@ MYPRN1|7875FMB4\$<%(NB=B^_66D76.J,2?1GC?#MF*PU,
<(SN.=|K2ONXP< MOHIMD0"Q#EO(O5K#W&^93'MC'N 8|3*OGLH#&.&JX8%-YVN:1?2G0FRW\$=Y7U M=
|O|J#:C|FAK@>N8|L2.V5@J<4|(I(NUKIYH)R,5,3E7U.8 +&H%MVJA|T+:Y+TY@UPM#2*%3 MZ-|)RX *%&"C D#%ONB2(IV/A=LK803*\$X1?CG=
ML'7.5 M'|^U3 R%|KDF@|2RH0DQ|) G2TAHO.|.=* W4 _&R:|+M4C\$XC0FY^2I&1'?L1G^R?A0|S88-9ZPLC|/T|W(MWVXIN":Q
MT:PV08|SAO|9|>Z08 5:BY:3*AA=IZ3?:E|F%<^'8>~.TM.&|EB"NN"|&KAY M@92:7D/Y|QPTD(>AAG@C>.KMS25|4_A3N6
MW:BA^BD:4G>D|K1N\$=ET15K+|=AA|1TY'8#~B1_%YK*5?K7B.H0=+U< M_A*2E+|X=E'|D3:|/1@K'911|ZB|V%=(7(1%VZ1KX4&9-L3T3|M1=9
R3X%D"# M&729|F LDO\$2~*|723K*4@K6GCX.Z\$J2L_R^+T3|I?E2S.FO:AI2Q_0+
M|ADFP*9IU6XJH_L\$JX%LP0+QTTYC2|HRO0**NHV."0M|EN>9+O^ZNY&8"OGO MOYDDDBZ/RRX6U4/ZR-A|J0SG8=:|Y@S?
^ALC:|N5N|@RML^D^XCSDUN+~|M.Z%&:DGPB:)HIMB^~*Q M8D+NK\$@SULBPTNC59:\$.U%"%(H|>8L-DT?>L G"-^VJG5+:~2-Y?V:~+9C44
M|N:~DNF&85\$GX/5MO?7|ZP-D-L*#|Z T^+Y|PB.DWB>D>QDG:4N G#|X M|?H?3F59P-QN|#GC_~:~TF-EZ".OMD.7|FOHC.5|V@V#PUVEMU
M8C. GLWXD2BIIM@RI=6.|NB+|ZORR:~5>F%@S'DPPGNO-!\$QAVV^Q2>ZFA G M4Y=6+19+N^%LI6|ODYG+'.7349%8^6JX.9/NQ26:X'K%|J|5|A
6|1ELN>^/G-MFX|VFA8DQ|IB|U)5A4S6G?Y7W27PZK|SGDQ.K%:K|D|TUXVY4@W2D^U@89.
MDRV<|AAXO.2JE2UGM*78555QTDZ:Z31;^=%F|A0|,* *BJUP:~%SKHT2PT^&* M=4E 6"Y|Y<#&ZD,P8DO:< =IKO.?D61X*P5:EQ%|;N5(=\$|X-N=+
W79V|JF M.2OR=6.G-NO&D=4 'CCQ3MK0# 1QHR0C=IAYOB:N 9M2.IZ _BI=Q|0.22TM0P M^P=U8WR:PB|.9ZV?MN)^|K+Z|JIMZ?
#|X(D.3NHP%N'|A^~L6SR.O& MB.9(25#|E^~&G|3XR@ED'H1+| T&UE""O&B\$|FY:B00D&="A-C52AXZ|)
M0Y*RAQFKAC'O=KJ|0#MP'B9+~|MH^|_PX%2KJ> M1DN9^2*(+&OC<^Y|1|PH:\$166\$O_4Y# M|LY\$WKM\$6|RW|^V3NFG#1"=ZPG:G+2^J6-
R#H=H8 V6ASZ#&+0S1R/W02PIT M^HY WLX6)=|D-31 N/|F+|&|TC:|J=U^S^2<4|AS-P2>B\$9?FM|FCK RC M|O-J8_!A+B4:\$5/YFU:A_@|"+P?
LFI"O@*@0|LTV")UE62Y% T9|@#M MS:W#|LA&:H>EX@-YK076\$+~X%|D3#GZ32)(OS^ MK<%Z(;<QR:|!>0+T-006UM&6H=2G3_Z4 M5|K'G9.F
/MLIV<("K0P7|BAM@|J|.4E9S<=&7|Y=Z\$~L% D&T=N#|&H@B9 M^B)07E|S:~|TQ&C%HL|LZ_1+U!+ P04 ~"IBPU90&SOV5E^~30P8 M%0_1N:VXM.C R-
V.S|2;&B+GAM:R:|7|=~18P_|ED|6>|1-2472% MLIW\$=7IY2E|+6|V|V1-2Z4R|JXN20)684.1MDE=+>OVV+W |\$|S1_~%QZ M4D\$<#8 |V?|P_|
|O|O|<|R*\$W^~7KK_>^0CA9IF&4W/SQJZN+W<7% O'O M5 _O3PCIGS |W|U=|!\$G. L**+K|)2?WJT0EA&ZS(|D7Z79?I1W+U\$N^BV
M^~8 Q'KU|(^P|9|)DR^C^?DEOB^?Z|=G2)A-64^QF&^7|GL\$+38WZ/4: M|_:#Z^ _&::|5Y3ZL?F&S:D_PACD|2KX<(<P|WDO_QVZE0^LL CK-
M:EZIV=|J^ZKZ|^OVY0^A(O6|PIOZ=>OW|I_XK^M?XTCT0?DFE?O_K^Y|7 MRUM|@^Q&25X\$R1(6R*?W:UC(C^|C:~%\$S<@<9:|O&O&GP?
M|C(=%WL_BK|^#Z1Y7_OHR+8+X4W^~XZ|0?Y2BQ6|'UKO|F|J|SA+KK0\$GV|M+|K8'-2BHS:~%SAYT|GA|G|^8A:G2|4K YS|C@9.0-|S_Z+UCO6G0?
R2A/\$ E=NR|A|>KGXA|87%>7%W-@KYR0#4.M./H|JZC M."HB-&Y%BS@8V|WP3#~X\$SS\$18R/G\$BX0\$2^O|SLTWG5@XW_G|I<#&3|N"-
BLO^3J^U=5&DRU|K7|8W>OTX|)%&(9@A4.B6 0S ME^X0_1#|#_ ^LY8~B+Y9A1@O)VIL2YW80F:(++=I)*WY&-U'Q-@JP=!:P M<8-TP5
>^CGW^~7 |O|LWK|'F\$CZ#M+O|PF4|E9T;B00G.0\$DPR3L3^+7)B1^H+I>AR>9&SDY| MVN5&WY-L|^@A2.I7U?>CQ0?C3|>7QX<?%R@>"XN3_?
^N?33P>^YQ?527GX MMZOCRY|Y@IHR7*F)PTC<::2 ^9FF>GV7I*AK|E<~/I%\$H=YI:6R W|K%/ M_&KB @|PS-I&Q?Z..5V#M3U*:~@X?
USC|1W| ==>W2XIT8%5|7?7|K M|+~+>(Z%<::'8?M|TDH3Z\$G:LY8R|?R-<9?V0\$SRH4&5|4MSB#~^OT8MR MQ.L=E&#EXN6A|P|J7&W??
E(N|B^D= M1\$O>|Q=|IWFN|X^~W2L+Y|L M5|4EF0\$MRS\$|JQZ082?>JQ_O.GZ|>4TCDL|M0T)'L<_ HH5G|OYX M'X3B^~4SY=H74X&=11-
9%86.355Y"5|7PN4NH@OL&\$B|JCDJ6\$PA+P/U D|H,8=(ASL@.R:G@\$/ZP2+V M+|@OSZ@B3QZ1&0YR?(&9 Y.^XTU(OC+6|V?Z4E|I9/AX^3|JG#3V-
F4K M#M^QH\$LRQ4|:M4%"#> @F2A^XZ-(58K+B_1D%|D::?|T@QG.2*?Q|_&4:6H%9|R|T@LR:1C%&_+*Q1=XN!%8JFEVA M|4@BVT?
1(PX1RWK>06|'FR|4-T27X?2>8R5W\$MSTG<>NRUDC@MJAA: 22SD|VJBM|@Z5|M|O6|J
(>9D%YF+5\$C^XG|&#M)ITA8R\$~5:R:"5^ZHC5TNE="9H(C|D4&5|M2U)"**=Y.UR|5+62H6W|V(U6HP1'I-(L0DS*|JEOVP-|71Q\$^3).|TV&|)H<M|
(N.K@:K|@.Q#|)|'A_Y:|79#<4QK|AR&?>#6B?L*NHU0Z|NQLQ'/7I M(BT^W0MQI7|9Y'K\$~1R-L4:-5PT\$=^Y/C%-"(ULPR(O=I0*%PA?D2& M-
/&TA#|GP1_-CG83*66|EK::113#_|+J2C34T0?0Y*?J- EE4S.(+H^X M569 \$:FEOR^T'DH.4D^>X3S^6+~N5/\$Z-E_5@/S\$&35UKF.KGNOS:MT3V
MY7)|1>|CO&^S|ZDQ51|J&8QUR&+5<#(H|D^&V?3P/HS)O>QX/S-VIJMZ M=LA@+5LT (AG@O-A0CC)60AHED&*~|L-8Y^4
KUX"++P=\$UKD"%\$XV=|:VWZOEYTW<78E@*(*OB ZF>BZ<)_|C:SOCO>+X MK#^CN:~*Q\$-WNA)IYX_W\$7Z+.6= L2U*R2?%U?Y!-|~#B.G|J6LEI^+
(^M\$?ECL_P6U_?RI4LU:~*2_1?<~"E:STZ@AA6YHRO:N+P=E:MB\$@:Q89P0F4 M&|D|V+|?VYF|ZKU@DQ68:~9@A<7X6684:&QE UOM+GH2R_8\$S\$XLS?
Q/~LSD MBM)H09-U|78F\$0:2|A|4&+IZW/F:~^|67|T BLC@ MXU5D#|VJ1PSA\$|8\$|L_O|NEY9*~)GT?YKW|77A\$LLB*(DF^X3G|JIM5S&=RLA
MD2I|Y..D*)MYTJN\$S**7)\$4C/O*RI2?|D#|J1M&:~)5)4.VI.13WINK2|KHT\$
M|JVB|BGO2FON(C.8|Q_7NA"N_79C<#A_~M*H47Y550+YPN6NE06#NG(A+5|A M77L>GF7MPLW3Z|F:|I|J:~2|UVRWV:DL#0ME45K<~*T
M|Q&3ZZOAZ8\$Y6\$6^U3EWPPI=\$@|DE> HD-05H_9|J@+GKTRODH>^O'L5RO^T| MSM T^B%_2AJ_>&|K:O=G\$K^1#|J3 P:K+L<:~%NHM "P/#?.KP.HK
L/D6 M#.IN:=V.(PN R8H39|)JBQ=JP9+(2SFRKO=#KZV4-KE?MK0BOZ4-C?GZY.)":2>WR0 K1|BL5 MW|/5%1%6&D:5&OY\$QDE.#(VHALU8+(8-
1NNMK=D| H:32GDA 2=LI\$ M|5\$F\$#SO.29=3|J0.2+CK9X|2C|^~S9L|5/#O *DP.DW\$ ST7NSM>?V|7I M02"| M@W*%V1?X#0+.%KG|J\$D"GM6V
(KIYD2)|D|W|=|?0G'(KM:/-9>O> M=V W*~LEH|J|_0 2%CKR6#D BWP48^D-HE3644HDEV*PA.%4Y@NJR'5X*|K6Z M+>4OT>MGXN?
|JBG|F|>K3>U2DGO|OY?4L> (3W+0VUZU W-O|Q(#HK*QK|K7W MXOH*1HD.PJ@>Z|Q|)(MRRK3P+T|^|~Z4\$@DVHQM_|I2@)VY|L8IUD5YU95
M)5IV< CRYNQM:&U.A:OFXD5;JF.4.TBWG0?M00FAN5K+ED^>@*#V&M2 _MG*0?KM(|# ^F5@Y|JL5':Q&1DYQF'.@/3/24AK(1(-7KRTP-J\$YK%|P%
M:HCXD6K5|03 \$J\$K|H(^AZ|Z)\$K(Z\$@OJX|7C(H3^~>4&4TTL>?Q\$?>A3?|Q| M|_&4?|DD&+W=VT%~O|J|S\$~?Z|I6OZV|<|B\$SRXQDMH3AD_~8Z
_A.=@Z| MEMKY|WKHLG>ND|).SBG?|A04GP:23%>D|LFTF\$Z\$A\$A7|7O.DCC.CR MEW|5ZKX.WYXF84R9O(A:=MD3DQ3|70?>
>A9!>Z\$!>=E:L^~9=M7OY|SIHH3)T.G(*GT|>Y|J=W:9|09SRPS6\$=00|93 M34 JP7/R/H|J)B\$5PQ2)F*.KZ_5/(3URJ\$QS,U=MG)S7X *BKY Z5^~
UO+3 M_|JWB\$G(F5M_|OAS'E\$| 5XBQ>F W>P>U+UV|T9+~+LFX&7#GBZPA0Y|Z|5 MG\$&^8^0^0S.XA9P.63FPS6U?4P_@=|J|I7^_ MO4:K(&-
=7Z|OMG|=F|O M9V|O#^6LLG2P*6|3#)XHAJ:"WZ.WWWZW|Z|I^F2ZWF(W@|I:0T5Y|J434 M^~(DLEYI**O\$#=EJ|NEX|J4R:TE95;Z
M@8RI@CM2?&L&N#|9|DQ|3'=G|UB|760:Z31Y|Y\$^~K/P|J@'K (MDTB|WY@&=>GP6*=T)-8021K3(+85%?2|1RM&7NF8DNR|4|*HOJN'D4|(@4
M\$2:7BOB@?|I+1+WT^Q.=JY%<~Q%6@:UD7^_H10S#<^~#&#&K+YXOE|+|)9IWC>YQ|1H|@KZ2U<6|6BTM\$|JRS:~^~N7:IQ6'P8"W M3DX\$|DQK|<~/I>?
=PT@?0UD|_|H#R(L=<9|D)6M'7F:6Q&J|FVUV:~|0FS M:4?LMR5P&|0QLO_|.IGIT|1 8D'995<~?J 2)?QV>ICFU@M+F U8^9I#) MF^9_1.B:|V&~>80 Q|
(1N1G:T@>~*1<_Y7K?7AM: 1ZH6|6#471P W|HWS M=@R8V%8=*>@/>~+24&Y|Y?Z LD&E
MZ*X:X%07U_|ME2:FQMA+N)P:J\$>39<-5R=8N1|I%R/ZUQ7CVVAJSD|K^Z^|JKN M"?Z|D^0U|_B"?Y:Y|_*\$N2-IVYWMCO|T|^GF6?#SC9Z?;X8|<~&JR
R| MY 28^EVL7\$XUO>D>R2>W-~|1Z40|RFQAIQL:62U.N:U:~0RB|?~S2IPGT MBLI9|8JOMCA&LYU|Q4.HV?|?O2|I?7-E|FX?
TI&M70\$9|V7GP|)=|4I=0 M9<~Q\$="16'O>#T\$>+>2<6 M(+&ZRM."(5\$BAI+&5^2A<|&#(M&DFQO_I6=SI|LAD2|C|I|MBW=F.GMS-X.
|I|F GMSQC58C^AH_8F@W1V:| M)SK.#3|90%KAZ:H3ITZ|F(FT\$#L8?|P95I!~*V:~|>2N7:OSNN%X|:O6H|OG_VHC|81*NILL;ZKNX^T M|O|FAN?
HV^|4|=|J2DL&F|U=5\$OK3|:Z9@|WS:0|J|1ZWK2#H|E(8T ME#U|5|71?|".J5G%Y^ZKNS|>D(H:Z3W4T|J#^>L|K^~^~^Y:W@L15\$
MM*|LP|R>~|W2?_59+A|(84|3G.1QZC.G_B|W&6M FD4Y=^!|I|DR=O ME(83)|J:7:A83(2/9|VTZ\$|+&EOA0_#JNA:GGOY(4|7O^4974P2
MUG)H^729|4E.IGN4)N1 H#_%?T|7#&V.EX^PT\$TK5>OHTD-NNG+~#L+~1 M0D4S^0KJ67P/Z>5Y|I-P+UA^2.5Q/FEZDND:CR|J#^3N"?T|021+I&OZ9
MGT.KASPJ 7.JJ.E9@?\$.5ZF-PF=<>3|Z J|SGM3G|3|?808:I=YH-7W>L.Y.Z5^LG 1_5|25N=\$YF89\$56?EP|!%GX.2.GS^BQ

M,AL82?PU*TBVEV3&L6O=YDV7UT+I,S(G:PUFMYV2*QZ#3(L:+8V"+-S%*>95H' MA/8%SLX;45:;)OWU^?)6DH,1-R\$A!/:1-6*CW+=VAM%09V_8_?
99&\$: Y3FO MOL3(>, KBD80 !AE1WXM<OPO"BC G*)
M*8+K&%^F9J\$4/0'0C.GGX0AS,JlA':I+9:EX/DJ&4E@3,V;IA2=X;J\$S\$>NIUF6UJN&AH,XV1X@0_ T#IY-4HTBIY(#+= &T<> M9Q,AV\$|
(C&T;.7+YJ,lJ#I2L7+.,(G3,J1T9EUY|ZSL15-YJ (+S,FB:7FJY M4/Q9WRX|+WVMDWFN'R.SO#Y7 AF L)F)B:H\$X+ #SD- 2'4A';269J1W'ZD@.V KJ M-
#93^0=VLL#?PY9DLM6B\$N^>G'N) LHO@2(DYDUZF?H5I TE =XJ3X&M'U'U# MO10J4I15B1|&ZJ:PV AWTO841N(8'C'HSWH|'25"/WBVDOPVK=*(
(E3&9,Z1 MIC?'9QF05KRA(I (2 CQ%|Y4\$ "5G&LIG7*F!>Q?X2I1S,D1I1EV MD&ZNB|4F7BR7Z69J|UR#|I16|T5 QZ:9YI"TZC-Z+4'-,9&XJZV>V9K&&?
'%=M9|@UNH<,C%|5^0:7A#%#;P<3U0|K_ R7KQS/8&4 M:9#|1&U\$ Q+,4IOLKE(=Y62!\$|Q,DIOH|GH^#E4M5/(&8^PF7I|/#!+ MC)FIEC,1|B.>AF3Z;
(/3U#P'<7T0?U"QK:7=U<.,0%'+F7P8?7VS;W>QWWX MJ14S\$?IVSO%#B4DO FJE)W?W|)M:Z H5. IFV41++?HBM[V=ZK8K9:'BK"B@R
M5E.#=W'NP'Q:NP'<|KU6(C:P*9+6N|H'50#;QQ6H<-+0%5C/;&|7 MH(\$!&+@=">2R%6*RSA+C.#|B|S#'#H|! 34MGFA-F3C&.,L^ATHS4|7DMX' MJ:5I
.:RN1<\$W=RF6:%+5KX3UU0O8_6SE84M8Z 5L<:Z6;^WNUF_G|'-^OVS MN%F_U|^LWTIOLOY%29
L|=ZL^#@F<|JH#216>I9GYVS&LB#P*#;J|S)1B=CPAQOD:X75:3K/A2|6| "RC"W M^Z'XOH;H"X|L)NY)U"G%Q+|)5N5P)S+K^?)_:R&|K?P=G(|YB>D
B:KY7&; M|CY2.(P>V\$5OT.H6:-UB6D74WDYR.-?>Q'IGH.2_ M?Q9'>N?R2iSk|MKJ5:DJ7>Z.GODOM?SH."G'6A|+&?#?P>B|D|R..O^1H# M2R#W4?
L7W)\$A\$F*T\$9J|M*5;|R+7WP*_*D|-WA:3HI;7^ MF8@%(W4->KUG=YR^WG-XT|7Z2-L15M\$ >|&|^:GMB.V? MGR;ML|/=%Q?:-
;KF%9Q#V+8^&|L4|J7K*ME.U|' <?7W>:QF@.F.ZMQH M=1#ERSC~U5G|JVA;CY/|< Z.2|5NY #SH->.*?S"3(|(W3*0EK,IEQ@>|F ML|L:K^O:
V0.F|Q|CF@|J4X4U5Y+R#)8U9962?Z5W-K7^ZWK*RI|&5_ @!|@ MZX9|2#N_#2+&|L;|,POV<0>A;J|I"%D|J>?CY4?RU44B3#|N?VIG(&#YLUJ,lU
M2|!^AFONE4|3AIQ?"8&*|-WE|H>0#&LCOH1>=EKW.5|&09Y|VA|#^/3U4#) MY%R.H#J| K28V79U|B|JCFVDIT@U>Q'W^~
Q1<|>G=|K|L4\$N)3LN9RPH518|) M>C*TDK|OTAAQ.K^GU^FHE|E)KJ.;0>TBL|3L8RHP|ODW|R&>Q:J7QK.?OF8 G M^<8:2ZE.804TLP%-F(NC0,|>~
(.F50C;)EYH^T|QIW:JRNHKCWVTZC7VB-Z M^|W%K|>+T|;|=U\$54).3,0,B2E|P67IU*HY^..|DN.J7|J518|ODOX@)=80@:X2*KAUQI-T1PB8AQ
TIN82?D_PHV MXQ|Q:FK'6 JZDY.GHR@/%2:0RA G+(1. MJ|+|Y|06Z2|)U|XK|0#3#;4(&Y-M2(|2|3U|5K^>Q-E^)BL2|Q=C=AE+O1
MFCX>+T:0R225P';Y&81|7YB7?KPNA7O8DP6R|=..9X&S#|Y1Q=,9(7%)|Y| MP>N|000|UAX%O(H|<|S*~?E8'J&XFKDW(12RWJE9*H)9-.7AOL;-S3R, E
M7\$KF"/.O:LWVS"N25\$^&|I9@CD-JV8^UMZ";D=L?U9D'C\$H0=>2B|Y\$2JV18L\$% M^JRH_-KZ7&N'E'EQQ7X263G'JM3P4_#>
(ZW<7TN|'YV1|@GD\$>|4M(C|Z|Y|VY|.=*BPJ.22CA2R-JA3G_-&K MJO_#+=M'L\$C.AAXO>,ZLORUGG5BSKV,3,G4*^GZ|'LH|L,K;S5|"
MCV2!+ABR&J_939|4E>#|'^?ADY.C|(<|<|B?G4RL|18RE?>_Z":A(=5)449K M0:Q@&L3'>7^+X\$(|?T1P42^!;XU
DV;|W=T^v1.MQ=|.@Y|T|D6|80#34RD\$&F#Z-X4Y C|O(OH= >6>.<P<1E00AR' M|PU.S4U1)|@14E_D9SF@.HLGD=WP
/;@X1D="MBO*A6|;')3+H)8M@+L+X'=: M3"9XK2TT#>#MU=9A,+##LK\$5VE%&@&0-LF2|,S8V:R5\$U.XNOX.:W5:M M@.@,2K|^O=YO+
+6T|9'H_VPVG#B44F:W^?PZG7TCS*(|H#|D 1|SCD76 M(CN^G^J|&5:JP2?:802N>B.\$*V/C=F^?%V JV_Z8Z0%OKN7^C
M*:#1M\$XZ|+1.B\$|GOKM2VH&N>;>-T|N#H="F"XA*|&G4"WL?WOP8X@ZM1 M(7:~7 *+&)>|T\$U(8RF6AW?
K.W'^Q|3P'W1KD#1I9& 7I>RGOJH-(<=RS M+>H'G3\$ 6Z4UC=W:S;|,|PH|OCR-&@D6|Z+|J2&2^8=8+N<>A":L;%SE:HQ MMU7&H)|4| 8-
V2J'^Z|'96RK>2_Z2HF'0=L4P|,7E6<-K7?|JGH9S+^C0DXXD\$5F3F^R'R M#&:GJR.B#_*:Q3S@8.X1U^ "G@/VX\$HD'PCBI<4P7|*|5E/GU'^2'9UU#S;X
MA.R2RP<W E"Y%"_KV^X|5 1ZB|&|L?RF19V'^7 M#ZDGX:U6=^WZ FA7%B_FZW2(>RC7SRA+|T5:07J>8>VWPL7L2#UU4(B*|J M,"UH2)
|J^X4C>*M=L|J|&2:RUKL1QC2X1"2>|J|N?H-B@&|+L.A.M#&:8N M#&:6.'3*H0K4*XVQ5VVH7S'6_UX\$)X29GONY,DY#W|B6FOU'>W<%CA< MW)?
WF PAD,H*2X.L\$>L:WD05=WH>XJ@52Y1E U|8CD14DBR07.J1*|8" M3(|3#0EFGR\$#.1.W:4R>3SE\$615|VF|IUV?F;K^BUC#)G,^2-_|@G>:
M1VP:GTIB;S9WN@ 84V1 KJ_?Q\$XCZ3|0|0_WN: "L?IFN8|+E@:L&FMIB, MY%QZ|X-LXONAN59L|KWVC1G+?V|0-; OI_QXGYI-2\$U|!%E8
O61%|@8|3EA/CRE"||> T\$|L|J AXR-H?B|/G^XQ MF#!'YOK7Z'5=)&BTTV1V2W@+#+|!|!|&A.|HTTGd:V=-Q\$|D)4H'4|Y M+XBV=+
|#1Z+H1>0Q34|8L7O@N(3<0V'R_?PD^|D:@|KW2S4(T5'H7Z:53^O:P M#?P^(<+&:V;|S' _+&#|X8
M:2|M_HH6Z2BNW|_?WOD"1|E|K9AU|""Y8|@M#W|EJZ|V|@&(|?15&G^&M^T|TV- MC|<,%0)7N)N|^WOD@J\$|QB(ZF&H-
<|)C%AO^#0QWBD^CALSEMLTIFEL%9UC M:AL/^|Q9.79G4+D-HC5*6|PW5:E|4^7_BV92=>|XNR|&NZ*!X8KU\$>
|I@^XXNE^9|>UQ>^3/O?79'D<0A_XL:7Q|P9^A7C|RB|O M|J+|MLU^CCKI1+|IJMG/AGNSL_UO2'PY)H%>2^U!>L^>(|E"Q <*7,|4)QN M\$#>6@-
|<F^K&.,JH(C%\$B|C R-58A>3^>C|2K|3*|2+>?"TCR|L|>| MG1D:3Q?0^2HEG:|-(U\$+|
(51)-2OXUB2F%DOO|,T4+|FP/F4M\$C(|+&|&SRBP/WV\$;|_ %70=|@-/T8VOG(3&0;F1V-9UY>W32J;*MA79N>TF=B=<.,1@/5H3T9_(HK76I
M@R>JL.P=-(LYKS)&|U/(KJ MBGBK|*25#(SYK5RR_PPMH_?W>8DX(U7S)|AE|=W.D&2|J_B25 2>|2:BBM MI +&C_49#|&5K^&|U(L|L|Q&-X@|P.L_+
=F221=>TBY)+2G&79D79TDQ:AGOL MYM88(HW:|J2|CF|H+575_V|CTOR22D>C.Q@&|L|X7K&|5^GX\$G7:(TS=D%_||S74 M0|>|J|&#?2?>
>|H|ACG80\$2*.)|W(CT)"N.F?3WCV")(|T0T<2 SC-|JZ?/U M^M9EY,9|IMT|)3^N^XOT|OIP|#!KX;3UD:@M"&^92P"(D (*N@F(OI M:S^;P'|
|H1P5UOQ\$>_>T30?1*8FSSI^_U07?BY;MS|H|N|N=N=;" 13LJ MAJGO&EO^<4H-8LY?#X1#^S^?2|I^?4|H^7
M3G9Z28.G:M14UB0|)UOF_1|Y0YEVG|HWZ.N82|,3H91=\$%TAM|B|3I\$ M49,^>JCL;6MT)AS8<|470)_Y3YPHB_9_ ^D^#S
9>89.NVY_81P=F^P&"" M/K#Q12>|P\$1H87BBYZHT= &|R1'2A\$VZ_>Z+D2=F|8K RABA%>Q_B;R< M95,|7+K5\$3|Q,|!|*F"|Z.XS@W90|4VHZ7-
(+F# MY^D2|HIC^*#X(3.IQ(Z^5(^#GX50|XK^H(BA(B8VS0_S<3X=+R/W@R*X"|C1>)D^3Q>X\$J3J0+TG&M2/%2
2#M;E%<C@K.R.7&Z6D5+L.WE\$|19M'M'(7_.\$" 1:M-EE|7|2QNS6K6@U?D2C:OUNVK_748WE^>?>7"/&UEO-L24X MTK98(A>OT\$%F)L^9X6_!A,
<|@9F+BU<(&G.7A#DOR,#Y|2;HSU\$5>9 M&1|Q(G>0)=|&0>9S2?0^Q^37-VZST^V^P9_ ^Y12U^<0R\$Z#4BRM.T@QJR"P%TU;#8'FRE3 M6S%)|F2P/-
T^X@1G00SY7^%=E\$0Y39F|QU_*FMF:|L7-""Z)S)5C=ZC8|:WA M,SGE>G&;#S|SLO24P3PK_G4.<6V+Q|@H9HP,X.2+_-3(5GNND9|7L4|H6@M*
MFQ<20N5%M QB|D'D\$KCT8\$T\$H|=(&-Y%R7Z;L#^711_*;K>D>|(8(\$ M=- 1W^402|0_/D3-EY29K^<00_4E2-J4|@#/#|=E<|LT^P<_D4F\$ _Y.N/K
MS2HAD<(<A^<W|Q Q704GI|F8S2IX/CIV>-R|VGQ-SV7+G_HB#J|?GBZ M|(C,FD|_Y.F1E1P7K;@>|J|N|=H|;#S(C99IO-RH;;5F_TAU%Q%"QI30@4
M!TYW_91_V9CEOS=1'M%LO/&%1K*8R5" H9\$ M8J|OS??Y3_1'PS5>;%0X6RL64#CK)+B:0|H33VZD50E?S*\$I& 3Q|_XN7
MAX@+|L|^M^D:T4')_?UQ2:13/F9%:SA4(X4 2_78S(Z+>W?W|A|N= IEG^M|+@E8M, >- N=4|G8UK-52AS|J|_8GRGT M>|D|Q8|(Z+C&2XT2:XO^RF#
|Y|&G?C3F^R8^T+WH>1""SRN9F>0THO|ZY MYK,9^>0%VTW^G|,H|H|^5N@C3AZ2ZGW^<.:!#S^?(Q@B/&<M^R|JX95!Y
MXBJ_U6/HY7'R^/L\$J^>^>1^9|IYTL3|1-2|TVD3N&=>TK.G8;W.NZ|DD@ MD>G1=8#&FG#HV_2FX5;KQ:Y"=SBG+&0|1HOP)I5FMFW,BBH3|J|
|7ZS@N:U.P.MR8H>PQ_P)*&X='OR@S5^+Y\$M\$?Z|=Z#|ZV1,Y0\$GU-/13P2.06^L@-T2: MX0BL_U|! 2?X^2@S(Z|H|X7>3>@&1F&^|JME|
|_ADYU<|Y@4|ZN94V_! M?F1894R702/**#3^9W;|VHYV1^L<78D@T05;A4UX5:K+&|6T9|_M_|@Z#+T@)|!F|JR_*5G04K2WDHUA89|NA5PD
=5K|J|_#XNBT_7NJBYS|^*E=1CGB L03|MT|TY7|6P4|4|1ZE|I M|L>UV?5?WD-28?T+I2V<5%;*B|N_@Y^Z^8S3<2-WC2DS24Z<|J_7KFT|X
M\$JE8R'4A\$#DH,E|^|^0D\$MPX_|V>?B&'RLZZ#JOTU6|W;BR1D\$S=7L|4D=V3I MT2|G_@#3@:31|G|=YY%R92'@AJL|Q|:(X)ED**## WM>>>S_-
QO8LP0^|L1Y= QE9TD^S3T+ MCYQ|K5|78A3M"|JFVR_T>X#RZ2>!%P-IQF32DWU5.XM.L@_|-O&C5<=Y|83VN MK/WL+5^&C\$..U^/ODUEI-
|+^3%+&|P2|Y8A_W|W^W|S1\$#|HF1| L2Y1D|! M9CK&ETX C""|W479=NW?A4UOL|80=Y_D&WEJ71&?*&|^4\$7N1>2_N,^")
M|ZDYS^)|UTCCT(*M>^CD^IK:7*.ESBZO^&I MFY/18&T?08O|)3UE|0%7,41.3YH1!E5W.<4WF\$E_9(CTY!*UI73HX2LM%5>
M@6T2SL@Q2:11KZ7=FR1Z0>KLT|V \$%=LL(0@U8:'P8'G+5-&7.R Q^>_ MH:PUZ+ZB>F(?IV|)NKO>5|J#98+=QB|Q\$;HNYV|
(^V&=15;MO@:QVPTU51 MK%|113HZ_#T\$?^E4?^4+NFU)|0)\$W#RJ_HGV|L&LLXBVZ?<8J'E7KMMD|O MRXHN55\$=X2.|?7FLO^>1(KHW'0A
\$70(CIM^H86>6^P47&J_#%#E>P6(M\$GMR'M_*#P9-GN^5HN=KD0Y|>-D^|FLX|2NWR1|_XYC5+8N|O^2BO@SO|IG M(LK^A|..@>IC2U2_X^'^J|
+D8DU?L4>Y0C<^8(#;UBY.Y#R|J|1\$|B|< MR^OX='5ZZ\$?2Q8S2^X*<8RN<|7VQ@U8|DXA?JF3SA2P.SX^Z=|1QL9_O.BYR?>-1&?EEM38%;2
M5044#G4G@.HHI4^4RX^&DZ@C|E)ZL_|X&J_2C\$>+&?7A=F8Q,K&U^""K") M>>_ DV/E>|?W\$25#I|J C6^Z=S_O|<#BGM2Q@^'= = 8ZR
L_HMPOFC|Q@= M6:3N^T5Z@&2YCK4 ZE=@0Y%"W^8M<@YU_*BF,M^MD,Z6' 6JR/M^Q^X3| M|/PHL|KKM8#YQ1250<|_1|&<3Y8J_L&B-(Q)>(<
QL(^EKYG>|LLS'E M1E1L=S_-+8-<.,?UA?IGPMH=|&-L54SFN_F|E9(C%CMS8-L (B/2D|8L9 M9F^TW-1:)734;*@^L A>K^3Q&1UY!'MNP(E=
|6|O:WQ@&4*07-Q<3<3 M?2|)YOY2U3%N8S76M@L9|UUY"6PLYB1C|A.Y?S4.8+=FEI=#N9\$|LZL^~3
M_GR5_7A8BU0/NMA&0YSCF1NM|UGOQ(6#_4|I?KJ;+|LPSH|H^&+8>|L.G|55? M4 |ZGBLIZ|X4-0ONMWL8|R.1?>
<+HXc6\$=%\$&K&)HH9_=.K=X@RGO<-+>J>4^"VX|:R"=+0PE"50*QZ0+PX:GY"QXHHT'H(L9(G_M_/|Q'&(&WOPX85\$%8_L| MDH#00U\$^
|12=%\$Z7|7H@|T^T|F|H^F^W^3_32EHG0",@|HT&^&4&5&J\$RS M.6TT D/|1E|PIGW;C|L.6%(|<+KKF(7ND|S6S^9K#;#ZW.M.L#G\$T(3'^!
M&5"15\$A|=CN34_4EBJKF5Y^DG_"/629GEGZ_W9=1517RK&|+441Y^HZ1= M\$S\$IP4+&Q?9@5_5HOC^R3=O,Z|12C@6_PQV^IC93"9Y?
X9P|3^=V;_TLQ-3 M:K8|JKNH944^S"\$\$.|(C\$AX|MD3+RS_YLE4WBO@:#&AXMZD;+5P/G@X9571%1 MD6%|L|@>OQT|Q@NF=|):0%:555D@?T+K|
H|_!S|&Y%1U60VR;/L>C^TX>\$ MT.@V6Q?J92=>EVT4PD).B4K094N7?>7N%;1M3;6HVJ9;_SH-FFM.AQ\$^3). M(1IAY TN7|>#<54^C-
8VZCL_1MK=218RA>9-D@/N<M^L6MT8TD^NG4)2D\$01;S:ZMTE|IOW(^GWN|&JTB25/L08KC|HA|B SARO M^DO:QH2:97&1QB\$59V+^E^Q- G".UT3.
H|>:>=<.:13|J|:06%8>5ZT:NDB_*Z"%Y<N<@5T5NX M1U087U7KL5"0F11G?PQC^XQP/XQ^64O38;TNG8W2F4;RKACN|?J7P2\$|=|F-
M|L>L=|+3X;_WN_\$5.I+^V4=&GB5@ CO/RJ|I-#^MS|ZS#-I^Z2:O M>5A.M:9K0^?_O/G_>Q7&|>?TJ^?1_!N|N^YJ>GYI@_|_Q7?;>^W5_?_U^>93|^Z7
MO^>W%PRE>#12X+|^> OXK^OEV+OOX^_WES|I=7|XX^?G_W:NPXL|B:UX_&M?W|_>Q|U=|^_!N|F.OW^IG+ Q|?|TOV#JY_QS\$^U|MD7M
MN5ICEOT>KXY^_W_IP.G%Q|W|I^>_C:P>? NE|!|>_W_W_ZG=WOR:?
MO%<^< N7#|B|8_27Y|)M,OWY^D/RX/WFY^NOWQFXO^Q^N_O'=S:SLN_G5U? M_?7:CZNWO_UX|+>??@Q/G9^|J M_'^J_6YUN7_ORY_?
/_KY?|UEGV|^Z_MW M#^&O|Q^>_O:M-V|Q_G'ZNF^+_ KT @K (WEX?#? 21>_/_A-?07C17KV-GYZ M=^+KW?7FO%_')|B_.=W|Z+KU-
C2:R75M2Q_@9 MS5C65<|D0SH0=>F^?TQZ0V.R# E@Q-E|M(G2VH+19UB|OZ|I4:T)|\$(&47^5
MP_OO_""B.S|7|P%#H+ATPX*1RU_*#V|:U|49+Y.LLQ(OK+C|L|Q7Z"\$|W(MB8LBT0_U;UEM&@/1#DF^7:|N<\$;J3VWCPS6%@02*V*^6WC)X1IM&
<.FC|F M@|P6B1+RAA>L+GK6:52EB|J|L40|NB1L\$^|A"-P^0=Z|)-|0@4ANT ICSRYO M^4|K>_ \$6-G%V16A6^PT|WG?_6T39(2X9M8KW22NS5
>:&3VT*;LF-0^O@ M^;B;.?6&I_0%)YMX,9PL|M&-Q|J&#&.)CWC L>43+H/M^&3%)?RW""**JEM)68H=O^_ JNS&0%TZ(EFQ=M MZHF?4|4Y?
PAMC^C9098&FSLR6BL6V.OU=90E1^L(D\$-V)|.#X_- VTBO@.ZWM^DPU_#(WAV^&#&N|C2.6-VO(D><5:8^PM79_!9W^T?DV.K|JUN3.8QW;ZIM>
M>:P|*X^|QTH^*8?(S4^T|IB@N-Z';&XVYG5+_UZ7B|Z:~22|YANZ/&-Q MZ&(<|JZNMK|J|37U|O?& MX#H^|2^C1" >7089 E1E|_#3+<
_SIQ496JNP=FHX\$%<5ISAD/+ |#J|G8 MRODPP-R^L|T)?>DEF|L_X93M<6L| ^|L^'^0\$|O1 C<1,U4J|T7@|HM M^HE(|!)_UP772L6#G-
J^12^X5F3K2J9F6&OLKK\$9PRUY(TDE SBI)UAF M=SZ|O?>X4|*K|L|Q_NE+Y<2^1 C(S%#4@G^A|'97%KCM7L9A|M.PI6BXA?
L|B#C&U(6|DH|KJ_3D*1ES^H8+BNL|JK >2";"AJY.ZT: KK@4?FPRUVR:A=A|5(U\$Y= XGD^FW&C>M^25L;ZM\$7GHQ|D9F;Y|HGFT
M2<|)G_9|B(YN#J^<! TP\$KS|I|RS8AL|Q;_N(#4|4#;N|<:03|70F)|!SK^* M#(AD2DC=
(R=85/00D=E^MY|O=1C|XBS|P3<3V(BN4@|T2+G0%;M%<@FEZ|! M|N=>202PID8YTKMQ) =&WNFL)<_@|^7;X%|G8%GZDFLVAK,HLDK^H| M|)
'PZE'=0' (4660<-T+Y MHO\$@0P;J<5% A_F8|7M|JA55P_H5CR|:FJPH:=50^3O.TC_1#!E|O^|WY MR>N|A@084ZRK)U#^'
MQME>&C|MK=Q=H|9S@W8_ ^|7<5NWA9: D_|9U6F^MF_Z%|O<^H|F|5XTE.9Q M|RPMD,IRM>V1MCVIR+3A|B,&N^D+(<^8>/RWB3ZDU5&\$K|A

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~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|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f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i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v_G8F108"5B MD98(GN #DNT/GQ<1ZPX8>X@PZ?X>&6%630/*<<'CD=A7ZB]=CE.%X? G M_V+U"3_ "3P!=I@:GVS\$G\$&&O3.H1.5TU1+:(OIETB.Z\$8+4IGK=Z.JMD?

#UJ'8:84L.QJ@:FBVOV49M1 RAKM 13\$ M=2UTJ:TR15G713A4#MQ!J5"O!PX-6DF(CI DE7 >A-.V9"&!A%&! :IJZNF1W MOYLOAU"&B!P34"OT=:/589 E!)&2AGHU 2*6XNO:5RMOJ!>@I5!@FXIKUEFO0#.O#FFSRNF4F>;BU" Q*6D70EFG4<LUR.B M8!\$!>ZMTIT.MOCH@ZB+ZVP*
/IG1\$1L.&N3G43NOJF U!P:XL.R8V/L!F*!6 M!7.(Y/9ZODLBNW4=I*FKF@<N3SN;|=..R%NO"NZT| MKP%&S.:PIQ0*.8!WN7=P\$9L
-3/Q>)&GAE)2)&*1@Z?Z54O.RXO .35Z:0N M>T/6HIG<>."T=O->^P@8(9BYRW9AS+N'(?M6NH'.(INDKJMI-10AE7 MAD7XJ\$S6IQ*=<K<3%
WZD&7O>9R21320F6(E .9!|O*Q+GB .9WQ';S?GFJ6P9<+C.43HAJFA A9#-9@W?MZOC4@H?(BZY MZ*M3J!^=.D2?< 6=Q* VM12:.*\$ #=Z A).0&
.:N48=0<60L31EQ89*?M.J.L.V: @U.(O.Q!05=8Q&+.7A+TOLO. 5.8I!YI)R7O!F@JL(MG<+K9UF+7H^W8H)&\$B .NZB*P MY(&!)O+Q U5PHJ|
|NCV|:D+O2\$>|60*"?|3DQ60?2PD18'. /P1PQF.P4!P2!&=V/< MDES%9%A7OH9U!U70HA)<<3#BEUIUWQIPI?+.#.IR2?-7PK@7...1J>2LUY+?<
M+^0|GL:XL^+L.B:|!7X.C<>O=(NG.5.&+3U5ME?M=F%GW+^+32D1@!<LFIU MWFT7**C@T#WG(0PA22TJD-138*J6:1E*&.@+I9C.(RUM'K6:2/;
/K<BBJ MR'DQO-T9*W*6.5 4W=TFNJO!6<1RAUK!''225\$S=2J5H3@'0!9?1!>+8TWTJZ M. /@<NO@<0P2DV#K..CD8TK>+ N 4)9STRTDV
MBJ>6*TND'='%Y43DQ:LV.%DD5CP*;GI^<1?%XXAR./K.>AM*FWH.-0VS'QFN# MPJ9@.M)5CN'F008MFL2=EF9:%9;'7OC48\$-"MOIX7?JR:H4A %<7@-
TN""IB MJ .Q*Q@YK@!>C+<4CFD|2G^!<XG&WES=05WXXRH@!|1N(AV.M F4NMEW5! MJZ\$4*#FBR.AMA4TG'551QUU2Z?J!|OQ!;
QI=6&R.'NMIT6G|50#+.PCLH MDZ1!>SDGH!>05*OZ'XS'AL:CUWC11J+<4)NC..MIM T+>|XDJ|=E=WJUTJ MH1D=68YRME8M6+2B5U+>'9?
A2"T/&@1)&H=1P.>^GP9=1/5Q\$ V2;K> L.3W MR0:8?KIJ16<2G>0DHW\$ZSK 9NX/JT6S'<..1%\$+4(RCBD#EA7#8VF%!(M MG3XYHN<#J9LZ>6!)?
|9!+<#DMUM5\$;F'5E:8XEM! /TXQO!UIY3 ?QOQO2"4T MZ8 .@^.:LFFK29IQ'5\$OE9.F3<:'0I-081#T!;0AJM=61>9%NSURJ@-
UAP.20/PT/S!+LM...K18@1. ^<NP M%&BKVP.9#;JZ-KXL 2GL2^<WPX.2>+\$/W10V3F J1" M+BB0.P>
M'3M5/W.G@:<SW9K#8HE.WA15S:8;CS@<7&LUFQ2L .QRFYF8^2;C'QW.\$ M=E'VX"1702R3B=|49JM< 0Q>?'\$XY:|ZO 19|LH-P@%T 3 YJ95U3F8FD!7
M039+!>EV'. (8VY.YHOTU.&Y-#C+3UD0<.G+AA%.- M?>O-8F>F(NX:44|IYIRW2Y M522U.M3!@.0:SW:51|0TF.Q:09L5P:1U.H ^1JLZHBI<.. ^/
SHH:C9A+4DGB.ESBZARIU*?>0;2/!|*S-H!T4 MK |B|D#AR0=ZE-JBL1D.HP*?SBOH>>G)S:I 6.@|U1+(!5/*L"%WU(WPE:F M?NM#&:(J?&?U(I/3%Q?
GN=16IRY!+SS1XK.#J^A6!9VK!>+>|B6.L!#*= R2: MNWQO!5\$P&175^ZE! "QO
M|ZL|=J&J=)=..24W=S5;85I2:*FCPTM2A0ET=WF.L+:/5OC7PX:KAH4USH(M<(I)4S/LE5T;|L:N2I'YKMKL>Z4.#M)"IS#WE2&N@NM2;.HI'!:1|CK?L3P
MP2D).L.M5\$J@<..L. E7?>GMCO\$Z+R>:W'D\$+*<3N:NK5ZF-2B'K'7(T'V M<047+U-6:E%=T<&PN@^\$J?7LOE'7=15#L!*>|B+9&(7D:|7D
%|734!<1QH M\$DC@>RY+>10\$!ACN9<XR6D38R)BE|KE|;^H |'K.O.&N:B|X0!>FHS\$# M+/'P\$T50'ME!I.(WSYH'P_AWF1SR%-
F&S'L:LP^GEI#8R\$20E. "%NG.:#D M%L:YHG+<ZCQE&:U46#NU?<>Z".O/IGE.#JN-A'DMI**>10OM." @B46W M=F7>
(!<^C2YDMPNY V_Q699"\$SOB9+0!T)Q:863J.LR6"U"WB8N@PK \$Q R!&@<RCLJ6QN\$AIG-ZHC 5@SG.X S M?JHIK.;|CNL*C?25J092&8|'3(P^#?
AO65Y3 6EL<^&JFLGN|!U'AU'P.3 M.CB."BE#&Z RDSIXA M2&)<C.X#;S8IR=&T;|AJHHT18+K>-K.@5#?99 MAY8.#%>F.ARMZC5^@-
G.'R=5 .4Y)T\$ D9&I:E+^HAKZ3HP\$=:A.=RO2!F' M3L050Y(XO ?YR1VUB4\$0#'.WF@&*E'P/|I4D61T4OH9|/1A5H=^C?
NK#94G=^C5IW!M.X' PM+HG|V|(.%OYBN /95YB M|PON2^9@<ZIY4(R(WCS+6|)'2P2|N!N!AN:T1YB4*#>DOXJ9ON>W8)T&9.K1 MLCVB#&T1W" |J
8.59"Q1E\$.K|BY98/AN:ATEP&J|K+|)' FT6<+).QM:|! M.#;#..6KD1)MIS?<X&L/8F)Q8@HPXJ'905R|AL)4YX+&N\$&4J|U-?<?SB# MFF#51.W\$-
VXN47TICZ7 ^K'4& 4L!>4\$'P8VO 7LOGSJ7\$NJF^&DLP.T 9<Q03 M'RKU(??&M30U! GMRZE6 #P& MU0&5\$PS1UVH:5D0SW%TMZQJ27.
|NR|>VH610+T*.GXILI49S6<|CNHR78 MP:E. N=P11O^>"Y\$Z1|7.0\$|R:06 \$W+N73|@ M^!Y.)@?
CK;P:7. ""30HQOQDZ#3Q+5J\$V5|J7X.HZC|SV@38LQO! GDD08#;J.E. M08B.FDM|I|BUD9,1|>J.:PIY@<U3|DV|*B9P;|=Q03)2M%V11O6HRS*&XQ
M'Z6E.Q2FRSO0!7IN+>^&B!S.WY*<^&RHU2'5-ED94<?JFY022.T&AYD16\$PZB>V.|J|J51 U.1=\$17IO:"3Q1H".*X MT5WXR9G(K+>#)L)B^UJER6'8-
7MBJ- MLED+^ASU:C3 D6^<#G^F N-J54CT>?<-(%RDGO)-(O/QU4P!4F%?L .J6.>V MRRM\$!N;?-'<%"G 53?HRIGMOGR U=W-
;MMPS#X57S=H8>|PIUM&+^N YKL M|L+N6B'P|I|L8FK>Q1/W1\$243VO?38V01\$BE%HL2'/F+N9)Z4 .7U|GDOD?5 MS|EZMB'HWXZ?@Z'I<..
%RN<!)5J<.!<LOQP.6&|^<+9=;M.RZ/PX3 B)8TPC M.R;+> 51D>+>VT|Y7V6M%#RU8@G&F+>BV%VN*QW.AFOJ? T79|31:ODR
MH16|8DLE+<NTPNEIUI!U:W /PS" >M'8059C9WVW1H<SYZ7?>Q->*%|J %! M:PA)>|SXA#XG5Z22U0P"XQ
MP4|B+@<1.9F|N|NM05\$>^2(2|X^<R@A5NUUEFIV<^BM#>SYOU3F(3) 2082G MR#="UI= KP.T5IDK5^0I=9 2R4G.
<(2M3|>SEFTW'F5 UL(C|WBWHV+.=IT M.:^@ 7M5HV4^<>^Q06VH<4NH7AY|Z04&U=)D)X|>?THA6Z/ #?X.PK8H!A: M')N(|BHPH_FE2?
95\$CA.|E'|(ADJL50)P6\$VJD2A#\$.Z>R>T. T 9 M 10.|6SET^T1)3WS^V|>NBFUZ->G%#>M<0^YUX%5V:..
#CL6S^8RRD3PHX7>=1RLO:X*UEC(EL&=59 M2OECF66%HA48|;W5|WIX&(' \$0C&^BZD'6UGVU9UX@0Q.J%=H')MXB=K7N;W= M
%M'W3MWMQ*Y4ICZQEGOL .95 \$1)XN..(URL>@2WEH.J2149?GZ=Q".P+<4 M DQ^ |8#8L5).0K|YY@WG1GP%#>YB:B8#2 MSIA3ZL;=W0..D.*?2
ZD|>=O^M.DJZA M'ZD^EAG=XLZE6\$LDGT36W"JG> MX567(GZ/D?>P.S+D0V7V|F|N!MIE(V13H^XJR.R#>O7FEI'!.|H|H'3=5\$!H" MG.C#|V%L
3(4|F.|@<|K(W?7=T)2 ::XG=>H7M3H9|B"JZI\$9C4);C0B|C)E M84*GLG/|1 =??>D?3K .H\$UM&V C8XTBXNY2|O35*4=ZHIAPW/7*&@<PQ@*\$
MA"B(4|D@<H@JGI^9UKNHLZG@<ED^L:|B|?2CF|5Y=\$+<2W9O&VKR)UOWPZ^M M^BG\$M5|B/^<(&2R5/Y9W4\$!#!!0 (<+V+>#5D44:9T># .#=# P 5
M=&YQ;BTR.#(T.#8S.%|P&UL|7U?<^VLN |?@J2N WUM;|R?9R:22 M>TJV|(D3C^T7=)B8YITZE:!*2D*%(<+4*\$UGSZ X"D1H\$8 -<O3X83<>6T(W M?2
MUH-|J-IA |WTZU11' 8 /3B|3>O7ARAP T|Q.>G%WW)T(M |T3|^ (^7+X|^H !%3HRH.U-O6FX7-VX^@<V@<(R'ZET?^E OZ.7Y
M(HY7/QP?/SPI?/2SQ 71XB\$2>OBPGYQ|/(E'3 2|C|". ?CCZ?>S=SHF1^| M?G|TYL|K| X=OOCNYN3X >O^K\$;2J5? SHX^#S04/O\$>4|(<#^!%|ZO(C|
M:)H?OSFU:NWQ.D7Z2? .&1 +>T^8>W-.OW|J 2|S NOTHP54?L.O/IC MX^<6NT!+YR4.2.P\$+B-|^\$ (R=)V8(|GUYP\$^Q?
+ /O62 >OGZSCHQ^CT\$>3-#OBG!O;U:HIQ<\$<U<^8XC .A&AV4IOXB .7C(\$ M7 WKI2LVQ!AJUO DK^<NLT\$CH8XIA)?
^+X."HW"X3B%T=LZ+OI16D2.;+?6B* MB>^8?>18^/UCSJ-9)O^Z=B(4Q L48|?Q25N>|X@K)IF\$P#LAA&A)G&SH..NOM^C|NWLWPF.-
|=TD#>A|\$:6Z9H1CLVLO\$' M+|J|\$S"UNW&6|<O\$VBN1 M+|R?8%WDA <('M<|^7.78P(DZ62R?>A+..M/ PC.L\$|(<|<-
TR'F.Y9UQ\$;7Q'D^98>CPBP. O(C)&A**87.EV|UO05HH M.MTHO=>|9XPH%1ZY :^1 31&|!P.|' @G&)' 4LD#FH..Q EPR0M'8? M?A:
NV5%7:XEC9K|)7=24|K'503U%+(!5W1' NYA+^43<)%P-L7DLX)A?PN MF%(7: JUWFS2)QO^D|1:T:U#|>WCKW!NPLMFH@<|VTTUKBN "ZD11?NI
MOEKUEP%Q2RV;8&E|X#Y= =F35'U1-^=2%M'DV-V:~! |T|T=U:5\$A^<L\$V MDQBO\$\$.>|APO!M7!1DCG+ TW\$J#@<BVF=F*1.O:>|4@<D|JRHU2UD-
7YK1\$% M+>WR8|C:FCGX3BBB@M=)TJ?%2E:5/DAM0Y^8*-C.4=<V-6%4 MZ&A8TXZG.6+K?2
+HRJUYR.J|V.4.U@<^\$4J2+|3K4MY%)FN.C+@<L'9T6> MBE|J|S45>2E "5 "Q%56T3#@<"V.=5XB8K.2HRD8:D824)IHL-@MQOYN'Z
MY\$<X\$S+V."Z">.5LLV":LZ""HPY6|FK4>+AHH>R M%2@|OH2Y.NR7EY2.C"2V:=(U:EM)4T2|I|H>RZR%&DA+U0|2T(91=3H51_DW? MN4?
^3R12|G+N."N MKY'75^Z0|M8L> #<EF+< NZ6 M%6\$-EC.W|KK&R| M%#>DOR3_S0Y9)9*+=:23K;KF6&Y'/JTA5 EW0XDI'G<CHL:4E3+451F
MW8G.C64"HK3=TG4 J. &B+<J|CZ+>?179AZ+9?3VQ6S:U'K1K&R1 M%#>DOR3_S0Y9)9*+=:23K;KF6&Y'/JTA5 EW0XDI'G<CHL:4E3+451F
5@|+Y6H49C\$Q25 M9@<L.'F'ED| TH^A0&^3|IOV2T 3DAHA9I78B"W:@E|J|RA: ^|EL.Q.@I7 M'(HWU\$Z|L@<|MB6OF&
<&:ROK2=F6G1Q6H16W#>G|LO6K%|>|GN=+>+L MA&IYVX % Q|OUMRJP.D^3K#7RS9W F M/(3T+>|!E>6HO@N6T>"C"6?>5/8T^MJ'0KR?
|3?^H1<:B9O=O5G7[.;V M&H@-0I"RP-D.M'LNUC>-6--^WM8IZ#LHV"7|T+>@>V#L14QK2N;P6L4R4|ZV< M(@Y??OC+GA<2ZG|DK XEN..9M)#
(>O21+I8%06KUSG^KN7UW (\$S\$Z2G|81 MS928&TGPVQ>|>|@3D=8A.C9OVT>QUJZ|ZU@IV+X-198:|Y0L|O:(W.B@<ZYA)YIDF7?^*?TOR|&J2DR X(C|I
Q|O\$SS M>B>GB>L|S&Z=1 A+|R7|MMJ|U"*U1563| FPP MGJOQ*W9@)KH*(3O1M8I3%#T7&9=|(IDAK>GX|OY^?CO?MI>?
ST."^2.KYZ.AV.:Y:ZBZ:BT G2T|@3R(3C.RR^N-NMN3B. / MXS'7?Q3QM@<)&|QI&81\$1NSD10?6A9|VX^XRGQRIL@HB1=AQ+32J|O/B UB|3U|0X-
YMUE'IREL5I7" A.@2|9&B.7: M2VH87FT16G#9H\$<"R.+ZB*@.5|C|H|.OFB5) Q?|OTT'A1> >F5<^|:NC.M1T2EQ0|8HC4*\$Q
LV^VPMG6|03#EO0<^L!9 ML1T^&1^%A*QXOP1W:LXLT|E8)L2F"TB<+ Y'|LWZ#DG8 .V6/Q.6.IB-Z=W2.4B.-O=K(I(5|F!L-|("=F)+E#5!9F+6H:?
BE|U.1|FC.MEQ-M3 UL.D66TIF9<4L;B#DVLNJ2:0(T'GSD6U78GU"5FT6D#55#UAL@:6 MAMS6|MBV0|L4BMC
U9W7T=.^>O. 15<*>+4QFIYD3G%M#2U*|I06 M5F):H)L.U=M%B6V;F:76|UB+05Q?+|B|+3T*W/45%AN.ZST\$S U\$=AZUM24464NR!"CL^27W|. M?2
69P=G&U^<OF45|P<?<\$ FE.QG|5>=0T|0?1|C:KV|O|TRIP(6|^|<763 MS>|C.A)&O/\$>W>+>Q\$A.+#!>X %!>^D:OIR->G>LF2V9L6K%GB=:"LZ
M! 6^N9C2G|J'7D+86^M3""J=>@|O?|U|5M0=^U&. 2O&?>@|HF|) M2V1UML'9?2ON4G FS?@S 2|)E2|SGG'L^Z8P.
(^>Y5+WMEF+|)HS>BHUA MR!#AX6_96CJ9ZL^ES K>_DSU2J5)NJ?M9->RC7SOI* I<68+062:L?X9OF M.D:50\$&(4\$5^65FI0C^HYD)
<@C8^DDU(9K75:2J3F"PT=|@<Q)&ZBF=CA^ M3PZ3>*K D 9-|C)"R@HP25HE*W|.K 7.2CP&O/T M2-
ZUE24Q4 |CB9V|IJZ0U#021PLWVB+>8VITK|.# |!>E2(Z M:?"(ZB|87V=J811-85?>*JHU:G(X\$+; ^BZ*DBG|JOIH7/-.\$7>H=&O\$BP
M'|\$| =5=MMN'6WA05|>5AD3C":IS!>HP>G.CC|<(Z7UB@<9MW90PMT?UDI59M M+>M%\$Q->MPK->M'ZC8^V2HP"
|Y.310X|L@B4NG#6/B">5HP|Y0U*05YQ" MO.|286|5F V>-7>0YK-B%6.1^t0W!>T>ZP|<IG#&P|P|XV"VY^>="ZH.F%Q>&D&|S\$KA+|^@<|T\$N?^#E-
=N@)7C(MY+3B.4="LS"YM3ARS.?!F#|>GL'|H4<1:4BT.N=1LLO&NHW">*1 G MF\$O"GB-MZU.W|BOT >=>9B.FP4!78ILU4M'.F90AMEJ^X>MQ+?
2UOJGU^F(MW Y>G^V=|B|V48G+V|N#N|J2"8C<^TFK8\$9(L V-B|RH@VMZ\$S|A(I|>30F M%|RI(U:|L.UGGG=9B|J8?<M|G+|PV@<|O?Q+|/%+F|
#NU@<U)*R|6|H3U>\$.E0K4J_W^<|J|V;L6?+DQF= MXX@0%!=UUE#Q8U7R7XO&J.L%#NM^LX1%Q|<EF.8/FJEK(\$NY)J^<D M.ZI'J.6^VH>LYJ-
K@<^SUP>O4N1M-SM3G%U^N _E\$+>Q.V>J03=8G?>MPE?E7=WIH5U'43 5@<@PKZ.T.K|WCAC)=M^|J+<K^X|F1>|E|)'FE MD(=8R^QS-
f<+>^3 M'J| P&B8(GWP-X@<ZWDG\$>K12G^V3&+36.M.R9L:..31N0M^<#%7O: MY.HM.M@<6)KY+>X8UVP.XLZ\$V&K+;M":(3|)=C|
M&3"-8BSL.91/F=4.'99JMR 9 G."UZ*G6CR|AT8' MK| 27R#Z1 X:@<ZFA-6 |3ZBTGD<^K_|=Z:S77A==IG>A'D9|M.+5);2CA
M^LX1+>WIK|/ 9L2:~7:H2D|NB^<EF^N|Y@<RSK^R.|F1& M^<?2:QID MT+M1\$C#(022G0H.K.F#<@I8'9RANHUKU96E^N|2.W/VZ"Z<8(ZF5.LF.6= M-8^<+>J: CW@R35|4@<OVI6JR&P|?1?>8<QS:BI:43QI&1Y):9BEJQ6I9.M+PV:O _V%* #NTH5!#0*.154?>H|L'9#LEKY?>.GT.Z(HB^T3)%WM!>?DFJ
M@WK*^@VECT)ZMZQ=>JRT9X3OGTV6!2Y;J^A8|LWT| ^DEI=*>?E|QYQ8N|3Y|H.(7B M'70HF9#894-HO.H SHO-2L.C61.O>R>@<(OCVN@#4*#10-
FB1S)>C:G|>Y(0 M^*=|&92*#MQZ|V +9.9UBM^GVI<%YB>S3^2.OIV13>U2.#QI9 BRW\$#TF64H MIY0^|J'92."VZ075@M)^7\$FE|FVU|/\$Y62Z=.;J;O^X-
8EB+>7QZ^<S4L M+J>+B@<A.O:"RPE0Z#V#|6|6\$A2KK53"E U 2W\$Y>?>OEB6)VY656(MG5PD MD03U8PR|H^AB+ST9=X5BNLV+TDANK\$4-
+HE>FQZ|T(I33P^)|-1XFEI# M2J2M^H2\$M +R51 MMH4082+60|K|U+YR.T7|D|)A&^&7LW8VXY4B.O6
M>N\$%EK.QN%TRM:J*#DN#>8EYL RU0(4>M\$&EA + X OA&Q07?&Q- *\$1#1 M3@<SLCV=I'8BHV';(ZD6V'TRNE.8<|X<|FE;
&:UJ|C&E+QO<^<U\$^V7B|HE M5\$XU.S0-Q\$>=+>ZB>C>|U>EG09E7A(B1Z&^29"TN9?D|?>3@<|OZ\$<5SS@<V.M@<BR2UH3L7H(")?
NID#;E|&Q 81>P|XISU!>22 M.M)MD&L JP(IV36B ^15D>G5DAG0E7A(B1Z&^29"TN9?D|?>3@<|OZ\$<5SS@<V.M@<BR2UH3L7H(")?
AAV*71C0^IVBDV56RLKDAV67U=5?T 7T=V/ M9C(F+L4#GP1.N^0P(V|0|B4Z=K1?UL) \$>(UND.LJ9+=+OSQ|9JUSD.3^<MM75+|I3??>..
AS""OHZSHV*V5 /CU/RRREGBC.LU<=<Y>@G6>(|H2IAO.5N4416>+Y591E2#60MR277D2@N M2/\$TH.E-L<^<7Q6R.YF@<M6VYFOT\$>K-
=A6IV=WC8@5320L_PBO2HG M<=<M>:H|J0TJG@<PBECEY9B'ELD^L.LB|>+>7G82Y/05C=<YX=X3C NSW&GIHW>=9MRV>UB MYTS4;1B'S
^M@>WZV|K)PWH@IOX93#<K<#<:XL6%N.%G>WQ2.TK2^K.QSK M*5.OM49'E:P49|MM&V8WT-@7F+D6.+6D3|48|>=|T+>|*+>LF#>=U6/F6|C4
M25G#E.;U=IMR?W|IGJ T2/NF=+5<-OV8\$YB.+2-^|R'D7@<JVF836KK%M9'D^V MD4F_S93+C^J|B)

```

1A8016^X=T+^$*U."MG16-1M%IVL^,7#M:ZR8CTRV-3RCL M5N1IP,+E-6N^~Z7:~$FJP)2HOF1>Q.UKVCV-P(45K@V;V6.*3KVJ]"++VWC
M&JA6J^~I7@2-GR>Z#<^#X#:#.Y2+K2UV&77BU(E5I+I)J9R2*5#14J0IM?C(MWBEI$%$K1D-6 ZO#D$UJ82U.(V3L9^+OVX@4BA#M-TT7;-17E+I)4I70041-
S^">+TRT9"OBLI^P=6)GZ=^# FWD; &H/E(E3M$C(KN MP-OCA"N"H5>?<#-GVTO$QOBN8K"=7IPUCX;ZBCN MO6-2%&M+=+1)3F9T 5+D&I5: SXVI
-8M7$+5>2F.QFV$5F+6(U#9L2AH2H#7 V 6BGX(MV^N-ZR3+QG1AY M8T3N^D~* W91Q5:PILMPRC(NBH)JP.=H=BJZWIZEN+6C. MZ+>
I^Q9R5FCH9=IR.%+YYO#C7HQ>?3?GSF^~MW-/A>?_2^KFHQ.#?2?K=TOK-Q?XN/XIOWRY=W;SX^OWKM7<3.7B$O17^OWIXN I2WWWHIOY??
CHQ7.FTHO3WX)7 MXIO)8X9/7Y7Y+I<- /I=P^KC^9:VL(I MAI^C= "LRKVI@M/WDD;<<$TX^K163QV6G1B)OPLQ(I@IQ15I9HD")MEJ9.=+F MX9G>
HF22%=WVY49^Q"HR+8R&59&R1OY06G1XK10=P5T1Q249&#5T.RIFYCX MRRIP4SQO?Q)94I^M.H%916.1>YG/@HJHMKVZ891Q9
M6K2'Z'D^6@O8VQ74ZD.^I7JVO5Q&ODI(JE1WL&59 MWNZ?Z.TGC'9Q$J&LPA/UTL)9I>OPDW.#JGR4VK6SX1>AXI140PETI# =7K<: MDQ::
(H.G1'6)382U- I RM.DV(U@.I25F78:W M#M1A2HXJA$^C@I RTV:Y@I)SE1B^UL5SYC2/6^>20@M24H.W>[M65=*LL4: M.+;I)8T@K;ISC-
M.:C$G#W/NIZT^.%O$C MW-IDT3^X+L^I(H9+ BHGIWLW6'7JCG6NJ:SL550U<-
M1Y69JZCV.$^0MQ OSJ>I HVL^FN(LUJZQI FM. ^TBVV58/3N1= &GK= #1'0 MC<@6P)+@!8;AM=%>@4.F%4-/Y.MCVHJ=C-
F.4JY;4.8A-/5>VTG@E:BOU6X M73A1AL5JPI^Z.SI99.5^9=I]M?2JXN=GVVHDK>ZKC>RO1 ZN/9B=.I@
M2?^T]7JXU@H^I695MM UD^V6IE44/RK MSJ(K=^OSU7EJE;..Z)WU^I^3G> &MHJ<^%DL^I^CMORBC EHHD]I (ODDRS MO@=Y^0JF74V>U?
Q)U^1=BS3JY?=>G2.VPNZM9+I]H#R=ZLN M99G2MTM^>B7G6G8N-R46.IG?>9L^GG*^10%5&^D1C&8(LSH.O0M5U^#X M$*6EF6NGP%7JS$D^LF-1
LBKJ7V5$ 5P^ MJ641U&5D/RNTC:QSJ=2X-TOSDIZ^MC4W.LK0I/6?BUA: LBSQ5?V1IEU$K.2M5Q?ZKF>JUPSB06ITK>Z&X-4?E4S^>-P%#^I^O^ (W;
MSLH=HLZ)O>X9=O$%9^HW2 M^2^R7HBB^OPA^Y;HN@QI9^>DIY^<A$GQ&K 6A2PHWDF-IAI>DY@F=7.UU^MN1H00I
(I/Q ZBUQOIE3>J.U.BEA.9J$#K.DC.H/I@I ME.93I$1#A17I2F3 MR^N=OZ8CP(M.DJCM).AHV6L^D.C^M<@1@^80I@M(W.(L7NTKK1G18
M78:$G(8I^VMOX&YXZU^/9S5-9^PVW1##:SDZ>JVB:@.D.(H/G2C:T%^2/R0 MHVG7QBL+O%0I7 Y4X+I)@/(WU1V@&9CMUC^P(C H%6^KU:>
Q2A<8T(HD: M6VHVISM2'D^I(H)OI@HHE5$#F3VMM5P#M:MMC104I^1'20.R-T^T^P49TG_MX%<>RTJ-ZI.KC4EM#XW.I^NVL7#AC+R*(7UNY=*I8Z5
MX^ZH4^%W4<R8C7@ FXO;B#<(XQD9>R>X7BOE^~CB6YCL(5BN+M<^V
MNHIG1O.T$4.IA69Z+1DC1^%VBU0ELX^Y+@UMIT^%6F1^4U<^&I^K)LAG-Z^I M_K.IH&^PTIN8^I(G9?0$^$^G:P)3IC^A1.
M]T&KG2.391>=<^@XAV3YI(^E93.>2IR=:(64O3P@.A1TY77DQ$GJ<04IVRN1 M44>+;JL^#I.FHF^$K^K 174N:5I4/IH>EQ#L52=0^IKI^Z#^KFOI#BIO
M@+8.7/4I6^M(QM15X0$2.U(3SREI/1G/F)Y%<:HVMDDPAJM6F<^+JW-MB$3 M^QT31^WNPEU(^CGX I XB6463+I+E12 MLKM7>ILHPQ%IH..1+1^1C?
@>Y^%M&SDEW=I@>20^>FDLAS=C 198VMM-4 G MCHM^#0099=0C^I^Q&BAN^M(.(95?3^3M^6H59I^W3^27^3QW2IH)
MYLQO%^7=K$C^%K^C^39(02.I>D)+3G5(9J^T^297KH+26GDP^8NUU9) MFD$&OFI^JN2M0CFM.Q7MQ5V&^JSH^8=23^V:N(I816% H?CSE>CHI
I^$>4SGGL H)H?7H%IOE)D;M1$#<:G1&A-FX.#<I(LHX-2^X(2I1T^#6A7+I^N M2A(ON2>^&+1+3;UW+P^N=P5$8+09(58^9)@SD=EBW R8^XC/#=-2-
^IME0M MM-(C1PGK(X^E5E-2^95AID^8QOUEL5: 5LHR00U^U(>YR5#D)J$S2U^ M5JNIF$C11%&^HJ+Z?
01R/20L.75$;TS^@AGTO)W&PJX(M31F.MI-39#2. MORQMD^ZE^I-2.Z>W&KK+C/O.3^O.3^O.3/3OPC9>ZD.VE64QJ<-6 V2B^ M4ZE>H^#+
S0^V7R20PW^#LK^80GZYY12PRRY@=2R.Y^C=TC EOS4 8XJ= M9.OU+RHS7447^>7IPIHF6D.MFQ>F>9P.XWKGIS?
4M-8^I LU.E^2N%>M0J3=7XV$12/I^B $34.N.I0I M.M:ZW44^9.20JIV.UDEJYH2.F++E3J^D(KG;+W 7N>2>4L35BKT M^6^N.H
MFZBRBYT6W$8J0JHOUN= E4Z5^5^I ZMMP^A+>+;^%X-T^I(^-V-@=*JN M^Y9+^PA K)VQ+8>IP-2AQO$& JI0+DEW+V:C
G2$>2>@^1RMP8^WH(R33HPBC^M11^#U&+>+^YWTU^#NOLZSZ.KBL28NDX1TIG.FKH%*Z%&NRS*1JLF4YFI@3 M$&^GKVIHTI^0+6AQF$?
S^%#JITT4 MZRAIH^>UIX.YC?>=QFRW^0+J0J8J0$=NF-@/(7E812PK<1N5;Y-M=)Y^X< M@K9C^WA&HN.^TEO4I^.)6FH?
I(T6TLI.9B.6G#<7F/GV4>#E^&OT.R#7@DTM-MXXU@RPOK BOL52I^&B5JWQ2VHIREQMVIH+8R>PXYI@OMF^3A.
$3)RJ64@F.&PQ%5/KO6S7BE.NO98^I M..&Q^ZF*&3D.M.S^9=I4.ZIUR(=Z^.*YB@J6%$%4R?ZFI@%#4L:MIK MI^IGJ^DD?
+8PS^H>YCDINFR(OHNN97.ZX2>[S3<+E^5^52Q^NR)P#..&U&B$1.MIG.HU44L-B$5B(+34T3B^+MQIMJL+L QF=I<?>I MZVGU6X(-E^#OL1:R-
4% HUM8B)&^%J$6@Q3+L V$UN@I&2$ZM80 MLOF6K$EQFZ17.0LA) ^VN$LE:7ID.H01JIS.QC6BIP+/IMNXSF^J^3WT M^+L%6.G$A80M7T6:2-
H$8XV<IU^RCC&:^RAP&.%R^8^KD.W/5E I^TD-M)5GD^P#2<&S?ITLE0^+@-(WCPV/&O^>O=I%G)#3-WMI6TI^91J8JO 3=I
MIU7880R@Y<I7T5I1HHA28V%UVT>2.^HIFSHH7.BG+UU(YZ)76J%HKM^P MRZ-BL^C)3I5F1+I^VP17#^I^H@PEHICP^LMD)5Q7.KT>8ILJIG
MM/OTXX@HR1>A^I^ MY I8Z2W:U7I^I^X1^Y86PFGOCC&I-M S^E2VWQ M-FH@QHS ^U$TVBM$AHHUC2+L.E^9^XG:=A&A^X$&K^N B>
M1XRY5^FEQ(F&8-V6)LE0@MDT5NB88N01HD-E@!<F M(X3ZURJMN2YV^ADIB$**2.ZTJF&H^I^7I0)ELB$5EFP M5Q:N^ER6NX6=I/T#
CY>^/NX.)@B^%&UAB=+I$)VD.SZIH(ZY>I-M:I^O2R4HMZ6W4 UN^I=K0.DP^I8:8^Z6&:>S5TH2H^:IL&MA-QZP6IZG<# M#W9)GHH<
^HC00.RNINSI>^%&.#$P.I)=H0?^ )B)^FB@STOR8+XAGI M01BK900ZK5Y^ZQ/I^>2>I^C^3^X^H JVRXIK(9X LX%>UQ384%BEI^M<6B&M7KV+=
P^IC&=78@9WDR&G&^XDDYMI^MH7I$ZX^2.NGUW9$XJXG-KJ+RLMG^I^KZ7P(M0D?@OP^J-2.
MT$^IWEKOH&I)MGI^DV5I)M^KH13#8Z$^FY+FB0^1GJVC^&I$WPGRRDUENK^4 M39<89EGC^IE<IQS.FOBM^I7BIB:#Z3OLBVVQO5T0^BM M@I
TY^4I(YI+4O1WI8.G@+G^I=Z+0I2RG%I^Z2JZB0:XH0.7M<K M33/D P$Z.VJB3PN8^X:W2.B^M^@/P$)0D6?1K)G2A14(I^XP3^@G2^;
M^I^TJ^B7NE4.T.ZI^I=^%KB+I(H;R6)2^TJW+M^+HN;9$=-6 BWXN^Y8
```

gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001560293 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001560293
us-gaap:WarrantMember 2024-01-01 2024-06-30 0001560293 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001560293 us-
gaap:ConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-06-30
0001560293 us-gaap:ConstructionInProgressMember 2024-06-30 0001560293 us-gaap:ConstructionInProgressMember 2023-12-31 0001560293
tnon:CatamaranTraySetsMember 2024-06-30 0001560293 tnon:CatamaranTraySetsMember 2023-12-31 0001560293 us-gaap:EquipmentMember
2024-06-30 0001560293 us-gaap:EquipmentMember 2023-12-31 0001560293 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001560293 us-
gaap:LeaseholdImprovementsMember 2023-12-31 0001560293 tnon:LabEquipmentMember 2024-06-30 0001560293 tnon:LabEquipmentMember
2023-12-31 0001560293 us-gaap:OfficeEquipmentMember 2024-06-30 0001560293 us-gaap:OfficeEquipmentMember 2023-12-31 0001560293
tnon:ConvertibleNotePayableMember 2023-11-30 0001560293 tnon:ConvertibleNotePayableMember 2024-06-30 0001560293
tnon:ConvertibleNotePayableMember 2024-01-01 2024-06-30 0001560293 tnon:ConvertibleNotePayableMember us-
gaap:SeriesAPreferredStockMember 2024-06-30 0001560293 tnon:ConvertibleNotePayableMember 2024-02-20 0001560293 us-
gaap:WarrantMember tnon:ConvertibleNotePayableMember 2024-02-20 0001560293 2014-02-18 0001560293 us-
gaap:SeriesAPreferredStockMember 2014-02-18 2014-02-18 0001560293 us-gaap:SeriesBPreferredStockMember 2014-02-18 2014-02-18
0001560293 2023-05-04 2023-05-04 0001560293 us-gaap:CommonStockMember tnon:AtTheMarketOfferingProgramMember 2024-01-01 2024-06-30
0001560293 tnon:LincolnParkCapitalFundLLCMember 2023-07-24 2023-07-24 0001560293 tnon:LincolnParkCapitalFundLLCMember 2024-01-01
2024-06-30 0001560293 tnon:LincolnParkCapitalFundLLCMember 2024-06-30 0001560293 tnon:EquityLineOfCreditMember 2024-01-01 2024-06-30
0001560293 tnon:SeriesAPreferredStockAndWarrantsMember tnon:PurchaseAgreementMember 2024-02-20 2024-02-20 0001560293
tnon:SeriesAPreferredStockAndWarrantsMember tnon:PurchaseAgreementMember 2024-02-20 0001560293 us-gaap:CommonStockMember us-
gaap:IPOMember tnon:PurchaseAgreementMember 2024-02-20 0001560293 us-gaap:CommonStockMember tnon:PurchaseAgreementMember 2024-
02-20 2024-02-20 0001560293 tnon:ConvertibleNotePayableMember 2024-02-20 2024-02-20 0001560293 us-gaap:SeriesAPreferredStockMember
2024-01-01 2024-06-30 0001560293 tnon:MergerTransactionMember 2024-06-30 0001560293 tnon:TwoThousandTwelvePlanMember us-
gaap:CommonStockMember 2021-04-30 0001560293 tnon:TwoThousandTwelvePlanMember us-gaap:CommonStockMember 2021-07-31 0001560293
srt:MinimumMember tnon:TwoThousandTwelvePlanMember us-gaap:CommonStockMember 2021-08-31 0001560293 srt:MaximumMember
tnon:TwoThousandTwelvePlanMember us-gaap:CommonStockMember 2021-08-31 0001560293
tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember us-gaap:CommonStockMember 2022-01-10 2022-01-10 0001560293
tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember us-gaap:CommonStockMember 2022-02-02 2022-02-02 0001560293
tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2022-01-10 2022-01-10 0001560293
tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2022-02-02 2022-02-02 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2024-
04-08 2024-04-08 0001560293 2024-04-08 2024-04-08 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2024-01-01 2024-
06-30 0001560293 tnon:UnderwritingAgreementMember 2022-04-30 0001560293 us-gaap:WarrantMember 2022-04-30 0001560293 us-
gaap:WarrantMember 2022-04-30 2022-04-30 0001560293 us-gaap:MeasurementInputExpectedTermMember 2022-04-30 0001560293 us-
gaap:MeasurementInputOptionVolatilityMember 2022-04-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember 2022-04-30
0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-30 0001560293 us-gaap:WarrantMember us-
gaap:AdditionalPaidInCapitalMember 2022-04-30 0001560293 2023-06-01 2023-06-30 0001560293 us-gaap:WarrantMember 2023-07-16 2023-07-16
0001560293 us-gaap:MeasurementInputExpectedTermMember 2023-06-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-06-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember 2023-06-30 0001560293 us-gaap:WarrantMember 2023-11-30
0001560293 us-gaap:WarrantMember 2023-11-30 2023-11-30 0001560293 us-gaap:MeasurementInputExpectedTermMember 2023-11-30
0001560293 us-gaap:MeasurementInputOptionVolatilityMember 2023-11-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember
2023-11-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-11-30 0001560293 us-gaap:WarrantMember us-
gaap:AdditionalPaidInCapitalMember 2023-11-30 0001560293 tnon:SeriesAWarrantsMember tnon:PurchaseAgreementMember 2024-02-20
0001560293 tnon:PurchaseAgreementMember 2024-02-20 2024-02-20 0001560293 us-gaap:MeasurementInputExpectedTermMember
tnon:PurchaseAgreementMember 2024-02-20 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:PurchaseAgreementMember
2024-02-20 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:PurchaseAgreementMember 2024-02-20 0001560293 us-
gaap:MeasurementInputRiskFreeInterestRateMember tnon:PurchaseAgreementMember 2024-02-20 0001560293 us-gaap:WarrantMember us-
gaap:IPOMember tnon:PurchaseAgreementMember 2024-02-20 0001560293 us-gaap:EmployeeStockOptionMember 2023-12-31 0001560293 us-
gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001560293 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001560293 us-
gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001560293 us-gaap:EmployeeStockOptionMember 2024-06-30 0001560293 us-
gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30
0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001560293 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001560293 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01
2023-06-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001560293 us-
gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-
30 0001560293 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001560293 us-
gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01
2023-06-30 0001560293 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001560293 us-
gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001560293 tnon:SalesRepresentativeAgreementMember 2020-04-01 2020-
04-30 0001560293 tnon:SalesRepresentativeAgreementMember 2021-05-31 0001560293 tnon:SalesRepresentativeAgreementMember 2021-05-01
2021-05-31 0001560293 tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2021-05-01 2021-05-31 0001560293
tnon:SalesRepresentativeAgreementMember 2021-10-31 0001560293 tnon:SalesRepresentativeAgreementMember 2022-04-30 0001560293
tnon:SalesRepresentativeAgreementMember 2024-06-30 0001560293 tnon:TerminationAgreementMember 2022-10-06 0001560293
tnon:TerminationAgreementMember 2022-10-06 2022-10-06 0001560293 country:US tnon:TerminationAgreementMember 2022-10-06 0001560293
tnon:TerminationAgreementMember 2022-01-01 2022-12-31 0001560293 tnon:TerminationAgreementMember 2024-01-01 2024-06-30 0001560293
us-gaap:FairValueInputsLevel3Member tnon:TerminationAgreementMember 2024-01-01 2024-06-30 0001560293 tnon:ConsultingAgreementMember
2022-10-07 2023-10-05 0001560293 tnon:ConsultingAgreementMember 2023-10-05 shares iso4217:USD iso4217:USD shares pure 10-Q true 2024-
06-30 2024 false 001-41364 TENON MEDICAL, INC. DE 45-5574718 104 Cooper Court Los Gatos CA 95032 (408) Common Stock, par value \$0.001
per share TNON NASDAQ YES Yes Non-accelerated Filer true true false false 3951767 1968000 2428000 679000 518000 609000 554000 831000
389000 4087000 3889000 904000 961000 51000 51000 525000 646000 439000 798000 6006000 6345000 1111000 433000 932000 808000 1089000
470000 271000 256000 0 77000 1173000 3403000 3140000 1481000 1999000 290000 428000 5174000 5567000 0.001 0.001 4500000 4500000
256968 256968 0 0 3300000 0.001 0.001 130000000 130000000 3780827 3780827 2600311 2600311 4000 3000 60003000 55894000 -62475000
-55073000 -46000 832000 778000 6006000 6345000 901000 743000 1620000 1176000 431000 549000 680000 1029000 470000 194000 940000
147000 708000 901000 1377000 1735000 1448000 1883000 2829000 3909000 2186000 1732000 4112000 3711000 4342000 4516000 8318000
9355000 -3872000 -4322000 -7378000 -9208000 39000 37000 66000 93000 34000 7000 -56000 46000 37000 -24000 93000 -3826000 -4285000
-7402000 -9115000 -1.02 -3.28 -2.24 -7.5 3749 1305 3301 1215 -3826000 -4285000 -7402000 -9115000 3000 16000 13000 46000 12000 -3826000
-4269000 -7356000 -9087000 256968 3300000 3726974 4000 58969000 -58649000 3624000 1034000 1034000 53853 -3826000 -3826000 256968
3300000 3780827 4000 60003000 -62475000 832000 1125128 1000 46883000 -44322000 -88000 2474000 1054000 1054000 37247 1000000 1000
1643000 1644000 16000 16000 -4285000 -4285000 2162375 2000 49580000 -48607000 -72000 903000 2600311 3000 55894000 -55073000 -46000
778000 2052000 2052000 1123439 1000 1803000 1804000 256968 -3300000 -254000 -3554000 57077 46000 46000 -7402000 -7402000 256968
3300000 3780827 4000 60003000 -62475000 832000 1123680 1000 45843000 -39492000 -100000 6252000 2094000 2094000 38695 1000000 1000
1643000 1644000 28000 12000 -9115000 -9115000 2162375 2000 49580000 -48607000 -72000 903000 -7402000 -9115000 2052000 2094000
189000 60000 46000 121000 111000 207000 373000 55000 155000 442000 325000 678000 362000 385000 698000 -123000 -109000 -4758000
-6752000 6503000 493000 119000 212000 -119000 5798000 2437000 1934000 -4808000 143000 4371000 4665000 46000 12000 -460000 3723000
2428000 2129000 1968000 5852000 1186000 130000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">1. Organization and
Business</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p><p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Nature of operations</i></p><p style="font: 10pt Times New Roman, Times, Serif,
margin: 0pt 0; text-align: justify;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Tenon Medical, Inc.
(the "Company") was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when
it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran™ SI Joint Fusion System ("the
Catamaran System") that offers a novel, less invasive approach to the sacroiliac joint (the "SI joint") using a single, robust, titanium implant for
treatment of the most common types of SI joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration
("FDA") clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran
System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI joint procedures, 2) Revision procedures of failed
SI joint implants and 3) SI joint fusion adjunct to a spine fusion construct.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;
text-align: justify;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Principles of consolidation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The condensed consolidated financial statements of the Company for the three and six months ended June
30, 2023 and as of December 31, 2023 include the accounts of its wholly-owned subsidiary, Tenon Technology AG ("TTAG"), a Swiss company. All
intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same

reporting period as the parent, using consistent accounting policies in all material respects. In 2024, TTAG was dissolved and, as such, the financial statements for the three and six months ended June 30, 2024 and as of June 30, 2024 only include the accounts of the Company.

2. Summary of Significant Accounting Principles

Basis of presentation—The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company’s audited consolidated financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 29, 2024. These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022 included in its Annual Report of Form 10-K filed with the SEC on March 29, 2024. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in management’s opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2024.

Going concern uncertainty and liquidity requirements—The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued.

Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Gatamaran System. Based on the Company’s expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of June 30, 2024 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Notice from Nasdaq—On May 7, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the 30 consecutive business day period between March 25, 2024 and May 6, 2024, the common stock of the Company had not maintained a minimum closing bid price of \$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until November 4, 2024 (the “Compliance Period”), to regain compliance with the Bid Price Rule.

If the Company does not regain compliance with the Bid Price Rule by November 4, 2024, the Company may be eligible for an additional 180-day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary.

If the Company cannot regain compliance during the Compliance Period or any subsequently granted compliance period, the common stock of the Company will be subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel.

The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock. The Company is currently evaluating its options for regaining compliance. On December 21, 2023, the Company’s shareholders approved an amendment to its Certificate of Incorporation to provide for a reverse stock split in a ratio ranging from one for two (1:2) to one for fifty (1:50) at the discretion of the Company’s Board of Directors.

Use of estimates—The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, allowance for credit losses, and stock-based compensation.

Reverse Stock Split—On November 2, 2023, the Company effected a 1-for-10 reverse stock split by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The reverse stock split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the reverse stock split into one share of common stock. No fractional shares were issued in connection with the reverse stock split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the reverse stock split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the reverse stock split.

Income Taxes—The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

Net loss per share—Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that certain potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive.

The following dilutive common stock equivalents as of June 30, 2024 and 2023 which were excluded from the calculation because their effect was anti-dilutive:

	June 30, 2024	June 30, 2023
Common stock equivalents	2024	2023

76%; text-align: left">Outstanding restricted stock units</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">136,690</td><td style="width: 1%; text-align: left"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">93,156</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left">Outstanding stock options</td><td></td><td style="text-align: left"></td><td style="text-align: right">72,563</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">96,934</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Outstanding warrants</td><td></td><td style="text-align: left"></td><td style="text-align: right">2,388,068</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">2,009,600</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt">Common shares convertible from preferred stock</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,625,016</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,199,690</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recent Accounting Pronouncements Not Yet Adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2023-07, <i>Segment Reporting</i> (Topic 280), <i>Improvements to Reportable Segment Disclosures</i>, which increases the disclosures about reportable segments including more detailed information about a reportable segment's expenses. This guidance will be effective for the Company for the fiscal year ending December 31, 2024 and the interim periods thereafter, with early adoption permitted. The guidance will have no effect on the Company's results of operations as the changes are disclosure related. The Company has elected not to early adopt.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In December 2023, the FASB issued Accounting Standards Update 2023-09, "Income Taxes" (Topic 740) - <i>Improvements to Income Tax Disclosures</i>, which requires additional tax disclosures about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This guidance will be effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basis of presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the "SEC"). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company's audited consolidated financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 29, 2024.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company's audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022 included in its Annual Report of Form 10-K filed with the SEC on March 29, 2024.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in management's opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Company's significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022. There have been no material changes in the Company's significant accounting policies during the six months ended June 30, 2024.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going concern uncertainty and liquidity requirements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company's ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. Based on the Company's expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of June 30, 2024 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Notice from Nasdaq</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>On May 7, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that for the 30 consecutive business day period between March 25, 2024 and May 6, 2024, the common stock of the Company had not maintained a minimum closing bid price of \$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until November 4, 2024 (the "Compliance Period"), to regain compliance with the Bid Price Rule.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If the Company does not regain compliance with the Bid Price Rule by November 4, 2024, the Company may be eligible for an additional 180-day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>If the Company cannot regain compliance during the Compliance Period or any subsequently granted compliance period, the common stock of the Company will be subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The notice from Nasdaq has no immediate effect on the listing of the Company's common stock. The Company is currently evaluating its options for regaining compliance. On December 21, 2023, the Company's shareholders approved an amendment to its Certificate of Incorporation to provide for a reverse stock split in a ratio ranging from one for two (1:2) to one for fifty (1:50) at the discretion of the Company's Board of Directors.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, allowance for credit losses, and stock-based compensation.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Reverse Stock Split</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>On November 2, 2023, the Company effected a 1-for-10 reverse stock split by filing an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The reverse stock split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the reverse stock split into one share of common stock. No fractional shares were issued in connection with the reverse stock split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the reverse stock split. The authorized number of shares and the par value per share of the Company's common stock were not affected by the reverse stock split.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Income Taxes</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Company accounts for income taxes utilizing ASC 740, "Income Taxes". ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company's financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</i></p></div>

Net loss per share

Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that certain potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company's weighted average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive.

The Company had the following dilutive common stock equivalents as of June 30, 2024 and 2023 which were excluded from the calculation because their effect was anti-dilutive:

	June 30, 2024	June 30, 2023
Outstanding restricted stock units	136,690	93,156
Outstanding stock options	72,563	96,934
Outstanding warrants	2,388,068	2,009,600
Common shares convertible from preferred stock	2,625,016	2,625,016
Total	3,182,274	2,718,706

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2023-07, "Segment Reporting" (Topic 280), "Improvements to Reportable Segment Disclosures", which increases the disclosures about reportable segments including more detailed information about a reportable segment's expenses. This guidance will be effective for the Company for the fiscal year ending December 31, 2024 and the interim periods thereafter, with early adoption permitted. The guidance will have no effect on the Company's results of operations as the changes are disclosure related. The Company has elected not to early adopt.

In December 2023, the FASB issued Accounting Standards Update 2023-09, "Income Taxes" (Topic 740), "Improvements to Income Tax Disclosures", which requires additional tax disclosures about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This guidance will be effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance.

3. Fixed Assets, Net

Fixed assets, net, consisted of the following:

	June 30, 2024	December 31, 2023
Construction in progress	\$ 718	\$ 718
Catamaran tray sets	602	538
IT equipment	56	56
Leasehold improvements	15	15
Lab equipment	14	14
Office furniture	9	9
Fixed assets, gross	1,315	1,315
Accumulated depreciation	(935)	(935)
Fixed assets, net	\$ 380	\$ 380

[illegible]

a total of \$1,250,000 in secured notes (the "Convertible Notes") and warrants to purchase 45,000 shares of the Company's common stock at an exercise price equal to \$1.94 per share.

The Convertible Notes bear an interest rate of 10% per annum with a default rate of 12% per annum and have a maturity date of November 21, 2024. All principal and accrued interest is payable at maturity. At any time during the term of the Convertible Notes, the principal amount together with all accrued interest thereon (the "Prepayment Amount") may be paid in full, but not in part, by the Company. The Prepayment Amount may be paid by the Company in cash or by the issuance to the Investors of shares of Series A Preferred Stock, if prior to such payment with Series A Preferred Stock (i) certain stockholder proposals described in the Convertible Notes are approved by the Company's stockholders; and (ii) the Company has commitments from investors other than the Investors to purchase shares of Series A Preferred Stock with a stated value of at least \$3,750,000. The Convertible Notes are secured by a first priority security interest in all of the assets of the Company. The warrants expire five years from the issuance date. The warrants contain a "cashless exercise" feature and contain anti-dilution rights on subsequent issuances of equity or equity equivalents.

On February 20, 2024, the Investors agreed to a complete prepayment of the Company's obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at \$1.2705 per share and the Convertible Notes were cancelled. See Note 7.

6. Leases

In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancellable operating lease expires in June 2026. Operating lease costs for the facility lease were \$73 and \$73 for the three months ended June 30, 2024 and 2023, respectively, and were \$146 and \$146 for the six months ended June 30, 2024 and 2023, respectively.

Supplemental balance sheet information related to leases was as follows:

	June 30, 2024	December 31, 2023
Operating lease right-of-use assets	525	525
Operating lease liability, current	646	646
Operating lease liability, noncurrent	290	290
Operating lease liability, total	936	936

Future maturities of operating lease liabilities as of June 30, 2024 were as follows:

	2024	2025	2026	2027	2028	2029	Thereafter
Operating lease liability, current	154	148	148	148	148	148	148
Operating lease liability, noncurrent	0	0	0	0	0	0	0
Operating lease liability, total	154	148	148	148	148	148	148

Less: imputed interest

Total lease payments

Present value of operating lease liabilities

Cash paid for operating leases for the six months ended June 30, 2024

Cash paid for operating leases for the six months ended June 30, 2023

Remaining lease term - operating leases (in years)

Average discount rate - operating leases

Supplemental balance sheet information related to leases was as follows:

	June 30, 2024	December 31, 2023
Operating lease right-of-use assets	525	525
Operating lease liability, current	646	646
Operating lease liability, noncurrent	290	290
Operating lease liability, total	936	936

Black 1.5pt solid; text-align: left"><td><td style="border-bottom: Black 1.5pt solid; text-align: right">(428</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 4pt double; text-align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">(561</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 4pt double; text-align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">(684</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><p>525000 646000 271000 256000 290000 428000 561000 684000 Future maturities of operating lease liabilities as of June 30, 2024 were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">2024</td><td style="width: 1%"></td><td style="width: 1%; text-align: left">\$</td><td style="width: 9%; text-align: right">154</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left">2025</td><td></td><td style="text-align: left"></td><td style="text-align: right">310</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">144</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td></td><td style="text-align: left"></td><td style="text-align: right">608</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="padding-left: 0.125in; text-align: left">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 4pt double; text-align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">561</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">Cash paid for operating leases for the six months ended June 30, 2024</td><td style="width: 1%"></td><td style="width: 1%; text-align: left">\$</td><td style="width: 9%; text-align: right">148</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left">Cash paid for operating leases for the six months ended June 30, 2023</td><td></td><td style="text-align: left"></td><td style="text-align: right">144</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Remaining lease term - operating leases (in years)</td><td></td><td style="text-align: left"></td><td style="text-align: right">2.00</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left"></td><td style="vertical-align: bottom;"><td style="text-align: left"></td><td style="text-align: right">8.0</td><td style="text-align: left"></td></tr></table>154000 310000 144000 608000 47000 561000 148000 144000 P2Y 0.08<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. Stockholders' Equity<p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's current Amended and Restated Certificate of Incorporation dated February 18, 2014 authorizes the issuance of 130,000,000 shares of common stock and 20,000,000 shares of preferred stock, both with a par value of \$0.001 per share. With respect to the preferred stock, 4,500,000 shares are designated Series A Preferred Stock and 491,222 shares are designated Series B Preferred Stock.<p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>At the Market Offering Program</i><p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>On May 4, 2023, the Company entered into an Equity Distribution Agreement to establish an at-the-market offering program, under which the Company may sell from time to time, at its option, shares of its common stock having an aggregate gross sales price of \$3.5 million. The Company is required to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares and has also agreed to provide the Sales Agents with customary indemnification rights. During the six months ended June 30, 2024, 1,033,592 shares of the Company's common stock were sold under the program at a weighted-average price of \$1.83 per share with aggregate proceeds, net of issuance costs, of \$1.834. No shares were sold under the program during the three months ended June 30, 2024. As of the date of this report, the Company may not sell additional shares under this program.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equity Line of Credit</i><p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>On July 24, 2023, the Company entered into a purchase agreement ("Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), under which, subject to specified terms and conditions, the Company may sell to Lincoln Park up to \$10 million of shares of common stock from time to time during the term of the Purchase Agreement. On September 22, 2023 (the "Commencement Date") and on May 10, 2024, the Company filed registration statements with the SEC covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Beginning on the Commencement Date and for a period of 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company's discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to \$10 million of shares of common stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, direct Lincoln Park to purchase on any single business day on which the closing price of its common stock on The Nasdaq Capital Market ("Nasdaq") is equal to or greater than \$1.50 up to 10,000 shares of common stock (a "Regular Purchase"); provided, that the Company may direct Lincoln Park to purchase in a Regular Purchase (i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least \$15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least \$25.00 per share. In no case, however, will Lincoln Park's commitment with respect to any single Regular Purchase exceed \$500,000; provided, that the parties may mutually agree at any time to increase the maximum number of shares of common stock the Company may direct Lincoln Park to purchase in any single Regular Purchase to up to 100,000 shares or any number of shares that shall not exceed 4.99% of the then outstanding shares of common stock. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to our common stock. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of the Company's common stock immediately preceding the time of sale, as determined under the Purchase Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>During the six months ended June 30, 2024, 89,847 shares of the Company's common stock were sold under the program at a weighted-average price of \$1.113 per share with aggregate net proceeds of \$96. No shares were sold under the program during the three months ended June 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series A Preferred Stock</i><p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>On February 20, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors, pursuant to which the Company agreed to sell, issue and deliver to these investors, in a private placement offering (the "Offering"), a total of 172,239 shares of the Company's Series A Preferred Stock and warrants (the "Series A Warrants") to purchase 258,374 shares of common stock, par value \$0.001 per share, of the Company ("Common Stock") at an exercise price equal to \$1.2705 per share for an aggregate offering price of \$2,605,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additionally, on February 20, 2024, the Investors agreed to a complete prepayment of the Company's obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at \$1.2705 per share and the Convertible Notes were cancelled. The Series A Warrants are immediately exercisable and expire five years from the date of issuance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Series A Preferred Stock is convertible, at any time, at the option of the holder into shares of Common Stock. Each share of Series A Preferred Stock shall be convertible, at any time after the date of issuance, at the option of the holder thereof (or, upon a Required Conversion (as defined below), at the option of the Corporation), into that number of shares of Common Stock determined by dividing the Stated Value (as defined below) for such share of Series A Preferred Stock by the Conversion Price (as defined below). "Stated Value" means for any share of Series A Preferred Stock, an amount equal to the product of (x) \$15.125 multiplied by (y) the sum of 1 plus the product of (A) 0.06 multiplied by (B) a fraction equal to the number of days that such share of Series A Preferred Stock has been issued divided by 365. "Conversion Price" means (i) for the shares of Series A Preferred Stock issued on the Closing Date, \$1.5125 and

the anti-dilution provision described below shall not vote on an "as converted" basis and shall only vote when issued upon conversion. Notwithstanding the foregoing, the vote of an individual holder of Series A Preferred Stock (and underlying Common Stock) shall be capped at 9.99% (or 4.99% if selected by the holder).

The Conversion Price is subject to anti-dilution adjustment as the result of any subdivision, combination of shares or recapitalization, stock dividends, stock splits and similar transactions affecting the Common Stock. In addition, the Series A Preferred Stock will have weighted average anti-dilution protection providing for adjustment of the Conversion Price in the event of issuance of, or commitments to issue, Common Stock for less than the Conversion Price then in effect immediately prior to such issue or sale (a "Dilutive Issuance"), subject to customary exceptions; provided however the anti-dilution for Dilutive Issuances shall not be operative until the stockholders of the Company have approved the terms of the Series A Preferred Stock. Upon any liquidation or winding up of the Company (a "Liquidation"), the holders of Series A Preferred Stock will be entitled to receive in preference to any other class or series of the Company's equity securities the greater of (i) the Stated Value plus accrued and unpaid dividends and (ii) what would be paid if the Series A Preferred Stock plus accrued and unpaid dividends had been converted into Common Stock. A consolidation or merger of the Company or sale or transfer of all or substantially all of its assets, or any transaction which results in the stockholders of the Company owning less than 50% of the equity or voting power of the surviving entity (excluding the issuance of Common Stock in any financing transaction unless more than 50% of the Company's shares are issued to one stockholder or a number of stockholders who act as a one group) shall be deemed a Liquidation (a "Deemed Liquidation") with respect to the shares of Series A Preferred Stock of any holder who opts to have such occurrence treated as a Deemed Liquidation; provided that if the liquidation preference payable on a Deemed Liquidation is less than 110% of the stated value of the Series A Preferred Stock, the dividend rate on any accrued and unpaid dividends payable with respect to such Deemed Liquidation will increase to 10%. All liquidation preferences payable in respect of a Deemed Liquidation will be payable in shares of Common Stock based on the closing price of the Common Stock on the date of such Deemed Liquidation. Consent of the majority of the holders will be required to (i) amend the Certificate of Incorporation or Bylaws of the Company so as to adversely alter the rights, preferences, privileges of the Series A Preferred Stock, (ii) create any new class of shares pari passu or senior to the Series A Preferred Stock or increase or decrease the number of authorized shares of Common Stock or preferred stock, (iii) pay or declare any dividend on Common Stock or other junior securities, or incur indebtedness in any single transaction in excess of \$1 million or (iv) redeem, purchase or otherwise acquire any share or shares of preferred stock or Common Stock (other than (a) the repurchase of shares of Common Stock pursuant to a written benefit plan or employment or consulting agreement, or (b) the repurchase of any equity securities in connection with the Company's right of first offer with respect to those securities contained in any written agreement with the Company).

The holders of vested shares of common stock are entitled to vote on any matter submitted to a vote of the stockholders and each such holder is entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock are entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock are entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company's Amended and Restated Certificate of Incorporation, as amended.

In 2012, the Board of Directors of the Company (the "Board") approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two to four years and have a 10-year expiration date. In April 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 662,516. In July 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan to 737,516. In August 2021, the Board increased the number of shares of common stock reserved for issuance under the 2012 Plan from 737,516 shares to 799,266 shares and approved the form of a 2022 Equity Incentive Plan.

On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan.

On April 8, 2024, the Company issued an offer to holders of outstanding stock options to purchase an aggregate of 90,987 shares of the Company's common stock to exchange their options for a lesser number of new restricted stock units ("RSUs") to be granted under the 2022 Plan upon the terms and subject to the conditions set forth in the Offer to Exchange Certain Outstanding Stock Options for Restricted Stock Units (the "Offer to Exchange"). The Offer to Exchange expired on May 6, 2024. A total of 27 eligible participants participated in the exchange. The Company accepted for exchange options to purchase an aggregate of 83,391 shares of common stock of the Company. All surrendered options were cancelled effective as of the expiration of the Option Exchange, and immediately thereafter, in exchange therefor, the Company granted a total of 41,698 new RSUs under the 2022 Plan. The incremental fair value of the new RSUs that were vested at the issuance date was \$32 and was immediately expensed.

A summary of the Company's stock option and restricted stock unit activity under its plans is as follows:

Number of	Shares Subject to Outstanding	Stock Options	Weighted Average Exercise Price per Share
Granted	119,351	66,967	\$69.50
Outstanding at December 31, 2023	42.54	76.916	32.05
Cancelled or forfeited	57,077	32.05	32.05
Released			

[illegible]

[illegible]

Agreement”). In connection with the amended agreement, the Company paid \$500 cash and issued 53,757 shares of common stock to the Representative, for which the Company recorded a combined total of \$880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October 2021, the Company issued 4,445 shares of common stock with a fair value of approximately \$333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 31,235 shares of common stock to the Representative in accordance with the anti-dilution provision, fully satisfying the Company’s obligations.

The Restated Sales Agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the Restated Sales Agreement as long as the bonus paid to the Representative is at least \$6,000.

On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative \$1,000 in cash; and (ii) the Company agreed to pay the Representative (a) \$85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal \$3,600. In the event of an acquisition of the Company, the Company will pay the Representative \$3,600 less previous amounts paid pursuant to clause (b) and clause (c) above. The Company recorded a charge of \$1,000 for the payment to the Representative in the fourth quarter of 2022 and expensed the \$85 per month charges as incurred over the six-month period. For payments under clause (b) and clause (c) above, the Company estimated the fair value of the liability using level 3 hierarchy inputs based on a Monte Carlo simulation of future revenues with a 25% quarterly estimated standard deviation of growth rates and a 10% probability of dissolution, discounted at an estimated discount rate of 15.4%. Based on the Company’s fair value analysis, a total of \$2,611 was charged to sales and marketing expense in the consolidated statements of operations and comprehensive loss and recorded as accrued commissions in the consolidated balance sheets. A reconciliation of the liability under clause (b) and clause (c) for the six months ended June 31, 2024 is as follows:

Balance at January 1, 2024	2,377	
Accretion		(252)
Balance at June 30, 2024	185	
Balance at June 30, 2024	2,310	

Per the terms of the Termination Agreement, the Company ultimately expects to expense \$3,600 under clause (b) and clause (c).

Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement.

The term of the Consulting Agreement was from October 6, 2022, until October 5, 2023, when it terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company paid the Representative a base consulting fee of \$700 per year, payable in monthly instalments, along with additional compensation of \$62.5 per quarter, if certain sales targets were met, for four quarters, along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services.

Litigation

In the normal course of business, the Company may possibly be named as a defendant in various lawsuits.

P5Y P5Y 500000 53757 880000 0.03 4445 333000 31235 6000000 1000000 85000 0.20 0.10 3600000 3600000 1000000 85000 0.25 0.10 0.154 2611000 A reconciliation of the liability under clause (b) and clause (c) for the six months ended June 31, 2024 is as follows:

Balance at January 1, 2024	2,377	
Accretion		(252)
Balance at June 30, 2024	185	
Balance at June 30, 2024	2,310	

9. Concentrations of Risk

Credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

The Company maintains cash balances at financial institutions located in California. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses.

false false false false 649-5760 -1.02 -2.24 -3.28 -7.50 1215 1305 3301 3749 2655 false --12-31 Q2-0001560293